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1. General Introduction 
Stereoselective syntheses have become indispensable for the pharmaceutical, agrochemical, 
flavor and fragrance industries.1 An enantiocontrolled preparation of pharmaceuticals is often of 
utmost significance not only to ensure proper biological function but also to avoid deleterious 
side effects.2 Thus, the synthesis of both natural and unnatural organic compounds in their 
optically pure forms has become an important and highly active field of research in modern 
organic chemistry. Many of today’s syntheses aim at compounds with increasingly complex 
scaffolds which require an accurate control of multiple stereocenters and even of chiral axes, 
planes and structure-inherent chiralities.1, 3 In order to meet these synthetic challenges a chemist 
must be able to benefit from a rich pool of versatile diastereo- and enantioselective 
transformations. Access to enantiomerically pure compounds is implemented by using one of the 
following main approaches: 
 
1. Resolution of a racemic mixture: 
Classical approaches comprise separation of the enantiomers via recrystallization or 
reaction of the racemic mixture with a stoichiometric amount of a chiral reagent followed 
by isolation of the resulting diastereomers. Kinetic resolution represents a further 
alternative. In this approach, the racemic mixture is subjected to an enantioselective 
reaction with only one enantiomer being selectively transformed. In all these cases, the 
highest possible yield for one enantiomer cannot exceed 50%. Dynamic kinetic resolution 
(DKR) represents an important advancement to the latter method as it allows full 
production of one single enantiomer from a racemic mixture by exploiting the 
configurational instability of the starting material and/or the reactive intermediates.4 
 
 
                                                 
1 (a) Asymmetric Synthesis ‒ The Essentials (Eds.: M. Christmann, S. Bräse), Wiley-VCH, 2007; (b) V. Farina, J. T. 
Reeves, C. H. Senanayake, J. J. Song, Chem. Rev. 2006, 106, 2734. 
2 D. Enders, R. W. Hoffmann, Chem. Unserer Zeit 1985, 19, 177. 
3 (a) M. S. Taylor, E. N. Jacobsen, Proc. Natl. Acad. Sci. USA 2004, 101, 5368; (b) J. T. Mohr, M. R. Krout, B. M. 
Stoltz, Nature 2008, 455, 323; (c) Comprehensive Asymmetric Catalysis, Vol. 1-3 (Eds.: E. N. Jacobsen, A. Pfaltz, 
H. Yamamoto), Springer, 2000; (d) Comprehensive Asymmetric Catalysis, Suppl. 1-2 (Eds.: E. N. Jacobsen, A. 
Pfaltz, H. Yamamoto), Springer, 2004; (e) B. M. Trost, Proc. Natl. Acad. Sci. USA 2004, 101, 5348. 
4 (a) H. Pellissier, Tetrahedron 2008, 64, 1563; (b) H. Pellissier, Tetrahedron 2003, 59, 8291; (c) F. F. Huerta, A. B. 
E. Minidis, J.-E. Bäckvall, Chem. Soc. Rev. 2001, 30, 321; (d) R. Noyori, M. Tokunaga, M. Kitamura, Bull. Chem. 
Soc. Jpn. 1995, 68, 36. 
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2. Synthesis from the “chiral pool” and synthesis using a chiral auxiliary: 
Before the advent of efficient asymmetric synthetic methods the “chiral pool” was limited 
to optically active compounds provided by nature, including, most essentially, 
carbohydrates and amino acids, which are usually produced in only one enantiomeric 
form. The development of asymmetric catalysis (see below) has expanded the scope of 
“the chiral pool” to unnatural chiral materials.3a, 5 Chiral auxiliaries can be viewed as 
chiral protective groups, as they are mostly introduced prior to the stereoselective reaction 
and removed afterwards.6 Asymmetric reactions using chiral auxiliaries depend on 
diastereocontrol. The fact that the auxiliary-substituted products are diastereomeric 
additionally enables chiral resolution for very high enantiomeric purities of the final 
products after removal of the chiral auxiliary. Asymmetric synthesis from the chiral pool 
or using a chiral auxiliary is often wrongfully considered as an obsolete synthetic 
approach. In fact, chiral auxiliaries continue to be essential tools in modern synthetic 
chemistry.1b, 6 Most of today’s chiral ligand or organocatalyst syntheses are based on the 
use of chiral auxiliaries or the “chiral pool”. Moreover, chiral auxiliaries have special 
properties that allow asymmetric inductions that cannot be easily achieved with 
asymmetric catalysis. 
 
 
Scheme 1: Ultra-remote stereocontrol over 22 bonds using chiral auxiliaries. 
 
                                                 
5 H.-U. Blaser, Chem. Rev. 1992, 92, 935. 
6 Y. Gnas, F. Glorius, Synthesis 2006, 1899. 
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An impressive example of their potential was given by J. Clayden et al. who used a chiral 
oxazolidine auxiliary for ultra-remote stereoinduction (Scheme 1).7 
 
3. Asymmetric catalysis: 
Asymmetric catalysis represents an ideal method for the induction of enantioselectivity. 
Here, a catalytic amount of a chiral promoter is already sufficient to produce both natural 
and unnatural chiral compounds in large quantities. The chirality multiplication efficiency 
{[(amount of major enantiomer of product) ‒ (amount of minor enantiomer of product)]/ 
(amount of chiral source)} represents a measure for the competence of the chiral catalyst. 
This factor can theoretically be infinite for asymmetric catalysis – an important property 
which renders this approach superior to intra- and intermolecular chirality transfer 
reactions.1a, 8 The three major fields of modern methodical organic chemistry, bioorganic 
chemistry, organocatalysis and organometallic chemistry, provide expedient access to 
asymmetric catalysis: Thus, enzymes have proved to be extremely reliable tools in 
asymmetric reduction, oxidation and desymmetrization processes.9 In asymmetric 
organocatalysis, small amounts of a chiral organic molecule are used for enantioselective 
transformations. 
 
 
Scheme 2: Asymmetric catalytic hydrogenation using frustrated Lewis pairs. 
 
                                                 
7 J. Clayden, A. Lund, L. Vallverdú, M. Helliwell, Nature 2004, 431, 966. 
8 Catalytic Asymmetric Synthesis (Ed.: I. Ojima), Wiley-VCH, 2000. 
9 (a) R. Wohlgemuth, Curr. Opin. Microb. 2010, 13, 283; (b) R. N. Patel, Adv. Synth. Catal. 2001, 343, 527. 
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Over the past decade, the significance of this methodology has immensely grown and its 
abilities have become multifaceted. 10 A recent example of the widespread abilities of 
today’s asymmetric organocatalysis is the enantioselective hydrogenation with chiral 
frustrated Lewis pairs (Scheme 2).11 Organometallic chemistry comprises the largest and 
most versatile scope of asymmetric reactions, including even asymmetric metathesis12 and 
cross-coupling reactions13 (Scheme 3). Thereby, the metal core of an organometallic 
species acts as the central docking site for the reactants. Asymmetry is induced by a 
suitable chiral ligand which partially complexes the respective metal, thus accurately 
defining its structural environment. The synthetic accessibility of chiral ligands, the 
possibility of diversifying and adapting their properties and their applicability to many 
distinct reactions have made their development one of the most important and popular 
research fields in modern organic chemistry.14 
 
O
achiral
OH
83%; 99% ee
O
tBu
tBu
O
Mo
N
tBu
5 mol%
toluene, -25 °C
TfO OTf
Me2N
Pd
PPh2
Cl Cl
Bn
5 mol%
PhMgBr (2.1 equiv)
LiBr (1.0 equiv)
Et2O/toluene, -30°C
Ph OTf
87%; 93% ee
  
Scheme 3: Asymmetric transition-metal catalyzed metathesis and cross-coupling. 
 
Many natural and unnatural bioactive molecules have multiple stereocenters giving rise to a large 
number of possible stereoisomers (2n, where n is the number of stereocenters). Efficient control 
of the relationship between stereocenters and an expedient transfer of chirality throughout the 
                                                 
10 (a) E. N. Jacobsen, D. W. C. MacMillan, Proc. Natl. Acad. Sci. USA 2010, 107, 20618; (b) C. Grondal, M. Jeanty, 
D. Enders, Nature Chem. 2010, 2, 167; (c) A. G. Doyle, E. N. Jacobsen, Chem. Rev. 2007, 107, 5713; (d) A. 
Dondoni, A. Massi, Angew. Chem. Int. Ed. 2008, 47, 4638; (e) S. Jaroch, H. Weinmann, K. Zeitler, ChemMedChem 
2007, 2, 1261; (f) H. Pellissier, Tetrahedron 2007, 63, 9267; (g) K. N. Houk, B. List, Acc. Chem. Res. 2004, 37, 487. 
11 D. Chen, Y. Wang, J. Klankermayer, Angew. Chem. Int. Ed. 2010, 122, 9665. 
12 H. F. T. Klare, M. Oestreich, Angew. Chem. Int. Ed. 2009, 48, 2085. 
13 (a) F. Glorius, Angew. Chem. Int. Ed. 2008, 47, 8347; (b) T. Hayashi, J. Organomet. Chem. 2002, 653, 41. 
14 M. Shibasaki, S. Matsunaga in Asymmetric Synthesis ‒ The Essentials (Eds.: M. Christmann, S. Bräse), Wiley-
VCH, 2007, 47. 
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synthesis can only be ensured with highly diastereoselective methods.3a, 15 Therefore, the 
development of diastereoselective reactions represents an important synthetic task, as exemplified 
by the total synthesis of the natural product (+)-castanospermine (Scheme 4).16 
 
  
Scheme 4: Importance of diastereocontrol in the asymmetric synthesis of (+)-castanospermine. 
                                                 
15 M. T. Reetz, Chem. Rev. 1999, 99, 1121. 
16 (a) H. Ina, C. Kibayashi, Tetrahedron Lett. 1991, 32, 4147; (b) H. Ina, C. Kibayashi, J. Org. Chem. 1993, 58, 52. 
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2. Enantiocontrol with Chiral Sulfoxides 
2.1 Chiral sulfoxides as steering molecules in asymmetric synthesis 
Its unique properties, such as central chirality at the sulfur, high configurational stability and the 
strongly polarized S-O bond make the chiral sulfinyl group a steering functionality of increasing 
importance in all fields of asymmetric synthesis6, 17 and pharmaceutical research.1b Chiral 
sulfoxides can be easily accessed via the reaction of an organometallic reagent with (‒)-menthyl 
(S)-p-toluenesulfinate (1) or its enantiomer , pioneered by K. K. Andersen as early as 1962,18 
which greatly adds to their attractiveness and usability in asymmetric reactions. The addition of 
the organometallic reagent occurs with inversion of the configuration at the chiral sulfur (Scheme 
5). Only recently, C. H. Senanayake et al. extended this approach to the use of N-sulfonyl-1,2,3-
oxathiazolidine-2-oxide derivatives, such as (S)-TMPOO (2), allowing a highly versatile 
construction of chiral sulfoxides.19  
 
Scheme 5: Introduction of the chiral sulfinate group via reaction with organometallic reagents. 
 
Alternative syntheses of chiral sulfoxides are mostly based on the asymmetric oxidation of 
sulfides.16a Chiral sulfoxides have proved to be suitable for the resolution of planar,20 axial21 and 
                                                 
17 (a) E. Wojaczyńska, J. Wojaczyński, Chem. Rev. 2010, 110, 4303; (b) M. C. Carreño, G. Hernández-Torres, M. 
Ribagorda, A. Urbano, Chem. Commun. 2009, 6129; (c) H. Pellissier, Tetrahedron 2006, 62, 5559; (d) Organosulfur 
Chemistry in Asymmetric Synthesis, (Eds.: T. Toru, C. Bolm), Wiley-VCH 2008; (e) I. Fernandéz, N. Khiar, Chem. 
Rev. 2003, 103, 3651; (f) C. H. Senanayake, D. Krishnamurthy, Z.-H. Lu, Z. Han, I Gallou, Aldrichim. Acta 2005, 
38, 93 and references therein. 
18 (a) K. K. Andersen, Tetrahedron Lett. 1962, 3, 93; for preparation see: (b) J. M. Klunder, K. B. Sharpless, J. Org. 
Chem. 1987, 52, 2598; (c) Y. Watanabe, N. Mase, T. Moto-aki, T. Toru, Tetrahedron: Asymmetry 1999, 10, 737. 
19 (a) Z. Han, D. Krishnamurthy, P. Grover, Q. K. Fang, X. Su, H. S. Wilkinson, Z.-H. Lu, D. Magiera, C. H. 
Senanayake, Tetrahedron 2005, 61, 6386; (b) Z. Han, D. Krishnamurthy, P. Grover, H. S. Wilkinson, Q. K. Fang, X. 
Su, Z.-H. Lu, D. Magiera, C. H. Senanayake, Angew. Chem. Int. Ed. 2003, 42, 2032. 
20 (a) F. Rebière, O. Riant, L. Ricard, H. B. Kagan, Angew. Chem. Int. Ed. 1993, 32, 568; (b) G. J. Rowlands, Org. 
Biomol. Chem. 2008, 6, 1527 and references therein. 
21 (a) J. Clayden, S. P. Fletcher, J. J. W. McDouall, S. J. M. Rowbottom, J. Am. Chem. Soc. 2009, 131, 5331 and 
references therein; (b) J. Clayden, P. M. Kubinski, F. Sammiceli, M. Helliwell, L. Diorazio, Tetrahedron 2004, 60, 
4387; (c) J. Clayden, D. Mitjans, L. H. Youssef, J. Am. Chem. Soc. 2002, 124, 5266; (d) M. S. Betson, A. 
Bracegirdle, J. Clayden, M. Helliwell, A. Lund, M. Pickworth, T. J. Snape, C. P. Worrall, Chem. Commun. 2007, 
754. 
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helical chiralities22 and are therefore widely used as key-intermediates in the syntheses of chiral 
ligands.17 Moreover, it was shown that the central chirality of the sulfinyl group strongly dictates 
the conformational preferences of atropisomers thus enabling the selective, stereocontrolled 
preparation of axially chiral molecules, such as amide 3 (Scheme 6).20a, 23  
 
 
Scheme 6: Control of the chiral axis by the central chirality at the sulfinyl group. 
 
The ability of the sulfoxide to induce remote and ultra-remote stereocontrol (see chapter 1, 
Scheme 1) makes it a valuable chiral auxiliary allowing highly diastereoselective 
transformations.22 Its use in the synthesis of optically pure allenes with central and axial 
chiralities, as developed by J. L. Garcià Ruano, is an outstanding example of the powerful 
capacities of the chiral sulfinyl functionality in asymmetric induction (Scheme 7).24 
 
S+
Et
O-
S+
Me
pTol
O-
[Cu]
S+
Me
•
H
Ph
Me
pTol
-O
R
M
1) LDA
2) CuCN
Me
OMs
Ph
rac-6
7: 58%; d.r.(R/S): 95:5
THF, -10 °C
(S)-4 5
control of stereocenter
and chiral axis
 
Scheme 7: Asymmetric induction with sulfoxides: simultaneous control of the 
stereoconfigurations of center and chiral axis. 
 
Starting from (S)-4, deprotonation with LDA and transmetalation with CuCN·2 LiCl furnished 
the benzyl copper intermediate 5 whose reaction with racemic propargyl mesylates, such as rac-
6, regioselectively gave the 1,1-disubstituted allene 7 in 58% yield with M-configuration at the 
chiral axis and R-configuration of the benzyl stereocenter (R/S 95:5). This result demonstrated 
                                                 
22 (a) A. Latorre, A. Urbano, M. C. Carreño, Chem. Commun. 2009, 6652; (b) M. C. Carreño, S. Garcìa-Cerrada, A. 
Urbano, Chem. Eur. J. 2003, 9, 4118. 
23 J. Clayden, N. Vassiliou, Org. Biomol. Chem. 2006, 4, 2667 and references therein. 
24 (a) J. L. García Ruano, V. Marcos, J. Alemán, Angew. Chem. Int. Ed. 2008, 47, 6836; (b) J. L. García Ruano, V. 
Marcos, J. Alemán, Angew. Chem. Int. Ed. 2009, 48, 3155. 
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that even dynamic kinetic resolution had occurred during the SN2’ reaction with the R-enantiomer 
of rac-6 being the most reactive substrate. The possibility of performing sulfoxide-lithium or 
-magnesium exchanges is an additional highly valuable feature of the sulfinyl group. Thus, it can 
be considered as a “chiral halogen” functionality that can “tracelessly” be removed or replaced by 
other functionalities. Remarkably, the configurations of the axis in atropisomers20a-b, 22 or even at 
the stereocenter25 in the resulting organometallic reagents were shown to be relatively stable over 
a few minutes at low temperatures (Scheme 8).  
 
 
Scheme 8: Sulfoxide-lithium and sulfoxide magnesium exchange: preservation of axial and 
central configurations. 
 
Recently, sulfoxides have also found applications as chiral Lewis bases inducing high 
enantioselectivities in the allylation of aldehydes and hydrazones with allyl trichlorosilane.26 
However, stoichiometric use of the respective chiral sulfoxide is necessary to obtain good 
conversions and high enantiomeric excesses (Scheme 9). 
 
                                                 
25 (a) R. W. Hoffmann, Chem. Soc. Rev. 2003, 32, 225; (b) R. W. Hoffmann, P. G. Nell, Angew. Chem. Int. Ed. 1999, 
38, 338. 
26 (a) A. Massa, M. R. Acocella, V. De Sio, R. Villano, A. Scettri, Tetrahedron: Asymmetry 2009, 20, 202; (b) S. 
Kobayashi, C. Ogawa, H. Konishi, M. Sugiura, J. Am. Chem. Soc. 2003, 125, 6610; (c) A. Massa, A. V. Malkov, P. 
Kočovský, A. Scettri, Tetrahedron Lett. 2003, 44, 7179; (d) G. Rowlands, W. K. Barnes, Chem. Commun. 2003, 
2712; (e) I. Fernández, V. Valdivia, B. Gori, F. Alcudia, E. Alvarez, N. Khiar, Org. Lett. 2005, 7, 1307; (f) F. 
García-Flores, L. Flores-Michel, E. Juaristi, Tetrahedron Lett. 2006, 47, 8235; (g) I. Fernández, V. Valdivia, M. 
Pernía Leal, N. Khiar, Org. Lett. 2007, 9, 2215. 
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Scheme 9: Asymmetric addition of allyl trichlorosilanes to hydrazones mediated by chiral 
sulfoxides. 
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2.2 Sulfoxides as a relatively new class of chiral ligands for transition-metal 
catalyzed reactions 
Although the coordination chemistry of sulfoxides has been well studied and despite the easy 
preparation and resolution of chiral sulfoxides,27 the success story of their application as chiral 
ligands in enantioselective transition-metal catalyzed reactions is a rather recent one. Initially, 
chiral mono- and bissulfoxides were used in hydrogenation reactions, diethylzinc addition to 
benzaldehyde, Diels-Alder reactions and allylic substitutions.17b,e, 28 Except for the latter two 
reactions, mostly low to moderate enantioselectivities were obtained. The breakthrough was 
achieved by the development of the axially chiral bissulfoxide ligands 8 and 9 for the Rh-
catalyzed Hayashi-Miyaura reaction29 by R. Dorta et al. (Scheme 10).30  
 
Me
Me
S+
S+
S+
S+
pTol
O-
O-
pTol
O-
O-
pTol
pTol
O
O
O
O
S+
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S+
tBu
tBu
O-
O-
S+
PPh2
tBu
O-
OMe
MeO
8 9 10 11 12
O O
Ph
*
L (cat.)
PhB(OH)2
L= 8: (1.5 mol% Rh)
L= 9: (0.5 mol% Rh)
L= 10: (0.5 mol% Rh)
L= 11: (1 mol% Rh)
L= 12: (1 mol% Rh)
99%, 98% ee
99%, >99% ee
89%, 99% ee
96%, 98% ee
99%, 98% ee  
Scheme 10: Chiral sulfoxide ligands for the asymmetric Hayashi-Miyaura reaction. 
 
High reactivities and excellent enantioselectivities (94-99% ee) were obtained for the addition 
products. Noteworthy are the low catalyst loadings (1.5 mol% with 8 and 0.5-1.0 mol% with 9) 
used in the 1,4-addition reaction. Compared to diphosphines, bissulfoxides behave as better σ-
donating ligands in the Rh-catalyzed conjugate transfer of aryl boronic acids to cyclic enones.29a 
                                                 
27 (a) M. Calligaris, O. Carugo, Coord. Chem. Rev. 1996, 153, 83; (b) H. B. Kagan, B. Ronan, Rev. Heteroat. Chem. 
1992, 7, 92. 
28 I. Fernandéz, N. Khiar in Organosulfur Chemistry in Asymmetric Synthesis, (Eds.: T. Toru, C. Bolm), Wiley-VCH, 
2008, 265 and references therein. 
29 Y. Takaya, M. Ogasawara, T. Hayashi, M. Sakai, N. Miyaura, J. Am. Chem. Soc. 1998, 120, 5579. 
30 (a) J. J. Bürgi, R. Mariz, M. Gatti, E. Drinkel, X. Luan, S. Blumentritt, A. Linden, R. Dorta, Angew. Chem. Int. Ed. 
2009, 48, 2768; (b) R. Mariz, X. Luan, M. Gatti, A. Linden, R. Dorta, J. Am. Chem. Soc. 2008, 130, 2172. 
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Further chiral bissulfoxides (10-11)31 and a sulfoxide-phosphine hybrid ligand (12)32 were 
developed and consequently used in this type of reaction. All of them induced very high levels of 
enantioselectivity in the addition of arylboronic acids to cyclohexen-2-one (Scheme 10). 
                                                 
31 (a) Q.-A. Chen, X. Dong, M.-W. Chen, D.-S. Wang, Y.-G. Zhou, Y.-X. Li, Org. Lett. 2010, 12, 1928; (b) J. Chen. 
F. Lang, X. Zhang, L. Cun, J. Zhu, J. Deng, J. Liao, J. Am. Chem. Soc. 2010, 132, 4552. 
32 F. Lang, D. Li, J. Chen, J. Chen, L. Li, L. Cun, J. Zhu, J. Deng, J. Liao, Adv. Synth. Catal. 2010, 352, 843. 
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3. Stereoselective Cross-Coupling Reactions 
3.1 Transition-metal catalyzed cross-coupling as one of the most important C-C bond 
forming reactions in modern organic synthesis 
Last year’s Nobel prize in chemistry was awarded to the three pioneers of transition-metal 
catalyzed cross-coupling, R. F. Heck, E.-i. Negishi and A. Suzuki, who initiated, with their 
groundbreaking works in the 1960s and 1970s,33 the development of one of today’s most 
important C-C bond forming reactions: transition-metal catalyzed cross-coupling.34 Today, this 
type of reaction has become an extremely valuable and well-developed method not only for 
complex total syntheses but also, and more significantly, for numerous industrial applications, 
including the syntheses of pharmaceuticals, artificial materials and agrochemicals.34, 35 Despite 
outstanding achievements, the development of improved, complementary and alternative methods 
for cross-coupling reactions is ongoing and represents one of the most active research fields in 
organic synthesis today. Thereby, one of the most important synthetic challenges is the 
development of efficient and general methods for the cross-coupling of secondary Csp3-centers.36 
For such reactions, the C-C bond formation is problematic due to competing β-hydride 
elimination and sluggish reductive elimination.37 In addition, the issue of stereoselectivity 
becomes revelant for unsymmetrically substituted substrates. 
                                                 
33 (a) R. F. Heck, J. P. Nolley, J. Org. Chem. 1972, 37, 2320; (b) E. Negishi, A. O. King, N. Okukado, J. Org. Chem. 
1977, 42, 1821; (c) N. Miyaura, T. Yanaga, A. Suzuki, Synth. Commun. 1981, 11, 513. 
34 X.-F. Wu, P. Anbarasan, H. Neumann, M. Beller, Angew. Chem. Int. Ed. 2010, 49, 9047. 
35 (a) Transition Metals for Organic Synthesis: Building Blocks and Fine Chemicals (Eds.: M. Beller, C. Bolm), 2nd 
ed., Wiley-VCH, 2004; (b) Metal-Catalyzed Cross-Coupling Reactions (Eds.: F. Diederich, P. J. Stang), Wiley-
VCH, 1998; (c) Metal-Catalyzed Cross-Coupling Reactions (Eds.: A. deMeijere, F. Diederich), 2nd ed., Wiley-VCH, 
2004. 
36 A. Rudolph, M. Lautens, Angew. Chem. Int. Ed. 2009, 48, 2656; (b) J. Terao, N. Kambe, Acc. Chem. Res. 2008, 
41, 1545; (c) S. R. Chemler, D. Trauner, S. J. Danishefsky, Angew. Chem. Int. Ed. 2001, 40 4544; (d) J.-P. Corbet, 
G. Mignani, Chem. Rev. 2006, 106, 2651; (e) C. Valente, S. Baglione, D. Candito, C. J. O'Brien, M. G. Organ, 
Chem. Commun. 2008, 735; (f) N. Hadei, E. A. B. Kantchev, C. J. O'Brien, M. G. Organ, Org. Lett. 2005, 7, 3805; 
(g) D. A. Powell, T. Maki, G. C. Fu,. J. Am Chem. Soc. 2005, 127, 510; (h) E.-i. Negishi, L. F. Valente, M. 
Kobayashi, J. Am Chem. Soc. 1980, 102, 3298; (i) T. Hayashi, M. Konishi, M. Kumada, Tetrahedron Lett. 1979, 
1871. 
37 T.-Y. Luh, M. K. Leung, K.-T. Wong, Chem. Rev. 2000, 100, 3187. 
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3.2 Stereoselective cross-couplings using secondary alkyl halides 
Ni-catalyzed cross-couplings of various aryl/alkenyl organometallic reagents with secondary 
alkyl halides were shown to proceed with exceedingly high levels of enantioselectivity in the 
presence of chiral bi- and tridentate nitrogen ligands, such as 13 and 14 (Scheme 11).13a, 38  
 
 
Scheme 11: Asymmetric Ni-catalyzed cross-coupling of racemic secondary alkyl halides. 
 
Using Ni-catalysis and diamine 14 as chiral ligand even a highly enantioselective Csp3-Csp3 
cross-coupling between primary organoboranes and secondary alkyl halides, such as the 
chlorohydrine derivative rac-15 could be achieved.38a Diastereoselective Ni-catalyzed cross-
couplings between aceto-α-D-bromoglucose (16) and various arylzinc reagents were reported by 
M. R. Gagné.39 The arylated glucoses were obtained with d.r. up to 94:6 in favor of the β-anomer 
(17) (Scheme 12). 
 
Scheme 12: Diastereoselective cross-coupling of aceto-α-D-bromoglucose (16). 
 
                                                 
38 (a) N. A. Owston, G. C. Fu, J. Am. Chem. Soc. 2010, 132, 11908; (b) P. M. Lundin, G. C. Fu, J. Am. Chem. Soc. 
2010, 132, 11027; (c) S. Lou, G. C. Gu, J. Am. Chem. Soc. 2010, 132, 1264; (d) P. M. Lundin, J. Esquivias, G. C. Fu, 
Angew. Chem. Int. Ed. 2009, 48, 154; (e) S. W. Smith, G. C. Fu, J. Am. Chem. Soc. 2008, 130, 12645; (f) B. Saito, G. 
C. Fu, J. Am. Chem. Soc. 2008, 130, 6694; (g) X. Dai, N. A. Strotman, G. C. Fu, J. Am. Chem. Soc. 2008, 130, 3302; 
(h) S. Son, G. C. Fu, J. Am. Chem. Soc. 2008, 130, 2756; (i) C. Fischer, G. C. Fu, J. Am. Chem. Soc. 2005, 127, 
4594. 
39 H. Gong, M. R. Gagné, J. Am. Chem. Soc. 2008, 130, 12177. 
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Further diastereoselective cross-couplings with cyclic secondary alkyl halides (18 and 19) 
catalyzed either by Fe or Co were reported by M. Nakamura, E. Nakamura, A. Fürstner and K. 
Oshima (Scheme 13).40, 41, 42  
 
 
Scheme 13: Rare examples of diastereoselective Fe- and Co-catalyzed cross-coupling of 
secondary alkyl halides. 
 
Diastereoselective Pd-catalyzed cross-coupling of this type has so far only been achieved for 
secondary bromo sulfoxides (20) using organoboronic acids as nucleophiles (Scheme 14).43  
 
 
Scheme 14: Diastereoselective Pd-catalyzed Suzuki-cross-coupling with secondary bromo 
sulfoxides. 
                                                 
40 (a) M. Nakamura, K. Matsuo, S. Ito, E. Nakamura, J. Am. Chem. Soc. 2004, 126, 3686; (b) M. Nakamura, S. Ito, 
K. Matsuo, E. Nakamura, Synlett 2005, 1794; 
41 A. Fürstner, R. Martin, H. Krause, G. Seidel, R. Goddard, C. W. Lehmann, J. Am. Chem. Soc. 2008, 130, 8773. 
42 H. Ohmiya, H. Yorimitsu, K. Oshima, J. Am. Chem. Soc. 2006, 128, 1886. 
43 N. Rodríguez, C. Ramírez de Arellano, G. Asensio, M. Medio-Simon, Chem. Eur. J. 2007, 13, 4223. 
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Interestingly, the reaction proceeds stereospecifically with inversion of configuration. When a 
mixture of the diastereomeric bromo-sulfoxides cis-20 and trans-20 was subjected to cross-
coupling with phenylboronic acid, only the diastereomer cis-20 was transformed in the cross-
coupling reaction leading to trans-21. Diastereomer trans-20 remained unaffected under these 
reaction conditions. Thus, this reaction is not stereoconvergent as the examples mentioned above 
and therefore requires diastereomerically pure substrates for complete conversion. The authors 
propose that the inversion occurs during the oxidative addition of the bromo sulfoxide to the Pd0 
center and that the reductive elimination step proceeds with retention of configuration.44 
                                                 
44 C. Gourlaouen, G. Ujaque, A. Lledós, M. Medio-Simon, G. Asensio, F. Maseras, J. Org. Chem. 2009, 74, 4049. 
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3.3 Stereoselective cross-couplings using secondary alkylmagnesium and –zinc 
reagents 
Enantioselective Ni- and Pd-catalyzed cross-coupling reactions of secondary alkylmagnesium 
reagents have already been known since the 1970s.13b In their groundbreaking studies, M. 
Kumada and T. Hayashi successfully subjected 1-phenylethylmagnesium chloride (22) to 
asymmetric cross-couplings with vinyl bromide using NiCl2 and PdCl2 in association with 
various optically active phosphine ligands (23-27; Scheme 15).45  
 
Fe PPh2
Me
NMe2
24
Ph
Me
MgCl
22
Br
[Ni] or [Pd] (cat.)
L* (cat.)
Ph
Me
*
Fe PPh2
Et
23
PPh2Me2N
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PPh2Me2N
Bn
26
PPh2Me2N
tBu
27
86%; 5% ee
95%; 65% ee
95%; 65% ee
95%; 38% ee
53%; 5% ee
95%; 71% ee
83%; 55% ee
95%; 83% ee
NiCl2, 23:
NiCl2, 24:
PdCl2, 24:
NiCl2, 25:
PdCl2, 25:
NiCl2, 26:
PdCl2, 26:
NiCl2, 27:
28
 
Scheme 15: Enantioselective cross-coupling of phenylethylmagnesium halides 22 with 
different chiral Ni- and Pd-catalysts. 
 
Product 28 was obtained with varying degrees of enantiomeric excess. Thereby, it was found that 
bulky phosphine ligands with a (dialkylamino)alkyl group as second coordinating functionality 
(24, 26-27) were most effective for both Ni- and Pd-catalyzed cross-couplings of 22 in terms of 
enantioselectivity. The use of 1-phenylethylzinc reagents (29a-b) in place of 22 was shown to 
increase the stereoselectivity (Scheme 16).46 
 
                                                 
45 (a) T. Hayashi, M. Tajika, K. Tamao, M. Kumada, J. Am. Chem. Soc. 1976, 98, 3718; (b) T. Hayashi, M. Konishi, 
M. Fukushima, T. Mise, M. Kagotani, M. Tajika, M. Kumada, J. Am. Chem. Soc. 1982, 104, 180; (c) T. Hayashi, M. 
Fukushima, M. Konishi, M. Kumada, Tetrahedron Lett. 1980, 21, 79; (d) T. Hayashi, M. Konishi, M. Fukushima, K. 
Kanehira, T. Hioki, M. Kuamada, J. Org. Chem. 1983, 48, 2195. 
46 (a) T. Hayashi, T. Hagihara, Y. Katsuro, M. Kumada, Bull. Chem. Soc. Jpn. 1983, 56, 363; (b) T. Hayashi, A. 
Yamamoto, M. Hojo, Y. Ito, J. Chem. Soc. Chem. Commun. 1989, 495; (c) T. Hayashi, A. Yamamoto, M. Hojo, K. 
Kishi, Y. Ito, E. Nishioka, H. Miura, K. Yanagi, J. Organomet. Chem. 1989, 370, 129. 
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Scheme 16: Enantioselective cross-coupling of phenylethylmagnesium and –zinc halides 22 
and 29a-b. 
 
Thus, asymmetric cross-coupling of 29a prepared from 22 via transmetalation with ZnCl2 
provided the olefin 28 in >70% yield with 85-86% ee. Reagent 29b obtained via the insertion of 
zinc metal to 1-phenylethylbromide 30 gave 28 with equal enantioselectivity, though the reaction 
was considerably slower (70 h vs. 40 h). Enantiocontrol in these cross-coupling reactions is 
exerted by a dynamic kinetic resolution (DKR) of the racemic alkylmagnesium and –zinc 
compounds during the transmetalation to the chiral Pd- or Ni-catalyst (Scheme 17).47 
 
 
Scheme 17: Dynamic kinetic resolution of the secondary alkyl organometallics in the 
enantioselective cross-coupling. 
 
Due to the relatively labile carbon-metal bond, the enantiomeric organometallic species are in a 
constant equilibrium. The enantiomer which is compatible with the chiral catalyst reacts 
preferentially and is withdrawn from the equilibrium enabling a full conversion of the racemic 
reagent. Thus, the higher configurational stability of C-Zn towards C-Mg bonds explains the 
longer reaction times for the enantioselective cross-coupling of 29a-b. This enantioselective 
                                                 
47 T. Hayashi in Asymmetric Synthesis ‒ The Essentials (Eds.: M. Christmann, S. Bräse), Wiley-VCH, 2007, 90. 
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cross-coupling could also be applied to 1-(trialkylsilyl)benzyl- and –ethylmagnesium chlorides.48 
Stereoconvergent diastereoselective cross-coupling reactions are scarcely reported in the 
literature. A rare example is the Ni-catalyzed stereoconvergent coupling between tropan-3-ylzinc 
bromide (31) and aryl halides that resulted in an exclusive formation of the exo-diastereomers 
(32) (Scheme 18).49 
 
 
Scheme 18: Ni-catalyzed stereoconvergent coupling of 31 with aryl halides. 
 
A further report on diastereoselective cross-coupling reactions using organozinc reagents is based 
on hydroboration and subsequent B-Zn exchange.50 Here, the authors suggested that the 
stereoselectivity is introduced by the stereodefined hydroboration, i.e. via syn-addition of HBEt2 
to the C=C bond. B-Zn exchange using ZniPr2 was assumed to proceed with retention of 
configuration and to furnish configurationally stable carbon-zinc compounds (33-34). 
 
 
Scheme 19: Diastereoselective hydroboration/B-Zn exchange/cross-coupling sequence. 
 
                                                 
48 (a) T. Hayashi, M. Konishi, H. Ito, M. Kumada, J. Am. Chem. Soc. 1982, 104, 4962; (b) T. Hayashi, M. Konishi, 
Y. Okamoto, K. Kabeta, M. Kumada, J. Org. Chem. 1986, 51, 3772; (c) T. Hayashi, Y. Okamoto, M. Kumada, 
Tetrahedron Lett. 1983, 24, 807. 
49 L. Melzig, A. Gavryushin, P. Knochel, Org. Lett. 2007, 9, 5529. 
50 A. Boudier, P. Knochel, Tetrahedron Lett. 1999, 40, 687. 
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Subsequent Pd-catalyzed cross-coupling and acylation occurred with no alteration of the 
stereoconfiguration leading to the expected trans-products (Scheme 19). Stereoselective product 
formation was observed for both cyclic and open-chain secondary organozinc compounds. 
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4. Objectives 
 
This work is divided into two main parts: 
  
1.  Enantiocontrol with chiral sulfoxides 
2. Diastereocontrol in the cross-couplings of substituted cycloalkyl and piperidinyl 
derivatives 
 
In the first part, the unique properties of the chiral sulfinyl group, i.e. strong polarity, central 
chirality, simple integration and removal, should be used to achieve a new, more straightforward 
synthesis and resolution of chiral QUINAP, one of the most successful P,N-ligands in 
asymmetric catalysis (Scheme 20).51 
 
 
Scheme 20: Chiral QUINAP ‒ one of the most successful P,N-ligands in asymmetric catalysis. 
 
QUINAP has an atropisomeric backbone and its chirality originates from the hindered rotation 
between the two naphthyl-type moieties. The carbon-carbon linkage between these moieties 
represents a relatively flexible chiral axis which allows optimal adjustment in the formation of a 
complex with the respective metal and thus makes it a valuable ligand to a broad range of 
transition-metals.51 Up to now, the synthesis of chiral QUINAP is difficult and costly as it is 
                                                 
51 (a) J. M. Brown, D. I. Hulmes, T. P. Layzell, J. Chem. Soc., Chem. Commun. 1993, 1673; (b) E. Fernandez, K. 
Maeda, M. W. Hooper, J. M. Brown, Chem. Eur. J. 2000, 6, 1840; (c) S. Trudeau, J. B. Morgan, M. Shrestha, J. P. 
Morken, J. Org. Chem. 2005, 70, 9538; (d) J. M. Brown, D. I. Hulmes, P. J. Guiry, Tetrahedron 1994, 50, 4493; (e) 
J. W. Faller, B. J. Grimmond, Organometallics 2001, 20, 2454; (f) C. Chen, X. Li, S. L. Schreiber, J. Am. Chem. 
Soc. 2003, 125, 10174; (g) X. Li, L. Kong, Y. Gao, X. Wang, Tetrahedron Lett. 2007, 48, 3915; (h) C. Koradin, K. 
Polborn, P. Knochel, Angew. Chem.. Int. Ed. 2002, 41, 2535; (i) C. Koradin, N. Gommermann, K. Polborn, P. 
Knochel, Chem. Eur. J. 2003, 9, 2797; (j) N. Gommermann, P. Knochel, Tetrahedron 2005, 61, 11418; (k) A. M. 
Taylor, S. L. Schreiber, Org. Lett. 2006, 8, 143; (l) T. Miura, M. Yamauchi, A. Kosaka, M. Murakami, Angew. 
Chem. Int. Ed. 2010, 49, 4955. 
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based on the use of stoichiometric amounts of PdCl2.
52 A cheaper method for its resolution is 
therefore highly desirable. 
 
Chiral bissulfoxides have proved as efficient ligands in the Rh-catalyzed asymmetric Hayashi-
Miyaura reaction.30, 31 We envisioned the design of a new ligand class, chiral sulfoxide-alkene 
hybrids of type 35, for this type of reaction (Scheme 21). These ligands are assumed to combine 
the advantages of both sulfoxide (easy preparation and resolution, strong coordination to Rh) and 
olefin ligands (strong influence of the chiral environment around the C=C bond on 
enantioselectivity). A concise synthesis of these ligands was to be designed and the ligands 
should be tested on their efficiency in the asymmetric Rh-catalyzed 1,4-addition to (hetero)cyclic 
enones. 
 
 
Scheme 21: Sulfoxide-alkene hybrids ‒ a new class of chiral ligands for the Hayashi-Miyaura 
reaction? 
 
The second part of this thesis deals with diastereocontrol in the cross-coupling reactions of 
substituted cycloalkyl and piperidinyl derivatives. The Pd-catalyzed cross-couplings of various 
substituted cycloalkylzinc reagents with aryl halides and bromoalkynes were tested on 
diastereocontrol and stereoconvergence (Scheme 22). 
 
 
Scheme 22: Diastereocontrol and stereoconvergence in the Pd-catalyzed cross-couplings of 
substituted cycloalkylzinc reagents? 
                                                 
52 C. W. Lim, O. Tissot, A. Mattison, M. W. Hooper, J. M. Brown, A. R. Cowley, D. I. Hulmes, A. J. Blacker, Org. 
Proc. Res. & Dev. 2003, 7, 379. 
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Mechanistic aspects, limits and scope of these cross-coupling reactions were to be examined. 
Thereby, the Pd-catalyzed Csp3-Csp2/Csp-coupling approach using substituted cycloalkylzinc 
reagents should be complemented with a diastereoselective Csp2-Csp3 cross-coupling of cyclic 
iodohydrine derivatives enabling the synthesis of molecules of type 36 which are not accessible 
by the former method (Scheme 23). 
 
 
 
Scheme 23: Designing a synthesis for 2-arylated cycloalcohol derivatives of type 36. 
 
Finally the diastereoselective Pd-catalyzed cross-coupling was to be extended to various 
piperidinylzinc compounds (37; Scheme 24). 
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Scheme 24: Diastereocontrol and stereoconvergence in the Pd-catalyzed cross-couplings of 
substituted cycloalkylzinc reagents? 
 
Piperidines constitute a pharmaceutically highly significant substance class.53 Broadening the 
scope of their stereoselective preparation is therefore a highly important synthetic task. 
 
                                                 
53 (a) C. de Risi, G. Fanton, G. P. Pollini, C. Trapella, F. Valente, V. Zanirato, Tetrahedron: Asymmetry 2008, 19, 
131; (b) C. Escolano, M. Amat, J. Bosch, Chem. Eur. J. 2006, 12, 8198; (c) M. G. P. Buffat, Tetrahedron 2004, 60, 
1701; (d) F.-X. Felpin, J. Lebreton, Eur. J. Org. Chem. 2003, 3693; (e) S. Laschat, T. Dickner, Synthesis 2000, 1781; 
(f) P. D. Bailey, P. A. Millwood, P. D. Smith, Chem. Commun. 1998, 633. 
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1. Enantiocontrol with Chiral Sulfoxides 
1.1 A Novel Synthetic Approach towards Chiral QUINAP via Diastereomeric Sulfoxide 
Intermediates 
1.1.1 Introduction 
Since its discovery by J. M. Brown et al.54 QUINAP has become one of the most outstanding 
chiral P,N-ligands. Its flexible chiral axis allows optimal adjustment in the formation of 
complexes with various metal salts. Thus, QUINAP has proved to be an excellent ligand for Pd, 
Ag, Cu, Ni, Ru, Rh and Ir permitting its use in a large number of asymmetric reactions, including 
hydro-51a-b and diboration,51c allylic alkylation,51d Diels-Alder reactions,51e [3+2]-
cycloadditions,51f hydrogenation of olefins51g and Cu(I)-catalyzed synthesis of 
propargylamines51h-k. Analogues of QUINAP based on pyridine55 and quinazoline56 could also be 
successfully used as chiral ligands in many asymmetric reactions. 
However, the preparation of chiral QUINAP and its derivatives, with the exception of E. M. 
Carreira’s PINAP,57 remains costly and difficult, as it is based on chiral resolution via 
diastereomeric cyclopalladated complexes formed with stoichiometric amounts of a complex of 
PdCl2 and (R)-(+)-dimethyl[1-(1-naphthyl)ethyl]amine (38; Scheme 25).52 
 
 
Scheme 25: Costly chiral resolution of QUINAP with stoichiometric amounts of PdCl2. 
 
                                                 
54 (a) N. W. Alcock, , J. M. Brown, D. I. Hulmes, Tetrahedron: Asymmetry 1993, 4, 743; for QUINAP derivatives 
see: (b) J. M. Valk, T. D. W. Claridge, J. M. Brown, Tetrahedron: Asymmetry 1995, 6, 2597; (c) H. Doucet, J. M. 
Brown, Tetrahedron: Asymmetry 1997, 8, 3775. 
55 F. Y. Kwong, Q. Yang, T. C. W. Mak, A. S. C. Chan, K. S. Chan, J. Org. Chem. 2002, 67, 2769. 
56 (a) D. J. Connolly, P. M. Lacey, M. McCarthy, C. P. Saunders, A.-M. Carroll, R. Goddard, P. J. Guiry, J. Org. 
Chem. 2004, 69, 6572; (b) M. McCarthy, P. J. Guiry, Tetrahedron 1999, 55, 3061; (c) P. M. Lacey, C. M. 
McDonnell, P. J. Guiry, Tetrahedron Lett. 2000, 41, 2475. 
57 T. F. Knöpfel, P. Aschwanden, T. Ichikawa, T. Watanabe, E. M. Carreira, Angew. Chem. Int. Ed. 2004, 43, 5971. 
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An attempt to obtain chiral 1-(2-methoxy-1-naphthyl)isoquinoline (39), a key intermediate in the 
QUINAP synthesis, via a sulfoxide ligand coupling reaction resulted in only low enantiomeric 
purity (14% ee; Scheme 26).58  
 
 
Scheme 26: Synthesis of 39, a key intermediate in the present QUINAP synthesis with 
insufficient enantiomeric excess. 
 
A more practical and efficient stereoselective synthesis of this important ligand is therefore 
highly desirable. 
 
1.1.2 Novel synthesis and chiral resolution of QUINAP via chiral diastereomeric sulfoxide 
intermediates 
We conceived a novel more expedient approach towards the synthesis of chiral QUINAP by 
resolution via simple chromatographic separation of diastereomeric sulfoxide intermediates: 
J. Clayden et al. have demonstrated that enantiopure sulfoxides are suited as useful intermediates 
for the chiral resolution of atropisomers.21b-d The diastereomeric character of the resulting 
molecule permits separation and the sulfoxide group can be easily exchanged with organolithium 
reagents.21b Therefore, we wondered, whether this method could also be applied to the resolution 
of QUINAP in a new synthetic approach. 
First, the preparation of key intermediate 40 was envisaged (Scheme 27). The bromo-substituent 
in 40 allows a convenient access to the 2’-position, as it can be easily subjected to halogen-metal 
exchange reactions. 2-Bromo-1-iodonaphthalene (41), which was prepared in two steps from 1-
naphthylamine via Zr(IV)-catalyzed bromination with NBS59 and a subsequent diazotation 
reaction60, was chosen as synthon for the naphthyl moiety. It was found to selectively undergo 
iodine-magnesium exchange with iPrMgCl·LiCl at -78 °C without elimination of the adjacent 
                                                 
58 R. W. Baker, S. O. Rea, M. V. Sargent, E. M. C. Schenkelaars, T. S. Tjahjandarie, A. Totaro, Tetrahedron 2005, 
61, 3733. 
59 Y. Zhang, K. Shibatomi, H. Yamamoto, Synlett 2005, 2837. 
60 H. H. Hodgson, D. E. Hathway, J. Chem. Soc. 1944, 538. 
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bromide. After transmetalation with ZnCl2 it was used as nucleophile in a Negishi-type cross-
coupling reaction33b with 1-iodoisoquinoline 42 which was obtained via simple deprotonation of 
isoquinoline and subsequent trapping with iodine.61 
 
N
Br
40: 74%
I
Br
1) iPrMgCl.LiCl, THF -78°C
2) ZnCl2, -78°C to rt
3)
N
I
Pd(dba)2 (5 mol%)
(o-furyl)3P (10 mol%)
THF, 60°C
41 42
 
Scheme 27: Preparation of 1-(2-bromo-1-naphthyl)isoquinoline (40). 
 
Compound 40 was obtained with 74% yield and subjected to a bromine-lithium exchange with 
tBuLi (2.0 equiv, Et2O, ‒78°C, 30 min). The resulting organolithium species was carefully 
reacted with (‒)-menthyl (S)-p-toluenesulfinate 1 (Andersen-sulfinate)18 at -78 °C. In order to 
preserve the configurational stability of the sulfoxide group, maintenance of this low temperature 
was crucial. To our delight, the resulting QUIN-sulfoxide intermediates 43 and 44 were obtained 
in excellent yields and could be easily separated via column chromatography (Scheme 28).62  
 
 
Scheme 28: Novel resolution via the chiral sulfoxide intermediates 43 and 44. 
                                                 
61 A. Krasovskiy, V. Krasovskaya, P. Knochel, Angew.Chem. Int. Ed. 2006, 45, 2958. 
62 For purification and separation of the two sulfoxide diastereomers the crude product was subjected to column 
chromatography with Florisil® (60-100 mesh). 44 was eluated with Et2O/n-pentane 4:1. 43 was eluated with 
Et2O/acetone 2:1. 
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Alternatively, transmetalation to MgCl2 prior to the reaction with sulfinate 1 allowed the 
preparation of 43 and 44 with no loss of enantioselectivity (99% ee). Synthetic intermediates 43 
and 44 were then subjected to a sulfoxide-lithium exchange reaction. Phenyllithium was chosen 
as exchange reagent, since it is known to minimize unwanted deprotonation of the diphenyl 
sulfoxide byproduct.63 The reaction was carried out at ‒78°C (15 min) to ensure the 
atropisomeric stability of the intermediate chiral organolithium species. Quenching with Ph2PCl 
and subsequent protection with sulfur afforded (S)-45 and (R)-45 with 60% and 63% yield 
(Scheme 29). Although QUINAP proved stable towards air and moisture during work-up, sulfur-
protection was chosen to simplify purification by column chromatography. Subsequent 
desulfurisation with Raney-Ni gave (S)- and (R)-QUINAP in 95% yield respectively.64 
 
 
Scheme 29: Sulfoxide-lithium exchange and QUINAP synthesis. 
 
                                                 
63 R. J. Kloetzing, P. Knochel, Tetrahedron: Asymmetry 2006, 17, 116. 
64 D. Liu, Q. Dai, X. Zhang, Tetrahedron 2005, 61, 6460. 
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1.2 Sulfoxide-alkene hybrids: A new class of chiral ligands for the Hayashi-Miyaura 
reaction 
1.2.1 Introduction 
The Rh-catalyzed 1,4-addition of organoboronic acids to enones, also known as the Hayashi-
Miyaura reaction,29 has been well established as an important and versatile tool for the 
enantioselective formation of C-C bonds in modern asymmetric synthesis.65 Chiral dienes66 and 
most recently chiral bissulfoxides30, 31 have proved very effective for the induction of high levels 
of enantioselectivity in this type of reaction. The outstanding successes of these novel ligand 
classes and the easy preparation17 and resolution of chiral diastereomeric sulfoxides, which can 
be achieved via simple column chromatographic separation,21, 67 led us to envision novel modular 
hybrid ligands of type 35 that combine both alkenes and sulfoxides as coordinative elements 
(Scheme 30). So far, tert-butylsulfinylphosphines of type 12 (Scheme 10)32 represent the only 
class of chiral sulfoxide-based hybrid ligands employed in the Hayashi-Miyaura reaction. Alkene 
hybrid ligands for this reaction are restricted to either phosphorus68 or nitrogen69 as second 
coordinating moiety. 
 
                                                 
65 For selected reviews see: (a) N. Miyaura, Bull. Chem. Soc. Jpn. 2008, 81, 1535; (b) T. Hayashi, Russ. Chem. Bull. 
2003, 52, 2595; (c) T. Hayashi, Synlett 2001, 879. 
66 Reviews: (a) R. Shintani, T. Hayashi, Aldrichim. Acta 2009, 42, 31; (b) C. Defieber, H. Grützmacher, E. M. 
Carreira, Angew. Chem. Int. Ed. 2008, 47, 4482; (c) F. Glorius, Angew. Chem. Int. Ed. 2004, 6, 3873; articles: (d) Y. 
Luo, A. J. Carnell, Angew. Chem. Int. Ed. 2010, 49, 2750; (e) X. Hu, Z. Cao, Z. Liu, Y. Wang, H. Du, Adv. Synth. 
Catal. 2010, 352, 651; ((f) Y. Wang, X. Hu, H. Du, Org. Lett. 2010, 12, 5482; (g) Z.-Q. Wang, C.-G. Feng, S.-S. 
Zhang, M.-H. Xu, G.-Q. Lin, Angew. Chem. Int. Ed. 2010, 49, 5780; (h) T. Gendrineau, J.-P. Genet, S. Darses, Org. 
Lett. 2009, 11, 3486; (i) R. Shintani, Y. Ichikawa, K. Takatsu, F.-X. Chen, T. Hayashi, J. Org. Chem. 2009, 74, 869; 
(j) R. Shintani, Y. Tsutsumi, M. Nagaosa, T. Nishimura, T. Hayashi, J. Am. Chem. Soc. 2009, 131, 13588; (k) X. Hu, 
M. Zhuang, Z. Cao, H. Du, Org. Lett. 2009, 11, 4744; (l) T. Gendrineau, O. Chuzel, H. Eijsberg, J.-P. Genet, S. 
Darses, Angew. Chem. Int. Ed. 2008, 47, 7669; (m) K. Okamoto, T. Hayashi, V. H. Rawal, Org. Lett. 2008, 10, 4387; 
(n) S. Sörgel, N. Tokunaga, K. Sasaki, K. Okamoto, T. Hayashi, Org. Lett. 2008, 10, 589; (o) C.-G. Feng, Z.-Q. 
Wang, C. Shao, M.-H. Xu, G.-Q. Lin, Org. Lett. 2008, 10, 4101; (p) C.-G. Feng, Z.-Q. Wang, P. Tian, M.-H. Xu, G.-
Q. Lin, Chem. Asian J. 2008, 3, 1511; (q) S. Helbig, S. Sauer, N. Cramer, S. Laschat, A. Baro, W. Frey, Adv. Synth. 
Catal. 2007, 349, 2331; (r) G. Berthon-Gelloz, T. Hayashi, J. Org. Chem. 2006, 71, 8957; (s) Y. Otomaru, A. Kina, 
R. Shintani, T. Hayashi, Tetrahedron: Asymmetry 2005, 16, 1673; (t) Y. Otomaru, K. Okamoto, R. Shintani, T. 
Hayashi, J. Org. Chem. 2005, 70, 2503; (u) C. Defieber, J.-F. Paquin, S. Serna, E. M. Carreira, Org. Lett. 2004, 6, 
3873; (v) T. Hayashi, K. Ueyama, N. Tokunaga, K. Yoshida, J. Am. Chem. Soc. 2003, 125, 11508. 
67 T. Thaler, F. Geittner, P. Knochel, Synlett 2007, 2655. 
68 (a) E. Drinkel, A. Briceño, R. Dorta, R. Dorta, Organometallics 2010, 29, 2503; (b) H. Grugel, T. Minuth, M. M. 
K. Boysen, Synthesis 2010, 3248; (c) T. Minuth, M. M. K. Boysen, Org. Lett. 2009, 11, 4212; (d) R. Mariz, A. 
Briceño, R. Dorta, R. Dorta, Organometallics 2008, 27, 6605; (e) W.-L. Duan, H. Iwamura, R. Shintani, T. Hayashi, 
J. Am. Chem. Soc. 2007, 129, 2130; (f) R. T. Stemmler, C. Bolm, Synlett 2007, 1365; (g) P. Kasák, V. B. Arion, M. 
Widhalm, Tetrahedron: Asymmetry 2006, 17, 3084; (h) E. Piras, F. Läng, H. Rüegger, D. Stein, M. Wörle, H. 
Grützmacher, Chem. Eur. J. 2006, 12, 5849; (i) R. Shintani, W.-L. Duan, T. Nagano, A. Okada, T. Hayashi, Angew. 
Chem. Int. Ed. 2005, 44, 4611. 
69 B. T. Hahn, F. Tewes, R. Fröhlich, F. Glorius, Angew. Chem. Int. Ed. 2010, 49, 1143. 
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Scheme 30: Chiral heterodentate ligands comprising the unique properties of sulfoxides and C=C 
bonds. 
 
Thus, this is the first synthesis of chiral sulfoxide-alkene hybrid ligands for the Hayashi-Miyaura 
reaction allowing a direct comparative study on the relative influences of the alkenyl and sulfinyl 
group on the reactivity and enantioselectivity of the Rh-catalyst. 
 
1.2.2 Synthesis and resolution of the new sulfoxide-alkene hybrids 
Inspired by Hayashi’s well-studied phosphorus-olefin hybrid ligand,68e,i we designed the 
straightforward, protective-group free synthesis of 46a and 46b from norbornene (47) within only 
four steps (Scheme 31).  
Br
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Scheme 31: Protective-group free synthesis and simple chiral resolution of the sulfoxide-
alkene hybrid ligands 46a and 46b. 
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Reaction of 47 with NBS in H2O and subsequent Swern-oxidation68e,i furnished bromoketone 48 
in 55% yield. LaCl3·2 LiCl-mediated addition
70 of 4-anisylmagnesium bromide to 48 followed by 
acidic elimination of H2O using MsOH (methanesulfonic acid) directly gave the racemic alkene 
49 with 67% overall yield without unnecessary protection-deprotection sequences. Br/Li-
exchange on 49 using tBuLi, subsequent transmetalation with MgCl2 and quenching with the 
easily available (‒)-menthyl (S)-p-toluene sulfinate (1; Andersen-sulfinate)18 furnished the two 
diastereomeric ligands 46a and 46b with 72% yield and 99% ee71 which could be easily separated 
via column chromatographic purification.72 This feature represents a preparative advantage 
towards the related phosphine-olefin hybrid ligands reported by Hayashi et al. which have to be 
resolved via preparative chiral HPLC.68e,i 1H and 13C NMR experiments on the Rh complex of 
46b obtained by reacting it with 0.5 equivalents of [(ethylene)2RhCl]2 in d8-1,4-dioxane clearly 
proved coordination of both the alkene and the sulfoxide moiety to the Rh atom with the signals 
for the respective C-atoms shifted upfield and split into doublets.[73] 
 
1.2.3 Use as chiral ligands in the Hayashi-Miyaura reaction 
In order to test the efficacy and scope of 46a as chiral ligand in the Hayashi-Miyaura reaction, 
we prepared the Rh-complex 50a by treating 46a with 0.5 equivalents of [(coe)2RhCl]2 (51) 74 
and a stoichiometric amount of CsOH·H2O in 1,4-dioxane and water. The resulting in situ formed 
catalyst 50a (2.5 mol%) was then directly used without isolation in the 1,4-addition reactions of 
various aryl- and alkenylboronic acids to cyclic α,β-unsaturated carbonyl compounds (Table 1). 
The expected chiral addition products 52-54 were obtained in 61-99% yield and with high 
enantioselectivities (82-97% ee) using only a slight excess of the respective organoboronic acid 
(1.2 equiv). The addition of arylboronic acids to cyclohex-2-enone typically proceeded with 
enantioselectivities between 90-93% ee. The (S)-configured products were obtained 
preferentially.75 Lower stereoselectivities were observed with sterically more demanding (52c; 
89% ee; entry 3 of Table 1) or electron-rich arylboronic acids (52f; 88% ee and 52i; 82% ee; 
entries 6 and 9). 
 
                                                 
70 A. Krasovskiy, F. Kopp, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 497. 
71 Transmetalation with MgCl2 prior to reaction with the sulfinate was necessary to prevent epimerization at the 
chiral sulfur center. 
72 Flash column chromatography: SiO2, CH2Cl2/EtOAc 2:1. 
73 See experimental section for details. 
74 A. van der Ent, A. L. Onderdelinden, Inorg. Synth. 1990, 28, 90. 
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Table 1: Enantioselective 1,4-addition of organoboronic acids to various electron-deficient 
alkenes using 46a as chiral ligand. 
 
Entry  Product Yield [%]a ee [%]b (conf.)c 
    
 
1 
 
 
 
52a: R=Ph 98 92 
2 52b: R=2-Et-C6H4 99 92 
3 52c: R=1-naphthyl 96 89 (S) 
4 52d: R=2-MeO-C6H4 90 90 
5 52e: R=2-F-C6H4 88 90 
6 52f: R=2,3-CH2O2-C6H3 86 88 
7 52g: R=3-MeO-C6H4 93 90 
8 52h: R=3-Cl-C6H4 90 90 
9 52i: R=4-MeO-C6H4 85 82 (S) 
10 52j: R=4-PhO-C6H4 90 93 
11 52k: R=4-Cl-C6H4 84 93 
12 52l: R=4-F-C6H4 89 92 
13 52m: R=4-F3C-C6H4 80 93 
14 52n: R=(E)-PhCH=CH 66 95 
15 52o: R=(E)-4-MeC6H4CH=CH 61 92 
     
16 
 
 
 
53a: R=Ph 85 97 (S) 
17 53b: R=1-naphthyl 99 94 
18 53c: R=2-MeO-C6H4 96 96 
19 53d: R=3-Cl-C6H4 99 96 
20 53e: R=4-MeO-C6H4 88 94 
21 53f: R=4-Me-C6H4 92 96 
22 53g: R=4-Cl-C6H4 99 96 
23 53h: R=4-F3C-C6H4 93 97 
24 53i: R=(E)-PhCH=CH 94 95 
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Table 1 continued 
 
 
 
 
 
   
25 54a: R=Ph 84 88
d (S) 
26 54b: R=4-MeO-C6H4 88 92
d (S) 
27 54c: R=3,5-Me2-C6H3 85 97
d (S) 
 
   
[a] Isolated yield of analytically pure product. [b] Determined via chiral HPLC analysis. See appendix for details. [c] 
Absolute configurations determined by comparison to chiral HPLC data reported in the literature.[75] [d] Reaction 
time: 12 h. Compound racemizes upon storage at room temperature. 
The reactions of (E)-styryl- and (E)-4-methylstyrylboronic acid with cyclohex-2-enone gave the 
chiral products 52n-o with decreased yields of 61-66% and high enantiomeric excesses (92-95% 
ee; entries 14-15). With cyclopent-2-enone as substrate, excellent yields and even higher 
enantioselectivities were achieved (53a-i; 94-97% ee; entries 16-24). In this case, switching from 
aryl- to alkenylboronic acids did not result in a deterioration of the yield (53i; entry 24). The use 
of N-benzyl maleimide as substrate led to the chiral (S)-configured addition products 54a-c with 
good yields (84-88%) and high enantioselectivities (88-97% ee; entries 25-27). 
Next, we examined diastereomeric 46b on its performance as chiral ligand in the Rh-catalyzed 
Hayashi-Miyaura reaction (Table 2). To our delight, we found that the corresponding 1,4-adducts 
were produced with equally high enantioselectivities and yields (79-92%; 90-99% ee), when 50b 
was used as chiral catalyst. Remarkably, the absolute configurations of the products were 
opposite to those obtained with 46a clearly hinting at a predominant stereocontrol through the 
chiral environment around the alkenyl moiety. Moreover, the addition of phenylboronic acid to 
heterocyclic Cbz-protected 2,3-dihydropyridin-4(1H)-one furnished 58 with 92% yield and an 
outstanding enantioselectivity of 99% ee (entry 9). 
                                                 
75 Comparison with HPLC data from 66d, 66o, 30b and 68i. 
 
B. Results and Discussion  34 
Table 2: Enantioselective 1,4-addition of organoboronic acids to various electron-deficient 
alkenes using 46b as chiral ligand. 
 
Entry  Product Yield [%]a ee [%]b (conf.)c 
    
 
1 
 
 
 
 
55a: R=Ph 87 92 
2 55b: R=1-naphthyl 92 92 (R) 
3 55c: R=4-MeO-C6H4 82 92 (R) 
4 55d: R=4-F3C-C6H4 85 90 
 
 
 
 
 
 
   
5 56a: R=1-naphthyl 82 96 
6 56b: R=4-Cl-C6H4 79 93 
7 56c: R=4-F3C-C6H4 83 95 
 
   
 
 
 
 
 
   
 
   
8 57: R=3,5-Me2-C6H3 80 96
d (R) 
 
   
 
 
 
 
 
 
 
   
 
   
 
   
9 58: R=Ph 92 99
e 
 
   
 
   
 
   
[a] Isolated yield of analytically pure product. [b] Determined via chiral HPLC analysis. See appendix for details. [c] 
Absolute configurations determined by comparison to chiral HPLC data reported in the literature.75 [d] Reaction 
time: 12 h. Compound racemizes upon storage at room temperature. [e] Reaction time: 12 h. 
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1.2.4 Rationale for the observed stereochemical outcome 
In order to rationalize the opposed stereochemical outcomes obtained with the diastereomeric 
ligands 46a and 46b, we propose the following model (Scheme 32): Since sulfinyl groups are 
known to be strong σ-donors to Rh,30a trans-configuration of the aryl group and the alkene 
moiety of the ligand in the complex can be assumed as it is reported for the related phosphine-
olefin hybrid ligands.68e 
 
 
Scheme 32: Stereochemical model explaining the opposite configurations of the addition 
products obtained with 46a and 46b. 
 
The stereoselectivity is controlled by the chiral environment around the alkenyl unit which forces 
the substrate, e.g. cyclohex-2-enone, via steric interactions to bind to the Rh-complex with its αsi 
face in the case of 46a and with its αre face in the case of 46b. Despite a strong coordination of 
the sulfinyl group to Rh the central chirality at the sulfur has only a minor influence on the 
observed enantioselectivities. 
 
1.2.5 Influence of steric and electronic modulations at the ligand 
Finally, we examined the influence of electronic and steric modulations at the sulfoxide-olefin 
hybrid ligand on reactivity and enantioselectivity of the Rh-complex in the Hayashi-Miyaura 
reaction. For this purpose, we prepared the analogues 59a-c bearing different sulfinyl moieties 
using subsequent addition of the corresponding Grignard reagents to (S)-TMPOO (2; Scheme 
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5).19 To investigate the role of the alkenyl moiety, we synthesized 60 with a more electron-rich 4-
dimethylaniline substituent at the C=C double bond (Table 3). These ligands were then applied to 
the Rh-catalyzed 1,4-addition of various arylboronic acids to cyclohexen-2-one (Table 3). Both 
increasing and reducing the electron-density at the sulfoxide (59a-b) led to an overall 
deterioration of yield and enantioselectivity (entries 1-7). 
  
Table 3: Enantioselective 1,4-addition to cyclohex-2-enone using analogues 59a-c and 60. 
 
Entry Ligand Product Yield [%]a ee [%]b 
 
 
 
 
 
 
 
 
 
 
59a 
   
 
   
1 61a: R=4-MeO-C6H4 57 83 
2 61b: R=4-Me-C6H4 63 88 
3 61c: R=Ph 69 81 
4 61d: R=4-F-C6H4 73 90 
    
    
  
 
 
 
 
 
 
 
 
59b 
   
    
5 62a: R=4-MeO-C6H4 77 84 
6 62b: R=Ph 84 86 
7 62c: R=4-F3C-C6H4 83 91 
 
   
 
   
  
 
 
 
 
 
 
 
 
59c 
   
 
   
 
   
8 63: R=Ph no reaction -
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Table 3 continued 
 
 
 
 
 
 
 
 
 
 
60 
   
 
   
 
   
 
   
9 64a: R=3-MeO-C6H4 79 89
 
10 64b: R=1-naphthyl 62 90
 
 
  
 
 
   
 
   
[a] Isolated yield of analytically pure product. [b] Determined via chiral HPLC analysis. See appendix for details. 
Interestingly, the use of electron-poor arylboronic acids as nucleophiles proved advantageous to 
yield and enantioselectivity with both ligands (entries 4 and 7). A negative effect of electron-rich 
arylboronic acids on the stereoselectivity was also found with 46a as ligand (entries 6 and 9 of 
Table 1). With ligand 59c bearing a sterically highly congested tBu group at the sulfoxide no 
reaction took place (entry 8). This may be due to an impaired coordination between the sulfoxide 
and Rh. The alkenyl moiety alone is not sufficient for efficiently binding to the Rh atom thus 
underlining the vital role of the sulfinyl group for chelation and formation of the reactive 
complex. An increase of the electron-density at the C=C bond (60) led only to a deterioration of 
yields, without impairing the enantioselectivities (entries 9-10). These experiments show that 
coordination of the sulfinyl group represents a crucial factor for the formation of the reactive Rh-
complex. Although binding of the alkenyl moiety to the Rh is less important for the reaction to 
proceed, its chiral environment predominantly dictates the stereochemical outcome. 
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2. Diastereocontrol in the Cross-Couplings of Substituted Cycloalkyl and 
Piperidinyl Derivatives 
2.1 Highly diastereoselective Csp3-Csp2 Negishi cross-coupling with 1,2-, 1,3- and 1,4-
substituted cycloalkylzinc compounds 
2.1.1 Introduction 
Pd-catalyzed Csp3-cross-coupling reactions are important methods for preparing complex organic 
molecules.36 The possibility of forming these C-C bonds in a stereocontrolled manner further 
increases their synthetic potential.13 Thus, a number of chiral ligands for asymmetric Pd- and Ni-
catalyzed cross-couplings have been successfully developed.38, 45, 46, 48, 76 In their pioneering 
work, T. Hayashi and M. Kumada have shown that secondary alkyl-magnesium and -zinc 
reagents allow the preparation of chiral cross-coupling products.45, 46 The Zn- or Mg-
organometallics used in these reactions are configurationally labile and subject to epimerization 
at the carbon-metal bond.47 We have developed highly diastereoselective Negishi cross-
couplings33b on various substituted cycloalkylzinc reagents. An unexpected remote 1,3- and 1,4-
stereocontrol was hereby observed. 
 
2.1.2 Pd-catalyzed cross-couplings with menthyl- and isopulegylzinc halides 
In our initial experiments, we have prepared menthylzinc halides 65 and 66 either by treating 
menthylmagnesium chloride77 67 with ZnCl2 (1.1 equiv, THF, 25 °C, 10 min, 81%) or by the 
reaction of neomenthyl iodide 6878 with zinc powder and LiCl79 (THF, rt, 6 h, 78%, Table 4). The 
resulting menthylzinc reagents 65 or 66 were then subjected to Pd-catalyzed cross-couplings with 
aryl halides at room temperature. Pd(dba)2/SPhos
80 (1:1) or Pd(PPh3)4 were used as catalysts. To 
our delight, the trans-cross-coupling products were obtained with high diastereomeric purities 
(d.r. = 96:4 to ≥99:1) and 63-81% yields (Table 4). Thus, the reaction of menthylzinc chloride 65 
with 4-iodoanisole in the presence of Pd(dba)2 (1 mol%) and SPhos (1 mol%, rt, 4 h) in a mixture 
of THF and NEP (N-ethyl-2-pyrrolidone; 6 vol%) furnished the arylated menthyl-derivative 69a 
in 78% yield and d.r. >99:1 (entry 1 of Table 4). 
                                                 
76 (a) G. Cross, B. K. Vriesema, G. Boven, R. M. Kellogg, F. Van Bolhuis, J. Organomet. Chem. 1989, 370, 357; (b) 
J. Caeiro, J. Perez Sestelo, L. A. Sarandeses, Chem. Eur. J. 2008, 14, 741. 
77 J. Beckmann, D. Dakternieks, M. Draeger, A. Duthie, Angew. Chem. Int. Ed. 2006, 45, 6509. 
78 G. L. Lange, C. Gottardo, Synth. Commun. 1990, 20, 1473. 
79 A. Krasovskiy, V. Malakhov, A. Gavryushin, P. Knochel, Angew. Chem. Int. Ed. 2006, 45, 6040. 
80 S. D. Walker, T. E. Barder, J. R. Martinelli, S. L. Buchwald, Angew. Chem. Int. Ed. 2004, 43, 1871. 
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Table 4: Cross-coupling products obtained with menthyl- and isopulegylzinc halides. 
 
Entry Product Yield [%]a, d.r.b Entry Product Yield [%]a, d.r.b 
      
 
 
  
 
 
1 69a 78, >99:1 5 70b 81, 98:2c 
 
 
  
 
 
2 69b 71, 98:2 6 71a 72, >99:1 
 
 
  
 
 
3 69c 63, 96:4 7 71b 71, >99:1 
      
 
N
N
 
  O
 
 
4 70a 76, 98:2c 8 71c 64, 99:1d 
 
     
[a] Isolated yield of analytically pure product. The major diastereomers are depicted. [b] Determined by capillary 
GC analysis before and after purification. [c] Pd(PPh3)4 (5 mol%) was used as catalyst. [d] The cross-coupling 
reaction was performed at -10 °C. 
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Similarly, the cross-coupling reactions with 1-chloro-4-iodobenzene and 1-iodo-3-
(trifluoromethyl)benzene produced the expected products 69b and 69c with d.r. = 98:2 and 96:4, 
respectively (entries 2 and 3). Cross-coupling with heteroaryl bromides, either electron-poor such 
as 5-bromopyrimidine or electron-rich such as ethyl 5-bromofuroate, led to the desired alkylated 
adducts 70a-b with d.r. = 98:2 (entries 4 and 5). The method could be extended to isopulegylzinc 
chloride which underwent highly diastereoselective cross-coupling reactions with methyl 4-
iodobenzoate (71a; 72%; d.r. > 99:1), 4-iodoanisole (71b; 71%; d.r. > 99:1) and 3-iodo-2-
cyclohexenone81 (71c; 64%; d.r. = 99:1; entries 6-8). It must be noted that in all cases, the 
thermodynamically more favored diastereomer was formed as proven by X-ray analysis (see 
appendix). 
 
2.1.3 Extension to further substituted cycloalkylzinc reagents ‒ observation of a remote 
stereocontrol 
This method could be extended to 2-methylcyclohexylzinc chloride 72 (Table 5). The methyl 
group is less bulky than an isopropyl group and its steric influence may be expected to be less 
pronounced. Still, a high diastereoselectivity was observed when 72 was reacted with methyl 4-
iodobenzoate in the presence of Pd(dba)2 and SPhos at ‒25 °C. Thus, the cross-coupling product 
73 was obtained with 82% yield and d.r. = 99:1 (entry 1 of Table 5). Rearrangement reactions as 
observed by G. A. Molander et al.82 could be mostly avoided at this low temperature. 
Remarkably, we found that similarly high stereoselectivities were obtained with cyclohexylzinc 
reagents bearing substituents at position 4 such as zinc compounds 74a-b or at position 3, such as 
77a-c. Hereby, a large steric effect cannot be expected due to the remoteness of the substituents. 
Thus, we have subjected 4-methylcyclohexylzinc chloride (74a) to a Negishi cross-coupling with 
methyl 4-iodobenzoate (Pd(PPh3)4, 2 mol%, rt, 15 h). The cross-coupling product 75 was 
obtained with a high diastereomeric ratio of 92:8 (entry 2). By screening several catalyst systems 
and reaction conditions, it was further possible to increase this diastereoselectivity to d.r. = 95:5 
(for details see appendix). A 2:1 combination of tris(2,4,6-trimethoxyphenyl)phosphine (TMPP)83 
and PdCl2 was found to be the most diastereoselective catalyst system. Using these conditions, 4-
substituted cyclohexylzinc chlorides such as 74a-b furnished the thermodynamically favored 
trans-4-substituted products (75-76) with diastereoselectivities up to 95:5 (entries 2-4). Similarly, 
                                                 
81 J. P. Barnier, L. Blanco, Synth. Commun. 2003, 33, 2487. 
82 S. D. Dreher, P. G. Dormer, D. L. Sandrock, G. A. Molander, J. Am. Chem. Soc. 2008, 130, 9257. 
83 K. R. Dunbar, J.-S. Sun, J.-S. J. Chem. Soc., Chem. Commun. 1994, 2387. 
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3-substituted cyclohexylzinc chlorides (77a-c) provided the cis-cross-coupling products (78-80) 
with d.r. up to 97:3 (entries 5-13). The relative stereochemistry of 78a was determined by X-ray 
analysis (see appendix).  
 
Table 5: Cross-coupling products obtained with 2-, 4- and 3-substituted cyclohexylzinc halides. 
 
 
Entry Product Yield [%]a, d.r.b Entry Product Yield [%]a, d.r.b 
      
 
 
  
 
 
1 73 82, 99:1c 8 78d 85, 95:5h 
 
 
  
 
 
2 75 84, 95:5; 
89, 92:8d 
9 79a 70, 96:4g 
 
 
  
 
 
3 76a 59, 95:5 10 79b 86, 96:4 
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Table 5 continued 
 
 
  
 
 
 
tBu
CF3
 
  
 
 
4 76b 60, 94:6 11 79c 71, 95:5 
 
 
  
 
 
5 78a 77, 97:3; 
96:4e; 96:4f 
12 79d 71, 97:3g 
 
 
  
 
 
6 78b 70, 96:4g 13 80 74, 96:4 
 
 
  
 
 
7 78c 81, 95:5h    
 
 
  
 
 
[a] Isolated yield of analytically pure product. The major diastereomers are depicted. [b] Determined by capillary 
GC analysis before and after purification. [c] 5% of regioiosmer detected. [d] The reaction was performed at rt 
using Pd(PPh3)4 (2 mol%) as catalyst. [e] d.r. obtained when a large excess (5 equiv) of electrophile was used. [f] 
d.r. obtained when a large excess of zinc reagent (5 equiv) was used. [g] The reaction was performed at ‒5 °C. [h] 
The reaction was performed with 3-methylcyclohexylzinc iodide (prepared via zinc insertion) at rt using Pd(PPh3)4 
(5 mol%) as catalyst. 
The diastereoselectivities were not affected by the bulkiness or the nature of the ring substituents. 
For example, the cross-couplings of 3-methylcyclohexyl- (77a), 3-isopropylcyclohexyl- (77b) 
and 3-trifluoromethylcyclohexylzinc chloride (77c) with methyl 4-iodobenzoate furnished the 
respective products 78a, 79b and 80 with similar diastereoselectivities (d.r. = 96:4 to 97:3; entries 
5, 10 and 13). Remarkably, these stereoselective Negishi cross-coupling reactions could be 
extended to various cyclic systems, including cyclopentanes, bicyclic compounds and steroids. 
Thus, cross-coupling of 2-isopropylcyclopentylzinc chloride (81) (prepared from 1-chloro-2-
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isopropylcyclopentane 82 via Mg insertion and transmetalation with ZnCl2) with methyl 4-
iodobenzoate furnished selectively the trans-product 83 (96%; d.r.= 96:4; Scheme 33). 
 
 
Scheme 33: Diastereoselective cross-coupling with various cycloalkylzinc reagents. 
 
An excellent diastereoselectivity was also observed with isopinocampheylzinc chloride (84) 
(prepared analogously to 81 from isopinocampheyl chloride84 85) leading to the arylated product 
86 (65%; d.r. = 95:5). Finally, the cholesterylzinc chloride (87) (prepared from cholesteryl 
chloride85) was arylated with 4-iodoanisole resulting in the steroid 88 (86%; d.r. = 97:3; Scheme 
33). 
 
2.1.4 Mechanistic considerations 
The performance of cross-coupling reactions with 77a using a large excess (5 equiv) of methyl 4-
iodobenzoate or the zinc reagent 77a (5 equiv) led to the cross-coupling product 78a with a 
similar diastereoselectivity as under standard conditions (0.7 equiv of the electrophile) (d.r. = 
                                                 
84 J. Scianowski, Z. Rafinski, A. Wojtczak, Eur. J. Org. Chem. 2006 3216. 
85 E. M. Kosower, S. Winstein, J. Am. Chem. Soc. 1956, 78, 4354. 
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96:4; compare to 97:3; see entry 5 of Table 5).86 Based on these observations, we propose a 
tentative mechanism in which both diastereomeric cyclohexylzinc complexes eq-89, ax-89a and 
ax-89b are in equilibrium (Scheme 34). Although the carbon-zinc bond is reported to be 
configurationally stable,87 it was shown that the presence of metallic salts facilitates its 
epimerization88 and PdX2, MgX2, ZnX2, LiCl present in the reaction mixture may be responsible 
for this fast equilibration.  
 
 
Scheme 34: Mechanistic proposal for the diastereoselective cross-coupling of substituted 
cycloalkylzinc reagents with aryl iodides. 
 
The transmetalation of the zinc reagent eq-89 with ArPdL2X (90), obtained by Pd(0)-insertion 
into an aryl halide (Ar-X), preferentially leads to the Pd-intermediate eq-91 provided that the 
transmetalation occurs with retention of configuration.89 The alternative formation of the Pd-
intermediates ax-91a and ax-91b is disfavored for steric reasons. In both of these conformers 
either the Pd-moiety or the R-group occupies the axial position. This results in repulsive 
interactions with the bulky phosphine ligands on Pd (as shown by the DFT-calculations below). 
After reductive elimination the trans-product eq-92 is selectively obtained from eq-91 (Scheme 
                                                 
86 R. Hirsch, R. W. Hoffmann, Chem. Ber. 1992, 125, 975. 
87 A. Guijarro, R. D. Rieke, Angew. Chem. Int. Ed. 2000, 39, 1475. 
88 (a) L. Micouin, M. Oestreich, P. Knochel, Angew. Chem. Int. Ed. 1997, 36, 245; (b) A. Boudier, C. Darcel, F. 
Flachsmann, L. Micouin, M. Oestreich, P. Knochel, Chem. Eur. J. 2000, 6, 2748. 
89 K. R. Campos, A. Klapars, J. H. Waldman, P. G. Dormer, C.-y. Chen, J. Am. Chem. Soc. 2006, 128, 3538. 
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34). In order to get an insight into the energetic differences between Pd-intermediates of type 91 
and to verify our mechanistic proposal, we have performed a DFT calculation-based 
conformational analysis on the respective organozinc and organopalladium complexes (Table 
6).90 Comparison of the energetically lowest conformers showed that only small and insignificant 
thermodynamical differences exist between the diastereomeric cycloalkylzinc chloride complexes 
(less than 0.77 kcal/mol in free energy for zinc complexes 65, 72, 74a, 77a and 81; Table 6) (for 
details see the appendix). However, the corresponding organopalladium complexes (93-97) show 
a significant change in thermodynamical energies favoring the diastereomers which bear all 
substituents in equatorial positions. The calculations demonstrated that considerable repulsive 
interactions between the substituents on the cycloalkyl moiety and the phosphine ligands on Pd 
increase the energetic gap between the diastereomeric complexes up to 9.84 kcal/mol in free 
energy (Table 6). This energetic increase gets experimentally significant and accounts for the 
diastereoselectivities observed in the cross-coupling reactions. For instance, complex ax-95 
bearing a methyl substituent in the axial position is strongly disfavored compared to eq-95 by 
2.08 kcal/mol explaining why the cross-coupling reaction only proceeds via intermediate eq-95 
(or via eq-91 and not via ax-91a or ax-91b in Scheme 34). 
 
Table 6: DFT calculation-based conformational analysis on the diastereomeric zinc and 
palladium complexes. 
Entry Organozinc complexes ∆G298eq-axa, ∆E0 ;eq-axa [kcal/mol] Entry 
Organopalladium complexes 
∆G298eq-axa, ∆E0 ;eq-axa [kcal/mol] 
      
 
 
eq-72  
ax-72 
 
 
eq-93 ax-93 
1 ‒0.55, ‒1.29 8 ‒4.85, ‒5.02 
    
                                                 
90 DFT calculations were carried out using the Gaussian03 Rev.B.04 program package90a with the nonlocal hybrid 
B3LYP exchange-correlation functionals90b. The basis set denoted as 631SVP consists of the Ahlrich def2-SVP all 
electron basis set90c for Zn atoms, all electron and ECP for Pd atoms and the 6-31G(d,p) basis set90d for other atoms. 
See appendix for full details of the computational study. (a) M. J. Frisch, et al. Gaussian 03; Gaussian, Inc., 
Wallingford CT, 2004; (b) R. G. Parr, W. Yang, Density Functional Theory of Atoms and Molecules; Oxford 
University Press: New York, 1989; T. Ziegler, Chem. Rev. 1991, 91, 651; C. Lee, W. Yang, R. G. Parr, Phys. Rev. B 
1988, 37, 785; A. D. Becke, Phys. Rev. A 1988, 38, 3098; (c) F. Weigend, R. Ahlrichs, Phys. Chem. Chem. Phys. 
2005, 7, 3297; (d) P. C. Hariharan, J. A. Pople, Theoret. Chimica Acta 1973, 28, 213; M. M. Francl, W. J. Petro, W. 
J. Hehre, J. S. Binkley, M. S. Gordon, D. J. DeFrees, J. A. Pople, J. Chem. Phys. 1982, 77, 3654; V. A. Rassolov, J. 
A. Pople, M. A. Ratner, T. L. Windus, J. Chem. Phys. 1998, 109, 1223. 
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Table 6 continued 
    
  
 
eq-77  ax-77 
 
 
eq-94 
 
ax-94 
2 ‒0.68, 0.10 9 ‒2.88, ‒2.59 
 
Zn
THF
Cl
THFMe
 
eq-74 ax-74 
 
 
eq-95 
Pd
PMe3
PMe3
Ph
Me
ax-95 
3 ‒0.52, ‒0.04 10 ‒2.08, ‒2.37 
 
 
eq-65 ax-65 
 
 
eq-96 
Me
iPr
Pd
Me3P
PMe3
Ph
 
ax-96 
4 ‒0.77, ‒0.36 11 ‒9.84, ‒10.08 
 
 
trans-81 
 
cis-81 
 
 
trans-97 
 
cis-97 
5 ‒0.43, 0.10 12 ‒5.54, ‒5.03 
    
[a] Calculated energetic difference (B3LYP/631SVP) between the energetically lowest conformers of the two 
diastereomers. 
To substantiate the results from the theoretical calculations which suggested that the 
diastereoselectivity is due to a fast transmetalation of the cycloalkylzinc reagent to the Pd 
complex eq-94, we have performed NMR studies on the reaction of 3-methylcyclohexylzinc 
chloride (77a) with (TMPP)2PdCl2 in d8-THF (0.3 M) at ‒10 °C (Scheme 35). Many signals of 
several zinc species (77a and aggregates) and Pd complexes were detected in the NMR spectra. 
However, using 1H31P-HMBC analysis only one 31P chemical shift simultaneously displays cross-
signals with the cyclohexyl and aromatic 1H-signals. 
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Scheme 35: NMR-studies on the transmetalation of 3-methylcyclohexyl-zinc chloride (77a) to 
(TMPP)2PdCl2; A 1D section from the 
1H31P-HMBC spectrum is shown displaying the proton 
signals from the Pd intermediate 98.91  
 
This shows that there is only one Pd-intermediate present in a detectable amount. J-coupling 
between the proton signals in the cyclohexyl ring identified the intermediate as a structure of type 
98 with the Pd occupying the equatorial position (3JHH-coupling was detected to be 11 Hz (± 0.5 
Hz) which corresponds to a coupling of axial protons; for details and spectra see the appendix). 
These results confirm the conformational preferences of the tentative mechanism proposed in 
Scheme 34. 
 
 
                                                 
91 The most intense of the cyclohexyl signals at δ = 2.8 ppm represents the methine signal showing the strongest 
coupling with the P-atom of the TMPP-ligand (3JHP). The neighboring methylene protons show signals in the region 
from δ = 1.4 ppm to 1.7 ppm with lower intensities (4JHP). 3JHH-coupling of 11 Hz (± 0.5 Hz) in the methine signal 
which corresponds to a coupling of axial protons identifies the structure to be of type 98 with the Pd moiety 
occupying the equatorial position. 
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2.2 Diastereoselective Csp3-Csp cross-couplings between 1,3- and 1,4-disubstituted 
cyclohexylzinc reagents and bromoalkynes via remote stereocontrol 
2.2.1 Introduction 
Alkynes are found in a vast array of natural products and bioactive molecules92 and make up 
important constituents in many functional materials,92c, 93 including liquid crystals94, dyes95 and 
organic light-emitting diodes (OLEDs).96 Therefore, the development of novel methods allowing 
an efficient and stereoselective introduction of the alkynyl unit into organic molecules is highly 
desirable. Whereas for the construction of Csp-Csp2 bonds the Sonogashira-reaction97 has been 
well established, much less synthetic methods are available for the coupling between a Csp3 and 
Csp center.98-100 For such reactions, the C-C bond formation is problematic due to competing β-
hydride elimination and sluggish reductive elimination.37 Most of the existing procedures are 
based on the coupling of an alkynyl organometallic or alkyne with an alkyl halide.98 Useful 
approaches for transition-metal catalyzed couplings involving alkyl organometallics have evolved 
only recently.99 Such methods include oxidative coupling of primary alkylzinc reagents with 
terminal alkynes99a or alkynylstannanes99b-c as well as Cu-catalyzed coupling of alkylmagnesium 
reagents with alkynyl halides. 99d Pd- and Cu-catalyzed decarboxylative couplings may also be 
                                                 
92 (a) B. W. Gung, C. R. Chimie 2009, 12, 489; (b) A. L. K. Shi Shun, R. R. Tykwinski, Angew. Chem. Int. Ed. 2006, 
45, 1034; (c) Modern Acetylene Chemistry (Eds.: P. J. Stang, F. Diederich), Wiley-VCH, Weinheim, 1995. 
93 For a review on acetylenic polymers see: J. Liu, J. W. Y. Lam, B. Z. Tang, Chem. Rev. 2009, 109, 5799. 
94 (a) H. K. Bisoyi, S. Kumar, Chem. Soc. Rev. 2010, 39, 264; (b) C. T. Imrie, P. A: Henderson, Chem. Soc. Rev. 
2007, 36, 2096; (c) A. L. Sadowy, R. R. Tykwinski in Modern Supramolecular Chemistry (Eds.: F. Diederich, P. J. 
Stang, R. R. Tykwinski), Wiley-VCH, Weinheim, 2008, pp. 185-231. 
95 (a) R. Ziessel, A. De Nicola, C. R. Chimie 2009, 12, 450; (b) S. Nakatsuji, K. Nakashima, S. Akiyama, H. 
Nakazumi, Dyes and Pigments 1994, 24, 37. 
96 M. Kivala, F. Diederich, Acc. Chem. Res. 2009, 42, 235. 
97 (a) K. Sonogashira, Y. Tohda, N. Haghihara, Tetrahedron Lett. 1975, 4467; for reviews on Csp2-Csp cross-
couplings see: (b) H. Doucet, J.-C. Hierso, Angew. Chem. Int. Ed. 2007, 46, 834; (c) H. Plenio, Angew. Chem. Int. 
Ed. 2008, 47, 6954. 
98 For couplings of alkynyl organometallics with alkyl halides see: (a) M. Peña-López, M. Ayán-Varela, L. A. 
Sarandeses, J. P. Sestelo, Chem. Eur. J. 2010, 16, 9905; (b) W. Shi, C. Liu, Z. Yu, A. Lei, Chem. Commun. 2007, 
2342; (c) M. Qian, E.-i. Negishi, Tetrahedron Lett. 2005, 46, 2927; (d) M. Qian, E.-i. Negishi, Synlett 2005, 1789; 
(e) L.-M. Yang, L.-F. Huang, T.-Y. Luh, Org. Lett. 2004, 6, 1461; stereoselective couplings: (f) H. Ohmiya, H. 
Yorimitsu, K. Oshima, Org. Lett. 2006, 8, 3093; (g) J. Caeiro, J. P. Sestelo, L. A. Sarandeses, Chem. Eur. J. 2008, 
14, 741; for couplings of alkyl halides and alkynes see: (h) O. Vechorkin, D. Barmaz, V. Proust, X. Hu, J. Am. 
Chem. Soc. 2009, 131, 12078; (i) G. Altenhoff, S. Würtz, F. Glorius, Tetrahedron Lett. 2006, 47, 2925; (j) M. 
Eckhardt, G. C. Fu, J. Am. Chem. Soc. 2003, 125, 13642. 
99 (a) M. Chen, X. Zheng, W. Li, J. He, A. Lei, J. Am. Chem. Soc. 2010, 132, 4101; (b) L. Jin, Y. Zhao, H. Wang, A. 
Lei, Synthesis 2008, 649; (c) Y. Zhao, H. Wang, X. Hou, Y. Hu, A. Lei, H. Zhang, L. Zhu, J. Am. Chem. Soc. 2006, 
128, 15048; (d) G. Cahiez, O. Gager, J. Buendia, Angew. Chem. Int. Ed. 2010, 49, 1278. 
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used.100 Stereoselective versions of these reactions are scarce and have so far only been 
developed for Csp-Csp3 couplings.98f-g From our results with the diastereoselective  Negishi-type 
cross-couplings between substituted cycloalkylzinc reagents and (hetero)aryl halides (chapter 
2.1),101 we deduced that a related cross-coupling between the cyclohexylzinc reagents (99 or 100) 
and alkynyl bromides (101) may be achieved, providing stereochemically defined alkynes of type 
102 and 103 with 1,3- or 1,4-remote stereocontrol (Scheme 36). 
 
 
Scheme 36: Diastereoselective Csp3-Csp coupling of substituted cyclohexylzinc reagents with 
remote stereocontrol. 
 
2.2.2 Diastereoselective Csp3-Csp cross-couplings with remote stereocontrol 
In a preliminary experiment, we have reacted the 3-substituted cyclohexylzinc reagent 99a - 
obtained via Zn-insertion in the presence of LiCl79 - with 1-bromophenylacetylene102 (3a) in THF 
using different catalysts (Table 7). With 10 mol% CuCN·2 LiCl,103 the expected cross-coupling 
product (102a) was obtained with a good conversion, yet only with a modest diastereoselectivity 
(d.r.: 68:32; entry 1 of Table 7). Switching to Pd-catalysts, we have found that the Pd complex 
TMPP2PdCl2,
83 provided 102a with a high d.r. of 95:5. We also observed the formation of some 
regioisomeric product (ca. 4%).104 This diastereoselectivity could be further improved by 
replacing the phosphine ligand TMPP with various bipyridines (104a-b; entry 3) and ortho-
phenanthrolines (105a-d; entry 4). 
                                                 
100 (a) W.-W. Zhang, X.-G. Zhang, J.-H. Li, J. Org. Chem. 2010, 75, 5259; (b) H.-P. Bi, Q. Teng, M. Guan, W.-W. 
Chen, Y.-M. Liang, X. Yao, C.-J. Li, J. Org. Chem. 2010, 75, 783; (c) H.-P. Bi, L. Zhao, Y.-M. Liang, C.-J. Li, 
Angew. Chem. Int. Ed. 2009, 48, 792; (d) D. K. Rayabarapu, J. A. Tunge, J. Am. Chem. Soc. 2005, 127, 13510. 
101 T. Thaler, B. Haag, A. Gavryushin, K. Schober, E. Hartmann, R. M. Gschwind, H. Zipse, P. Mayer, P. Knochel, 
Nature Chem. 2010, 2, 125. 
102 Y. Zhang, R. P. Hsung, M. R. Tracey, K. C. M. Kurtz, E. L. Vera, Org. Lett. 2004, 6, 1151. 
103 (a) M. C. P. Yeh, P. Knochel, Tetrahedron Lett. 1989, 30, 4799; (b) P. Knochel, M. C. P. Yeh, S. C. Berk, J. 
Talbert, J. Org. Chem. 1988, 53, 2390. 
104 The Cu-catalyzed coupling only furnished the two diastereomeric products. Small amounts of regioisomers (same 
mass on GC-MS as the diastereomeric compounds) were only formed using Pd-catalysis. 
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Table 7: Optimization of the diastereoselectivity. 
 
Entry Catalyst Ligand d.r.a 
     
1 10% CuCN  none 68:32 
     
2 PdCl2  TMPP 95:5 (4) 
  
 
 
 
  
3 PdCl2 R=H: 104a 104a: 96:4 (<3) 
  R=Me: 104b 104b: 98:2 (<2) 
    
  
 
 
 
 
 
  
  R=H: 105a 105a: 96:4 (<3) 
4 PdCl2 R=Me: 105b 105b: 98:2 (<2) 
  R=Ph: 105c 105c: 96:4 (<4) 
  R=tBu: 105d 105d: 96:4 (<3) 
     
5 PdCl2(PhCN)2  105b 96:4 (3) 
     
6 Pd(dba)2  105b 97:3 (2) 
     
7 Ni(acac)2  105b 87:13 
     
[a] Determined by capillary GC analysis. The percentage of regioisomers is given in parentheses. 
The N-ligands clearly proved to be superior. The commercially available and inexpensive 
neocuproine (105b)105 combined excellent diastereoselectivity with a low formation of 
regioisomers (<2%). PdCl2 was found to be the best Pd source and switching from Pd to Ni as 
catalyst resulted in a deterioration of the d.r. (d.r.: 87:13; entry 7). Bidentate N-ligands are known 
to stabilize Pd(0) more efficiently than monodentate phosphines105b leading to a faster reductive 
                                                 
105 (a) L. Canovese, F. Visentin, C. Santo, A. Dolmella, J. Organomet. Chem. 2009, 694, 411; (b) A. Svennebring, P. 
J. R. Sjöberg, M. Larhed, P. Nilsson, Tetrahedron 2008, 64, 1808; (c) K. S. Yoo, H. Cheol, K. W. Jung, J. Am. 
Chem. Soc. 2006, 128, 16384. 
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elimination thus minimizing unwanted β-hydride elimination and formation of regioisomeric 
products. 
The 3-substituted cyclohexylzinc reagent 99a was subsequently subjected to cross-couplings with 
a range of 1-bromoalkynes (101a-d) using the optimized catalyst system (2 mol% PdCl2, 4 mol% 
105b). The expected thermodynamically preferred cis-1,3-disubstituted cyclohexane106 
derivatives were obtained with good yields and excellent diastereoselectivities (d.r.: 94:6 to 98:2; 
entries 1-5 of Table 8). Bromoalkynes bearing aromatic (101a-b), aliphatic (101c) and silyl 
moieties (101d) were successfully coupled. Increasing the steric bulk of the substituent from iPr 
to tBu at the cyclohexylzinc reagent did not have an effect on the diastereoselectivity or yield 
(compare 102c (77%; d.r.: 97:3) and 102f (74%; d.r.: 97:3); entries 3 and 6). Replacing the 
relatively large iPr-group with the sterically much less demanding methyl group only led to a 
slight loss of diastereoselectivity (compare 102a (82%; d.r.: 98:2) with 102g (79%; d.r.: 96:4); 
entries 1 and 7). Functionalized cyclohexylzinc reagents bearing an OTBS (OSiMe2tBu) 
functionality underwent the Pd-catalyzed cross-couplings with equally high diastereoselectivities 
(d.r.: 96:4 to 98:2; 102i-j; entries 9-10). 
 
Table 8: Diastereoselective Csp3-Csp coupling of 3-substituted cyclohexylzinc reagents. 
 
Entry  Product Yield [%]a (d.r.)b 
 
 
 
 
 
 
 
  
1 102a: R= Ph 82 (98:2) 
2 102b: R= 4-NC-C6H4 87 (94:6) 
3 102c: R= (CH2)2OTBS 77 (97:3) 
4 102d: R= TIPS 79 (94:6), 76 (96:4)c 
 
  
                                                 
106 The relative configurations of 102i and 103h were determined via desilylation and subsequent tosylation of the 
resulting alcohols. The crystals of the tosylates proved suitable for X-ray crystallography. The relative 
stereoconfiguration of 103b was directly determined via X-ray crystallography. See appendix. 
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Table 8 continued 
    
 
 
 
 
 
tBu
R  
  
 
  
5 102e: R= 4-NC-C6H4 85 (95:5) 
6 102f: R= (CH2)2OTBS 74 (97:3) 
   
 
  
 
   
 
 
 
 
 
 
 
  
 
  
7 102g: R= Ph 79 (96:4) 
8 102h: R= 4-NC-C6H4 88 (96:4) 
 
  
 
  
    
 
 
 
 
 
 
 
  
 
  
9 102i: R= TIPS 81 (98:2) 
10 102j: R= (CH2)2OTBS 94 (96:4) 
 
  
 
  
[a] Isolated yield of analytically pure product. [b] Determined by capillary GC analysis before and after purification. 
The percentage of regioisomers produced as byproducts was between 0-5%. See experimental section for details. [c] 
4% bipyridine 104b was used. 
Next, we performed the Csp3-Csp couplings with the 4-substituted cyclohexylzinc reagents 103a-
c (Table 9). To our delight, the diastereomeric ratios were as high as those obtained for the 
couplings of the 3-substituted cyclohexylzinc iodides (d.r.: 94:6 to 98:2; compare Tables 8 and 9) 
showing an excellent remote stereocontrol. In all cases, the thermodynamically favored trans-1,4-
disubstituted cyclohexanes were preferentially formed (Table 9).106 Like for the 3-substituted 
cyclohexylzinc reagents, the size of the respective substituents only had a minor effect on the 
diastereoselectivity. Thus, cyclohexylzinc reagent 100a bearing a bulky tBu-group furnished the 
coupling products 103a-d with d.r. ≥96:4 (entries 1-4), while the couplings of the methyl-
substituted zinc reagent 100b resulted in a slightly lower d.r. of 95:5 (entries 5-6). Cross-
couplings of the functionalized organozinc iodide 100c also proceeded highly 
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diastereoselectively (d.r.: 95:5 to 96:4) providing the trans-configured products 103g-i with 
excellent yields (88-94%; entries 7-9). 
 
Table 9: Diastereoselective Csp3-Csp coupling of 4-substituted cyclohexylzinc reagents. 
 
Entry  Product Yield [%]a (d.r.)b 
 
 
 
 
 
 
 
  
1 103a: R= Ph 76 (97:3) 
2 103b: R= 4-NC-C6H4 84 (96:4) 
3 103c: R= (CH2)2OTBS 79 (98:2) 
4 103d: R= TIPS 75 (96:4) 
 
  
    
 
 
 
 
 
  
5 103e: R= (CH2)2OTBS 74 (95:5) 
6 103f: R= TIPS 71 (95:5) 
   
 
   
 
 
 
 
R
TBSO
 
  
7 103g: R= (CH2)2OTBS 88 (96:4) 
8 103h: R= TIPS 93 (95:5) 
9 103i: R= 4-NC-C6H4 94 (96:4) 
 
  
[a] Isolated yield of analytically pure product. [b] Determined by capillary GC analysis before and after purification. 
The percentage of regioisomers produced as byproducts was between 1-6%. See the experimental section. 
trans-1,4-Disubstituted cyclohexanes,107 including their alkynyl-substituted derivatives,108 
constitute important building blocks for liquid crystals due to their unique properties, such as low 
                                                 
107 (a) R. Eidenschink, D. Erdmann, J. Krause, L. Pohl, Angew. Chem. Int. Ed. Engl. 1977, 16, 100; (b) D. Pauluth, 
K. Tarumi, J. Mater. Chem. 2004, 14, 1219; (c) R. Dąbrowski, Mol. Cryst. Liq. Cryst. 2004, 421, 1; (d) P. Kirsch, M. 
Bremer, Angew. Chem. Int. Ed. 2000, 39, 4216; (e) V. F. Petrov, S. I. Torgova, L. A. Karamysheva, S. Takenaka, 
Liq. Cryst. 1999, 26, 1141. 
108 (a) B. Chen, G. Sun, S. Xu, Liq. Cryst. 2004, 31, 767; (b) B. Chen, G. Sun, S. Xu, Liq. Cryst. 2004, 31, 421. 
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viscosity coefficients and higher optical anisotropy. The new coupling procedure offers a direct 
and highly stereoselective access to such compounds (Table 9). Supramolecular chirality can be 
induced in liquid crystals via the use of chiral dopants.109 Since menthyl-capped dopants110 have 
already been successfully applied for amplifying chirality in liquid crystals, we envisioned the 
synthesis of 106, which may serve as a building block for chiral dopants due to its structural 
similarity to some 1,4-disubstituted cyclohexyl-based mesogens.108 Thus, the functionalized 
cyclohexylzinc reagent 100c was subjected to cross-coupling with the bromoalkyne 107 
furnishing the trans-1,4-cyclohexylalkyne 108 (79%; d.r.: 94:6; Scheme 37). The aromatic iodo 
substituent of 108 allowed a further cross-coupling with (‒)-menthylzinc iodide (66) using 
Pd(dba)2 and SPhos
80 as catalyst system. Deprotection with TBAF furnished the rod-shaped, 
chiral product 106 with complete diastereoselectivity (74%; d.r.: >99:1). 
 
*
**
*
 
Scheme 37: Sequential diastereoselective Csp3-Csp and Csp3-Csp2 coupling leading to 106, a 
potential building block for chiral dopants. 
                                                 
109 R. Eelkema, B. L Feringa, Org. Biomol. Chem. 2006, 4, 3729. 
110 (a) J.-H. Liu, P.-C. Yang, H.-J. Hung, D.-J. Liaw, Liq. Cryst. 2007, 34, 891; (b) A. Yu. Bobrovsky, V. P. Shibaev, 
Adv. Funct. Mater. 2002, 12, 367; (c) R. A. Vora, A. K. Prajapati, J. B. Kevat, K. K. Raina, Liq. Cryst. 2001, 28, 
983; (d) A. Yu. Bobrovsky, N. I. Boiko, V. P. Shibaev, E. Prudnikova, S. I. Torgova, Liq. Cryst. 2000, 27, 1381; (e) 
M. M. Green, S. Zanella, H. Gu, T. Sato, G. Gottarelli, S. K. Jha, G. P. Spada, A. M. Schoevaars, B. Feringa, A. 
Teramoto, J. Am. Chem. Soc. 1998, 120, 9810. 
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2.3 Diastereoselective Fe-mediated Csp2-Csp3 cross-couplings between aryl Grignard 
reagents and cyclic iodohydrine derivatives 
2.3.1 Introduction 
Transition-metal catalyzed cross-coupling reactions have been established as indispensible tools 
for C-C bond forming reactions in modern organic synthesis.35 Most of these reactions depend on 
the use of Pd- or Ni-based complexes as catalysts. Although these metals are used in only 
catalytic amounts, they have the disadvantage of toxicity111 and/or high costs.112 Fe-mediated 
coupling reactions113 were found to be a valuable alternative since Fe is one of the most abundant 
transition-metals and its salts are inexpensive and environmentally benign. Despite spectacular 
advances114 and insights into the role of Fe in coupling reactions,115 only few stereoselective 
versions of Fe-mediated or -catalyzed Csp3-couplings are known.40, 41, 116 Since our method for 
the diastereoselective cross-coupling of substituted cyclohexylzinc reagents (chapters 2.1 and 
2.2)101, 117 could not be applied to the preparation of α-arylated cyclohexanol derivatives of type 
36, with the required zinc reagent 109 being subject to fast elimination leading to cyclohexene 
                                                 
111 (a) Handbook on the Toxicology of Metals (Eds.: L. Friberg, G. F. Nordberg, V. B. Vouk), Elsevier, Amsterdam, 
1986; (b) M. N. Hughes, Compr. Coord. Chem. 1987, 67, 643; (c) Nickel and the Skin: Absorption, Immunology, 
Epidemology, and Metallurgy (Eds.: J. J. Hostynek, H. I. Maibach), CRC Press, Boca Raton, 2002. 
112 World market prices for Pd: 515 $ per ounce and Ni 10 $ per pound. 
113 (a) E. Nakamura, N. Yoshikai, J. Org. Chem. 2010, 75, 6061; (b) W. M. Czaplik, M. Mayer, J. Cvengroš, A. 
Jacobi von Wangelin, ChemSusChem 2009, 2, 396; (c) A. Correa, O. G. Mancheño, C. Bolm, Chem. Soc. Rev. 2008, 
37, 1108; (d) B. D. Sherry, A. Fürstner, Acc. Chem. Res. 2008, 41, 1500; (e) A. Fürstner, R. Martin, Chem. Lett. 
2005, 34, 624; (f) C. Bolm, J. Legros, J. Le Paih, L. Zani, Chem. Rev. 2004, 104, 6217; (g) S. M. Neumann, J. K. 
Kochi, J. Org. Chem. 1975, 40, 599. (h) M. Tamura, J. K. Kochi, J. Am. Chem. Soc. 1971, 93, 1487. 
114 (a) T. Hatakeyama, T. Hashimoto, Y. Kondo, Y. Fujiwara, H. Seike, H. Takaya, Y. Tamada, T. Ono, M. 
Nakamura, J. Am. Chem. Soc. 2010, 132, 10674; (b) T. Hatakeyama, S. Hashimoto, K. Ishizuka, M. Nakamura, J. 
Am. Chem. Soc. 2009, 131, 11949; (c) B.-J. Li, L. Xu, Z.-H. Wu, B.-T. Guan, C.-L. Sun, B.-Q. Wang, Z.-J. Shi, J. 
Am. Chem. Soc. 2009, 131, 14656; (d) W. M. Czaplik, M. Mayer, A. Jacobi von Wangelin, Angew. Chem. Int. Ed. 
2009, 48, 607; (e) G. Cahiez, L. Foulgoc, A. Moyeux, Angew. Chem. Int. Ed. 2009, 48, 2969; (f) M. Carril, A. 
Correa, C. Bolm, Angew. Chem. Int. Ed. 2008, 47, 4862; (g) A. Guérinot, S. Reymond, J. Cossy, Angew. Chem. Int. 
Ed. 2007, 46, 6521; (h) T. Hatakeyama, M. Nakamura, J. Am. Chem. Soc. 2007, 129, 9844; (i) G. Cahiez, V. Habiak, 
C. Duplais, A. Moyeux, Angew. Chem. Int. Ed. 2007, 46, 4364; (j) R. B. Bedford, M. Betham, D. W. Bruce, A. A. 
Danopoulos, R. M. Frost, M. Hird, J. Org. Chem. 2006, 71, 1104; (k) A. Fürstner, A. Leitner, Angew. Chem. Int. Ed. 
2002, 41, 609; (l) A. Fürstner, A. Leitner, M. Méndez, H. Krause, J. Am. Chem. Soc. 2002, 124, 13856. 
115 (a) S. L. Buchwald, C. Bolm, Angew. Chem. Int. Ed. 2009, 48, 5586; (b) J. Kleimark, A. Hedström, P.-F. Larsson, 
C. Johansson, P.-O. Norrby, ChemCatChem 2009, 1, 152; (c) D. Noda, Y. Sunada, T. Hatakeyama, M. Nakamura, H. 
Nagashima, J. Am. Chem. Soc. 2009, 131, 6078; (d) S. H. Wunderlich, P. Knochel, Angew. Chem. Int. Ed. 2009, 48, 
9717; (e) A. Fürstner, K. Majima, R. Martin, H. Krause, E. Kattnig, R. Goddard, C. W. Lehmann, J. Am. Chem. Soc. 
2008, 130, 1992. 
116 (a) S. Ito, T. Itoh, M. Nakamura, Angew. Chem. Int. Ed. 2011, 50, 454; (b) M. Nakamura, K. Matsuo, T. Inoue, E. 
Nakamura, Org. Lett. 2003, 5, 1373; (c) M. Nakamura, A. Hirai, E. Nakamura, J. Am. Chem. Soc. 2000, 122, 978; 
for a diastereoselective CoCl2-catalyzed coupling see: (d) H. Ohmiya, H. Yorimitsu, K. Oshima, J. Am. Chem. Soc. 
2006, 128, 1886. 
117 T. Thaler, L.-N. Guo, P. Mayer, P. Knochel, Angew. Chem. Int. Ed. 2011, manuscript accepted. 
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(110), we envisioned a new retrosynthetic approach for their stereoselective synthesis (Scheme 
38). 
 
 
Scheme 38: Retrosynthesis of 2-arylcyclohexanol derivatives (36). 
 
Products of type 36 are versatile building blocks for pharmaceuticals,118 chiral ligands119 and 
auxiliaries.120 They are usually obtained by the opening of the corresponding epoxides with aryl 
organometallics. Enantioselective versions of this opening are of limited scope.121 In fact, the 
most efficient procedures for the desymmetrization of oxacycles using aryl Grignard reagents are 
only reported for oxabenzonorbornadienes122 and 2,3-disubstituted 7-oxabicyclo[2.2.1]hept-5-
enes.116b-c These problems can be solved by an alternative retrosynthesis involving a 
diastereoselective coupling of the readily available iodohydrine derivative 111 with ArMgX 112 
(Scheme 38). 
 
2.3.2 Development of the Fe-mediated diastereoselective cross-coupling 
In preliminary experiments, we have examined the cross-coupling of the TBS-protected 
iodohydrine 111 with PhMgCl in the presence of various Fe-salts (Table 10). Thus, the addition 
of PhMgCl to the cyclohexyl iodide (111, 75:25 cis:trans mixture) in the presence of 10% 
Fe(salen)Cl114l, 123 exclusively resulted in the formation of protonated product (cHexOTBS; entry 
1 of Table 10). Further attempts with Fe-salts, such as Fe(acac)3
114i and FeCl3,
40a in catalytic 
amounts furnished the desired cross-coupling product 36a with 27% yield at best and 
diastereoselectivities between d.r.: 76:24 and 96:4 (entries 2-4). 
 
                                                 
118 R. G. Naik, V. N. Mumbaikar, R. Vasumathy, A. D. Lakdawala, M. B. Alreja, B. Lal, J. Blumbach, K. U. 
Weithmann, R. R. Bartlett, K. S. Joshi, S. Bal-Tembe, S. Raghavan (Hoechst AG), US 6159988, 2000. 
119 K. Kumazawa, K. Ishihara, H. Yamamoto, Org. Lett. 2004, 6, 2551. 
120 J. K. Whitesell, Chem. Rev. 1992, 92, 953. 
121 (a) N. Oguni, Y. Miyagi, K. Itoh, Tetrahedron Lett. 1998, 39, 9023; (b) S. G. Davies, S. Wollowitz, Tetrahedron 
Lett. 1980, 21, 4175. 
122 R. Millet, L. Gremaud, T. Bernardez, L. Palais, A. Alexakis, Synthesis 2009, 2101. 
123 R. B. Bedford, D. W. Bruce, R. M. Frost, J. W. Goodby, M. Hird, Chem. Commun. 2004, 2822. 
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Table 10: Optimization of the conditions for the diastereoselective cross-coupling. 
 
 
Entry Metal Mediator Additive Yield [%]a d.r.a 
     
1b 10% Fe(salen)Cl - 0c n. d. 
     
2d 10% Fe(acac)3
 20% TMEDA, 10% HMTAe traces n. d. 
     
3d 5% FeCl3
 TMEDA (1.2 equiv) 17 76:24 
     
4 10% FeCl3 10% DPEphos 27 96:4 
     
5 FeCl2·2LiCl (0.85 equiv) - 59 (48) 96:4 
     
6 FeCl2·2LiCl (0.85 equiv) TMEDA (1.2 equiv) 86 83:17 
     
7f FeCl2·2LiCl (0.85 equiv) 4-fluorostyrene (0.5 equiv) 78 (61) 96:4 
     
8g FeCl2·2LiCl (0.85 equiv) 
(99.99% Fe) 
4-fluorostyrene (0.5 equiv) 73 (57) 96:4 
     
9 10% Ni(acac)2 10% DPEphos traces n. d. 
     
[a] Determined by capillary GC analysis. Tridecane (C13H28) was used as internal standard. Numbers in brackets 
indicate isolated yields. [b] 2.0 equiv of PhMgCl were used. [c] Only cHexOTBS was obtained. [d] 1.2 equiv of 
PhMgCl were used. [e] HMTA: hexamethylenetetramine [f] The use of catalytic amounts of FeCl2·2 LiCl did not 
lead to a satisfactory conversion of 111. [g] ICP analysis showed that no traces of other transition metals were 
present in the reaction mixture apart from Fe. 
 
Significant improvements were achieved by using substoichiometric amounts (0.85 equiv) of the 
in THF well soluble FeCl2·2 LiCl complex
115d which preferentially gave the thermodynamically 
more stable trans-isomer124 36a in 48% isolated yield (59% GC yield) and with a d.r. of 96:4 
                                                 
124 The relative stereoconfiguration of 36i was determined via X-ray crystallography. 
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(entry 5). The addition of TMEDA40a led to a deterioration of the diastereoselectivity (d.r.: 83:17; 
entry 6). Using 4-fluorostyrene as additive, which is known to facilitate the reductive elimination 
step in Ni-catalyzed cross-couplings,125 resulted in a higher isolated yield of 61% (78% GC yield) 
with an excellent d.r. of 96:4 (entry 7).126, 127 In order to elucidate whether traces of other 
transition metals present in the reaction mixture were responsible for the cross-coupling, we used 
FeCl2 with a purity of 99.99% (Alfa Aesar; entry 8). Thereby, 36a was obtained with a similar 
yield of 57% (73% GC yield). Using a combination of 10% Ni(acac)2 and 10% DPEphos (bis(2-
diphenylphosphinophenyl)ether)128 as catalyst gave 36a only in traces (<3%; entry 9). 
 
2.3.3 Scope of the Fe-mediated diastereoselective cross-coupling 
Next, we have examined the scope of the diastereoselective Fe-mediated cross-coupling using 
various functionalized arylmagnesium reagents (Table 11). These Grignard reagents were 
prepared either by LiCl-promoted insertion of Mg129 or by a Br/Mg-exchange using 
iPrMgCl·LiCl.130 In all cases, the thermodynamically favored trans-1,2-disubstituted 
cyclohexanols were preferentially formed with d.r. ≥95:5.131 Arylmagnesium reagents bearing 
methyl and trifluoromethyl groups were efficiently coupled with high d.r. (95:5 to 99:1 ; entries 
1-3). The cross-couplings of the bulky naphthalen-1-ylmagnesium bromide and the sterically 
congested mesitylmagnesium bromide with 111 gave the trans-products 36e-f with high yields 
(80-90%) and excellent diastereoselectivities (d.r.: 98:2 to >99:1; entries 4-5). Grignard reagents 
bearing sensitive cyano-functions underwent smooth couplings with 4 furnishing the respective 
products 36g-h with 62-65% yield as single diastereomers (entries 6-7). 
 
 
                                                 
125 A. E. Jensen, P. Knochel, J. Org. Chem. 2002, 67, 79. 
126 We assume that a low-valent diaryliron complex is the nucleophilic species in the coupling. A [4-
fluorostyrene·Fe(A(r)C6H10OTBS] complex may form. Complexation with the electron-poor 4-fluorostyrene 
facilitates the reductive elimination process. 
127 The use of TIPS-protected 2-iodocyclohexanol led to the same d.r. (96:4) whereas protection with the bulky 
TBDPS-group resulted in a decreased diastereoselectivity (d.r.: 90:10). 
128 M. Kranenburg, Y. E. M. van der Burgt, P. C. J. Kamer, K. Goubitz, J. Fraanje, P. W. N. M. van Leeuwen, 
Organometallics 1995, 14, 3081. 
129 F. M. Piller, A. Metzger, M. A. Schade, B. A. Haag, A. Gavryushin, P. Knochel, Chem. Eur. J. 2009, 15, 7192. 
130 A. Krasovskiy, P. Knochel, Angew. Chem. Int. Ed. 2004, 43, 3333. 
131 The relative stereoconfiguration of 36i was determined via X-ray crystallography. 
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Table 11: Products of the diastereoselective cross-coupling with 111. 
Entry Product Yield [%]a (d.r.)b Entry Product Yield [%]a (d.r.)b 
      
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
1 36b 62 (95:5) 6 36g 65 (>99:1) 
 
 
 
 
 
 
   
 
 
 
 
 
  
2 36c 67 (99:1) 7 36h 62 (>99:1) 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
TBSO
OPiv
  
3 36d 75 (97:3) 8 36i 62 (95:5) 
 
 
 
 
 
 
  
 
 
 
 
 
  
4 36e 90 (98:2) 9 36j 57 (>99:1) 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
5 36f 80 (>99:1) 10 36k 80 (>99:1) 
      
[a] Isolated yield of analytically pure product. [b] Determined by capillary GC analysis before and after purification. 
Although a pivaloyloxy function is a well known leaving group in Fe-catalyzed cross-couplings 
with Grignard reagents,114c the reaction of (4-(pivaloyloxy)phenyl)magnesium bromide (4-
PivOC6H4MgBr) with 111 exclusively led to the formation of 36i (62%; d.r.: 95:5; entry 8). 
Heteroaryl Grignard reagents, such as 3-quinolinylmagnesium bromide and 3-
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pyridinylmagnesium chloride, were also successfully coupled giving 36j and 36k as single 
diastereomers (entries 9-10). 
In order to underline its synthetic utility, we applied this reaction to the cross-coupling of the 
enantioenriched 2-iodocyclohexanol derivative 113 which was obtained from the readily 
prepared mixture of (R,R)-114 and (R,R)-115132 (92% ee) in only 4 steps with an overall yield of 
39% (Scheme 39). 
 
 
Scheme 39: Preparation and cross-coupling of the chiral 2-iodocyclohexanol 9 (NMI: N-
methylimidazole). 
 
The Fe-mediated cross-couplings of 113 with various aryl Grignard reagents produced the trans-
products 116a-d in a stereoconvergent manner with no loss of chirality (92-93% ee) and excellent 
diasteteroselectivities (d.r.: ≥98:2; Table 12).  
 
Table 12: Products of type 12 of the Fe-mediated cross-coupling with enantioenriched 113. 
Entry Product Yielda (d.r.)b eec 
    
 
 
 
 
 
   
1 116a 87% (98:2) 92% 
 
 
 
 
 
   
2 116b 64% (>99:1) 92% 
    
                                                 
132 S. Demay, F. Volant, P. Knochel, Angew. Chem. Int. Ed. 2001, 40, 1235. 
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Table 12 continued 
    
 
 
 
 
 
 
   
3 116c 69% (>99:1) 93% 
 
 
 
 
 
   
4 116d 73% (>99:1) 92% 
    
[a] Isolated yield of analytically pure product. [b] Determined by capillary GC analysis before and after purification. 
[c] Enantiomeric excess (ee) was determined by chiral HPLC. See appendix. 
Thus, the reaction is suitable for an efficient propagation of stereoinformation and represents a 
valuable alternative to enantioselective openings of symmetrical epoxides. 
Finally, we have tried this diastereoselective Fe-mediated coupling on the TBS-protected 2-
iodocyclopentanol 117 using various functionalized (hetero)aryl Grignard reagents (Scheme 40). 
 
TBSO TBSOa) FeCl22 LiCl (0.85 equiv)
4-fluorostyrene (0.5 equiv)
b) ArMgX 112 (1.7 equiv)
THF, -50 °C to rt, 8 h117 118a-j: 42-80%;
d.r.: 98:2 to >99:1
I Ar
 
Scheme 40: Diastereoselective cross-coupling of the 2-iodocyclopent-anol derivative 117. 
 
To our delight, the trans-coupling products133 118a-j were obtained with excellent d.r. from 98:2 
to >99:1 (Table 13). trans-2-Arylcyclopentanols are reported to constitute important building 
blocks for drugs treating diabetes134 and chiral phosphine ligands.135 
 
                                                 
133 The relative stereoconfiguration of 118d was determined via desilylation. The crystals of the resulting alcohol 
proved suitable for X-ray crystallography. 
134 (a) E. Sher (Eli Lilly and Company), WO 2002089848, 2002; (b) T. A. Shepherd, J. A. Aikins, D. Bleakman, B. 
E. Cantrell, J. P. Rearick, R: L. Simon, E. C. R. Smith, G. A. Stephenson, D. M. Zimmerman, J. Med. Chem. 2002, 
45, 2101. 
135 B. E. Bosch, A. Monsees, U. Dingerdissen, P. Knochel, E. Hupe (Degussa AG), WO 2002014330, 2002. 
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Table 13: Products of the diastereoselective cross-coupling with 117. 
Entry Product Yield [%]a (d.r.)b Entry Product Yield [%]a (d.r.)b 
      
 
 
 
 
 
 
  
 
 
 
 
 
  
1 118a 56 (98:2) 6 118f 68 (>99:1) 
 
 
 
 
 
   
 
 
 
 
  
2 118b 80 (>99:1) 7 118g 69 (>99:1) 
 
 
 
 
 
  
 
 
 
 
 
 
  
3 118c 65 (>99:1) 8 118h 68 (>99:1) 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
4 118d 75 (>99:1) 9 118i 42 (>99:1) 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
  
5 118e 60 (>99:1) 10 118j 60 (>99:1) 
      
[a] Isolated yield of analytically pure product. [b] Determined by capillary GC analysis before and after purification. 
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2.4 Diastereoselective arylations of substituted piperidines via Pd-Catalyzed Csp3-Csp2 
cross-couplings 
2.4.1 Introduction 
Substituted piperidines are ubiquitous structural motifs present in numerous bioactive alkaloids.53 
In order to ensure appropriate biological activity, many of them have to be prepared in a 
stereodefined manner.53 Therefore, the development of efficient methods for the 
diastereoselective construction of piperidines bearing more than one stereocenter represents an 
important synthetic task.136 Still, procedures for the direct stereoselective arylation of the 
piperidine ring are scarce.137 Only one isolated example of the diastereoselective coupling of a 2-
methylpiperidinyl organometallic with 4-bromoveratrole furnishing the trans-2,6-disubstituted 
product has been reported.137c So far the direct stereoselective synthesis of 2,4- and 2,5-
disubstituted arylated piperidines via Csp3-Csp2 cross-coupling remains a challenging problem. 
Following our series of diastereoselective cross-couplings with substituted cycloalkyl derivatives 
(chapters 2.1, 2.2 and 2.3),101, 117, 138 we extended our investigations to the heterocyclic 
piperidinyl system. In chapter 2.1, it was shown that the cross-couplings of substituted 
cyclohexylzinc reagents with diverse aryl halides result in the stereoconvergent formation of the 
thermodynamically favored arylpalladium intermediates which after reductive elimination afford 
                                                 
136 (a) A. Larivée, A. B. Charette, Org. Lett. 2006, 8, 3955; (b) T. A. Johnson, D. O. Jang, B. W. Slafer, M. D. Curtis, 
P. Beak, J. Am. Chem. Soc. 2002, 124, 11689; (c) M. K. S. Vink, C. A. Schortinghuis, J. Luten, J. H. van 
Maarseveen, H. E. Schoemaker, H. Hiemstra, F. P. J. T. Rutjes, J. Org. Chem. 2002, 67, 7869; (d) P. S. Watson, B. 
Jiang, B. Scott, Org. Lett. 2000, 2, 3679; (e) M. A. Wijdeven, F. L. van Delft, F. P. J. T. Rutjes, Tetrahedron 2010, 
66, 5623; ((f) M.-E. Ragoussi, S. M. Walker, A. Piccanello, B. M. Kariuki, P. N. Horton, N. Spencer, J. S. Snaith, J. 
Org. Chem. 2010, 75, 7347; (g) M. M. A. R. Moustafa, B. L. Pagenkopf, Org. Lett. 2010, 12, 4732; (h) A. Guérinot, 
A. Serra-Muns, C. Gnamm, C. Bensoussan, S. Reymond, J. Cossy, Org. Lett. 2010, 12, 1808; (i) T. Urushima, D. 
Sakamoto, H. Ishikawa, Y. Hayashi, Org. Lett. 2010, 12, 4588; (j) M. Z. Chen, G. C. Micalizio, Org. Lett. 2009, 11, 
4982; (k) J. M. Humphrey, E. P. Arnold, T. A. Chappie, J. B. Feltenberger, A. Nagel, W. Simon, M. Suarez-
Contreras, N. J. Tom, B. T. O’Neill, J. Org. Chem. 2009, 74, 4525; (l) Y. Chen, C. Zhong, J. L. Petersen, N. G. 
Akhmedov, X. Shi, Org. Lett. 2009, 11, 2333; (m) J. L. Bilke, S. P. Moore, P. O’Brien, J. Gilday, Org. Lett. 2009, 
11, 1935; (n) G. Barbe, M. St-Onge, A. B. Charette, Org. Lett. 2008, 10, 5497; (o) S. Mix, S. Blechert, Adv. Synth. 
Catal. 2007, 349, 157; (p) G. A. Cortez, R. R. Schrock, A. H. Hoveyda, Angew. Chem. 2007, 119, 4618; Angew. 
Chem. Int. Ed. 2007, 46, 4534; (q) M. Amat, O. Bassas, N. Llor, M. Cantó, M. Pérez, E. Molins, J. Bosch, Chem. 
Eur. J. 2006, 12, 7872; (r) G. S. Kauffman, P. S. Watson, W. A. Nugent, J. Org. Chem. 2006, 71, 8975; (s) A. 
Takemiya, J. F. Hartwig, J. Am. Chem. Soc. 2006, 128, 6042; (t) H. M. Peltier, J. A. Ellman, J. Org. Chem. 2005, 70, 
7342; (u) H. Poerwono, K. Higashiyama, T. Yamauchi, H. Kubo, S. Ohmiya, H. Takahashi, Tetrahedron 1998, 54, 
13955. 
137 (a) H. Prokopcová, S. D. Bergman, K. Aelvoet, V. Smout, W. Herrebout, B. Van der Veken, L. Meerpoel, B. U. 
W. Maes, Chem. Eur. J. 2010, 16, 13063; (b) S. J. Pastine, D. V. Gribkov, D. Sames, J. Am. Chem. Soc. 2006, 128, 
14220; for stereoselective versions see: (c) I. Coldham, D. Leonori, Org. Lett. 2008, 10, 3923; (d) R. Shintani, N. 
Tokunaga, H. Doi, T. Hayashi, J. Am. Chem. Soc. 2004, 126, 6240; (e) M. Amat, J. Bosch, J. Hidalgo, M. Cantó, M. 
Pérez, N. Llor, E. Molins, C. Miravitlles, M. Orozco, J. Luque, J. Org. Chem. 2000, 65, 3074; (f) M. Amat, M. 
Pérez, A. T. Minaglia, J. Bosch, J. Org. Chem. 2008, 73, 6920. 
138 A. K. Steib, T. Thaler, P. Mayer, P. Knochel, Angew. Chem. Int. Ed. 2011, manuscript accepted. 
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the desired arylated products with retention of configuration (d.r. up to >99:1).101 Due to the 
structural importance of piperidines, we have envisioned the performance of diastereoselective 
cross-couplings with the related substituted piperidinylzinc compounds. By exploiting the 
pseudo-allylic strain induced by the protecting group at nitrogen,139 we were able to prepare both 
the cis- and trans-2,4-disubstituted piperidine derivatives with excellent levels of 
diastereoselectivity. 
 
2.4.2 Cross-coupling of 3- and 4-substituted piperidin-2-ylzinc reagents 
First, we have generated various piperidin-2-ylzinc reagents of type 119 starting from the 
respective piperidines 120a-e according to the procedures of Beak140 and Coldham.137c To our 
delight, the Pd-catalyzed cross-coupling of 119a-e with various aryl and heteroaryl iodides using 
2% SPhos80 or 5% RuPhos141 (dicyclohexyl(2',6'-diisopropoxy-[1,1'-biphenyl]-2-yl)phosphine) 
and 2-5% Pd(dba)2 as catalyst system furnished the desired α-arylated products 121 in 54-84% 
yield and with an exceptional level of diastereoselectivity (d.r. of 95:5 to >99:1; Scheme 41). 
 
 
Scheme 41: Preparation and diastereoselective cross-coupling of 4- and 5-substituted N-Boc 
piperidin-2-ylzinc reagents (119). 
 
Thus, cross-coupling of the 4-methyl-substituted piperidinylzinc reagent 119a with electron-rich 
4-iodoanisole using 2% Pd(dba)2 and 2% SPhos at 55 °C furnished exclusively the cis-configured 
                                                 
139 (a) H. Paulsen, K. Todt, Angew. Chem. Int. Ed. Engl. 1966, 5, 899. (b) R. A. Johnson, J. Org. Chem. 1967, 33, 
3627. 
140 (a) P. Beak, W. K. Lee, J. Org. Chem. 1993, 58, 1109; (b) P. Beak, W. K. Lee, J. Org. Chem. 1990, 55, 2578. 
141 M. D. Charles, P. Schultz, S. L. Buchwald, Org. Lett. 2005, 7, 3965. 
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product 121a in 78% yield (entry 1 of Table 14).142 Coupling of 119a with electron-poor aryl 
iodides and 4-iodopyridine under the same conditions gave the products 121b-f with d.r. from 
95:5 to 98:2 (entries 2-6).  
 
 
Table 14: Diastereoselective cross-coupling of substituted piperdin-2-ylzinc reagents. 
Entry  Product Yield [%]a (d.r.)b 
    
1 
 
 
 
 
 
121a: Ar= 4-MeO-C6H4 78 (>99:1)c 
2 121b: Ar= 4-F3C-C6H4 81 (95:5)c 
3 121c: Ar= 3-Cl-C6H4 76 (96:4)c 
4 121d: Ar= 3-NC-C6H4 64 (97:3)c 
5 121e: Ar= 4-EtO2C-C6H4 67 (98:2)c 
6 121f: Ar= 4-pyridinyl 73 (95:5)c 
 
 
 
 
 
 
 
  
 
  
7 121g: Ar= 4-F3C-C6H4 64 (97:3)d 
8 121h: Ar= 4-NC-C6H4 79 (>99:1)d 
9 121i: Ar= 4-MeO2C-C6H4 67 (99:1)d 
 
  
 
  
 
 
 
 
 
 
 
  
10 121j: Ar= 4-EtO2C-C6H4 84 (97:3)e 
11[e] 121k: Ar= 4-F-C6H4 83 (95:5)e 
12[e] 121l: Ar= 4-F3C-C6H4 81 (95:5)e 
13[e] 121m: Ar= 4-NC-C6H4 81 (97:3)e 
 
  
 
 
 
 
 
 
 
  
 
  
14 121n: Ar= 4-F3C-C6H4 69 (>99:1)d 
15 121o: Ar= 4-NC-C6H4 54 (>99:1)d 
16 121p: Ar= 4-MeO-C6H4 60 (97:3)d 
 
  
 
   
                                                 
142 The relative configurations of 121d and 121h were directly determined via X-ray analysis. The relative 
configurations of 121n and 121q were determined via acidic removal of the Boc-protective group and subsequent 
tosylation. The crystals of the tosylates (121na and 121qa) proved suitable for X-ray analysis. See appendix. 
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Table 14 continued 
 
 
 
 
 
 
  
 
  
17 121q: Ar= 4-NC-C6H4 62 (96:4)f 
18 121r: Ar= 4-EtO2C-C6H4 59 (95:5)f 
 
  
 
  
[a] Isolated yield of analytically pure product. [b] Determined by capillary GC or 1H /13C NMR analysis. [c] 2% 
Pd(dba)2, 2% SPhos, THF, 55 °C, 12 h. [d] 5% Pd(dba)2, 5% RuPhos, THF, 55 °C, 12 h. [e] 5% Pd(dba)2, 5% 
RuPhos, THF, 55 °C, 60 h. [f] 5% Pd(dba)2, 5% Ru-Phos, THF, 0 °C (6 h), then rt (12 h), then 40 °C (12 h). 
The piperidinylzinc reagent 119b bearing a large phenyl ring instead of the smaller methyl-
substituent provided, under slightly altered conditions (5% Pd(dba)2 and 5% RuPhos at 55 °C), 
the cis-products 121g-i with comparable yields (64-79%) and equally high diastereoselectivities 
(97:3 to >99:1; entries 7-9). Even the functionalized piperidinylzinc reagent 119c bearing an 
OTIPS (OSi(iPr)3) group in position 4 reacted smoothly furnishing the cis-α-arylated products 
121j-m with high yields (81-84%) and d.r. between 95:5 and 97:3 (entries 10-13). The method 
also proved applicable to the trans-decahydroisoquinolinyl scaffold. By using Beak’s method140 
we were able for the first time to regioselectively metalate this heterocycle at position 3. Cross-
coupling of the resulting organozinc species 119d led to the stereodefined 2,4,5-trisubstituted 
products 121n-p in 54-69% yield with excellent d.r. (97:3 to >99:1; entries 14-16). In the case of 
the 5-methyl-substituted reagent 119e, lower temperatures were necessary for achieving high 
diastereoselectivities (Table 14). Thus, the trans-2,5-disubstituted products 121q-r were obtained 
in moderate yields of 59-62% with a high d.r. of 95:5 (entries 17-18).142 
 
2.4.3 Cross-coupling of 2-substituted piperidin-4-ylzinc reagents 
Complementary to the diastereoselective preparation of the cis-2,4-disubstituted piperidines, we 
were also able to implement the synthesis of the corresponding trans-isomers by switching the 
positions of the substituent and the C-Zn bond. Thus, in preliminary experiments, we have 
prepared the 2-substituted piperidin-4-ylzinc reagent 122a via LiCl-promoted Zn-insertion into 
the iodide 123a79 and subjected it to cross-coupling with 4-iodobenzonitrile and iodobenzene 
using 5% TMPP2PdCl2
83 as catalyst (Scheme 42).101 
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Scheme 42: Preparation and diastereoselective cross-coupling of 2-substituted piperidin-4-ylzinc 
iodides (122). 
 
The trans-coupling products 124a-b were obtained in 50-74% yield with diastereoselectivities of 
d.r.: 91:9 and 92:8 (entries 1 and 2 of Table 15).143 
 
Table 15: Diastereoselective cross-coupling of 2-substituted piperidin-4-ylzinc reagents. 
Entry  Product Yield [%]a (d.r.)b 
 
 
 
 
 
 
 
  
 
  
1 124a: Ar= 4-NC-C6H4 74 (91:9) 
2 124b: Ar= Ph 50 (92:8) 
 
  
 
  
 
 
 
 
 
 
 
  
 
  
3 124c: Ar= 4-NC-C6H4 70 (>99:1) 
4 124d: Ar= 4-MeO2C-C6H4 69 (96:4) 
 
  
 
  
 
 
 
 
 
 
 
  
 
  
5 124e: Ar= 4-NC-C6H4 84 (97:3) 
6 124f: Ar= 4-MeO2C-C6H4 89 (97:3) 
 
  
 
  
[a] Isolated yield of analytically pure product. [b] Determined by capillary GC or 1H /13C NMR analysis. 
                                                 
143 The relative configuration of 124a was determined via acidic removal of the Boc-protective group and subsequent 
tosylation. The crystals of the tosylate proved suitable for X-ray analysis. The relative configurations of 124c and 
124e were directly determined via X-ray analysis. See appendix for details. 
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By examining the NMR spectra of the N-Boc protected products 124a and 124b, we found that 
both revealed the presence of two Boc-conformers at room temperature. These findings are 
supported by DFT-analysis.144 Furthermore, X-ray structures of the already prepared N-Boc 
protected piperidines 121d and 121h142 (entries 6 and 8 of Table 14) showed a twisted ring 
conformation, whereas the structures of the N-Ts protected piperidines 121na and 121qa142 
displayed an almost perfect chair-like structure. We, therefore, prepared the corresponding N-
tosylated zinc reagent 122b. Cross-coupling of 122b with 4-iodobenzonitrile under the same 
reaction conditions led to the exclusive formation of the trans-isomer 124c in 70% yield (entry 3). 
Remarkably, the couplings of the zinc reagent 122c bearing only a small methyl group in position 
2 also gave the respective trans-isomers 124e-f with an excellent diastereoselectivity of d.r.: 97:3 
(entries 5 and 6). 
 
2.4.4 Mechanistic considerations 
In order to explain the distinct stereochemical outcome of these couplings, the cis/trans stability 
differences between 121g and 124b together with the respective data for the Zn- and Pd-
intermediates were analyzed at the B3LYP/631SVP level (Scheme 43 and Table 16).145 From our 
former studies (chapter 2.1),101 it was clear that the relative stabilities of the Pd-intermediates 
represent the crucial factor for the determination of the final diastereoselectivity of the cross-
coupling. The stabilities of the products (121g and 124b) and of the corresponding zinc 
intermediates have been calculated in order to refine our mechanistic picture. In contrast to the 
corresponding cyclohexanes, in which an overall equatorial substitution pattern is 
thermodynamically preferred,101 the pseudo-allylic strain in N-Boc piperidines caused by the 
partial double-bond character of the amide bond forces the substituent vicinal to the nitrogen into 
an axial orientation.139 Therefore, cis-isomer 121g was found to be significantly less stable (by 
13.4 kJ/mol) than trans-isomer 124b. Detailed DFT conformational analysis (chair vs. twist boat) 
shows that the energy difference between the chair and twist boat conformation is negligible for 
121g, whereas it is large for 124b. 
 
                                                 
144 1H and 13C NMR analyses of 124a and 124b at 70 °C showed an average spectrum of the two conformers. This 
finding is supported by the conformational analysis of product 124b at the B3LYP/6-31G(d,p) level. 
145 The theoretical methods used herein are identical to those in chapter 2.190 and involve the combination of the 
B3LYP hybrid functional with the def2-SVP all-electron basis set on Zn, the ECP-based def2-SVP basis set on Pd, 
and the 6-31G(d,p) basis set on all other elements. 
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Scheme 43: DFT-conformational analysis of cis-isomer 121g and trans-isomer 124b. 
Conformations are indicated as twist-boat (TB) or chair (C). 
 
The stabilities of the respective Pd- and Zn-intermediates involved in the formation of the cross-
coupling products 121g and 124b have been calculated using the same model as in our recent 
study of the analogous cyclohexyl systems (chapter 2.1).101 Whereas the diastereomeric 
substituted cyclohexylzinc complexes possessed very similar energies, large differences in the 
stabilities of the corresponding piperidinylzinc species were found. In the case of piperidin-2-
ylzinc reagent 119b, the equatorial orientation of the C-Zn bond is stabilized by its coordination 
to the carbonyl oxygen atom of the Boc group leading to a pentacoordinated Zn-center. This 
results in an energetic preference for eq-119b by 15.4 kJ/mol (entry 1 of Table 16). Since pseudo-
allylic strain in the 4-zincated piperidinyl species 122a dictates an axial position of the 
substituent at C2, axial orientation of the C-Zn bond is hampered by 1,3-diaxial repulsions 
resulting in ax-122a as the most stable conformer (entry 2). This underlines the “Janus-like” 
nature of the Boc-group showing its sterically demanding, repulsive character towards vicinal 
substituents, yet turning into an electrostatically attractive neighbor with Lewis-acidic metal 
centers present at the same position. 
Analogously to the cyclohexyl systems, the Pd moiety shows a preference for the equatorial 
position in all cases. In the piperidin-2-ylpalladium intermediates (eq-125 and ax-125; entry 1), in 
which the square-planar coordination sphere of Pd is not perturbed, this natural preference is 
augmented by a close contact between the Pd-center and the carbonyl oxygen atom of the Boc 
group. If, however, C2 is occupied by an aryl/alkyl substituent, 1,3-allylic strain139 takes effect 
and causes axial orientation (ax-126 vs. eq-126; entry 2). Without this interaction, diaxial 
repulsions dictate equatorial orientation of the aryl/alkyl substituent (eq-125 vs. ax-125; entry 1). 
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Table 16: DFT calculation-based conformational analysis on the diastereomeric zinc and 
palladium complexes. 
Entry Zn-intermediates
a 
∆H298ax-eq [kJ/mol]b 
Pd-intermediatesa,c 
∆H298ax-eq [kJ/mol]b 
     
 
 
 
 
 
 
eq-119b (C) 
 
 
 
 
 
ax-119b (C) 
 
 
 
 
 
eq-125 (C) 
 
 
 
 
 
ax-125 (C) 
1 +15.4 +15.0 
 
 
 
 
 
 
 
eq-122a (TB) 
 
 
 
 
 
 
ax-122a (C) 
 
 
 
 
 
 
eq-126 (TB) 
 
 
 
 
 
 
ax-126 (C) 
2 -8.4 -8.6 
   
[a] Ar= 4-F3C-C6H4. Preferred conformations are indicated as twist-boat (TB) or chair (C). [b] Calculated energetic 
differences (B3LYP/631SVP) between the thermodynamically lowest conformers of the two diastereomers. [c] L= 
PMe3. 
Considering the energetic differences of the organometallic intermediates, the diastereoselectivity 
in the couplings of the piperidinylzinc reagents (119 and 122) is always determined on the stage 
of the respective Pd-complexes via a selective transmetalation step leading to the 
thermodynamically most stable intermediate, as proposed for the cyclohexyl systems (chapter 
2.1).101 
 
2.4.5 Diastereoselective Pd-1,2-migration 
In continuation of our study, we found by performing cross-couplings with the 2-methyl-
substituted piperidin-2-ylzinc reagent 127, a consistent highly stereoselective formation of the 5-
arylated trans-configured products of type 128 (d.r.: 93:7 to 96:4),146 whereas the expected trans-
2,6-disubstituted product 129 was not obtained (Scheme 44). It is noteworthy that the coupling 
proceeded equally well with electron-rich (128b) and electron-poor aryl iodides (128c-e). 
 
                                                 
146 The relative configuration of 128c was determined via acidic removal of the Boc-protective group and subsequent 
tosylation. The crystals of the tosylate proved suitable for X-ray analysis. 
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Scheme 44: Diastereoselective cross-coupling of 6-substituted N-Boc piperidin-2-ylzinc chloride 
(127) – observation of a 1,2-migration. 
 
We assume that this reaction proceeds via β-hydride elimination of the Pd moiety.147 The 
resulting ArPdL2H
148 complex stays bound to the same side of the tetrahydropyridinyl ring and 
its subsequent syn-addition149 places the Pd in the sterically less hindered position 5. Rapid 
reductive elimination furnishes the observed δ-arylated 2,5-disubstituted coupling products (128). 
                                                 
147 (a) R. Ogawa, Y. Shigemori, K. Uehara, J. Sano, T. Nakajima, I. Shimizu, Chem. Lett. 2007, 36, 1338. (b) G. C. 
Lloyd-Jones, P. A. Slatford, J. Am. Chem. Soc. 2004, 126, 2690 and references therein. 
148 (a) I. D. Hills, G. C. Fu, J. Am. Chem. Soc. 2004, 126, 13178; (b) V. V. Grushin, Chem. Rev. 1996, 96, 2011; (c) 
R. F. Heck, Acc. Chem. Res. 1979, 12, 146. 
149 (a) A. F. Schmidt, V. V. Smirnov, Kinet. Catal. 2003, 44, 518; (b) P. M. Henry, G. A. Ward, J. Am. Chem. Soc. 
1972, 94, 673. 
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3. Summary 
This work dealt with two different subjects: enantiocontrol with chiral sulfoxides and 
diastereocontrol in the cross-coupling reactions of substituted cycloalkyl and piperidinyl 
derivatives. The enantiocontrol exerted by chiral sulfoxides was used for the design of a novel 
enantioselective synthesis of chiral QUINAP and the preparation and use of new chiral sulfoxide-
alkene hybrid ligands in the Hayashi-Miyaura reaction. The diastereocontrol in the Pd-catalyzed 
cross-couplings of substituted cycloalkylzinc reagents was thoroughly examined and its scope 
was extended to the use of 1,3- and 1,4-substituted cyclohexylzinc reagents. These 
diastereoselective cross-couplings were shown to be applicable to both (hetero)aryl halides and 
alkynyl bromides. The diastereoselective synthesis of cyclic 2-arylalcohol derivatives which are 
not accessible via this method was achieved by developing a complementary Fe-mediated cross-
coupling of aryl Grignard reagents with protected cyclic 2-iodohydrines. Finally, the 
diastereoselective Pd-catalyzed cross-coupling was applied to various substituted piperidinylzinc 
reagents allowing a convenient and stereoselective access to the pharmacologically important 
class of arylated piperidines. Thereby, a stereoselective 1,2-Pd migration was discovered in the 
cross-coupling of 6-methyl substituted piperidin-2-ylzinc chloride with aryl iodides. 
 
3.1 Novel enantioselective QUINAP synthesis via diastereomeric sulfoxide intermediates 
In summary, we have developed a novel practical resolution of chiral QUINAP avoiding the use 
of half-equivalents of Pd salts. Both (S)- and (R)-QUINAP were efficiently obtained (Scheme 
45). In terms of yields, time and effort, this approach readily competes with the conventional 
preparation.52 Furthermore, the chiral organolithium intermediate gives the possibility for the 
preparation of various QUINAP analogues, as it may be trapped with a broad range of 
electrophiles. 
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Scheme 45: Novel synthesis of chiral QUINAP via chiral sulfoxide-intermediates. 
 
3.2 Development of sulfoxide-alkene hybrids as a novel class of chiral ligands for the 
Hayashi-Miyaura reaction 
We have developed a concise, protective group free synthesis of sulfoxide-alkene hybrid ligands 
which combine the properties of chiral sulfoxide and olefin ligands (Scheme 46). Chiral 
resolution is achieved via simple column chromatographic separation of the diastereomeric 
ligands which can both be efficiently used in the Hayashi-Miyaura reaction furnishing the chiral 
products with excellent yields, equally high enantioselectivities and opposite 
stereoconfigurations.  
 
S+
Ar
R
O-
sulfoxide:
a) simple resolution via
column chromatographic
separation
b) vital f or the reactivity of
the Rh-catalyst
C=C bond:
a) chiral environment dictates
conf iguration of products
=> diastereomeric ligands
(dif f erent chiral backbone
same conf iguration at the sulf ur)
give chiral products with
opposite conf igurations
S+
Ar
R
O-
 
Scheme 46: New chiral ligand class combining the properties of sulfoxide and alkene ligands. 
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Experiments with analogues of 46a and 46b with different steric and electronic properties 
showed that coordination of the sulfinyl group represents a crucial factor for efficient chelation 
and formation of the reactive Rh-complex. Although efficient binding of the alkenyl moiety to 
the Rh is less important for the reaction to proceed, its chiral environment dictates the 
stereochemical outcome. 
 
3.3 Diastereoselective Csp3-Csp2 cross-couplings with 1,2-, 1,3- and 1,4-substituted 
cycloalkylzinc compounds 
A highly diastereoselective method for the cross-coupling of variously substituted cycloalkylzinc 
reagents with aryl and heteroaryl halides using Pd-catalysis has been successfully developed. 
Remarkably, not only substituents in position 2 strongly influence the diastereoselectivity of the 
cross-coupling, but also substituents in positions 3 and 4 of the cyclohexyl ring. Excellent 
diastereoselectivities are also obtained for bicyclic systems, cyclopentane derivatives and steroids 
(Scheme 47). 
 
 
Scheme 47: Pd-catalyzed diastereoselective cross-coupling of substituted cycloalkylzinc 
reagents. 
 
In order to understand the origin of this diastereoselectivity, we performed NMR experiments on 
a Pd-intermediate and DFT calculations which clearly show that remote substituents (e.g. in 
position 4) exert a strong influence on the stability of the resulting Pd-intermediates. Based on 
these results, a tentative mechanism has been proposed. 
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3.4 Diastereoselective Csp3-Csp cross-couplings between 1,3- and 1,4-substituted 
cyclohexylzinc reagents and bromoalkynes 
A general and highly diastereoselective method for the Pd-catalyzed cross-coupling of 3- and 4-
substituted cyclohexylzinc reagents with alkynyl bromides via remote stereocontrol was 
developed. With the easily available and inexpensive ortho-phenanthroline-derivative 
neocuproine as ligand, diastereomeric ratios of up to 98:2 were achieved. The method can be 
used for the synthesis of building blocks which may be relevant for the synthesis of liquid crystal 
mesogens and their chiral dopants (Scheme 48). 
 
 
Scheme 48: Sequential diastereoselective Csp3-Csp and Csp3-Csp2 coupling for the preparation 
of potential chiral dopants for liquid crystals. 
 
3.5 Diastereoselective Fe-mediated Csp2-Csp3 cross-couplings 
A highly diastereoselective method for the Fe-mediated cross-coupling of cyclic TBS-protected 
iodohydrines with aryl Grignard reagents was disclosed with Fe being truly the mediating 
transition-metal in the coupling. The method can be applied to a broad range of functionalized 
(hetero)arylmagnesium reagents furnishing the respective trans-2-arylcycloalcohol derivatives 
with d.r. up to >99:1. The stereoconvergent cross-coupling of chiral TBS-protected 2-
iodocyclohexanol provides the corresponding 2-arylcyclohexanols with no loss of chirality 
(Scheme 49). Therefore, this method represents a valuable alternative to the enantioselective 
opening of symmetrical epoxides. 
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Scheme 49: Diastereoselective Fe-mediated cross-coupling. 
 
3.6 Diastereoselective arylations of substituted piperidines 
A highly diastereoselective methodology for the preparation of various substituted piperidines via 
Negishi cross-couplings with (hetero)aryl iodides was developed. At will, either the trans- or the 
cis-2,4-disubstituted piperidines can be obtained by choosing the position of the reactive C-Zn 
bond (C2 vs. C4; Scheme 50). DFT-calculations on the relative stabilities of the Pd-intermediates 
show that the stereoselectivity is determined by a selective formation of the respective 
thermodynamically most stable Pd-complex. A novel Pd-1,2-migration further expands this 
method to the stereoselective preparation of 5-arylated 2,5-disubstituted piperidines (Scheme 50). 
 
 
Scheme 50: Directable diastereoselective cross-coupling of substituted piperidinylzinc reagents 
and Pd-1,2-migration. 
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1. General Considerations 
All reactions were carried out with magnetic stirring and, if the reagents were air or moisture 
sensitive, in flame-dried glassware under argon or nitrogen. Syringes which were used to transfer 
reagents and solvents were purged with argon or nitrogen prior to use.  
 
1.1. Solvents 
Solvents were dried according to standard procedures by distillation over drying agents and 
stored under argon. 
CH2Cl2 was predried over CaCl2 and distilled from CaH2. 
DMF was heated to reflux for 14 h over CaH2 and distilled from CaH2. 
1,4-Dioxane was heated to reflux for 14 h over CaH2 and distilled from CaH2. 
Et2O was predried over calcium hydride and dried with the solvent purification system SPS-400-
2 from INNOVATIVE TECHNOLOGIES INC. 
NEP was heated to reflux for 14 h over CaH2 and distilled from CaH2. 
Pyridine was dried over KOH and distilled. 
THF was continuously refluxed and freshly distilled from sodium benzophenone ketyl under 
nitrogen. 
Toluene was predried over CaCl2 and distilled from CaH2. 
Triethylamine was dried over KOH and distilled 
Solvents for column chromatography were distilled prior to use.  
 
1.2. Reagents 
iPrMgCl·LiCl solution in THF was purchased from Chemetall. 
iPrMgCl solution in THF was purchased from Chemetall 
PhMgCl solution in THF was purchased from Chemetall 
nBuLi solution in n-hexane was purchased from Chemetall. 
sBuLi solution in cyclohexane was purchased from Chemetall. 
tBuLi solution in n-pentane was purchased from Chemetall. 
PhLi solution was prepared by slowly adding tBuLi (1.5 M in n-pentane; 2.2 ml; 3.3 mmol) to a 
solution of iodobenzene (0.337 g; 1.65 mmol) in anhydrous Et2O (3 ml) at -78 °C under argon 
atmosphere. The reaction mixture was stirred for 10 min at -78°C before it was allowed to reach 
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room temperature. The solvents were subsequently removed in vacuo until a white precipitate 
remained. The flask was then flushed with argon and recooled to -78°C. Anhydrous THF (3 ml) 
were carefully added and the mixture was then allowed to warm to 0°C in order to receive a 
homogeneous solution. The reagent was not stored but immediately used in the respective 
reaction. 
 
Content determination of organometallic reagents: 
The respective organometallic reagents were titrated using either the method reported by 
Paquette150 or Knochel151 prior to their use. 
 
ZnCl2 solution (1.0 M) was prepared by drying ZnCl2 (100 mmol, 136 g) in a Schlenk-flask under 
high vacuum at 140 °C for 5 h. After cooling to room temperature, anhydrous THF (100 mL) was 
added and stirring was continued until the salt was dissolved. The reagent was stirred under a 
nitrogen atmosphere. 
MgCl2 solution (0.5 M) was prepared by drying magnesium turnings (0.73 g, 30 mmol) in a 
Schlenk-flask under high vacuum at 140 °C for 15 min. After cooling to room temperature 
anhydrous THF (60 mL) was filled in. The mixture was vigorously stirred and 1,2-dichloroethane 
(2.38 mL, 30 mmol) was carefully added dropwise until all magnesium filings had been 
consumed (15 h; caution, exothermic reaction! , gas development). The reagent was stirred under 
a nitrogen atmosphere. 
FeCl2·2LiCl solution (1.0 M) was prepared by drying LiCl (110 mmol, 4.7 g) in a Schlenk-flask 
under high vacuum at 150 °C for 3 h. After cooling to room temperature under argon, FeCl2 
(50 mmol, 6.34 g) was added under a nitrogen atmosphere inside a glove-box. The Schlenk-flask 
was further heated to 130 °C for 5 h under high vacuum, cooled to room temperature and charged 
with anhydrous THF (50 mL) under argon. The mixture has to be stirred for approximately 4 h 
until all solids are dissolved. The reagent appears as a dark brown solution that is stable for 
several weeks at room temperature. 
CuCN·2LiCl solution (1.0 M) was prepared by drying CuCN (80.0 mmol, 7.17 g) and LiCl 
(160 mmol, 6.77 g) in a Schlenk-tube under high vacuum at 140 °C for 5 h. After cooling to room 
temperature, anhydrous THF (80 mL) was added under argon and stirring was continued until the 
                                                 
150 H.-S. Lin, L. A. Paquette, Synth. Commun. 1994, 24, 2503. 
151 A. Krasovskiy, P. Knochel, Synthesis 2006, 890. 
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salt was dissolved. The Schlenk-tube was wrapped in an aluminum-foil to protect from light. The 
reagent appears as a slightly greenish solution and has to be stored under argon. 
LaCl3·2LiCl solution (0.3 M in THF) was purchased from Chemetall. 
 
1.3. Chromatography 
Flash column chromatography was performed using silica gel 60 (0.040-0.063 mm) from 
Merck or Florisil® (60-100 mesh) from Alfa Aesar. 
Thin layer chromatography was performed using SiO2 pre-coated aluminum plates (Merck 60, 
F-254). The chromatograms were examined under UV light at 254 nm and/or by staining of the 
TLC plate with one of the solutions given below followed by heating with a heat gun: 
- K2CO3 (40 g), KMnO4 (6.0 g) in H2O (600 mL), then 10% NaOH (5 mL) was added. 
- Phosphomolybdic acid (5.0 g), Ce(SO4)2 (2.0 g) and conc. H2SO4 (12 mL) in H2O 
(230 mL). 
- Phosphomolybdic acid (16.0 g) in EtOH (40 mL). 
 
1.4. Analytical data 
NMR spectra were recorded on VARIAN Mercury 200, BRUKER AXR 300, VARIAN VXR 
400 S and BRUKER AMX 600 instruments. Chemical shifts are reported as δ-values in ppm 
relative to the residual solvent peaks of CHCl3 (δH : 7.25, δC : 77.0), benzene (δH : 7.16, δC : 
128.4), THF (δH1 : 1.73, δH2 : 3.58, δC1 : 25.4, δC2 : 67.6) or 1,4-dioxane (δH : 3.53, δC : 66.7). For 
the characterization of the observed signal multiplicities the following abbreviations were used: s 
(singlet), d (doublet), t (triplet), q (quartet), quint (quintet), sept (septet), m (multiplet) as well as 
br (broad). 
Mass spectroscopy: High resolution (HRMS) spectra were either recorded on a FINNIGAN 
MAT 95Q (EI) or a Thermo Finnigan LTQ FT instrument (ESI). Electron impact ionization (EI) 
was conducted with an electron energy of 70 eV. Electrospray ionization (ESI) was conducted 
with an IonMax ion-source equipped with an ESI head. ESI spectroscopy was performed with a 
voltage of 4 kV at the spray capillary tube, a heating filament temperature of 250 °C and a 
nitrogen gas flow of 25 units. 
For the combination of gas chromatography with mass spectroscopic detection (low resolution 
spectra), a GC/MS from Hewlett-Packard HP 6890 / MSD 5973 was used.  
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Infrared spectra (IR) were recorded from 4500 cm-1 to 650 cm-1 on a PERKIN ELMER 
Spectrum BX-59343 instrument. For detection a SMITHS DETECTION DuraSamplIR II 
Diamond ATR sensor was used. The absorption bands are reported in wavenumbers (cm-1). 
Melting points (m.p.) were determined on a BÜCHI B-540 apparatus and are uncorrected. 
High Performance Liquid Chromatography (HPLC) was performed using a Gynkotec-HPLC 
(GINA 50) with a diode-array UV-VIS detector. Chiral columns: OD, OD-H, OJ, OB-H, AD, 
AD-H and AS-H (Daicel Chemical Industries) with n-heptane/i-propanol as mobile phase. 
Racemic compounds were used for optimizing the operation conditions for the resolution of the 
enantiomers and diastereomers. 
Gas chromatography (GC) was performed with machines of type Hewlett-Packard 6890 or 
5890 series II, using a column of type HP 5 (Hewlett-Packard, 5% phenylmethylpolysiloxane; 
length: 15 m, diameter: 0.25 mm; film thickness: 0.25 µm). 
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2. Novel Synthesis of Chiral QUINAP. 
2.1. Preparation of 2-bromo-1-iodonaphthalene 
 
 
2-Bromo-1-naphthylamine59 (6.2 g; 28 mmol) was suspended in a mixture of H2O (220 mL) and 
H2SO4 (8.5 mL). The suspension was then cooled to 0°C by an ice bath and NaNO2 (2.0 g; 
29 mmol) was added portionwise (caution: spontaneous, exothermic reaction!). The reaction 
mixture was stirred for 1 h at 0°C before the excess of NaNO2 was removed by addition of urea 
(1.6 g; 27 mmol). The reaction mixture was then carefully treated with KI (14.1 g; 85 mmol) 
under vigorous stirring at the same temperature. After 4 h of stirring at 0°C the reaction was 
allowed to warm to room temperature and was left to stir overnight. 100 mL Et2O were added to 
the dark reddish suspension on the next day. The layers were separated and the aqueous phase 
was extracted with Et2O (4 x 70 mL). The combined organic layers were washed with sat. 
Na2S2O3 solution (2 x 25 mL), dried over MgSO4 and the solvent was removed by a rotary 
evaporator. The resulting dark reddish solid was then subjected to purification via column 
chromatography (SiO2; n-pentane) yielding the title compound as yellow crystals (6.6 g; 71%). 
 
m. p.: 62–63 °C. 
1H-NMR (CDCl3, 300 MHz): δ: 8.27 (d, J=7.9 Hz, 1H), 7.78 (d, J=7.9 Hz, 1H), 7.72 (s, 2H), 
7.63-7.52 (m, 2H). 
13C-NMR (CDCl3, 75 MHz): δ: 137.0, 134.2, 132.2, 130.2, 129.9, 129.0, 128.7, 127.0, 106.9. 
MS (70 eV, EI): m/z (%): 335 (11), 334 (96), 333 (11), 332 (100) [M+H+], 207 (24), 205 (24), 
125.8 (68). 
IR (ATR) ν~ (cm-1): 3087 (vw), 3065 (vw), 3050 (vw), 3014 (vw), 2984 (vw), 2445 (vw), 2299 
(vw), 2076 (vw), 1956 (vw), 1937 (vw), 1925 (vw), 1904 (vw), 1838 (vw), 1820 (vw), 1809 
(vw), 1753 (vw), 1724 (vw), 1698 (vw), 1669 (vw), 1614 (vw), 1579 (w), 1545 (m), 1493 (s), 
1472 (vw), 1440 (vw), 1418 (vw), 1384 (vw), 1360 (vw), 1340 (w), 1300 (s), 1269 (vw), 1246 
(s), 1206 (vw), 1165 (w), 1148 (vw), 1134 (w), 1103 (m), 1028 (w), 989 (vw), 958 (w), 941 (vs), 
894 (vw), 862 (m), 843 (vw), 826 (m), 809 (vs), 762 (vs), 741 (vs), 650 (s), 619 (m). 
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HR MS (EI) for C10H6BrI (331.8698): 331.8670. 
 
2.2. Preparation of 1-(2-bromonaphthalen-1-yl)isoquinoline (40) 
 
 
A 0.5 M solution of 2-bromo-1-iodonaphthalene (2.93 g; 8.8 mmol) in THF was placed in a dry 
and Ar-flushed Schlenk-flask equipped with a magnetic stirring bar. It was cooled to ‒78°C and a 
1.2 M solution of iPrMgCl.LiCl (7.40 mL; 8.8 mmol) was slowly added. The reaction was 
allowed to proceed for 45 min at the same temperature before a 1.0 M solution of ZnCl2 in THF 
(8.80 mL; 8.8 mmol) was slowly dropped to the yellowish mixture. After stirring for 30 min the 
reaction mixture was allowed to warm to 0°C and was then cannulated to a solution containing 1-
iodoisoquinoline (2.04 g; 8.0 mmol), Pd(dba)2 (0.230 g; 0.4 mmol) and tri(2-furyl)phosphine (tfp) 
in 16 mL dry THF. The resulting mixture was subsequently heated to 60°C and left to stir 
overnight at that temperature. After completion of the cross-coupling reaction (checked by GC-
MS), the reaction was cooled to room temperature and sat. NH4Cl solution (20 mL) was added. 
The layers were separated and the aqueous phase was extracted with 4 x CH2Cl2 (20 mL). The 
combined organic layers were first washed with brine (20 mL), then dried over MgSO4. The 
solvents were removed in vacuo. The blackish crude product was subjected to column 
chromatography yielding the title compound as slightly yellow powder (1.98 g; 74%). 
 
m. p.: 164–166 °C. 
1H-NMR (CDCl3, 600 MHz): δ: 8.74 (d, J=5.7 Hz, 1 H), 7.95 (d, J=8.2 Hz, 1 H), 7.90 (d, J=8.2 
Hz, 1 H), 7.86 (d, J=8.8 Hz, 1 H), 7.80 (d, J=5.7 Hz, 1 H), 7.78 (d, J=8.8 Hz, 1 H), 7.72 - 7.67 
(m, 1 H), 7.50 - 7.46 (m, 1 H), 7.44 - 7.40 (m, 2 H), 7.32 - 7.27 (m, 1 H), 7.05 (d, J=8.6 Hz, 1 H). 
13C-NMR (CDCl3, 150 MHz): δ: 159.4, 142.6, 136.7, 136.3, 133.9, 132.3, 130.4, 130.0, 129.8, 
128.1, 127.8, 127.6, 127.2, 127.0, 126.8, 126.2, 125.9, 121.5, 120.6. 
MS (70 eV, EI): m/z (%): 336 (11), 335 (60), 334 (100) [M+H+], 333 (62) [M+], 332 (88), 255 
(11), 254 (46), 253 (63), 252 (46), 252 (19), 226 (11), 224 (10), 127 (39), 127 (4), 126 (15), 126 
(21). 
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IR (ATR) ν~ (cm-1): 3065 (w), 3052 (w), 2916 (vw), 1988 (vw), 1955 (vw), 1924 (vw), 1840 
(vw), 1788 (vw), 1714 (vw), 1620 (w), 1581 (m), 1557 (m), 1502 (m), 1498 (m), 1449 (w), 1426 
(vw), 1418 (vw), 1406 (w), 1377 (vw), 1340 (w), 1319 (m), 1310 (m), 1275 (w), 1258 (w), 1239 
(w), 1205 (w), 1159 (w), 1135 (w), 1114 (m), 1070 (w), 1044 (w), 1024 (vw), 1012 (w), 994 
(vw), 974 (vw), 963 (vw), 952 (m), 879 (w), 864 (m), 838 (s), 828 (vs), 818 (vs), 798 (m), 790 
(m), 774 (m), 756 (vs), 744 (vs), 692 (s), 678 (m), 665 (m), 633 (s), 618 (w), 602 (m), 577 (m). 
HR MS (EI) for C19H12BrN (333.0153): 333.0129. 
 
2.3. Preparation and resolution of (Ra)-1-(2-((S)-p-tolylsulfinyl)naphthalen-1-yl)isoquinoline 
(44) and (Sa)-1-(2-((S)-p-tolylsulfinyl)naphthalen-1-yl)isoquinoline (43) 
 
 
A 0.2 M solution of 1-(2-bromo-1-naphthyl)isoquinoline (40) (3.34 g; 10 mmol) in anhydrous 
Et2O was placed in a flame-dried Schlenk-flask equipped with a magnetic stirring bar under Ar-
atmosphere. The solution was cooled to ‒78 °C and tBuLi (1.5 M in n-pentane; 13.4 mL; 20 
mmol) was added dropwise. The reaction mixture was stirred for additional 30 min at -78°C 
before it was allowed to reach room temperature. It was then slowly and very carefully added to a 
0.2 M solution of (‒)-menthyl (S)-p-toluenesulfinate18 (1; 3.53 g; 12 mmol) in THF which was 
kept at ‒78°C under Ar atmosphere. The reaction was left to proceed at ‒78 °C for 30 min before 
it was quenched with 2 M NaOH (10 mL) at ‒78 °C. (Alternatively, the organolithium reagent 
can be transmetalated with MgCl2 (0.5 M in THF) at ‒78 °C before reacting with 1. In this case, 
the reaction time does not need to be controlled and the reaction mixture can be allowed to warm 
to room temperature without epimerization at the sulfur.) It was then allowed to warm to room 
temperature and transferred to a separation funnel. The layers were separated and the aqueous 
layer was extracted with 3x CH2Cl2 (10 mL). The combined organic layers were washed with 
brine (5 mL) and dried over MgSO4. The solvents were removed in vacuo. For purification and 
separation of the two sulfoxide diastereomers, the crude product was subjected to column 
chromatography with Florisil® (60-100 mesh). 44 was eluated with a Et2O : n-pentane mixture of 
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4 : 1. 43 was eluated with a Et2O : acetone mixture of 2 : 1. The two diastereomers were obtained 
as slightly yellow crystals yielding 1.89 g (47%) of 43 and 1.89 g (47%) of 44. 
 
(Ra)-1-(2-((S)-p-tolylsulfinyl)naphthalen-1-yl)isoquinoline (44) 
m. p.: 148-150 °C. 
1H-NMR (CDCl3, 600 MHz): δ: 8.72 (d, J=5.7 Hz, 1 H), 8.07 (d, J=8.8 Hz, 1 H), 7.99 - 7.95 (m, 
2 H), 7.91 (d, J=8.2 Hz, 1 H), 7.84 (d, J=5.7 Hz, 1 H), 7.75 - 7.71 (m, 1 H), 7.61 (d, J=8.2 Hz, 2 
H), 7.58 (d, J=8.4 Hz, 1 H), 7.52 - 7.56 (m, 1 H), 7.46 - 7.52 (m, 1 H), 7.32 - 7.37 (m, 1 H), 7.18 
- 7.22 (m, 3 H), 2.32 (s, 3 H). 
13C-NMR (CDCl3, 150 MHz): δ: 156.2, 142.8, 142.7, 141.3, 141.2, 135.9, 135.4, 134.0, 132.1, 
130.1, 129.8, 129.2, 128.5, 128.3, 127.4, 127.2, 127.0, 127.0, 126.8, 126.3, 125.7, 121.2, 120.3, 
21.1. 
MS (70 eV, EI): m/z (%): 394 (28), 393 (100) [M+], 374 (18), 373 (15), 343 (10), 342 (33), 285 
(19), 283 (14), 254 (18), 253 (27), 252 (15). 
IR (ATR) ν~ (cm-1): 3052 (w), 2921 (w), 2858 (vw), 1920 (b, vw), 1725 (vw), 1620 (vw), 1583 
(w), 1556 (w), 1495 (w), 1450 (w), 1425 (vw), 1404 (w), 1376 (vw), 1342 (vw), 1315 (w), 1274 
(vw), 1258 (w), 1237 (vw), 1205 (vw), 1179 (vw), 1165 (vw), 1140 (vw), 1120 (vw), 1082 (m), 
1041 (vs), 1016 (m), 954 (m), 876 (w), 810 (vs), 780 (w), 746 (vs), 704 (w), 694 (s), 680 (w), 670 
(m), 638 (s), 621 (w), 608 (vw), 574 (w). 
HR MS (EI) for C26H19NOS (393.1187): 393.1175. 
 
(Sa)-1-(2-((S)-p-tolylsulfinyl)naphthalen-1-yl)isoquinoline (43) 
m. p.: 99-101 °C. 
1H-NMR (CDCl3, 600 MHz): δ: 8.79 (d, J=5.7 Hz, 1 H), 8.36 (d, J=8.8 Hz, 1 H), 8.21 (d, J=8.8 
Hz, 1 H), 7.96 (d, J=8.2 Hz, 1 H), 7.84 (d, J=8.2 Hz, 1 H), 7.80 (d, J=5.7 Hz, 1 H), 7.55 (t, J=7.5 
Hz, 1 H), 7.52 (t, J=7.2 Hz, 1 H), 7.28 - 7.24 (m, 1 H), 7.04 (d, J=8.6 Hz, 1 H), 7.01 (t, J=7.6 Hz, 
1 H), 6.79 (d, J=8.2 Hz, 2 H), 6.69 - 6.65 (m, 3 H), 2.07 (s, 3 H). 
13C-NMR (CDCl3, 150 MHz): δ: 156.9, 143.1, 142.0, 141.9, 140.6, 136.2, 136.2, 134.5, 131.9, 
130.9, 130.8, 129.7, 128.7, 128.3, 128.3, 127.9, 127.5, 127.0, 126.9, 126.8, 124.8, 121.2, 120.5, 
21.3. 
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MS (70 eV, EI): m/z (%): 394 (28), 393 (100) [M+], 375 (15), 374 (13), 343 (30), 285 (16), 283 
(12), 254 (15), 253 (22), 252 (11). 
IR (ATR) ν~ (cm-1): 3052 (vw), 2921 (vw), 2856 (vw), 1914 (b, vw), 1731 (vw), 1620 (vw), 1595 
(vw), 1582 (w), 1556 (w), 1494 (w), 1450 (vw), 1437 (w), 1401 (w), 1372 (w), 1338 (vw), 1318 
(m), 1257 (w), 1237 (w), 1194 (w), 1178 (w), 1164 (w), 1140 (vw), 1118 (w), 1082 (m), 1045 
(vs), 1038 (vs), 1014 (s), 954 (m), 869 (w), 824 (s), 806 (vs), 779 (m), 746 (vs), 720 (s), 695 (vs), 
670 (s), 637 (vs), 622 (s), 608 (m), 586 (m), 569 (m). 
HR MS (EI) for C26H19NOS (393.1187): 393.1197. 
HPLC Data: 
44: Chiralcel AD; n-heptane : i-propanol 80:20; flow: 0.5 mL/min 
  
43: Chiralcel AD; n-heptane : i-propanol 80:20; flow: 1.0 mL/min 
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2.4 Enantioselective preparation of (Sa)-1-(2-(diphenylphosphino)naphthalen-1-
yl)isoquinoline ((S)-QUINAP) 
 
 
In a dry and Ar-flushed Schlenk-flask equipped with a stirring bar, iodobenzene (0.337 g; 
1.65 mmol) was diluted in 3 mL Et2O. The solution was then cooled to ‒78 °C and tBuLi (1.5 M 
in n-pentane; 2.2 mL; 3.3 mmol) was added dropwise. The reaction was stirred for 10 min at 
‒78 °C before it was allowed to warm to room temperature. The solvents were subsequently 
removed in vacuo until a white precipitate remained. The flask was then flushed with Ar and 
cooled to ‒78 °C. 3 mL THF were carefully added and the mixture was then allowed to warm to 
0°C in order to receive a homogeneous solution. The solution was then again cooled to ‒78 °C. A 
0.5 M solution of 43 (0.590 g; 1.50 mmol) was added dropwise. The reaction was left to stir for 
15 min at ‒78 °C before a 1.0 M solution of Ph2PCl (0.397 g; 1.80 mmol) was slowly added. The 
reaction mixture was additionally stirred for 15 min at ‒78 °C before sulfur (0.063 g; 1.95 mmol) 
was added. The reaction mixture was then heated to 45 °C and left to stir overnight at that 
temperature. The reaction mixture was then cooled to room temperature and quenched with 
10 mL NH4Cl sat. solution before it was transferred to a separation funnel. The layers were 
separated and the aqueous phase was extracted with 3x 10 mL CH2Cl2. The combined organic 
layers were washed with brine (5 mL) and dried over MgSO4. The solvents were removed in 
vacuo and the crude product was subjected to purification via column chromatography (SiO2; 
Et2O : n-pentane 1 : 2). The product was then redissolved in CH2Cl2 and 0.3 mL MeSO3H was 
added. The product was then filtrated over SiO2 using pure Et2O in order to remove the impurities 
and 5 mL NEt3 in Et2O in order to wash down the product. After removal of the solvents the 
product was redissolved in CH2Cl2 and transferred to a separation funnel. The organic phase was 
washed with NH4Cl sat. solution (5 mL). The aqueous phase was extracted with 3x 10 mL 
CH2Cl2. The combined organic layers were dried over MgSO4. The solvent was evaporated. (S)-
45 was directly subjected to desulfurisation with Raney-Ni: Therefore, Raney-Ni (30 equiv) was 
placed in a N2-flushed flask. It was washed five times with MeOH and finally suspended in 
MeOH. A solution of (S)-45 in MeOH/THF was then dropped to the Raney-Ni suspension. The 
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reaction was left to stir overnight at room temperature. Filtration and removal of the solvent 
yielded (S)-QUINAP (0.395 g; 60%; 99% ee) as a white solid. The preparation of (R)-QUINAP 
was analogous (0.376 g; 57%; 99% ee). 
 
m. p.: 224.6-226.8 °C. (217.4-218.6 °C for (R)-QUINAP) 
1H-NMR (CDCl3, 600 MHz): δ: 8.62 (d, J=5.5 Hz, 2 H), 7.89 (t, J=8.0 Hz, 3 H), 7.74 (d, J=5.5 
Hz, 2 H), 7.63 - 7.56 (m, 2 H), 7.49 - 7.44 (m, 2 H), 7.42 (dd, J1=8.5 Hz, J1=3.0 Hz, 1 H), 7.30- 
7.17 (m, 7 H), 7.17 - 7.12 (m, 2 H), 7.09 (d, J=8.60 Hz, 1 H). 
13C-NMR (CDCl3, 150 MHz): δ: 160.4 (d, J=6.7 Hz), 144.4, 144.1, 142.2, 137.39 (d, J=12.3 
Hz), 137.29 (d, J=11.5 Hz), 135.9, 134.81 (d, J=13.5 Hz), 133.7 (d, J=20.2 Hz), 133.6, 133.2 (d, 
J=18.5 Hz), 132.6 (d, J=7.8 Hz), 130.0-126.6, 120.3 (due to the complexity of the P-C couplings 
in this spectrum not all coupling constants could be accurately attributed; data correspond to 
those given in the literature: 54a). 
HPLC Data (for a better resolution the phosphines were reprotected with sulfur): 
Chiralcel OD-H; n-heptane : i-propanol 90:10; flow: 0.5 mL/min 
(S)-QUINAP: 
 
                                                                                                      mix of (R)- and (S)-QUINAP (not racemic) 
(R)-QUINAP: 
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3. Sulfoxide-Alkene Hybrid Ligands: Preparation and Use in the Hayashi-
Miyaura Reaction. 
 
3.1. Preparation of aryl Grignard reagents 
 
Mg-Insertion:  
A dry and Ar-flushed 50 mL Schlenk-tube, equipped with a stirring bar and a septum, was 
charged with anhydrous LiCl (25 mmol; 1.06 g) and heated to 130 °C under high vacuum (1 
mbar) for 3 h. After cooling to room temperature under Ar, Mg turnings (25 mmol; 608 mg), 1,2-
dibromoethane (0.1 ml) and freshly distilled THF (20 mL) were added. The reaction mixture was 
shortly heated to reflux and was cooled to room temperature under Ar. Under vigorous stirring 
the respective aryl bromide (20 mmol) was added slowly at the appropriate temperature. The 
reaction mixture was stirred under Ar overnight and was titrated by using a stoichiometric 
amount of iodine (50 mg) in THF (2 mL).129 
 
(4-Methoxyphenyl)magnesium bromide: 
 
 
0.81 M in THF (81%); reaction temperature: 40 °C 
 
(4-(Trifluoromethyl)phenyl)magnesium bromide: 
 
 
C. Experimental Section  90 
 
 
0.68 M in THF (68%); reaction temperature: 0 °C. (Caution: Mg filings (no Mg powder) must be 
used in order to avoid an uncontrollable reaction). 
 
Bis(4-(dimethylamino)phenyl)magnesium: 
 
 
A dry and Ar-flushed 250 mL Schlenk-flask, equipped with a stirring bar and a septum, was 
charged with a solution of 4-bromo-N,N-dimethylaniline (4.0 g; 20 mmol) in 20 mL THF. The 
solution was cooled to ‒78 °C and tBuLi (1.89 M in n-pentane; 21.2 mL; 40 mmol) was added 
dropwise via syringe. The reaction was stirred for 1.5 h at ‒78 °C, before MgCl2 (0.5 M in THF; 
20 mL; 10 mmol) was added. The mixture was allowed to reach room temperature. The resulting 
solution was titrated by using a stoichiometric amount of iodine (50 mg) in THF (2 mL) 
indicating a concentration of 0.31 M (62%). 
 
3.2. Preparation of 7-bromo-2-arylbicyclo[2.2.1]hept-2-enes 
A dry and Ar-flushed 500 mL Schlenk-flask, equipped with a stirring bar and a septum, was 
charged with 7-bromobicyclo[2.2.1]heptan-2-one (48; 3.77 g; 20 mmol)68e,i and a solution of 
LaCl3·2 LiCl in THF (0.33 M; 90 mL; 30 mmol).
70 The mixture was stirred at room temperature 
for 1 h. Then, the solution was cooled to ‒78 °C and a solution of the respective aryl Grignard 
reagent (30 mmol) was added dropwise. After stirring for 1 h at ‒78 °C, the cold bath was 
removed and the mixture was allowed to reach room temperature within 1 h. The reaction 
mixture was further stirred for 2 h at room temperature. It was then cooled to ‒78 °C and MsOH 
(methanesulfonic acid; 4.68 mL; 72 mmol) was added dropwise and the mixture was allowed to 
reach room temperature. After 1.5 h, the clear yellow solution was quenched with NEt3 (9.9 mL; 
72 mmol). The mixture was filtrated and the precipitate was washed with Et2O (3x). NH4Cl sat. 
solution (250 mL) was added to the filtrate. Phases were separated and the aqueous phase was 
extracted with Et2O (3x 100 mL). The recombined organic phases were dried over Na2SO4 and 
the solvents were evaporated. The crude product was subjected to purification via column 
chromatography. 
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7-Bromo-2-(4-methoxyphenyl)bicyclo[2.2.1]hept-2-ene (49) 
 
 
yellow oil (67%) 
1H-NMR (300 MHz, CDCl3) δ: 7.40 (d, J=8.8 Hz, 2 H), 6.89 (d, J=8.8 Hz, 2 H), 6.16 (d, J=2.9 
Hz, 1 H), 4.02 (d, J=0.7 Hz, 1 H), 3.82 (s, 3 H), 3.44 (d, J=1.0 Hz, 1 H), 3.17 (br. s., 1 H), 2.00 - 
1.85 (m, 2 H), 1.38 - 1.21 (m, 2 H). 
13C-NMR (75 MHz, CDCl3) δ: 159.1, 144.9, 127.7, 126.5, 124.1, 114.0, 65.2, 55.3, 50.9, 50.5, 
25.0, 23.0. 
MS (70 eV, EI) m/z (%): 278 (6) [M+], 200 (5), 199 (39), 172 (12), 171 (100), 156 (5), 128 (8), 
121 (4). 
IR (ATR) ν~  (cm-1): 1678 (s), 1610 (s), 1598 (vs), 1570 (s), 1506 (vs), 1306 (s), 1294 (s), 1248 
(vs), 1222 (s), 1176 (vs), 1036 (s), 868 (s), 838 (s), 804 (vs), 788 (s), 750 (s), 702 (s), 608 (s).  
HRMS (EI) for C14H15BrO (278.0306): 278.0297. 
 
4-(7-Bromobicyclo[2.2.1]hept-2-en-2-yl)-N,N-dimethylaniline 
 
 
slightly red solid (71%) 
m.p.: 100.4 – 101.3 °C.  
1H-NMR (400 MHz, C6D6) δ: 7.36 (d, J=9.0 Hz, 2 H), 6.57 (d, J=9.0 Hz, 2 H), 5.97 (d, J=2.9 
Hz, 1 H), 3.68 (s, 1 H), 3.29 (d, J=1.2 Hz, 1 H), 2.90 (br. s., 1 H), 2.52 (s, 6 H), 1.50 - 1.36 (m, 2 
H), 1.07 - 0.95 (m, 2 H). 
13C-NMR (101 MHz, C6D6) δ: 150.7, 146.2, 127.1, 124.4, 122.3, 113.2, 65.8, 52.5, 52.1, 40.5, 
25.8, 23.6. 
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MS (70 eV, EI) m/z (%): 291 (8) [M+], 213 (5), 212 (29), 185 (15), 184 (100), 183 (4), 168 (10), 
139 (6), 115 (5), 92 (7), 91 (7), 58 (12), 43 (35). 
IR (ATR) ν~  (cm-1): 2970 (m), 2942 (m), 2870 (m), 2800 (w), 1612 (vs), 1520 (vs), 1480 (m), 
1460 (m), 1444 (m), 1364 (s), 1340 (m), 1298 (m), 1284 (w), 1230 (s), 1198 (s), 1188 (s), 1172 
(m), 1160 (m), 1116 (s), 1064 (m), 946 (m), 866 (w), 824 (m), 806 (s), 794 (s), 786 (vs), 746 (s), 
720 (m), 700 (m). 
HRMS (EI) for C15H18BrN (291.0623): 291.0603. 
3.3. Preparation and resolution of sulfoxide-alkene ligands using Andersen-sulfinate (1)  
A dry and Ar-flushed 250 mL Schlenk-flask, equipped with a stirring bar and a septum, was 
charged with a solution of the respective 7-bromo-2-arylbicyclo[2.2.1]hept-2-ene (8 mmol) in 
THF (16 mL) and cooled to ‒78 °C. tBuLi (1.89 M in n-pentane; 9.31 mL; 17.6 mmol) was 
slowly added via syringe and the mixture was stirred for 2 h. A solution of MgCl2 in THF (0.5 M; 
18 mL; 9 mmol) was added and the mixture was further stirred at -78 °C for 30 min before a 
solution of the Andersen-sulfinate18 (1; 2.65 g; 9 mmol) in THF (9 mL) was added dropwise. 
After 4 h at ‒78 °C, the reaction mixture was allowed to slowly reach room temperature. H2O 
(100 mL) was added. Phases were separated and the aqueous phase was extracted with CH2Cl2 
(3x 50 mL). The recombined phases were washed with brine (50 mL) and dried over Na2SO4. 
The solvents were evaporated and the crude product was subjected to column chromatography 
yielding the pure diastereomeric chiral sulfoxides. 
 
(1R,4S,7R)-2-(4-Methoxyphenyl)-7-((R)-p-tolylsulfinyl)-bicyclo[2.2.1]hept-2-ene (46a) and 
(1S,4R,7S)-2-(4-methoxyphenyl)-7-((R)-p-tolylsulfinyl)-bicyclo[2.2.1]hept-2-ene (46b) 
 
 
46a: white solid (35%) 
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m.p.: 213.1 – 214.2 °C.  
1H-NMR (300 MHz, C6D6) δ: 7.61 (d, J=8.0 Hz, 2 H), 7.39 (d, J=8.8 Hz, 2 H), 6.95 (d, J=7.8 
Hz, 2 H), 6.79 (d, J=8.8 Hz, 2 H), 5.96 (d, J=2.7 Hz, 1 H), 4.07 (d, J=1.9 Hz, 1 H), 3.32 (s, 3 H), 
2.77 (s, 1 H), 2.45 (br. s., 1 H), 2.01 (s, 3 H), 1.56 - 1.45 (m, 1 H), 1.31 – 1.21 (m, 1 H), 1.12 – 
1.03 (m, 1 H), 0.97 – 0.88 (m, 1 H). 
13C-NMR (75 MHz, C6D6) δ: 160.4, 146.4, 144.7, 141.0, 130.2, 127.9, 127.7, 125.0, 124.5, 
114.8, 88.0, 55.2, 46.5, 45.4, 27.7, 25.0, 21.5. 
MS (70 eV, EI) m/z (%): 338 (6) [M+], 323 (9), 322 (37), 294 (6), 200 (16), 199 (100), 198 (22), 
185 (7), 184 (11), 172 (10), 171 (72), 156 (7), 135 (8), 128 (10), 121 (13), 67 (6). 
IR (ATR) ν~  (cm-1): 2974 (w), 2926 (w), 1610 (w), 1594 (w), 1506 (m), 1490 (m), 1466 (m), 
1456 (w), 1442 (w), 1296 (w), 1272 (w), 1258 (m), 1246 (m), 1222 (m), 1184 (w), 1176 (m), 
1120 (w), 1110 (w), 1080 (m), 1030 (vs), 1012 (s), 992 (m), 972 (w), 840 (m), 828 (w), 808 (s), 
800 (s). 
HRMS (EI) for C21H22O2S (338.1340): 338.1344. 
 
46b: white solid (37%) 
m.p.: 173.5 – 174.5 °C.  
1H-NMR (300 MHz, C6D6) δ: 7.57 (d, J=8.0 Hz, 2 H), 7.20 (d, J=8.8 Hz, 2 H), 6.89 (d, J=8.0 
Hz, 2 H), 6.80 (d, J=8.8 Hz, 2 H), 6.07 (d, J=2.9 Hz, 1 H), 3.66 (br. s., 1 H), 3.33 (s, 3 H), 2.87 - 
2.71 (m, 2 H), 1.98 (s, 3 H), 1.60 - 1.49 (m, 1 H), 1.28 - 1.17 (m, 1 H), 1.10 - 1.01 (m, 1 H), 0.94 
- 0.84 (m, 1 H). 
13C-NMR (75 MHz, C6D6) δ: 160.2, 146.0, 144.6, 141.1, 130.2, 127.9, 127.1, 125.3, 124.9, 
114.8, 88.3, 55.2, 46.3, 45.8, 27.3, 25.6, 21.5. 
MS (70 eV, EI) m/z (%): 338 (19) [M+], 322 (25), 200 (10), 199 (68), 198 (15), 184 (12), 172 
(14), 171 (100), 156 (10), 135 (28), 128 (15), 121 (18). 
IR (ATR) ν~  (cm-1): 2982 (vw), 2934 (w), 1612 (w), 1598 (w), 1572 (w), 1508 (m), 1492 (w), 
1464 (w), 1446 (w), 1416 (w), 1294 (w), 1276 (w), 1246 (s), 1222 (w), 1210 (w), 1194 (w), 1182 
(m), 1124 (w), 1110 (w), 1082 (w), 1030 (vs), 1014 (m), 990 (w), 964 (w), 950 (w), 842 (w), 814 
(s), 794 (s), 704 (w). 
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HRMS (EI) for C21H22O2S (338.1340): 338.1325. 
HPLC Data: 
Chiralcel AD; n-heptane : i-propanol 80:20; flow: 0.3 mL/min 
46a: 
 
 
                  without transmetalation to MgCl2 (72% ee)       after acidic epimerization of 46a (HCl 1 M in CH2Cl2) 
                                                                                                            shows 46a, 46b and their enantiomers 
46b: 
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N,N-Dimethyl-4-((1R,4S,7R)-7-((R)-p-tolylsulfinyl)bicyclo-[2.2.1]hept-2-en-2-yl)aniline (60) 
 
 
white solid (28%; only one diastereomer isolated) 
m.p.: 224.7 – 226.9 °C.  
1H-NMR (400 MHz, d8-THF) δ: 7.50 (d, J=8.2 Hz, 2 H), 7.37 (d, J=8.8 Hz, 2 H), 7.31 (d, J=7.8 
Hz, 2 H), 6.70 (d, J=9.0 Hz, 2 H), 6.11 (d, J=2.5 Hz, 1 H), 3.84 (d, J=2.0 Hz, 1 H), 2.94 (s, 6 H), 
2.64 (s, 2 H), 2.38 (s, 3 H), 1.91 - 1.80 (m, 1 H), 1.79 - 1.73 (m, 1 H), 1.28 - 1.16 (m, 2 H). 
13C-NMR (101 MHz, d8-THF) δ: 151.3, 146.9, 145.2, 141.4, 130.3, 127.2, 125.0, 123.9, 122.6, 
113.1, 88.2, 46.4, 45.6, 40.6, 30.7, 28.3, 21.4. 
MS (70 eV, EI) m/z (%): 352 (5) [M+], 212 (18), 184 (47), 168 (9), 148 (19), 91 (9), 67 (9), 58 
(27), 43 (100). 
IR (ATR) ν~  (cm-1): 2924 (w), 2866 (w), 1612 (m), 1520 (m), 1492 (m), 1460 (w), 1444 (w), 
1364 (m), 1274 (w), 1234 (w), 1218 (w), 1200 (m), 1190 (m), 1178 (w), 1116 (w), 1078 (m), 
1032 (vs), 1014 (m), 976 (w), 952 (w), 868 (w), 826 (m), 812 (s), 794 (vs), 706 (w). 
HRMS (EI) for C22H25NOS (352.1657): 352.1644. 
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3.4. Preparation and resolution of sulfoxide-alkene ligands using (S)-TMPOO (2)  
A dry and Ar-flushed 50 mL Schlenk-tube, equipped with a stirring bar and a septum, was 
charged with a solution of the 7-bromo-2-(4-methoxyphenyl)bicyclo[2.2.1]hept-2-ene (49; 
0.838 g; 3 mmol) in THF (6 mL) and cooled to ‒78 °C. tBuLi (1.89 M in n-pentane; 3.49 mL; 6.6 
mmol) was slowly added via syringe and the mixture was stirred for 2 h. A solution of MgCl2 in 
THF (0.5 M; 13.2 mL; 6.6 mmol) was added. Meanwhile, a dry and Ar-flushed 100 mL Schlenk-
flask, equipped with a stirring bar and a septum, was charged with a solution of (S)-TMPOO19 
(1.11 g; 3.15 mmol) in THF (8.4 mL) and cooled to ‒78 °C. The cold Grignard reagent, which 
was further kept at ‒78 °C was transferred to the (S)-TMPOO solution dropwise using a Teflon-
cannula. After the addition was finished, the reaction mixture was stirred for further 2 h before 
the respective second Grignard reagent (3.3 mmol) was added. The reaction mixture was stirred 
for 1.5 h at ‒78 °C and was then allowed to warm to room temperature. The reaction was 
quenched with NaHCO3 sat. solution (8 mL). H2O (20 mL) was added and phases were 
separated. The aqueous phase was extracted with EtOAc (3x 40 mL). The combined organic 
layers were washed with brine (50 mL) and dried over Na2SO4. The solvents were evaporated and 
the crude products were subjected to column chromatography yielding the respective pure 
diastereomeric chiral sulfoxide. 
 
(1S,4R,7S)-2-(4-methoxyphenyl)-7-((S)-(4-methoxyphenyl)-sulfinyl)bicyclo[2.2.1]hept-2-ene 
(59a) 
 
 
white solid (31%; only one diastereomer isolated) 
m.p.: 184.8 – 186.2 °C.  
1H-NMR (400 MHz, C6D6) δ: 7.55 (d, J=8.8 Hz, 2 H), 7.34 (d, J=8.8 Hz, 2 H), 6.74 (d, J=8.8 
Hz, 2 H), 6.69 (d, J=8.8 Hz, 2 H), 5.92 (d, J=2.7 Hz, 1 H), 4.01 (d, J=1.8 Hz, 1 H), 3.28 (s, 3 H) , 
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3.16 (s, 3 H), 2.73 (s, 1 H), 2.38 (br. s., 1 H), 1.56 - 1.45 (m, 1 H), 1.30 - 1.21 (m, 1 H), 1.08 - 
1.00 (m, 1 H), 0.94 - 0.85 (m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 161.5, 159.6, 145.7, 137.9, 127.2, 126.9, 125.9, 123.8, 114.4, 
114.1, 87.5, 54.6, 54.5, 45.8, 44.7, 27.0, 24.4. 
MS (70 eV, EI) m/z (%): 354 (4) [M+], 338 (26), 200 (16), 199 (100), 198 (18), 197 (11), 184 
(13), 172 (14), 171 (89), 156 (10), 155 (10), 135 (12), 128 (17), 121 (23), 91 (19), 67 (22). 
IR (ATR) ν~  (cm-1): 2967 (w), 2945 (vw), 1594 (m), 1577 (w), 1508 (m), 1493 (m), 1307 (w), 
1295 (w), 1245 (s), 1176 (m), 1084 (m), 1027 (vs), 1009 (m), 1004 (m), 993 (m), 838 (m), 823 
(s), 817 (m), 802 (s), 796 (m), 789 (m), 616 (w), 609 (m). 
HRMS (EI) for C21H22O3S (354.1290): 354.1282. 
 
(1S,4R,7S)-2-(4-methoxyphenyl)-7-((S)-(4-(trifluoromethyl)-
phenyl)sulfinyl)bicyclo[2.2.1]hept-2-ene (59b) 
 
S+
OMe
CF3
O-
 
white solid (19%; only one diastereomer isolated) 
m.p.: 152.6 – 152.6 °C.  
1H-NMR (300 MHz, C6D6) δ: 7.47 (d, J=8.0 Hz, 2 H), 7.38 (d, J=8.8 Hz, 2 H), 7.30 (d, J=8.3 
Hz, 2 H), 6.80 (d, J=8.8 Hz, 2 H), 5.92 (d, J=2.7 Hz, 1 H), 3.99 (d, J=1.7 Hz, 1 H), 3.33 (s, 3 H), 
2.60 (s, 1 H), 2.30 (br. s., 1 H), 1.53 - 1.42 (m, 1 H), 1.29 - 1.19 (m, 1 H), 1.10 - 1.02 (m, 1 H), 
0.97 - 0.88 (m, 1 H). 
13C-NMR (75 MHz, C6D6) δ: 160.5, 152.1 (d, J=1.3 Hz), 146.4, 132.7 (q, J=32.5 Hz), 127.7, 
127.6, 126.3 (q, J=3.6 Hz), 125.3, 124.8 (q, J=272.9 Hz), 124.2, 114.9, 87.6, 55.2, 46.6, 45.2, 
27.7, 24.8. 
MS (70 eV, EI) m/z (%): 392 (13) [M+], 376 (22), 199 (56), 184 (10), 172 (13), 171 (100), 135 
(33), 128 (13), 121 (14). 
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IR (ATR) ν~  (cm-1): 2974 (w), 2960 (w), 2936 (w), 1606 (w), 1596 (w), 1508 (s), 1468 (w), 
1458 (w), 1400 (w), 1332 (s), 1306 (m), 1296 (s), 1274 (m), 1258 (m), 1248 (s), 1220 (m), 1174 
(s), 1162 (s), 1150 (s), 1122 (vs), 1102 (s), 1084 (m), 1062 (s), 1042 (vs), 1028 (vs), 1012 (s), 974 
(m), 870 (w), 832 (s), 818 (m), 804 (s), 712 (w), 702 (m), 610 (w). 
HRMS (EI) for C21H19F3O2S (392.1058): 392.1060. 
 
(1S,4R,7S)-7-((S)-tert-butylsulfinyl)-2-(4-methoxyphenyl)-bicyclo[2.2.1]hept-2-ene (59c) 
 
 
white solid (17%; only one diastereomer isolated) 
m.p.: 105.4 – 106.6 °C.  
1H-NMR (400 MHz, C6D6) δ: 7.45 (d, J=8.8 Hz, 2 H), 6.76 (d, J=8.8 Hz, 2 H), 5.95 (d, J=2.9 
Hz, 1 H), 3.94 (br. s., 1 H), 3.31 (s, 3 H), 2.70 (s, 1 H), 2.61 (br. s., 1 H), 1.66 - 1.52 (m, 2 H), 
1.20 - 1.07 (m, 2 H), 1.02 (s, 9 H). 
13C-NMR (101 MHz, C6D6) δ: 160.3, 146.6, 128.0, 128.0, 123.9, 114.7, 75.9, 55.2, 52.7, 46.6, 
46.5, 28.6, 24.0, 23.5. 
MS (70 eV, EI) m/z (%): 304 (9) [M+], 249 (10), 248 (65), 231 (14), 200 (21), 199 (100), 198 
(20), 197 (33), 185 (38), 184 (10), 172 (35), 171 (98), 156 (12), 153 (10), 150 (25), 135 (23), 128 
(21), 121 (11), 57 (14). 
IR (ATR) ν~  (cm-1): 2944 (w), 2872 (vw), 1612 (vw), 1598 (w), 1520 (m), 1464 (w), 1446 (w), 
1364 (w), 1296 (w), 1274 (w), 1262 (w), 1244 (m), 1224 (w), 1186 (m), 1126 (w), 1026 (vs), 994 
(w), 878 (w), 846 (m), 816 (s), 804 (m), 786 (w). 
HRMS (EI) for C18H24O2S (304.1497): 304.1493. 
 
3.5. In situ preparation of the chiral sulfoxide-alkene hybrid/Rh catalysts 
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An Ar-flushed 10 mL Schlenk-tube, equipped with a stirring bar and a septum, was charged with 
a solution of the respective chiral sulfoxide-alkene hybrid ligand (200 µmol) and [Rh(coe)2Cl]274 
(72 mg; 100 µmol) in 1,4-dioxane (2 mL). CsOH·H2O (34 mg; 200 µmol) along with 0.8 mL 
H2O (HPLC grade) was added. The resulting suspension was stirred overnight at room 
temperature. The next day, a clear yellow solution had formed. 
 
3.6. NMR experiments 
For NMR experiments 46b (34 mg; 100 µmol) and [Rh(ethylene)2Cl]2 were mixed in d8-1,4-
dioxane (1 mL). The suspension was stirred for 12 h until a clear orange solution had formed 
which was immediately subjected to NMR measurements. The results of the NMR-experiments 
in d8-dioxane showing the coordinative sites in the Rh-complex of 46b through signal shifts in 
the 1H- and doublet-splittings in the 13C-spectrum are summarized below: 
 
 
 
3.7. Enantioselective Hayashi-Miyaura reaction 
An Ar-flushed 10 mL Schlenk-tube, equipped with a stirring bar and a septum, was charged with 
a solution of the respective electron-deficient alkene (0.5 mmol), the corresponding boronic acid 
(0.6 mmol) and CsF (0.6 mmol) in 1,4-dioxane (1.5 mL). A solution of the catalyst (see 3.5) in 
1,4-dioxane (0.036 M; 0.35 mL; 12.5 µmol) was slowly added to the reaction mixture. After the 
addition was complete, the mixture was warmed to room temperature. Progress of the reaction 
 
C. Experimental Section  100 
 
was followed via TLC analysis. After all the starting material was consumed, Et2O (6 mL) was 
added to the reaction mixture along with SiO2. The solvents were removed and the product was 
subjected to column chromatography. 
 
3.7.1 Compounds of Table 1 
 
(S)-3-(2-Ethylphenyl)cyclohexanone (52b): 
 
 
colorless oil 0.100 g (99%) 
1H-NMR (400 MHz, C6D6) δ: 7.14 - 7.04 (m, 2 H), 7.04 – 6.93 (m, 2 H), 3.02 - 2.93 (m, 1 H), 
2.48 - 2.42 (m, 1 H), 2.37 (q, J=7.5 Hz, 2 H), 2.29 - 2.23 (m, 1 H), 2.15 (t, J=13.4 Hz, 1 H), 1.88 
(td, J1=13.3 Hz, J2= 6.0 Hz, 1 H), 1.62 - 1.52 (m, 2 H), 1.42 - 1.22 (m, 2 H), 0.99 (t, J=7.6 Hz, 3 
H). 
13C-NMR (101 MHz, C6D6) δ: 207.8, 141.9, 140.7, 128.8, 126.4, 126.2, 125.5, 48.7, 40.8, 39.4, 
32.5, 25.5, 25.4, 15.6. 
MS (70 eV, EI) m/z (%): 202 (86) [M+], 173 (33), 160 (12), 159 (100), 145 (45), 145 (32), 132 
(12), 131 (17), 129 (14), 128 (10), 118 (12), 117 (54), 115 (20), 91 (11). 
IR (ATR) ν~  (cm-1): 2962 (m), 2934 (m), 2872 (w), 1708 (vs), 1490 (w), 1448 (m), 1420 (w), 
1374 (w), 1364 (w), 1344 (w), 1314 (w), 1286 (w), 1252 (w), 1222 (m), 1182 (w), 1052 (w), 
1032 (w), 972 (w), 914 (vw), 884 (vw), 796 (w), 788 (w), 752 (s), 714 (w), 650 (w). 
HRMS (EI) for C14H18O (202.1358): 202.1346. 
HPLC Data: Chiralcel OD-H; n-heptane : i-propanol 99:1; flow: 0.3 mL/min 
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(S)-3-(Benzo[d][1,3]dioxol-4-yl)cyclohexanone (52f): 
 
 
colorless crystals 0.094 g (86%) 
m.p.: 78.8 – 79.9 °C. 
1H-NMR (300 MHz, CDCl3) δ: 6.83 - 6.69 (m, 2 H), 6.69 - 6.58 (m, 1 H), 5.93 (s, 2 H), 3.01 – 
2.84 (m, 1 H), 2.60 - 2.29 (m, 4 H), 2.20 - 1.97 (m, 2 H), 1.86 - 1.65 (m, 2 H). 
13C-NMR (75 MHz, CDCl3) δ: 210.7, 147.8, 146.1, 138.4, 119.4, 108.2, 106.9, 100.9, 49.2, 
44.4, 41.0, 33.0, 25.3. 
MS (70 eV, EI) m/z (%): 218 (100) [M+], 175 (14), 162 (10), 161 (57), 148 (36), 147 (14), 135 
(22), 103 (11), 89 (10). 
IR (ATR) ν~  (cm-1): 2956 (m), 2918 (m), 2852 (m), 1702 (vs), 1608 (w), 1504 (s), 1486 (s), 
1440 (s), 1414 (m), 1350 (w), 1250 (m), 1218 (vs), 1188 (s), 1090 (m), 1030 (vs), 974 (m), 928 
(vs), 902 (m), 874 (s), 860 (m), 810 (vs), 774 (m), 748 (m). 
HRMS (EI) for C13H14O3 (218.0943): 218.0952. 
HPLC Data: 
Chiralcel AS-H; n-heptane : i-propanol 80:20; flow: 1.0 mL/min 
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(S)-3-(4-Phenoxyphenyl)cyclohexanone (52j): 
 
 
colorless crystals 0.120 g (90%) 
m.p.: 99.3 – 100.5 °C.  
1H-NMR (300 MHz, CDCl3) δ: 7.34 (t, J=8.0 Hz, 2 H), 7.19 (d, J=8.4 Hz, 2 H), 7.11 (t, J=7.4 
Hz, 1 H), 7.02 (d, J=7.9 Hz, 2 H), 6.98 (d, J=8.6 Hz, 2 H), 3.01 (dddd, J1=15.5 Hz, J2=7.8 Hz, 
J3=3.8 Hz, J4=3.7 Hz, 1 H), 2.66 - 2.32 (m, 4 H), 2.24 - 2.03 (m, 2 H), 1.92 - 1.70 (m, 2 H). 
13C-NMR (75 MHz, CDCl3) δ: 210.8, 157.2, 155.8, 139.2, 129.7, 127.7, 123.2, 118.9, 118.8, 
49.0, 44.0, 41.1, 32.9, 25.4. 
MS (70 eV, EI) m/z (%): 266 (100) [M+], 223 (16), 210 (11), 209 (79), 196 (25), 183 (12), 116 
(22), 115 (27), 97 (14), 85 (16), 83 (11), 77 (16), 71 (24), 69 (14), 57 (32), 43 (14). 
IR (ATR) ν~  (cm-1): 2944 (w), 2922 (w), 1702 (s), 1588 (m), 1504 (s), 1486 (s), 1456 (m), 1446 
(m), 1422 (w), 1366 (w), 1250 (s), 1234 (vs), 1222 (vs), 1198 (s), 1180 (m), 1166 (m), 1110 (w), 
1068 (w), 910 (w), 870 (m), 828 (m), 802 (m), 784 (m), 752 (m), 738 (m), 694 (s). 
HRMS (EI) for C18H18O2 (266.1307): 266.1296. 
HPLC Data: 
Chiralcel AS-H; n-heptane : i-propanol 80:20; flow: 1.0 mL/min 
 
C. Experimental Section  103 
 
  
 
Compounds known in the literature:30, 31, 32, 66, 68 
 
(S)-3-Phenylcyclohexanone (52a): 
 
 
HPLC Data: 
Chiralcel AD; n-heptane : i-propanol 90:10; flow: 0.3 mL/min 
  
 
(S)-3-(Naphthalen-1-yl)cyclohexanone (52c): 
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HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 95:5; flow: 0.5 mL/min 
 
 
(S)-3-(2-Methoxyphenyl)cyclohexanone (52d): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 95:5; flow: 0.5 mL/min 
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(S)-3-(2-Fluorophenyl)cyclohexanone (52e): 
 
 
HPLC Data: 
Chiralcel AD; n-heptane : i-propanol 99.5:0.5; flow: 1.0 mL/min 
  
 
(S)-3-(3-Methoxyphenyl)cyclohexanone (52g): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 99:1; flow: 1.0 mL/min 
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(S)-3-(3-Chlorophenyl)cyclohexanone (52h): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 99.5:0.5; flow: 0.5 mL/min 
  
 
(S)-3-(4-Methoxyphenyl)cyclohexanone (52i): 
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HPLC Data: 
Chiralcel AD-H; n-heptane : i-propanol 98:2; flow: 0.5 mL/min 
  
 
(S)-3-(4-Chlorophenyl)cyclohexanone (52k): 
 
 
HPLC Data: 
Chiralcel OJ; n-heptane : i-propanol 99:1; flow: 0.5 mL/min 
  
 
(S)-3-(4-Fluorophenyl)cyclohexanone (52l): 
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HPLC Data: 
Chiralcel AD; n-heptane : i-propanol 99:1; flow: 1.0 mL/min 
  
 
(S)-3-(4-(Trifluoromethyl)phenyl)cyclohexanone (52m): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 90:10; flow: 0.5 mL/min 
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(S,E)-3-Styrylcyclohexanone (52n): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 98:2; flow: 1.0 mL/min 
 
 
(S,E)-3-(4-Methylstyryl)cyclohexanone (52o): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 99:1; flow: 1.0 mL/min 
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(S)-3-Phenylcyclopentanone (53a): 
 
 
HPLC Data: 
Chiralcel OB-H; n-heptane : i-propanol 99:1; flow: 0.5 mL/min 
 
  
 
(S)-3-(Naphthalen-1-yl)cyclopentanone (53b): 
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HPLC Data: 
Chiralcel AS-H; n-heptane : i-propanol 80:20; flow: 0.7 mL/min 
 
 
(S)-3-(2-Methoxyphenyl)cyclopentanone (53c): 
 
 
HPLC Data: 
Chiralcel OB-H; n-heptane : i-propanol 90:10; flow: 0.7 mL/min 
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(S)-3-(3-Chlorophenyl)cyclopentanone (53d): 
 
 
HPLC Data: 
Chiralcel OB-H; n-heptane : i-propanol 90:10; flow: 0.7 mL/min 
  
 
(S)-3-(4-Methoxyphenyl)cyclopentanone (53e): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 95:5; flow: 0.5 mL/min 
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(S)-3-(p-Tolyl)cyclopentanone (53f): 
 
 
HPLC Data: 
Chiralcel OB-H; n-heptane : i-propanol 95:5; flow: 0.7 mL/min 
 
 
(S)-3-(4-Chlorophenyl)cyclopentanone (53g): 
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HPLC Data: 
Chiralcel OB-H; n-heptane : i-propanol 90:10; flow: 0.5 mL/min 
  
 
(S)-3-(4-(Trifluoromethyl)phenyl)cyclopentanone (53h): 
 
 
HPLC Data: 
Chiralcel OB-H; n-heptane : i-propanol 90:10; flow: 0.5 mL/min 
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(S,E)-3-Styrylcyclopentanone (53i): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 99:1; flow: 1.0 mL/min 
 
 
(S)-1-Benzyl-3-phenylpyrrolidine-2,5-dione (54a): 
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HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 90:10; flow: 1.0 mL/min 
 
 
(S)-1-Benzyl-3-(4-methoxyphenyl)pyrrolidine-2,5-dione (54b): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 90:10; flow: 1.0 mL/min 
  
 
(S)-1-Benzyl-3-(3,5-dimethylphenyl)pyrrolidine-2,5-dione (54c): 
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HPLC Data: 
Chiralcel AD-H; n-heptane : i-propanol 95:5; flow: 1.0 mL/min 
 
 
3.7.2 Compounds of Table 2 
 
(R)-3-Phenylcyclohexanone (55a): 
 
 
HPLC Data: 
Chiralcel AD; n-heptane : i-propanol 90:10; flow: 0.3 mL/min 
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(R)-3-(Naphthalen-1-yl)cyclohexanone (55b): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 95:5; flow: 0.5 mL/min 
 
 
(R)-3-(4-Methoxyphenyl)cyclohexanone (55c): 
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HPLC Data: 
Chiralcel AD-H; n-heptane : i-propanol 98:2; flow: 0.5 mL/min 
 
 
(R)-3-(4-(Trifluoromethyl)phenyl)cyclohexanone (55d): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 95:5; flow: 0.5 mL/min 
 
 
(R)-3-(Naphthalen-1-yl)cyclopentanone (56a): 
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HPLC Data: 
Chiralcel AD-H; n-heptane : i-propanol 80:20; flow: 0.7 mL/min 
 
 
(R)-3-(4-Chlorophenyl)cyclopentanone (56b): 
 
 
HPLC Data: 
Chiralcel OB-H; n-heptane : i-propanol 90:10; flow: 0.5 mL/min 
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(R)-3-(4-(Trifluoromethyl)phenyl)cyclopentanone (56c): 
 
 
HPLC Data: 
Chiralcel OB-H; n-heptane : i-propanol 90:10; flow: 0.5 mL/min 
 
 
(R)-1-Benzyl-3-(3,5-dimethylphenyl)pyrrolidine-2,5-dione (57): 
 
 
HPLC Data: 
Chiralcel AD-H; n-heptane : i-propanol 95:5; flow: 0.6 mL/min 
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(R)-Benzyl 4-oxo-2-phenylpiperidine-1-carboxylate (58): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 90:10; flow: 0.6 mL/min 
 
 
 
3.7.3 Compounds of Table 3 
 
3-(4-Methoxyphenyl)cyclohexanone (61a): 
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HPLC Data: 
Chiralcel AD-H; n-heptane : i-propanol 98:2; flow: 0.5 mL/min 
 
 
3-(p-Tolyl)cyclohexanone (61b): 
 
 
HPLC Data: 
Chiralcel AS-H; n-heptane : i-propanol 95:5; flow: 0.5 mL/min 
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3-Phenylcyclohexanone (61c): 
 
 
HPLC Data: 
Chiralcel AD; n-heptane : i-propanol 90:10; flow: 0.3 mL/min 
 
 
3-(4-Fluorophenyl)cyclohexanone (61d): 
 
 
HPLC Data: 
Chiralcel AD; n-heptane : i-propanol 99:1; flow: 1.0 mL/min 
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3-(4-Methoxyphenyl)cyclohexanone (62a): 
 
 
HPLC Data: 
Chiralcel AD-H; n-heptane : i-propanol 98:2; flow: 0.5 mL/min 
 
 
3-Phenylcyclohexanone (62b): 
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HPLC Data: 
Chiralcel AD; n-heptane : i-propanol 90:10; flow: 0.3 mL/min 
 
 
 
3-(4-(Trifluoromethyl)phenyl)cyclohexanone (62c): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 90:10; flow: 0.5 mL/min 
 
 
3-(3-Methoxyphenyl)cyclohexanone (64a): 
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HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 99:1; flow: 1.0 mL/min 
 
 
 
3-(Naphthalen-1-yl)cyclohexanone (64b): 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 95:5; flow: 0.5 mL/min 
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4. Pd-Catalyzed Diastereoselective Csp3-Csp2 Cross-Coupling Reactions. 
4.1 Preparation of starting materials 
 
Synthesis of 3-isopropylcyclohexanone 
 
 
To a stirred solution of CuI (5.71 g; 30 mmol) and LiCl (2.52 g; 60 mmol) in THF and cooled to 
0 °C, was added 2-cyclohexenone (28.8 g; 300 mmol) and TMSCl (41.4 mL; 300 mmol) and the 
stirring was continued for 1 h before the mixture was cooled to ‒78 °C. Then, iPrMgCl·LiCl 
(1.30 M in THF; 242 mL; 315 mmol) was added within 45 min and the stirring was continued for 
4 h. Sat. NH4Cl aq. solution (200 mL) was added and the reaction mixture was allowed to warm 
to rt. Most of the solvents were removed under reduced pressure. The residue was extracted with 
Et2O (3 x 150 mL). The combined organic phases were washed several times with sat. NH4Cl aq. 
solution (3 x 50 mL) until the aqueous phase remained colorless. The combined organic phases 
were then washed with brine and dried (Na2SO4). Solvents were removed on the rotary 
evaporator. The crude product was treated with a mixture of EtOH and H2O (1:1; 80 mL) and 
HCl (2 M; 50 mL) and stirred at room temperature overnight. Et2O (200 mL) was added and the 
phases were separated. The aqueous phase was extracted with 3 x 100 mL Et2O. The combined 
organic phases were dried (Na2SO4). The solvents were removed via rotary evaporation to give 3-
isopropylcyclohexanone as a colorless liquid (41 g) in 97% yield. 
 
1H-NMR (300 MHz, CDCl3) δ: 2.33 (t, J=13.8 Hz, 1 H), 2.24-2.18 (m, 1 H), 2.06-2.02 (m, 1 H), 
1.83 (d, J=13.4 Hz, 1 H), 1.61-1.50 (m, 1 H), 1.37-1.30 (m, 1 H), 0.88-0.86 (m, 1 H). 
13C-NMR (75 MHz, CDCl3) δ: 212.6, 45.4, 45.3, 41.4, 32.4, 28.3, 25.5, 19.5, 19.3. 
MS (70 eV, EI) m/z (%): 140 (18) [M+], 98 (10), 97 (100), 96 (10), 82 (19), 69 (36), 55 (14), 55 
(26), 41 (34). 
IR (ATR) ν~  (cm-1): 2958 (m), 2871 (m), 1709 (vs), 1464 (w), 1448 (w), 1423 (w), 1387 (w), 
1369 (w), 1347 (w), 1314 (m), 1258 (w), 1226 (m), 1197 (w), 1122 (w), 1058 (w), 902 (w), 871 
(w), 565 (w). 
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HRMS (EI) for C9H16O (140.1201): 140.1194. 
 
Synthesis of 3-isopropylcyclohexanol 
 
 
LiAlH4 (3.42 g; 90 mmol) was suspended in Et2O (90 mL). The suspension was heated to reflux 
for 1 h. After cooling to 0 °C, a solution of 3-isopropylcyclohexanone (41 g; 296 mmol) in 24 ml 
Et2O was added dropwise. After the addition was complete, the reaction mixture was heated to 
reflux (12 h). The reaction mixture was cooled to 0 °C and carefully quenched via addition of a 
1:1 mixture of NaOH (2 M) and H2O (7 mL). Additional 20 mL of H2O were added along with 
24 g of Celite. The suspension was stirred for 2 h at room temperature and filtered. The 
precipitate was washed with Et2O (4 x 200 mL). The solvent was removed via rotary evaporation 
to give 3-isopropylcyclohexanol (37.5 g) as a colorless liquid in 89% yield. 
 
1H-NMR (300 MHz, CDCl3) δ: 3.54 (tt, J1=10.7 Hz, J2=4.3 Hz, 1 H), 1.94 (d, J=12.4 Hz, 2 H), 
1.81-1.70 (m, 2 H), 1.59 (ddd, J1=12.8 Hz, J2=1.5 Hz, J3=1.3 Hz, 1 H), 1.45 (dd, J1=12.6 Hz, 
J2=6.8 Hz, 1 H), 1.25-1.06 (m, 3 H), 0.97-0.77 (m, 8 H). (mixture of diastereomers; signals of the 
major isomer are given) 
13C-NMR (75 MHz, CDCl3) δ: 71.3, 42.7, 39.2, 35.9, 32.6, 28.6, 24.2, 19.8, 19.6. (mixture of 
diastereomers; signals of the major isomer are given) 
MS (70 eV, EI) m/z (%): 124 (18), 109 (21), 99 (16), 83 (13), 82 (42), 81 (100), 80 (12), 69 (18), 
66 (17), 57 (33), 55 (37), 43 (19), 43 (10), 41 (31). 
IR (ATR) ν~  (cm-1): 3328 (m), 2929 (vs), 2856 (s), 1705 (w), 1463 (m), 1450 (m), 1385 (m), 
1368 (m), 1088 (m), 1043 (vs), 978 (m). 
HRMS (EI) for C9H18O (142.1358): 142.1349. 
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Synthesis of 2-isopropylcyclopentanol152 
 
 
To a solution of CuBr·SMe2 (6.2 g; 30 mmol) in THF (300 mL) cooled to ‒30 °C was added 
iPrMgCl-LiCl (1.23 M in THF; 312 mL; 384 mmol) over 45 min. After the addition was 
complete, the mixture was stirred for 30 min and cyclopentene oxide (25 g; 300 mmol) was 
added. The reaction mixture was stirred for 1 h at ‒30 °C and was then warmed to room 
temperature (12 h). The reaction mixture was quenched with sat. NH4Cl aq. solution (200 mL). 
Phases were separated and the aqueous phase was extracted with Et2O (3 x 200 mL). The 
combined organic layers were dried (Na2SO4) and the solvents were evaporated. The crude 
product was distilled to give 2-isopropylcyclopentanol (22.3 g) as a colorless liquid in 59% yield. 
 
(Mixture of diastereomers; signals of the major isomer are given) 
1H-NMR (300 MHz, CDCl3) δ: 3.95 (dt, J1=6.6 Hz, J2=4.7 Hz, 1 H), 1.87-1.76 (m, 2 H), 1.70-
1.61 (m, 1 H), 1.60-1.41 (m, 5 H), 1.26-1.13 (m, 1 H), 0.96 (d, J=6.6 Hz, 3 H), 0.86 (d, J=6.6 Hz, 
3 H).  
13C-NMR (75 MHz, CDCl3) δ: 77.1, 55.7, 35.9, 30.8, 28.3, 22.8, 21.5, 20.2. 
MS (70 eV, EI) m/z (%): 109 (22), 95 (88), 85 (14), 82 (19), 81 (18), 69 (79), 68 (30), 67 (46), 57 
(100), 56 (53), 55 (35), 44 (22), 43 (69), 41 (64). 
IR (ATR) ν~  (cm-1): 3335 (m), 3332 (m), 2953 (vs), 2870 (s), 1466 (m), 1449 (m), 1385 (m), 
1367 (m), 1342 (m), 1316 (m), 1163 (m), 1079 (m), 1026 (s), 987 (m), 967 (m), 931 (m), 913 
(m), 848 (m). 
HRMS (EI) for C8H16O (128.1201): 128.1205. 
 
 
 
 
 
 
                                                 
152 C. M. Grise, L. Barriault, Org. Lett. 2006, 8, 5905. 
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Synthesis of 3-(trifluoromethyl)cyclohexanol 
 
 
This compound was prepared from commercially available 3-(trifluoromethyl)phenol according 
to literature procedure.153 
 
4.2 Preparation of cycloalkyl chlorides 
To a suspension of N-chlorosuccinimide (1.3 equiv) in THF (0.5 M) cooled to 0 °C was carefully 
added a solution of PPh3 (1.0 equiv) in THF (1.5 M). After the addition was complete the 
respective cycloalcohol was added. After 4 h, the reaction mixture was allowed to warm to room 
temperature and was stirred overnight. The reaction mixture was carefully concentrated in vacuo 
(some cycloalkyl chlorides are volatile!). The residue was treated with n-pentane. The precipitate 
was filtered off and washed with n-pentane. Removal of n-pentane and distillation of the resulting 
oils furnished the respective chlorides with up to 72% yield. 
 
(1S,2S,4R)-2-Chloro-1-isopropenyl-4-methylcyclohexane 
 
 
colorless oil (72%) 
1H-NMR (300 MHz, CDCl3) δ: 4.87 (d, J=1.2 Hz, 1 H), 4.73 (s, 1 H), 4.53 (d, J=1.7 Hz, 1 H), 
2.15-2.06 (m, 2 H), 2.01-1.86 (m, 1 H), 1.85-1.70 (m, 5 H), 1.64-1.58 (m, 1 H), 1.45 (ddd, 
J1=14.1 Hz, J2=11.7 Hz, J3=2.9 Hz, 1 H), 1.04-0.89 (m, 4 H). 
13C-NMR (75 MHz, CDCl3) δ: 145.8, 111.2, 62.0, 48.0, 43.1, 34.5, 25.9, 24.1, 21.8, 21.7.  
MS (70 eV, EI) m/z (%): 138 (31), 123 (100), 96 (88), 95 (38), 94 (31), 83 (25), 82 (48), 81 (27), 
69 (59), 68 (42), 67 (62), 56 (24), 55 (77), 54 (31), 53 (26), 43 (47), 41 (67). 
                                                 
153 I. M. Zalesskaya, A. N. Blakitnyi, E. P. Saenko, Y. A. Fialkov, L. M. Yagupol'skii, Zh. Org. Khim. 1980, 16, 
1194. 
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IR (ATR) ν~  (cm-1): 2949 (m), 2928 (m), 2868 (m), 1647 (m), 1455 (m), 1444 (m), 1375 (m), 
1297 (m), 1276 (m), 1246 (m),  1179 (w), 994 (w), 949 (m), 902 (m), 887 (vs), 860 (m), 683 (vs), 
668 (w). 
HRMS (EI) for C10H19Cl (174.1175): 174.1197. 
 
1-Chloro-2-methylcyclohexane 
 
 
colorless liquid (40%) 
(Mixture of diastereomers; signals of the major isomer are given) 
1H-NMR (300 MHz, CDCl3) δ: 4.26 (d, J=2.9 Hz, 1 H), 2.07-1.91 (m, 1 H), 1.84-1.62 (m, 4 H), 
1.50-1.35 (m, 3 H), 1.33-1.18 (m, 1H), 0.98 (d, J=6.8 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 66.7, 37.0, 34.3, 28.5, 24.9, 20.3, 19.2. 
MS (70 eV, EI) m/z (%): 97 (11), 96 (52), 81 (100), 70 (15), 67 (11), 55 (25). 
IR (ATR) ν~  (cm-1): 2932 (s), 2857 (m), 1445 (m), 1269 (m), 961 (m), 876 (w), 821 (m), 766 
(m), 685 (vs). 
HRMS (EI) for C7H13Cl (132.0706): 132.0703. 
 
1-Chloro-4-methylcyclohexane 
 
 
colorless liquid (41%) 
(Mixture of diastereomers; signals of the major isomer are given) 
1H-NMR (600 MHz, CDCl3) δ: 4.39 (s, 1 H), 1.96-1.94 (m, 2 H), 1.79-1.73 (m, 2 H), 1.52-1.41 
(m, 5 H), 0.92 (d, J=6.0 Hz, 3 H). 
13C-NMR (150 MHz, CDCl3) δ: 59.8, 37.2, 34.8, 33.7, 31.5, 29.0, 21.9. 
MS (70 eV, EI) m/z (%): 97 (11), 96 (40), 81 (100), 68 (16), 67 (15), 55 (41), 54 (13), 41 (23). 
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IR (ATR) ν~  (cm-1): 2947 (m), 2923 (s), 2856 (m), 1456 (m), 1441 (m), 1428 (w), 1377 (w), 
1367 (w), 1357 (w), 1310 (w), 1268 (w), 1255 (s), 1217 (w), 1148 (w), 1113 (w), 1028 (w), 972 
(w), 967 (w), 961 (w), 952 (m), 873 (w), 868 (w), 852 (s), 790 (w), 749 (w), 740 (w), 709 (vs). 
HRMS (EI) for C7H13Cl (132.0706): 132.0696. 
 
1-Chloro-4-tert-butylcyclohexane 
 
 
colorless liquid (52 %) 
(Mixture of diastereomers; signals of the major isomer are given) 
1H-NMR (300 MHz, CDCl3) δ: 4.47-4.45 (m, 1 H), 2.06-2.00 (m, 2 H), 1.77-1.66 (m, 2 H), 
1.60-1.45 (m, 4 H), 1.07-0.94 (m, 1 H), 0.86 (s, 9 H). 
13C-NMR (75 MHz, CDCl3) δ: 60.0, 47.7, 34.5, 32.6, 27.4, 20.9.  
MS (70 eV, EI) m/z (%): 123 (26), 81 (12), 57 (100), 56 (48), 41 (66). 
IR (ATR) ν~  (cm-1): 2945 (vs), 2906 (s), 2867 (s), 2841 (m), 1738 (w), 1479 (s), 1441 (s), 1365 
(vs), 1314 (m), 1263 (s), 1025 (s), 999 (s), 904 (m), 860 (vs), 770 (s), 692 (vs). 
HRMS (EI) for C10H19Cl (174.1175): 174.1174. 
 
1-Chloro-3-methylcyclohexane 
 
 
colorless liquid (40%) 
(Mixture of diastereomers; signals of the major isomer are given) 
1H-NMR (600 MHz, CDCl3) δ: 4.46 (s, 1 H), 1.93 (d, J=12.6 Hz, 2 H), 1.78 (d, J=10.3 Hz, 1 H), 
1.68 (d, J=9.5 Hz, 2 H), 1.55 (d, J=3.1 Hz, 1 H), 1.42 (d, J=11.7 Hz, 1 H), 0.97-0.88 (m, 4H).  
13C-NMR (150 MHz, CDCl3) δ: 60.0, 45.9, 42.4, 37.0, 34.1, 34.0, 26.4, 21.7, 20.3. 
MS (70 eV, EI) m/z (%): 97 (14), 96 (40), 96 (74), 82 (12), 81 (22), 68 (30), 67 (34), 55 (100), 54 
(20), 53 (11), 41 (12), 40 (31). 
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IR (ATR) ν~  (cm-1): 2929 (s), 2866 (m), 2843 (m), 1457 (m), 1446 (m), 1427 (w), 1378 (w), 
1267 (s), 1106 (w), 1037 (w), 974 (w), 960 (w), 876 (m), 862 (s), 848 (m), 839 (w), 771 (m), 740 
(m), 684 (vs). 
HRMS (EI) for C7H13Cl (132.0706): 132.0698. 
 
1-Chloro-3-isopropylcyclohexane 
 
 
colorless liquid (54%) 
(Mixture of diastereomers; signals of the major isomer are given) 
1H-NMR (300 MHz, CDCl3) δ: 4.54-4.52 (m, 1 H), 1.99-1.88 (m, 2 H), 1.81-1.37 (m, 7 H), 
1.06-0.93 (m, 1 H), 0.87 (d, J=1.9 Hz, 3 H), 0.84 (d, J=1.9 Hz, 3 H).  
13C-NMR (75 MHz, CDCl3) δ: 60.6, 37.6, 37.3, 34.2, 32.0, 28.9, 20.4, 19.7, 19.5. 
MS (70 eV, EI) m/z (%): 124 (36), 109 (15), 82 (20), 81 (100), 80 (27), 67 (17), 55 (10), 43 (10), 
41 (20). 
IR (ATR) ν~  (cm-1): 2955 (vs), 2935 (vs), 2887 (m), 2870 (s), 1464 (m), 1447 (m), 1430 (m), 
1386 (m), 1368 (m), 1268 (s), 904 (m), 862 (m), 680 (s), 577 (s). 
HRMS (EI) for C9H17Cl (160.1019): 160.1003. 
 
1-Chloro-3-(trifluoromethyl)cyclohexane 
 
CF3
Cl  
colorless liquid (37%) 
(Mixture of diastereomers; signals of the major isomer are given) 
1H-NMR (600 MHz, CDCl3) δ: 4.6 (s, 1 H), 2.66-2.56 (m, 1 H), 2.2 (d, J=14.1 Hz, 1 H), 2.00-
1.92 (m, 2 H), 1.86-1.81 (m, 1 H), 1.78-1.67 (m, 3 H), 1.36-1.24 (m, 1 H).  
13C-NMR (150 MHz, CDCl3) δ: 127.7 (q, J=278.2 Hz), 57.5, 36.3 (q, J=27.0 Hz), 32.99, 32.8 
(d, J=2.7 Hz), 24.3 (d, J=2.4 Hz), 18.6. 
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19F-NMR (282 MHz, CDCl3) δ: ‒73.5 (d, J=9.0 Hz; major isomer), ‒73.7 (d, J=9.0 Hz; minor 
isomer).  
MS (70 eV, EI) m/z (%): 152 (17), 150 (88), 135 (21), 131 (46), 130 (56), 111 (14), 81 (100), 41 
(13). 
IR (ATR) ν~  (cm-1): 2952 (w), 2874 (w), 1459 (w), 1452 (w), 1434 (w), 1393 (m), 1353 (w), 
1340 (m), 1313 (w), 1297 (m), 1254 (s), 1217 (w), 1202 (m), 1152 (s), 1115 (s), 1086 (vs), 1056 
(m), 1039 (m), 987 (m), 975 (w), 913 (m), 893 (m), 770 (w), 752 (m), 734 (w), 729 (w), 724 (w), 
710 (s), 695 (w), 690 (w), 678 (m), 663 (m). 
HRMS (EI) for C7H10ClF3 (186.0423): 186.0419 
 
1-Chloro-2-isopropylcyclopentane (82) 
 
 
colorless liquid (70%) 
(Mixture of diastereomers; signals of the major isomer are given) 
1H-NMR (600 MHz, CDCl3) δ: 4.43 (t, J=3.5 Hz, 1 H), 2.06 (ddd, J1=13.9 Hz, J2=8.6 Hz, 
J3=2.3 Hz, 1 H), 2.02-1.95 (m, 1 H), 1.93-1.88 (m, 1 H), 1.84-1.80 (m, 1 H), 1.70-1.65 (m, 1 H), 
1.54-1.46 (m, 1 H), 1.31-1.22 (m, 1 H), 0.96 (d, J=6.7 Hz, 3 H), 0.91 (d, J=6.7 Hz, 3 H), 0.89-
0.85 (m, 1 H).  
13C-NMR (150 MHz, CDCl3) δ: 67.2, 54.9, 36.6, 30.1, 26.9, 21.7, 21.6, 21.3. 
MS (70 eV, EI) m/z (%): 110 (25), 95 (49), 81 (19), 70 (14), 69 (65), 68 (100), 67 (81), 66 (12), 
56 (47), 55 (29), 43 (34), 41 (48). 
IR (ATR) ν~  (cm-1): 2958 (vs), 2872 (s), 1468 (m), 1436 (m), 1386 (m), 1368 (m), 1322 (m), 
1260 (m), 928 (m), 904 (m), 605 (m). 
HRMS (EI) for C8H15Cl (146.0862): 146.0848. 
 
(1R,2R,3S,5S)-3-Chloro-2,6,6-trimethylbicyclo[3.1.1]heptane (85) 
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This compound was prepared from commercially available (1R,2R,3R,5S)-(‒)-isopinocampheol 
according to literature procedure.84 
 
(3β)-3-Chlorocholest-5-ene 
 
 
 
This compound was prepared from commercially available cholesterol according to literature 
procedure.85 
 
4.3 Preparation of cycloalkylmagnesium chlorides 
In an Ar-flushed Schlenk-flask equipped with a magnetic stirring bar, a reflux condenser and a 
dropping funnel, Mg turnings (1.2 equiv) were suspended in THF (0.7 mL per 1 mmol Mg). A 
catalytic amount of 1,2-dibromoethane (5 mol%) was added. The mixture was heated to reflux 
and a solution of the respective cyclohexyl or cyclopentyl chloride (1.0 equiv) in THF (0.3 mL 
per 1 mmol cycloalkyl chloride) was added dropwise. After the addition was complete, the 
reaction was stirred without further heating. For the Mg insertion into isopulegyl and cholesteryl 
chloride the reaction mixture was refluxed until all starting material was converted (checked by 
GC analysis). The concentrations of all cycloalkylmagnesium chlorides were determined via 
titration with I2 (150 mg in 2 mL THF). 
 
(‒)-Menthylmagnesium chloride (67a) 
 
 
0.64 M solution in THF (73%) 
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(‒)-Isopulegylmagnesium chloride (67b) 
 
 
0.62 M solution in THF (71%) 
 
2-Methylcyclohexylmagnesium chloride 
 
 
0.63 M solution in THF (72%) 
 
4-Methylcyclohexylmagnesium chloride 
 
 
0.70 M solution in THF (80%) 
 
 
4-tert-Butylcyclohexylmagnesium chloride 
 
 
0.71 M solution in THF (81%) 
 
3-Methylcyclohexylmagnesium chloride 
 
 
0.74 M solution in THF (84%) 
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3-Isopropylcyclohexylmagnesium chloride 
 
 
0.70 M solution in THF (80%) 
 
3-Trifluoromethylcyclohexylmagnesium chloride 
 
 
0.65 M solution in THF (74%) 
 
2-Isopropylcyclopentylmagnesium chloride 
 
 
0.62 M solution in THF (71%) 
 
(R)-Isopinocampheylmagnesium chloride 
 
 
0.54 M solution in THF (62%) 
 
Cholesterylmagnesium chloride 
 
 
0.42 M solution in THF (48%) 
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4.4 Cross-coupling of menthyl-, isopulegyl-, isopinocampheyl-, cholesteryl-, 2-
methylcyclohexyl- and 2-isopropylcyclopentylzinc chlorides 
A dry and Ar-flushed 10 mL Schlenk-tube, equipped with a magnetic stirring bar and a septum, 
was charged with ZnCl2 (1.2 mmol; 1.2 mL of a 1.0 M THF solution) and NEP (N-ethyl-2-
pyrrolidone) (0.12 mL; 10 vol%). A solution of the respective cycloalkylmagnesium chloride (1.0 
mmol) in THF was added at room temperature. The reaction mixture was stirred for 10 min. 
Meanwhile, in a second dry and argon-flushed 10 mL Schlenk-flask, a solution of Pd(dba)2 (0.01 
mmol; 5.75 mg), SPhos (0.01 mmol; 4.11 mg) and the respective aryl iodide (0.7 mmol) in THF 
(0.7 mL) was stirred for 5 min, cooled to the appropriate temperature (see Tables 4 and 5 and 
Scheme 33) and the organozinc reagent was added. The reaction progress was monitored by GC 
analysis. Conversion was complete after 6-12 h. The reaction mixture was quenched with sat. 
NH4Cl aq. solution (2 mL). Water was added (2 mL). Phases were separated and the aqueous 
phase was extracted with Et2O (3 x 10 mL). The combined organic layers were dried over 
Na2SO4 and the solvents were evaporated. The crude product was purified via column 
chromatography. 
 
1-[(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl]-4-methoxybenzene (69a) 
 
 
colorless crystals (78%) 
m.p.: 81.6 – 83.2 °C.  
1H-NMR (300 MHz, CDCl3) δ: 7.07 (d, J=8.5 Hz, 2 H), 6.83 (d, J=8.5 Hz, 2 H), 3.78 (s, 3 H), 
2.37 (td, J1=11.5 Hz, J2=3.3 Hz, 1 H), 1.83-1.70 (m, 3 H), 1.52-1.35 (m, 3 H), 1.16-0.97 (m, 3 H), 
0.88 (d, J=6.6 Hz, 3 H), 0.79 (d, J=6.8 Hz, 3 H), 0.66 (d, J=6.8 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 157.5, 138.8, 138.2, 128.2, 116.3, 113.6, 55.1, 47.6, 47.0, 45.6, 
35.3, 33.3, 27.3, 24.6, 22.5, 21.5, 15.3.  
MS (70 eV, EI) m/z (%): 246 (41) [M+], 162 (11), 161 (100), 121 (36), 44 (11). 
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IR (ATR) ν~  (cm-1): 2952 (m), 2904 (m), 2871 (w), 2841 (w), 1608 (m), 1524 (s), 1456 (m), 
1387 (w), 1367 (w), 1299 (m), 1243 (vs), 1176 (m), 1105 (m), 1032 (s), 831 (m), 817 (m), 754 
(w), 637 (w). 
HRMS (EI) for C17H26O (246.1984): 246.1980. 
 
1-Chloro-4-[(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl]benzene (69b) 
 
 
colorless liquid (71%) 
1H-NMR (300 MHz, CDCl3) δ: 7.27 (d, J=8.6 Hz, 2 H), 7.11 (d, J=8.4 Hz, 2 H), 2.43 (td, 
J1=11.5 Hz, J2=3.4 Hz, 1 H), 1.86-1.74 (m, 3 H), 1.55-1.36 (m, 3 H), 1.22-1.00 (m, 3 H), 0.91 (d, 
J=6.6 Hz, 3 H), 0.82 (d, J=6.8 Hz, 3 H), 0.68 (d, J=6.8 Hz, 3 H).  
13C-NMR (75 MHz, CDCl3) δ: 145.1, 131.1, 128.8, 128.4, 47.4, 45.2, 35.2, 33.2, 27.4, 24.5, 
22.5, 21.5, 15.3.  
MS (70 eV, EI) m/z (%): 250 (67) [M+], 167 (28), 166 (11), 165 (95), 140 (29), 139 (15), 138 
(100), 127 (22), 125 (77), 115 (11). 
IR (ATR) ν~  (cm-1): 2969 (m), 2953 (s), 2917 (s), 2869 (m), 2845 (m), 1739 (vs), 1492 (s), 1455 
(s), 1366 (s), 1217 (s), 1092 (s), 1014 (s), 1014 (s), 826 (s), 809 (s), 719 (m), 689 (m). 
HRMS (EI) for C16H23Cl (250.1488): 250.1481. 
 
1-[(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl]-3-(trifluoromethyl)benzene (69c) 
 
 
colorless liquid (63%) 
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1H-NMR (300 MHz, CDCl3) δ: 7.43-7.32 (m, 4 H), 2.50 (td, J1=11.7 Hz, J2=3.4 Hz, 1 H), 1.85-
1.73 (m, 3 H), 1.52-1.43 (m, 1 H), 1.39-1.31 (m, 1 H), 1.21-0.99 (m, 3 H), 0.94-0.84 (m, 4 H), 
0.80 (d, J=7.0 Hz, 3 H), 0.66 (d, J=6.8 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 147.6, 130.9-130.7 (m), 130.4, 128.7, 126.1, 124.1-124.0 (m), 
122.6-122.5 (m), 47.9, 47.3, 45.2, 35.1, 33.2, 27.5, 24.5, 22.4, 21.4, 15.3 (due to low resolution of 
the spectrum, coupling constants could not be accurately attributed). 
19F-NMR (376 MHz, CDCl3) δ: ‒62.47 (s; minor isomer), ‒62.50 (s; major isomer). 
MS (70 eV, EI) m/z (%): 284 (66) [M+], 214 (31), 199 (71), 185 (29), 173 (47), 172 (76), 159 
(85), 125 (21), 112 (33), 111 (23), 97 (24), 95 (21), 85 (14), 84 (14), 83 (49), 81 (26), 71 (21), 70 
(21), 69 (100), 57 (50), 56 (26), 55 (48), 44 (16), 43 (31), 41 (31). 
IR (ATR) ν~  (cm-1): 2955 (m), 2918 (m), 2871 (w), 1739 (m), 1447 (m), 1369 (m), 1324 (vs), 
1227 (m), 1176 (m), 1162 (s), 1123 (vs), 1073 (s), 896 (m), 798 (s), 703 (s), 664 (m). 
HRMS (EI) for C17H23F3 (284.1752): 284.1752. 
 
5-[(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl]pyrimidine (70a) 
 
 
slightly yellow liquid (76%) 
1H-NMR (300 MHz, CDCl3) δ: 9.02 (s, 1 H), 8.52 (s, 2 H), 2.42 (td, J1= 11.8 Hz, J2= 3.4 Hz, 1 
H), 1.84-1.72 (m, 2 H), 1.53-1.41 (m, 2 H), 1.35-1.26 (m, 1 H), 1.20-0.97 (m, 3 H), 0.89-0.63 (m, 
9 H). 
13C-NMR (75 MHz, CDCl3) δ: 156.7, 156.1, 139.1, 46.9, 44.6, 43.1, 34.8, 33.0, 27.6, 24.3, 22.2, 
21.3, 15.1. 
MS (70 eV, EI) m/z (%): 218 (42) [M+], 133 (18), 107 (100), 94 (22), 69 (15), 55 (16). 
IR (ATR) ν~  (cm-1): 2956 (w), 2920 (w), 1559 (m), 1412 (m), 907 (m), 729 (vs). 
HRMS (EI) for C14H22N2 (218.1783): 218.1776. 
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Ethyl 5-[(1R,2S,5R)-2-isopropyl-5-methylcyclohexyl]-2-furoate (70b) 
 
 
colorless liquid (81%) 
1H-NMR (300 MHz, CDCl3) δ: 7.05 (d, J = 3.4 Hz, 1 H), 6.06 (d, J = 3.4 Hz, 1 H), 4.31 (q, J = 
7.0 Hz, 2 H), 2.64 (td, J1= 11.5 Hz, J2= 3.5 Hz, 1 H), 1.86-1.66 (m, 3 H), 1.56-1.40 (m, 2 H), 1.34 
(t, J = 7.0 Hz, 3 H), 1.15-0.95 (m, 4 H), 0.89-0.69 (m, 9 H). 
13C-NMR (75 MHz, CDCl3) δ: 164.8, 158.9: 142.8, 118.8, 106.8, 60.5, 46.3, 41.6, 41.3, 34.7, 
32.7, 28.4, 24.6, 22.3, 21.1, 15.7, 14.4. 
MS (70 eV, EI) m/z (%): 278 (64) [M+], 233 (34), 193 (47), 166 (100), 138 (39), 91 (21). 
IR (ATR) ν~  (cm-1): 2954 (m), 1723 (s), 1297 (vs), 1140 (s), 1121 (s), 1014 (s), 760 (s). 
HRMS (EI) for C17H26O3 (278.1882): 278.1891. 
 
Methyl 4-[(1R,2R,5R)-2-isopropenyl-5-methylcyclohexyl]benzoate (71a) 
 
 
colorless crystals (72%) 
m.p.: 85.7 – 87.1 °C. 
1H-NMR (300 MHz, CDCl3) δ: 7.91 (d, J=8.2 Hz, 2 H), 7.19 (d, J=8.2 Hz, 2 H), 4.50 (d, J=7.3 
Hz, 2 H), 3.87 (s, 3 H), 2.62 (td, J=11.6 Hz, 3.2 Hz, 1 H), 2.26 (td, J=11.5 Hz, 3.2 Hz, 1 H), 1.84-
1.75 (m, 3 H), 1.58-1.42 (m, 5 H), 1.20-1.07 (m, 2 H), 0.92 (d, 6.5 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 167.1, 152.6, 147.8, 129.5, 127.7, 127.5, 111.4, 52.8, 50.8, 48.1, 
44.2, 35.0, 33.0, 32.6, 22.4, 19.7.  
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MS (70 eV, EI) m/z (%): 272 (26) [M+], 229 (25), 213 (100), 201 (24), 157 (25), 150 (33), 149 
(84), 145 (29), 143 (44), 131 (47), 129 (30), 128 (26), 123 (93), 115 (26), 109 (44), 105 (21), 95 
(26), 91 (25), 81 (39), 77 (22), 69 (21), 68 (23), 67 (25), 55 (33), 40 (30). 
IR (ATR) ν~  (cm-1): 2944 (m), 2918 (s), 2864 (m), 2846 (m), 1730 (m), 1718 (vs), 1608 (m), 
1454 (m), 1446 (m), 1430 (m), 1312 (m), 1288 (vs), 1276 (vs), 1190 (m), 1178 (m), 1114 (s), 
1096 (s), 882 (m), 852 (m), 768 (s), 704 (s). 
HRMS (EI) for C18H24O2 (272.1776): 272.1769. 
 
1-[(1R,2R,5R)-2-Isopropenyl-5-methylcyclohexyl]-4-methoxybenzene (71b) 
 
 
colorless liquid (71%) 
1H-NMR (300 MHz, CDCl3) δ: 7.05 (d, J=8.5 Hz, 2 H), 6.79 (d, J=8.5 Hz, 2 H), 4.54 (d, J=5.3 
Hz, 2 H), 3.77 (s, 3 H), 2.52 (td, J1=11.5 Hz, J2=3.2 Hz, 1 H), 2.22 (td, J1=11.5 Hz, J2=3.3 Hz, 1 
H), 1.83-1.75 (m, 3 H), 1.56-1.42 (m, 5 H) , 1.17-1.01 (m, 2 H), 0.92 (d, J=6.3 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 157.5, 148.6, 138.3, 128.2, 113.4, 111.0, 55.1, 52.1, 47.1, 45.1, 
35.2, 33.1, 32.9, 22.5, 19.7.  
MS (70 eV, EI) m/z (%): 244 (100) [M+], 229 (13), 201 (11), 192 (12), 187 (14), 173 (23), 162 
(12), 161 (82), 134 (18), 121 (45), 91 (16), 44 (26). 
IR (ATR) ν~  (cm-1): 2946 (m), 2916 (s), 2866 (m), 2858 (m), 2840 (m), 1610 (m), 1522 (s), 1454 
(s), 1442 (s), 1374 (m), 1302 (m), 1278 (m), 1260 (s), 1244 (vs), 1176 (s), 1098 (m), 1036 (s), 
900 (m), 886 (s), 820 (s), 802 (s), 586 (m), 566 (m). 
HRMS (EI) for C17H24O (244.1827): 244.1830. 
 
(1'R,2'R,5'R)-2'-Isopropenyl-5'-methyl-1,1'-bi(cyclohexan)-1-en-3-one (71c) 
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colorless liquid (64%) 
1H-NMR (400 MHz, C6D6) δ: 5.92 (s, 1 H), 4.65 (s, 1 H), 4.56 (s, 1 H), 2.21-2.08 (m, 2 H), 1.94-
1.79 (m, 3 H), 1.74-1.66 (m, 1 H), 1.57-1.47 (m, 4 H), 1.45 (s, 3 H), 1.37 (ddd, J1=12.7 Hz, 
J2=5.0 Hz, J3=3.2 Hz, 1 H), 1.21-1.11 (m, 2 H), 0.82-0.69 (m, 5 H). 
13C-NMR (150 MHz, CDCl3) δ: 197.7, 167.3, 148.1, 126.7, 111.4, 49.7, 48.8, 40.2, 38.0, 34.9, 
32.4, 32.1, 26.4, 23.1, 22.6, 18.9.  
MS (70 eV, EI) m/z (%): 232 (100) [M+], 217 (24), 199 (43), 189 (23), 176 (24), 175 (25), 173 
(25), 161 (34), 159 (28), 148 (50), 133 (26), 123 (47), 123 (23), 119 (32), 110 (23), 107 (31), 105 
(52), 93 (38), 91 (40), 81 (49), 79 (34), 77 (25), 67 (27), 55 (26), 40 (27). 
IR (ATR) ν~  (cm-1): 2970 (m), 2946 (s), 2921 (s), 2867 (m), 1739 (vs), 1668 (vs), 1619 (m), 
1455 (s), 1373 (s), 1350 (s), 1323 (m), 1230 (s), 1217 (s), 1134 (m), 1111 (m), 965 (m), 884 (vs), 
758 (m). 
HRMS (EI) for C16H24O (232.1827): 232.1820. 
 
Methyl 4-(trans-2-methylcyclohexyl)benzoate (73) 
 
 
colorless liquid (82%) 
1H-NMR (400 MHz, C6D6) δ: 8.15 (d, J=8.2 Hz, 2 H), 6.97 (d, J=8.2 Hz, 2 H), 3.53 (s, 3 H), 
1.89 (t, J=11.2 Hz, 1 H), 1.72-1.60 (m, 4 H), 1.39-1.31 (m, 1 H), 1.29-1.15 (m, 3 H), 0.98-0.89 
(m, 1 H), 0.61 (d, J=6.5 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 166.8, 152.2, 130.1, 128.7, 52.6, 52.4, 37.6, 35.8, 35.4, 27.0, 
26.8, 20.8.  
MS (70 eV, EI) m/z (%): 232 (75) [M+], 201 (17), 176 (11), 173 (17), 163 (18), 162 (100), 150 
(14), 149 (11), 131 (34), 115 (12). 
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IR (ATR) ν~  (cm-1): 2922 (m), 1720 (s), 1609 (m), 1435 (m), 1273 (vs), 1190 (m), 1179 (m), 
1111 (s), 1101 (s), 1019 (w), 848 (w), 771 (m), 756 (m), 707 (m). 
HRMS (EI) for C15H20O2 (232.1463): 232.1465. 
 
 
 
Methyl 4-[trans-2-isopropylcyclopentyl]benzoate (83) 
 
 
colorless liquid (96%) 
1H-NMR (300 MHz, C6D6) δ: 8.14 (d, J=8.0 Hz, 2 H), 7.03 (d, J=8.0 Hz, 2 H), 3.53 (s, 3 H), 
2.48 (q, J=8.4 Hz, 1 H), 1.94-1.82 (m, 1 H), 1.75-1.39 (m, 6 H), 1.35-1.23 (m, 1 H), 0.75 (d, 
J=6.7 Hz, 3 H), 0.72 (d, J=6.7 Hz, 3 H). 
13C-NMR (75 MHz, C6D6) δ: 166.7, 152.6, 130.1, 127.8, 54.3, 52.5, 50.2, 36.9, 30.6, 28.5, 24.8, 
22.2, 18.9.  
MS (70 eV, EI) m/z (%): 246 (86) [M+], 215 (24), 163 (17), 162 (100), 150 (23), 149 (24), 131 
(17), 131 (45), 128 (13), 117 (11), 116 (13), 115 (27), 103 (10), 91 (12). 
IR (ATR) ν~  (cm-1): 2952 (m), 2870 (w), 1720 (s), 1609 (m), 1435 (m), 1274 (vs), 1179 (m), 
1111 (s), 1101 (s), 1019 (m), 968 (w), 852 (w), 771 (m), 706 (s). 
HRMS (EI) for C16H22O2 (246.1620): 246.1620. 
 
Methyl 4-[(1R,2R,3R,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]benzoate (86) 
 
 
colorless liquid (65%) 
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1H-NMR (300 MHz, C6D6) δ: 8.17 (d, J=8.3 Hz, 2 H), 7.13 (d, J=8.4 Hz, 2 H), 3.55 (s, 3 H), 
2.93-2.84 (m, 1 H), 2.41-2.33 (m, 1 H), 2.31-2.21 (m, 1 H), 1.99-1.85 (m, 2 H), 1.82-1.74 (m, 2 
H), 1.21 (s, 3 H), 1.05 (s, 3 H), 0.98 (d, J=9.9 Hz 1 H), 0.92 (d, J=7.2 Hz, 3 H). 
13C-NMR (75 MHz, C6D6) δ: 166.7, 154.7, 130.2, 128.6, 128.5, 52.5, 48.2, 45.8, 45.2, 42.1, 
39.2, 37.4, 35.1, 30.2, 28.6, 23.0, 21.0.  
MS (70 eV, EI) m/z (%): 272 (11) [M+], 241 (15), 229 (17), 218 (14), 217 (100), 216 (11), 204 
(21), 203 (19), 190 (27), 185 (20), 176 (13), 171 (13), 163 (11), 149 (12), 143 (21), 131 (23), 129 
(22), 128 (20), 117 (11), 115 (18), 110 (18), 95 (23), 91 (10), 83 (48), 69 (10), 59 (10), 55 (16), 
41 (14). 
IR (ATR) ν~  (cm-1): 2949 (w), 2924 (m), 2901 (m), 2870 (w), 1720 (s), 1609 (m), 1453 (w), 
1434 (m), 1418 (w), 1384 (w), 1372 (w), 1309 (w), 1274 (vs), 1178 (m), 1141 (w), 1105 (s), 1018 
(m), 968 (w), 850 (w), 827 (w), 769 (m), 752 (m), 706 (s). 
HRMS (EI) for C18H24O2 (272.1776): 272.1780. 
 
(3β)-3-(4-Methoxyphenyl)cholest-5-ene (88) 
 
 
white solid (86%) 
m.p.: 123.2 – 125.0 °C. 
1H-NMR (600 MHz, CDCl3) δ: 7.15 (d, J=8.6 Hz, 2 H), 6.84 (d, J=8.6 Hz, 2 H), 5.34 (d, J=4.8 
Hz, 1 H), 3.78 (s, 3 H), 2.50-2.44 (m, 1 H), 2.39 (td, J1=13.2 Hz, J2=2.1 Hz, 1 H), 2.16 (d, J=13.4 
Hz, 1 H), 2.04-1.94 (m, 3 H), 1.84 (ddd, J1=13.1 Hz, J2=9.5 Hz, J3=3.6 Hz, 1 H), 1.74-1.67 (m, 2 
H), 1.62-1.44 (m, 7 H), 1.40-1.33 (m, 3 H), 1.28-1.10 (m, 7 H), 1.07 (s, 3 H), 1.04-0.99 (m, 3 H), 
0.93 (d, J=6.7 Hz, 3 H), 0.87 (d, J=2.4 Hz, 3 H), 0.87 (d, J=2.4 Hz, 3 H), 0.70 (s, 3 H). 
13C-NMR (150 MHz, CDCl3) δ: 157.8, 143.1, 139.3, 127.7, 127.5, 120.0, 114.1, 113.7, 56.8, 
56.2, 55.2, 50.5, 44.9, 42.3, 40.9, 39.9, 39.8, 39.5, 36.9, 36.2, 35.8, 31.9, 31.9, 30.2, 28.3, 28.0, 
24.3, 23.8, 22.8, 22.6, 21.0, 19.6, 18.7, 11.9. 
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MS (70 eV, EI) m/z (%): 476 (100) [M+], 474 (15), 461 (23), 330 (21), 329 (74), 148 (36), 147 
(73), 134 (70), 121 (22), 121 (56), 119 (19), 109 (18), 107 (25), 105 (16), 95 (29), 91 (19), 83 
(17), 81 (21), 71 (16), 69 (23), 57 (28), 55 (27), 42 (24), 40 (19). 
IR (ATR) ν~  (cm-1): 2962 (m), 2953 (m), 2928 (s), 2898 (s), 2879 (s), 2864 (m), 2852 (m), 1509 
(vs), 1464 (s), 1460 (s), 1441 (m), 1255 (s), 1240 (s), 1234 (s), 1175 (s), 1039 (s), 822 (vs), 802 
(s), 766 (m), 591 (m). 
HRMS (EI) for C34H52O (476.4018): 476.4015. 
 
4.5 Cross-coupling of 4- and 3-substituted cyclohexylzinc reagents 
A dry and Ar-flushed 10 mL Schlenk-tube, equipped with a magnetic stirring bar and a septum, 
was charged with 1.2 mL (1.2 mmol) of a solution of ZnCl2 in THF (1.0 M) and NEP (N-ethyl-2-
pyrrolidone) (0.12 mL; 10 vol%). A solution of the respective 4- or 3-substituted 
cyclohexylmagnesium chloride (1.0 mmol) in THF was added at room temperature. The reaction 
was stirred for 10 min. Meanwhile, in a second dry and Ar-flushed 10 mL Schlenk-flask, a 
solution of TMPP2PdCl2 (0.02 mmol; 25 mg) and the respective aryl iodide (0.7 mmol) in THF 
(0.7 mL) was prepared and cooled to the appropriate temperature (see Table 5). Subsequently, the 
organozinc reagent was slowly added. The reaction progress was monitored by GC analysis. 
Conversion was complete after 12 h. The reaction mixture was quenched with sat. NH4Cl aq. 
solution (2 mL). Water was added (2 mL). Phases were separated and the aqueous phase was 
extracted with Et2O (3 x 10 mL). The combined organic layers were dried over Na2SO4 and the 
solvents were evaporated. The crude product was purified via column chromatography. 
 
Methyl 4-(trans-4-methylcyclohexyl)benzoate (75) 
 
colorless crystals (84%) 
m.p.: 56.5 – 58.0 °C. 
1H-NMR (300 MHz, CDCl3) δ: 7.98 (d, J=8.0 Hz, 2 H), 7.29 (d, J=8.0 Hz, 2 H), 3.91 (s, 3 H), 
2.53 (t, J=12.0 Hz, 1 H), 1.87 (t, J=14.1 Hz, 4 H), 1.56-1.43 (m, 3 H), 1.16-1.03 (m, 2 H), 0.96 
(d, J=6.6 Hz, 3 H).  
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13C-NMR (75 MHz, CDCl3) δ: 167.2, 153.3, 129.6, 127.8, 127.0, 126.9, 52.9, 44.3, 35.4, 34.0, 
32.3, 31.8, 28.3, 27.4, 22.6.  
MS (70 eV, EI) m/z (%): 232 (85) [M+], 201 (36), 176 (21), 175 (14), 173 (49), 163 (16), 162 
(100), 149 (18), 145 (11), 137 (11), 131 (55), 117 (24), 116 (12), 115 (21), 105 (16), 103 (13), 95 
(13), 91 (42), 81 (17), 77 (13), 69 (13), 57 (15), 55 (25), 41 (19). 
IR (ATR) ν~  (cm-1): 2945 (m), 2921 (m), 2846 (m), 1716 (vs), 1609 (m), 1439 (s), 1416 (m), 
1275 (s), 1193 (m), 1178 (s), 1112 (s), 1103 (s), 1018 (m), 956 (m), 850 (s), 833 (m), 807 (m), 
773 (vs), 759 (s), 706 (vs). 
HRMS (EI) for C15H20O2 (232.1463): 232.1450. 
 
Methyl 4-(trans-4-tert-butylcyclohexyl)benzoate (76a) 
 
 
colorless crystals (59%) 
m.p.: 112.3 – 114.4 °C. 
1H-NMR (300 MHz, C6D6) δ: 8.19 (d, J=7.8 Hz, 2 H), 7.07 (d, J=7.8 Hz, 2 H), 3.54 (s, 3 H), 
2.21 (t, J=11.9 Hz, 1 H), 1.78-1.71 (m, 4 H), 1.27-1.17 (m, 3 H), 0.95-0.83 (m, 11 H). 
13C-NMR (75 MHz, C6D6) δ: 166.8, 153.2, 130.1, 127.2, 52.5, 47.7, 44.7, 34.6, 32.4, 27.7, 27.7.  
MS (70 eV, EI) m/z (%): 274 (40) [M+], 243 (13), 219 (16), 218 (100), 217 (17), 163 (13), 162 
(37), 159 (24), 150 (10), 149 (24), 131 (18), 91 (10), 57 (32). 
IR (ATR) ν~  (cm-1): 2946 (m), 2916 (m), 2853 (w), 1719 (vs), 1609 (m), 1433 (m), 1366 (m), 
1275 (vs), 1179 (m), 1106 (s), 1017 (m), 958 (m), 820 (w), 769 (m), 705 (s). 
HRMS (EI) for C18H26O2 (274.1933): 274.1926. 
 
1-(trans-4-tert-Butylcyclohexyl)-3-(trifluoromethyl)benzene (76b) 
 
 
colorless liquid (60%) 
1H-NMR (300 MHz, CDCl3) δ: 7.45-7.37 (m, 4 H), 2.56-2.45 (m, 1 H), 1.98-1.89 (m, 4 H), 
1.54-1.38 (m, 2 H), 1.26-1.08 (m, 3 H), 0.89 (s, 9 H). 
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13C-NMR (75 MHz, CDCl3) δ: 148.6, 130.5 (q, J=31.8 Hz), 130.3, 126.2, 124.4 (q, J=272.2 Hz), 
123.5 (q, J=3.4 Hz), 122.6 (q, J=4.0 Hz), 47.6, 44.4, 34.6, 32.6, 32.5, 27.6. 
19F-NMR (376 MHz, CDCl3) δ: ‒62.48 (s, minor isomer), ‒62.53 (s, major isomer). 
MS (70 eV, EI) m/z (%): 284 (10) [M+], 228 (62), 173 (11), 172 (48), 159 (19), 57 (100), 56 (10), 
41 (11). 
IR (ATR) ν~  (cm-1): 2969 (m), 2940 (m), 2858 (w), 1739 (s), 1449 (m), 1365 (s), 1329 (s), 1230 
(m), 1217 (m), 1200 (m), 1161 (s), 1122 (vs), 1074 (s), 908 (w), 892 (m), 798 (m), 701 (s), 667 
(m). 
HRMS (EI) for C17H23F3 (284.1752): 284.1739. 
 
Methyl 4-[cis-3-methylcyclohexyl]benzoate (78a) 
 
 
colorless crystals (77%) 
m.p.: 52.3 – 53.2 °C. 
1H-NMR (300 MHz, CDCl3) δ: 7.98 (d, J=8.0 Hz, 2 H), 7.29 (d, J=8.0 Hz, 2 H), 3.91 (s, 3 H), 
2.62 (t, J=11.7 Hz, 1 H), 1.88 (d, J=10.2 Hz, 3 H), 1.77 (d, J=13.1 Hz, 1 H), 1.63-1.30 (m, 4 H), 
1.12 (q, J=12.0 Hz, 1 H), 0.96 (d, J=6.6 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 167.2, 153.2, 129.7, 127.7, 126.8, 52.9, 44.5, 42.8, 34.7, 33.6, 
33.0, 26.5, 22.8.  
MS (70 eV, EI) m/z (%): 232 (100) [M+], 201 (45), 189 (25), 176 (13), 173 (57), 163 (15), 162 
(79), 150 (28), 149 (46), 131 (20), 131 (53), 129 (13), 117 (26), 115 (20), 105 (28), 103 (14), 95 
(14), 91 (53), 83 (15), 81 (21), 77 (16), 69 (17), 55 (26), 41 (21). 
IR (ATR) ν~  (cm-1): 2919 (s), 1716 (s), 1609 (m), 1438 (s), 1277 (vs), 1193 (m), 1179 (s), 1103 
(s), 1018 (s), 958 (s), 852 (m), 840 (m), 830 (m), 801 (m), 779 (m), 760 (vs), 703 (vs), 666 (m). 
HRMS (EI) for C15H20O2 (232.1463): 232.1456. 
 
1-[cis-3-Methylcyclohexyl]-4-(trifluoromethyl)benzene (78b) 
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colorless liquid (70%) 
1H-NMR (300 MHz, CDCl3) δ: 7.53 (d, J=8.0 Hz, 2 H), 7.30 (d, J=8.0 Hz, 2 H), 2.65-2.55 (m, 1 
H), 1.90-1.73 (m, 4 H), 1.63-1.27 (m, 4 H), 1.09 (q, J=12.3 Hz, 1 H), 0.94 (d, J=6.6 Hz, 3 H).  
13C-NMR (75 MHz, CDCl3) δ: 152.8 (d, J=1.0 Hz), 128.1 (q, J=32.2 Hz), 127.1, 125.2 (q, J=3.8 
Hz), 124.4 (q, J=271.7 Hz), 44.3, 42.9, 34.7, 33.7, 33.0, 26.5, 22.8.    
19F-NMR (282 MHz, CDCl3) δ: ‒62.27 (s). 
MS (70 eV, EI) m/z (%): 242 (38) [M+], 199 (23), 186 (12), 185 (11), 173 (13), 172 (100), 159 
(39), 83 (20), 81 (11), 69 (10), 55 (23), 41 (14). 
IR (ATR) ν~  (cm-1): 2950 (w), 2922 (m), 2898 (w), 2854 (w), 1620 (w), 1458 (w), 1448 (w), 
1420 (w), 1322 (vs), 1188 (w), 1162 (s), 1120 (vs), 1106 (s), 1086 (m), 1066 (s), 1018 (m), 832 
(s), 814 (w), 656 (m), 602 (m). 
HRMS (EI) for C14H17F3 (242.1282): 242.1278. 
 
{4-[cis-3-Methylcyclohexyl]phenyl}(phenyl)methanone (78c) 
 
 
colorless oil (81%) 
1H-NMR (300 MHz, CDCl3) δ: 7.82-7.70 (m, 4 H), 7.65-7.53 (m, 2 H), 7.50-7.42 (m, 2 H), 
7.35-7.26 (m, 1 H), 2.67-2.57 (m, 1 H), 1.89-1.25 (m, 8 H), 1.10-1.06 (m, 1 H), 0.94 (d, J= 
6.0 Hz, 1 H). 
13C-NMR (75 MHz, CDCl3) δ: 196.5, 152.9, 137.9, 135.2, 132.1, 130.4, 129.9, 128.2, 126.8, 
44.5, 42.8, 34.7, 33.6, 33.0, 26.5, 22.8. 
MS (70 eV, EI) m/z (%): 278 (100) [M+], 201 (73), 181 (12), 131 (12), 105 (54), 77 (23). 
IR (ATR) ν~  (cm-1): 2922 (w), 1656 (s), 1605 (w), 1315 (m), 1278 (s), 922 (w), 700 (vs). 
HRMS (EI) for C20H22O (278.1671): 278.1670. 
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2-[(cis-3-Methylcyclohexyl]-5-(trifluoromethyl)pyridine (78d) 
 
 
yellow oil (85%) 
1H-NMR (300 MHz, CDCl3) δ: 8.78-8.75 (m, 1 H), 7.80 (dd, J1= 8.3 Hz, J2= 1.9 Hz, 1 H), 7.25 
(d, J = 8.3 Hz, 1 H), 2.79 (tt, J1= 12.0 Hz, J2= 3.3 Hz, 1 H), 1.93-1.82 (m, 3 H), 1.77-1.65 (m, 1 
H), 1.60-1.36 (m, 3 H), 1.18 (q, J= 6.6 Hz, 1 H), 1.18 (d, J = 6.6 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 170.3, 146.0, 132.0 (d, J = 13 Hz), 124.1 (q, J = 33 Hz), 123.7 
(q, J = 272 Hz), 46.5, 41.1, 34.6, 32.7, 26.2, 22.7. 
MS (70 eV, EI) m/z (%): 243 (100) [M+], 228 (45), 214 (22), 200 (76), 174 (54), 161 (23). 
IR (ATR) ν~  (cm-1): 2924 (w), 1606 (m), 1324 (vs), 1120 (vs), 1080 (s), 1015 (m), 840 (w). 
HRMS (EI) for C13H16F3N (243.1235): 243.1237. 
 
1-[cis-3-Isopropylcyclohexyl]-4-(trifluoromethyl)benzene (79a) 
 
 
colorless liquid (70%) 
1H-NMR (300 MHz, CDCl3) δ: 7.54 (d, J=8.0 Hz, 2 H), 7.32 (d, J=8.3 Hz, 2 H), 2.63-2.53 (m, 1 
H), 1.95-1.75 (m, 4 H), 1.54-1.23 (m, 4 H), 1.20-1.12 (m, 1 H), 1.08-0.98 (m, 1 H), 0.89 (d, J=2.7 
Hz, 3 H), 0.88 (d, J=2.7 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 152.0 (d, J=1.3 Hz), 128.1 (q, J=32.2 Hz), 127.2, 125.2 (q, J=3.8 
Hz), 124.4 (q, J=271.7 Hz), 44.7, 44.3, 37.7, 34.1, 33.0, 29.2, 26.6, 19.8, 19.7.  
19F-NMR (282 MHz, CDCl3) δ: ‒62.27 (s). 
MS (70 eV, EI) m/z (%): 270 (86) [M+], 228 (13), 227 (56), 226 (13), 185 (52), 173 (20), 172 
(60), 159 (100), 83 (10), 81 (22). 
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IR (ATR) ν~  (cm-1): 2958 (w), 2926 (m), 2856 (w), 1620 (w), 1322 (vs), 1162 (s), 1120 (vs), 
1106 (s), 1068 (s), 1016 (m), 832 (s), 654 (w), 604 (m). 
HRMS (EI) for C16H21F3 (270.1595): 270.1605. 
 
 
 
 
 
Methyl 4-[cis-3-isopropylcyclohexyl]benzoate (79b) 
 
 
colorless liquid (86%) 
1H-NMR (300 MHz, CDCl3) δ: 7.98 (d, J=8.3 Hz, 2 H), 7.30 (d, J=8.5 Hz, 2 H), 3.92 (s, 3 H), 
2.64-2.54 (m, 1 H), 1.96-1.77 (m, 4 H), 1.55-1.25 (m, 4 H), 1.23-1.15 (m, 1 H), 1.05 (td, J1=12.1 
Hz, J2=3.6 Hz, 1 H), 0.95-0.89 (m, 6 H).  
13C-NMR (75 MHz, CDCl3) δ: 167.1, 153.4, 137.7, 131.0, 129.7, 127.8, 126.9, 52.9, 44.8, 44.3, 
37.5, 34.0, 33.0, 29.2, 26.6, 19.7, 19.7.  
MS (70 eV, EI) m/z (%): 260 (100) [M+], 229 (29), 218 (11), 217 (48), 201 (18), 185 (28), 163 
(27), 162 (57), 150 (24), 149 (98), 137 (13), 131 (39), 129 (12), 117 (12), 115 (16), 105 (41), 103 
(12), 91 (23), 81 (19), 77 (10), 69 (10), 59 (11), 55 (16), 41 (15). 
IR (ATR) ν~  (cm-1): 2952 (w), 2924 (m), 2854 (w), 1720 (vs), 1610 (m), 1434 (m), 1274 (vs), 
1246 (m), 1178 (m), 1110 (s), 1102 (s), 1020 (m), 850 (m), 768 (m), 706 (s). 
HRMS (EI) for C17H24O2 (260.1776): 260.1767. 
 
1-{4-[cis-3-Isopropylcyclohexyl]phenyl}ethanone (79c) 
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colorless liquid (71%) 
1H-NMR (300 MHz, CDCl3) δ: 7.88 (d, J=8.3 Hz, 2 H), 7.29 (d, J=8.3 Hz, 2 H), 2.62-2.57 (m, 4 
H), 1.91-1.74 (m, 4 H), 1.52-1.22 (m, 4 H), 1.20-1.12 (m, 1 H), 1.02 (td, J1=12.1 Hz, J2=3.4 Hz, 1 
H), 0.89 (d, J=8.3 Hz, 3 H), 0.86 (d, J=8.3 Hz, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 197.8, 153.7, 135.1, 128.5, 128.4, 127.2, 127.0, 44.8, 44.3, 37.5, 
33.9, 33.0, 29.2, 26.6, 26.5, 19.7, 19.7.  
MS (70 eV, EI) m/z (%): 244 (74) [M+], 230 (63), 229 (100), 229 (100), 229 (72), 147 (11), 134 
(14), 133 (36), 131 (29), 115 (12), 105 (18), 103 (10), 91 (17), 77 (10), 55 (13), 43 (96), 41 (14). 
IR (ATR) ν~  (cm-1): 2924 (m), 2854 (m), 1682 (vs), 1606 (s), 1414 (m), 1358 (m), 1266 (vs), 
1182 (m), 956 (m), 826 (s), 594 (vs). 
HRMS (EI) for C17H24O (244.1827): 244.1830. 
 
Ethyl 3-[cis-3-isopropylcyclohexyl]benzoate (79d) 
 
 
colorless liquid (71%) 
1H-NMR (300 MHz, CDCl3) δ: 7.89-7.83 (m, 2 H), 7.43-7.31 (m, 2 H), 4.37 (q, J=7.2 Hz, 2 H), 
2.61-2.52 (m, 1 H), 1.92-1.73 (m, 4 H), 1.50-1.35 (m, 6 H), 1.27-1.13 (m, 2 H), 1.02 (td, J1=12.3, 
J2=3.6 Hz, 1 H), 0.93-0.85 (m, 6 H).  
13C-NMR (75 MHz, CDCl3) δ: 166.9, 148.3, 131.5, 130.4, 128.3, 128.0, 127.1, 60.9, 44.6, 44.4, 
37.8, 34.1, 33.0, 29.2, 26.7, 19.8, 19.7, 14.4.  
MS (70 eV, EI) m/z (%): 274 (100) [M+], 231 (25), 229 (40), 203 (14), 185 (13), 177 (19), 176 
(48), 164 (20), 163 (62), 159 (14), 149 (19), 135 (17), 131 (23), 129 (15), 119 (45), 117 (29), 115 
(16), 105 (14), 103 (13), 91 (41), 81 (24), 69 (14), 55 (20), 41 (15). 
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IR (ATR) ν~  (cm-1): 2956 (w), 2924 (m), 2854 (w), 2360 (w), 2342 (w), 1716 (vs), 1446 (m), 
1366 (m), 1274 (vs), 1192 (s), 1106 (s), 1024 (m), 924 (w), 868 (w), 816 (w), 752 (s), 696 (m). 
HRMS (EI) for C18H26O2 (274.1933): 274.1929. 
 
Methyl 4-[cis-3-(trifluoromethyl)cyclohexyl]benzoate (80) 
 
 
colorless liquid (74%) 
1H-NMR (300 MHz, CDCl3) δ: 8.00 (d, J=8.3 Hz, 2 H), 7.29 (d, J=8.5 Hz, 2 H), 3.92 (s, 3 H), 
2.69-2.60 (m, 1 H), 2.30-2.18 (m, 1 H), 2.14-2.01 (m, 3 H), 1.96-1.93 (m, 1 H), 1.63-1.29 (m, 4 
H). 
13C-NMR (75 MHz, CDCl3) δ: 167.0, 152.2, 129.9, 128.4, 127.5 (q, J= 278.6 Hz), 126.8, 52.0, 
43.1, 42.3 (q, J=26.6 Hz), 33.1, 32.0 (q, J=2.3 Hz), 25.0, 24.5 (q, J=2.5 Hz). 
19F-NMR (282 MHz, CDCl3) δ: ‒73.85 (d, J = 9.4 Hz). 
MS (70 eV, EI) m/z (%): 286 (90) [M+], 256 (15), 255 (100), 228 (13), 227 (97), 175 (13), 162 
(11), 149 (29), 131 (13), 130 (21), 129 (10), 115 (16), 103 (11), 91 (85), 77 (12), 59 (13). 
IR (ATR) ν~  (cm-1): 2946 (w), 2866 (w), 1718 (s), 1610 (w), 1436 (m), 1391 (w), 1276 (s), 1252 
(s), 1207 (m), 1163 (s), 1139 (m), 1109 (s), 1102 (s), 1089 (vs), 1040 (w), 1019 (m), 974 (m), 938 
(w), 850 (m), 770 (m), 706 (s), 692 (s), 580 (w). 
HRMS (EI) for C15H17F3O2 (286.1181): 286.1182. 
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5. Pd-Catalyzed Diastereoselective Csp3-Csp Cross-Coupling Reactions. 
5.1 Preparation of starting materials 
 
Preparation of cyclohexyl iodides78 
A dry and N2-flushed Schlenk-flask, equipped with a magnetic stirring bar and a septum, was 
charged with a solution of I2 (1.2 equiv) in CH2Cl2 (0.5 M) and cooled to 0 °C. PPh3 (1.1 equiv) 
was carefully added at this temperature. The resulting bright yellow suspension was stirred for 
1.5 h. Then, N-methylimidazole (NMI; 1.25 equiv) was added. After 10 min of further stirring, 
the respective cyclohexanol (1.0 equiv) was added. After 4 h the reaction mixture was allowed to 
warm to room temperature and was stirred overnight. The reaction mixture was quenched with 
NH4Cl sat. aq. solution. The phases were separated and the aqueous layer was extracted with 3 x 
CH2Cl2. The combined organic layers were washed with brine and dried over Na2SO4. The 
solvents were evaporated and the crude product was subjected to column chromatography 
furnishing the neat cyclohexyl iodide with up to 62% yield. 
 
1-Iodo-3-isopropylcyclohexane 
 
 
colorless liquid (62%) (store at -30 °C) 
1H-NMR (300 MHz, CDCl3) δ: 4.94 (t, J=3.3 Hz, 1 H), 2.12 - 2.00 (m, 2 H), 1.82 - 1.60 (m, 4 
H), 1.54 - 1.41 (m, 2 H), 1.30 (ddd, J1=14.3 Hz, J2=10.8 Hz, J3=3.3 Hz, 1 H), 1.15 - 1.01 (m, 1 
H), 0.87 (d, J=6.6 Hz, 6 H). (Mixture of diastereomers; signals of the major diastereomer are 
given)  
13C-NMR (75 MHz, CDCl3) δ: 39.9, 39.7, 37.3, 36.7, 31.8, 29.1, 22.8, 19.8, 19.7. 
MS (70 eV, EI) m/z (%): 252 (1) [M+], 125 (64), 83 (41), 81 (17), 69 (100), 67 (17), 57 (30), 55 
(40), 43 (29), 41 (45). 
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IR (ATR) ν~  (cm-1): 2954 (vs), 2928 (vs), 2872 (s), 2832 (m), 1464 (m), 1456 (m), 1444 (m), 
1434 (m), 1426 (m), 1386 (m), 1368 (m), 1270 (m), 1256 (m), 1240 (vs), 1204 (m), 1174 (m), 
1162 (s), 898 (m), 850 (m), 642 (m). 
HRMS (EI) for C9H17I (252.0375): 252.0371.  
 
tert-Butyl((3-iodocyclohexyl)oxy)dimethylsilane 
 
OTBS
I  
slightly yellow liquid (56%) 
1H-NMR (400 MHz, C6D6) δ: 4.47 - 4.40 (m, 1 H), 3.78 (br. s., 1 H), 2.01 - 1.90 (m, 2 H), 1.74 - 
1.65 (m, 2 H), 1.56 - 1.47 (m, 1 H), 1.33 (br. s., 2 H), 1.15 - 1.02 (m, 1 H), 0.92 (s, 9 H), -0.01 (s, 
3 H), -0.02 (s, 3 H). 
(Mixture of diastereomers; signals of one diastereomer are given) 
13C-NMR (101 MHz, C6D6) δ: 71.37, 69.53, 68.54, 50.64, 47.42, 39.73, 38.95, 35.94, 35.37, 
34.12, 32.54, 28.96, 26.48, 26.36, 25.85, 24.91, 24.16, 22.94, 18.59, 18.55, -4.14, -4.18, -4.40, -
4.42. 
MS (70 eV, EI) m/z (%): 340 (2) [M+], 284 (12), 283 (100), 185 (10), 155 (18), 81 (80), 75 (32), 
73 (12). 
IR (ATR) ν~  (cm-1): 2930 (m), 2886 (w), 2856 (m), 1472 (w), 1462 (w), 1448 (w), 1252 (m), 
1152 (m), 1140 (w), 1100 (m), 1082 (m), 1070 (m), 1052 (m), 1034 (m), 1006 (m), 988 (w), 978 
(w), 966 (w), 902 (m), 872 (m), 854 (m), 834 (vs), 800 (m), 772 (vs), 688 (m), 672 (m), 654 (m). 
HRMS (EI) for C12H25IOSi (340.0719): 340.0703. 
 
tert-Butyl((4-iodocyclohexyl)oxy)dimethylsilane 
 
 
slightly yellow liquid (52%) 
 
C. Experimental Section  157 
 
1H-NMR (400 MHz, C6D6) δ: 3.93 (t, J=8.6 Hz, 1 H), 3.68 - 3.49 (m, 1 H), 2.20 (d, J=9.8 Hz, 1 
H), 1.99 - 1.86 (m, 1 H), 1.70 - 1.52 (m, 4 H), 1.19 (ddd, J1=12.8 Hz, J2=8.7 Hz, J3=4.0 Hz, 2 H), 
0.96 - 0.91 (m, 9 H), -0.02 (s, 6 H). 
(Mixture of diastereomers; signals of one diastereomer are given) 
13C-NMR (101 MHz, C6D6) δ: 68.8, 67.6, 35.9, 35.3, 35.0, 32.5, 31.1, 26.5, 26.4, 24.9, 18.6, 
18.6, -4.1, -4.1, -4.2, -4.3. 
MS (70 eV, EI) m/z (%): 339 (1) [M-H-], 282 (23), 155 (11), 81 (100), 75 (48), 74 (30), 73 (13), 
59 (44), 45 (30), 41 (14). 
IR (ATR) ν~  (cm-1): 2950 (m), 2930 (m), 2886 (w), 2856 (m), 1472 (w), 1462 (w), 1440 (w), 
1370 (w), 1362 (w), 1252 (m), 1232 (w), 1222 (w), 1166 (w), 1156 (w), 1092 (s), 1042 (s), 1006 
(m), 992 (m), 874 (m), 830 (vs), 810 (m), 772 (vs), 678 (m), 656 (m). 
HRMS (EI) for C12H2IOSi+ (339.0641) [M-H-]: 339.0649. 
 
Preparation of bis(4-iodophenyl)zinc 
 
 
A dry and Ar-flushed 100 mL Schlenk-flask, equipped with a magnetic stirring bar and a septum, 
was charged with a solution of 1,4-diiodobenzene (9.9 g; 30 mmol) in THF (30 mL) and cooled 
to ‒78 °C. At that temperature, a solution of iPrMgCl·LiCl (1.16 M in THF; 33 mmol; 28.4 mL) 
was slowly added via syringe. After complete addition, the reaction mixture was stirred for 1.5 h 
at ‒78 °C before a solution of ZnCl2 in THF (1.0 M; 16.5 mL; 16.5 mmol) was added dropwise. 
After stirring for 15 min at ‒78 °C, the reaction mixture was allowed to warm to room 
temperature. The solvents (THF and isopropyl iodide from the I-Mg exchange reaction) were 
removed via high vacuum (1 mbar; 3 h). The residue was redissolved in THF (60 mL). Titration 
of an aliquot of the resulting organozinc with I2 (50 mg in 2 mL THF) gave a concentration of 
0.20 M (80%). 
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Synthesis of ((4-iodophenyl)ethynyl)triisopropylsilane 
 
I
TIPS  
A dry and Ar-flushed 500 mL Schlenk-flask, equipped with a magnetic stirring bar and a septum, 
was charged with a solution of (bromoethynyl)triisopropylsilane102 (5.22 g; 20 mmol) in THF 
(120 mL) and cooled to ‒78 °C. CuCN·2 LiCl103 solution (1 M in THF; 20 mL; 20 mmol) was 
added and the reaction mixture was stirred for 30 min. Then, bis(4-iodophenyl)zinc (0.2 M in 
THF; 50 mL; 10 mmol) was slowly added via syringe. The reaction mixture was stirred for 6 h at 
‒78 °C. NH4Cl sat. aq. solution (200 mL) was added. Phases were separated and the aqueous 
phase was extracted with Et2O (3 x 50 mL). The combined organic layers were washed with brine 
(100 mL) and dried over Na2SO4. The solvents were evaporated and the crude product was 
subjected to column chromatography (SiO2; n-pentane) furnishing 3.30 g (43%) of the title 
compound as a colorless oil. 
 
1H-NMR (300 MHz, CDCl3) δ: 7.65 (d, J=8.3 Hz, 2 H), 7.20 (d, J=8.3 Hz, 2 H), 1.14 (s, 21 H). 
13C-NMR (75 MHz, CDCl3) δ: 137.3, 133.5, 123.0, 106.0, 94.1, 92.4, 18.6, 11.3. 
MS (70 eV, EI) m/z (%): 384 (12) [M+], 342 (18), 341 (100), 313 (22), 299 (23), 285 (30), 271 
(47). 
IR (ATR) ν~  (cm-1): 2942 (m), 2890 (w), 2864 (m), 2156 (w), 1482 (m), 1468 (m), 1236 (w), 
1224 (w), 1214 (w), 1006 (m), 996 (m), 882 (m), 818 (s), 666 (vs), 654 (s). 
HRMS (EI) for C17H25ISi (384.0770): 384.0770. 
 
Synthesis of 1-(bromoethynyl)-4-iodobenzene (107)154 
 
 
To a solution of ((4-iodophenyl)ethynyl)triisopropylsilane (2.69 g; 7 mmol) in MeCN (70 mL) 
were subsequently added NBS (1.50 g; 8.4 mmol) and AgF (1.07 g; 8.4 mmol) in the dark. The 
                                                 
154 T. Lee, H. R. Kang, S. Kim, S. Kim, Tetrahedron 2006, 62, 4081. 
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reaction mixture was stirred for 3 h at room temperature and then filtered through a pad of Celite. 
The pad was washed with Et2O (3 x 100 mL). The combined filtrates were dried over Na2SO4. 
The solvents were evaporated and the crude product was purified via column chromatography 
(SiO2; n-pentane) furnishing 1.45 g (67%) of the title compound as white crystals  
 
m.p.: 104.3 - 105.8 °C 
1H-NMR (300 MHz, CDCl3) δ: 7.66 (d, J=8.3 Hz, 2 H), 7.17 (d, J=8.3 Hz, 2 H). 
13C-NMR (75 MHz, CDCl3) δ: 137.5, 133.4, 122.2, 94.7, 79.2, 52.5. 
MS (70 eV, EI) m/z (%): 306 (67) [M+], 181 (58), 179 (63), 100 (95), 99 (59), 98 (35), 74 (100), 
50 (46). 
IR (ATR) ν~  (cm-1): 2194 (w), 1896 (w), 1638 (w), 1574 (w), 1478 (m), 1456 (w), 1386 (m), 
1262 (w), 1234 (w), 1054 (w), 1006 (m), 836 (m), 812 (vs), 776 (w). 
HRMS (EI) for C8H4BrI (305.8541): 305.8528. 
 
5.2 Preparation of cyclohexylzinc compounds 
Anhydrous LiCl (0.38 g; 9 mmol) was placed in a dry and N2-flushed 25 mL Schlenk-tube and 
dried over 20 min at 150-170 °C at high vacuum (1 mbar). Zn powder (1.18 g; 18 mmol) was 
added under N2 and the heterogeneous mixture of Zn and LiCl was dried one more time at 150-
170 °C for 20 min under high vacuum. The reaction flask was evacuated and refilled with N2 
three times. 1,2-Dibromoethane (0.02 mL) and THF (12 mL) was added. The mixture was then 
gently heated in order to activate the Zn surface. The respective cyclohexyl iodide (6 mmol) was 
added neat at room temperature. The resulting reaction mixture was stirred for 6 h. The solution 
was then separated from the remaining Zn powder via syringe filter (25 mm with 1 µm glass fiber 
membrane) and transferred to a dry N2-flushed Schlenk-tube.
79 The concentrations of all 
cyclohexylzinc reagents were determined via titration of a small aliquot with I2 (50 mg in 2 mL 
THF). 
 
(3-Isopropylcyclohexyl)zinc iodide: 
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0.36 M (72%) 
 
 
 
 
(3-(tert-Butyl)cyclohexyl)zinc iodide: 
 
 
0.38 M (76%) 
 
(3-Methylcyclohexyl)zinc iodide: 
 
 
0.39 M (78%) 
 
(3-((tert-Butyldimethylsilyl)oxy)cyclohexyl)zinc iodide: 
 
 
0.42 M (84%) 
 
(4-(tert-Butyl)cyclohexyl)zinc iodide: 
 
 
0.40 M (80%) 
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(4-Methylcyclohexyl)zinc iodide: 
 
 
0.41 M (82%) 
 
(4-((tert-Butyldimethylsilyl)oxy)cyclohexyl)zinc iodide: 
 
 
0.35 M (70%) 
 
5.3 Cross-coupling of 3-, and 4-substituted cyclohexylzinc compounds with alkynynl 
bromides 
A dry and N2-flushed 10 mL Schlenk-tube, equipped with a magnetic stirring bar and a septum, 
was charged with a solution of the respective alkynyl bromide (0.4 mmol), PdCl2 (10 µmol; 1.8 
mg) and neocuproine (105b; 20 µmol; 4.2 mg) in THF (1.5 mL) and cooled to ‒30 °C. A solution 
of the respective cyclohexylzinc iodide in THF (0.5 mmol) was slowly added at this temperature. 
The reaction mixture was stirred for 12 h. NH4Cl sat. aq. solution (5 mL) was added. Phases were 
separated and the aqueous phase was extracted with Et2O (3 x 20 mL). The combined organic 
layers were washed with brine (10 mL) and dried over Na2SO4. The solvents were evaporated 
and the alkynylated product was purified via column chromatography. 
 
((cis-3-Isopropylcyclohexyl)ethynyl)benzene (102a) 
 
 
colorless oil (82%; regioisomer: <2%) 
1H-NMR (300 MHz, CDCl3) δ: 7.48 - 7.35 (m, 2 H), 7.34 - 7.21 (m, 3 H), 2.52 - 2.39 (m, 1 H), 
2.12 - 1.98 (m, 2 H), 1.87 - 1.77 (m, 1 H), 1.70 (d, J=12.5 Hz, 1 H), 1.56 - 1.41 (m, 1 H), 1.39 - 
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1.24 (m, 2 H), 1.20 - 1.05 (m, 2 H), 0.99 (td, J1=12.1 Hz, J2=3.3 Hz, 1 H), 0.90 (d, J=6.7 Hz, 6 
H). 
13C-NMR (75 MHz, CDCl3) δ: 131.5, 128.1, 127.4, 124.0, 94.8, 43.6, 79.9, 36.4, 33.2, 32.8, 
30.6, 28.9, 26.0, 19.7, 19.6. 
MS (70 eV, EI) m/z (%): 226 (41) [M+], 211 (100), 183 (95), 155 (40), 142 (27), 141 (52), 130 
(22), 129 (32), 91 (24). 
IR (ATR) ν~  (cm-1): 2954 (m), 2928 (m), 2856 (m), 1598 (w), 1490 (m), 1460 (w), 1444 (m), 
1386 (w), 1368 (w), 1070 (w), 912 (w), 754 (vs), 690 (s), 668 (w). 
HRMS (EI) for C17H22 (226.1722): 226.1711. 
 
4-((cis-3-Isopropylcyclohexyl)ethynyl)benzonitrile (102b) 
 
iPr
CN  
slightly yellow oil (87%; regioisomer: <2%) 
1H-NMR (599 MHz, CDCl3) δ: 7.56 (d, J=8.2 Hz, 2 H), 7.46 (d, J=8.1 Hz, 2 H), 2.45 (td, 
J1=11.2 Hz, J2=3.3 Hz, 1 H), 2.02 (d, J=7.4 Hz, 2 H), 1.85 - 1.79 (m, 1 H), 1.70 (d, J=12.1 Hz, 1 
H), 1.52 - 1.43 (m, 1 H), 1.37 - 1.24 (m, 2 H), 1.18 - 1.10 (m, 2 H), 1.00 - 0.92 (m, 1 H), 0.89 (d, 
J=6.9 Hz, 6 H). 
13C-NMR (152 MHz, C6D6) δ: 132.1, 131.8, 129.1, 118.6, 110.7, 99.8, 78.8, 43.5, 36.1, 32.9, 
32.8, 30.6, 28.8, 25.9, 19.6, 19.5. 
MS (70 eV, EI) m/z (%): 259 (15), 258 (71), 215 (18), 214 (100), 131 (27), 75 (11), 57 (18), 56 
(18). 
IR (ATR) ν~  (cm-1): 2954 (m), 2930 (m), 2856 (m), 2226 (m), 1604 (m), 1500 (m), 1462 (w), 
1448 (w), 1368 (w), 838 (vs). 
HRMS (EI) for C18H21N (252.1674): 252.1664. 
 
tert-Butyl((4-(cis-3-isopropylcyclohexyl)but-3-yn-1-yl)oxy)dimethylsilane (102c) 
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slightly yellow oil (77%; regioisomer: 2%) 
1H-NMR (300 MHz, CDCl3) δ: 3.69 (t, J=7.2 Hz, 2 H), 2.38 (td, J1=7.2 Hz, J2=2.1 Hz, 2 H), 
2.16 (dd, J1=7.5 Hz, J2=1.9 Hz, 1 H), 1.90 (ddd, J1=5.8 Hz, J2=3.9 Hz, J3=1.5 Hz, 2 H), 1.80 - 
1.71 (m, 1 H), 1.64 (d, J1=12.4 Hz, 1 H), 1.48 - 1.37 (m, 1 H), 1.24 - 1.14 (m, 2 H), 1.11 - 0.93 
(m, 3 H), 0.91 (s, 9 H), 0.86 (d, J=6.8 Hz, 6 H), 0.08 (s, 6 H). 
13C-NMR (75 MHz, CDCl3) δ: 86.2, 76.2, 62.5, 43.6, 36.8, 33.6, 32.8, 30.1, 29.0, 26.0, 25.9, 
23.2, 19.7, 19.5, 18.4, ‒5.2. 
MS (70 eV, EI) m/z (%): 252 (9) [M-tBu]+, 175 (8), 75 (28), 59 (8), 58 (34), 57 (10), 43 (100), 41 
(9). 
IR (ATR) ν~  (cm-1): 2954 (m), 2928 (m), 2856 (m), 1472 (w), 1462 (w), 1252 (m), 1102 (s), 
1058 (w), 916 (w), 860 (m), 834 (vs), 812 (m), 774 (vs), 738 (w), 664 (w). 
HRMS (EI) for C15H27OSi (252.1831) [M-tBu]+: 252.1837. 
 
Triisopropyl((cis-3-isopropylcyclohexyl)ethynyl)silane (102d) 
 
 
colorless oil (79%; regioisomer: <4%) 
1H-NMR (599 MHz, CDCl3) δ: 2.27 - 2.22 (m, 1 H), 1.98 - 1.94 (m, 2 H), 1.77 - 1.73 (m, 1 H), 
1.65 (d, J=13.19 Hz, 1 H), 1.47 - 1.39 (m, 2 H), 1.29 - 1.19 (m, 3 H), 1.10 - 1.04 (m, 18 H), 1.04 - 
0.99 (m, 4 H), 0.87 (d, J=3.1 Hz, 3 H), 0.86 (d, J=3.1 Hz, 3 H). 
13C-NMR (152 MHz, CDCl3) δ: 114.2, 78.6, 43.6, 36.7, 33.6, 32.8, 31.1, 28.9, 26.0, 19.7, 19.7, 
18.6, 11.3. 
MS (70 eV, EI) m/z (%): 306 (1) [M+], 264 (3), 263 (100), 235 (2), 221 (1), 207 (2), 193 (2), 73 
(1). 
IR (ATR) ν~  (cm-1): 2956 (m), 2938 (m), 2894 (m), 2864 (m), 2170 (w), 1462 (m), 1448 (w), 
996 (w), 882 (m), 676 (vs), 666 (vs). 
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HRMS (EI) for C20H38Si (306.2743): 306.2739. 
 
4-((cis-3-(tert-Butyl)cyclohexyl)ethynyl)benzonitrile (102e) 
 
tBu
CN  
slightly yellow oil (85%;regioisomer: 2%) 
1H-NMR (300 MHz, CDCl3) δ: 7.56 (d, J=8.3 Hz, 2 H), 7.46 (d, J=8.3 Hz, 2 H), 2.50 - 2.40 (m, 
1 H), 2.15 - 1.96 (m, 2 H), 1.88 - 1.74 (m, 2 H), 1.41 - 1.23 (m, 2 H), 1.22 - 0.94 (m, 3 H), 0.88 
(s, 9 H). 
13C-NMR (75 MHz, CDCl3) δ: 132.1, 131.8, 129.1, 118.6, 110.7, 99.9, 78.9, 47.6, 34.0, 32.8, 
32.5, 30.9, 27.4, 26.5, 26.1. 
MS (70 eV, EI) m/z (%): 265 (23) [M+], 209 (40), 208 (32), 180 (11), 166 (12), 141 (32), 140 
(11), 57 (100), 40 (17). 
IR (ATR) ν~  (cm-1): 2940 (m), 2860 (m), 2226 (m), 1604 (m), 1500 (m), 1478 (w), 1462 (w), 
1448 (m), 1406 (w), 1394 (w), 1366 (m), 1268 (w), 1240 (w), 1176 (w), 1104 (w), 930 (w), 838 
(vs). 
HRMS (EI) for C19H23N (265.1830): 265.1820. 
 
tert-Butyl((4-(cis-3-(tert-butyl)cyclohexyl)but-3-yn-1-yl)oxy)dimethylsilane (102f) 
 
 
colorless oil (74%; regioisomer: <3%) 
1H-NMR (300 MHz, CDCl3) δ: 3.69 (t, J=7.2 Hz, 2 H), 2.38 (td, J1=7.2 Hz, J2=1.9 Hz, 2 H), 
2.16 (t, J=8.5 Hz, 1 H), 1.99 (d, J=11.4 Hz, 1 H), 1.89 (d, J=6.8 Hz, 1 H), 1.82 - 1.67 (m, 2 H), 
1.28 - 1.14 (m, 2 H), 1.13 - 0.93 (m, 3 H), 0.91 (s, 9 H), 0.85 (s, 9 H), 0.08 (s, 6 H). 
13C-NMR (75 MHz, CDCl3) δ: 86.2, 76.3, 62.4, 47.6, 34.8, 33.5, 32.5, 30.4, 27.5, 26.6, 26.3, 
25.9, 23.2, 18.4, -5.2. 
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MS (70 eV, EI) m/z (%): 321 (1) [M-H-], 265 (28), 189 (11), 147 (17), 137 (15), 133 (12), 123 
(11), 115 (11), 97 (10), 95 (16), 89 (40), 83 (26), 81 (16), 75 (79), 73 (100), 69 (17), 67 (10), 59 
(14), 57 (98), 55 (18), 43 (13), 41 (20). 
IR (ATR) ν~  (cm-1): 2948 (m), 2930 (m), 2858 (m), 1472 (w), 1462 (w), 1366 (w), 1252 (m), 
1100 (s), 1058 (w), 918 (w), 862 (m), 834 (vs), 812 (m), 774 (vs), 738 (w), 664 (w). 
HRMS (EI) for C20H37OSiN (321.2614) [M-H-]: 321.2613. 
 
((cis-3-Methylcyclohexyl)ethynyl)benzene (102g) 
 
 
colorless oil (79%; regioisomer: <1%) 
1H-NMR (599 MHz, CDCl3) δ: 7.40 (dd, J1=7.7 Hz, J2=1.4 Hz, 2 H), 7.31 - 7.23 (m, 3 H), 2.50 - 
2.42 (m, 1 H), 2.04 (d, J=11.2 Hz, 2 H), 1.81 - 1.75 (m, 1 H), 1.69 (dd, J1=13.0 Hz, J2=1.4 Hz, 1 
H), 1.45 - 1.37 (m, 1 H), 1.36 - 1.27 (m, 2 H), 1.12 (q, J=12.3 Hz, 1 H), 0.94 (d, J=6.6 Hz, 3 H), 
0.92 - 0.86 (m, 1 H). 
13C-NMR (152 MHz, CDCl3) δ: 131.5, 128.1, 127.4, 124.1, 94.6, 79.9, 41.7, 34.4, 32.8, 32.3, 
30.3, 25.8, 22.6. 
MS (70 eV, EI) m/z (%): 198 (100) [M+], 183 (36), 169 (28), 156 (29), 155 (60), 143 (20), 142 
(46), 141 (72), 130 (21), 129 (35), 128 (57), 115 (44), 102 (21), 91 (25). 
IR (ATR) ν~  (cm-1): 2946 (m), 2924 (m), 2854 (m), 1492 (w), 1458 (w), 1444 (m), 754 (vs), 690 
(s), 668 (w). 
HRMS (EI) for C15H18 (198.1409): 198.1401. 
 
4-((cis-3-Methylcyclohexyl)ethynyl)benzonitrile (102h) 
 
Me
CN  
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colorless oil (88%; regioisomer: ‒) 
1H-NMR (599 MHz, CDCl3) δ: 7.55 (d, J=8.2 Hz, 2 H), 7.44 (d, J=8.1 Hz, 2 H), 2.47 (tt, 
J1=11.6 Hz, J2=3.4 Hz, 1 H), 2.06 - 1.94 (m, 2 H), 1.77 (dt, J1=6.4 Hz, J2=3.1 Hz, 1 H), 1.68 (d, 
J=12.9 Hz, 1 H), 1.44 - 1.37 (m, 1 H), 1.36 - 1.24 (m, 2 H), 1.09 (q, J=12.1 Hz, 1 H), 0.92 (d, 
J=6.6 Hz, 3 H), 0.91 - 0.85 (m, 1 H). 
13C-NMR (152 MHz, CDCl3) δ: 132.0, 131.8, 129.1, 118.6, 110.7, 99.6, 78.8, 41.2, 34.2, 32.4, 
32.2, 30.3, 25.7, 22.5. 
MS (70 eV, EI) m/z (%): 223 (96) [M+], 194 (50), 180 (52), 168 (33), 167 (65), 166 (55), 154 
(68), 153 (61), 142 (27), 140 (34), 127 (45), 116 (32), 107 (31), 94 (87), 79 (29), 78 (27), 77 (69), 
55 (45), 46 (100), 41 (81). 
IR (ATR) ν~  (cm-1): 2924 (m), 2854 (m), 2224 (m), 1604 (m), 1500 (m), 1458 (m), 1446 (w), 
836 (vs). 
HRMS (EI) for C16H17N (223.1361): 223.1359. 
 
tert-Butyldimethyl((cis-3-((triisopropylsilyl)ethynyl)-cyclohexyl)oxy)silane (102i) 
 
 
colorless oil (81%; regioisomer: 5%) 
1H-NMR (400 MHz, C6D6) δ: 3.37 - 3.28 (m, 1 H), 2.28 (d, J=12.5 Hz, 1 H), 2.13 (tt, J1=12.2 
Hz, J2=3.5 Hz, 1 H), 1.78 (d, J=13.1 Hz, 1 H), 1.70 (d, J=11.9 Hz, 1 H), 1.60 - 1.52 (m, 1 H), 
1.44 - 1.37 (m, 1 H), 1.20 - 1.16 (m, 18 H), 1.14 - 1.05 (m, 4 H), 0.95 (s, 9 H), 0.93 - 0.81 (m, 2 
H), 0.01 (s, 6 H). 
13C-NMR (101 MHz, C6D6) δ: 113.6, 79.8, 71.0, 43.3, 36.2, 33.3, 30.3, 26.4, 24.4, 19.3, 18.6, 
12.0, ‒4.09. 
MS (70 eV, EI) m/z (%): 394 (1) [M+], 352 (23), 339 (12), 338 (32), 337 (100), 296 (11), 295 
(35), 267 (10), 253 (18), 203 (12), 161 (18), 147 (11), 133 (21), 129 (14), 120 (10), 119 (11), 115 
(11), 112 (21), 87 (15), 81 (33), 75 (58), 73 (41), 59 (30). 
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IR (ATR) ν~  (cm-1): 2938 (m), 2892 (w), 2862 (m), 2172 (w), 1464 (m), 1372 (w), 1360 (w), 
1252 (m), 1142 (w), 1126 (w), 1098 (s), 1076 (m), 1056 (s), 1026 (w), 1018 (w), 1006 (w), 996 
(w), 894 (w), 880 (s), 860 (s), 834 (vs), 814 (m), 774 (s), 666 (vs), 650 (s). 
HRMS (EI) for C23H46OSi2 (394.3087): 394.3083. 
 
tert-Butyl((cis-3-(4-((tert-butyldimethylsilyl)oxy)but-1-yn-1-
yl)cyclohexyl)oxy)dimethylsilane (102j) 
 
 
colorless oil (94%; regioisomer: 5%) 
1H-NMR (400 MHz, C6D6) δ: 3.66 (t, J=6.9 Hz, 2 H), 3.43 - 3.35 (m, 1 H), 2.40 (td, J1=7.0 Hz, 
J2=2.1 Hz, 2 H), 2.31 (d, J=12.5 Hz, 1 H), 2.20 (t, J=12.1 Hz, 1 H), 1.84 (d, J=11.7 Hz, 1 H), 
1.74 (d, J=12.3 Hz, 1 H), 1.57 (d, J=11.1 Hz, 1 H), 1.49 - 1.42 (m, 1 H), 1.29 - 1.14 (m, 3 H), 
0.97 (s, 9 H), 0.96 (s, 9 H), 0.04 (s, 12 H). 
13C-NMR (101 MHz, C6D6) δ: 85.4, 77.6, 71.1, 63.0, 43.9, 36.3, 33.3, 29.4, 26.5, 26.4, 24.4, 
24.0, 18.9, 18.6, -4.06, ‒4.08, ‒4.79. 
MS (70 eV, EI) m/z (%): 396 (1) [M+], 341 (10), 340 (26), 339 (100), 249 (11), 208 (12), 207 
(66), 147 (56), 133 (20), 131 (12), 105 (15), 91 (14), 89 (15), 81 (14), 75 (72), 73 (85), 59 (12). 
IR (ATR) ν~  (cm-1): 2930 (m), 2886 (w), 2858 (m), 1472 (w), 1464 (w), 1360 (w), 1252 (m), 
1092 (s), 1006 (w), 900 (w), 880 (m), 860 (m), 832 (vs), 814 (m), 772 (vs), 666 (m). 
HRMS (EI) for C22H44O2Si2 (396.2880): 396.2886. 
 
((trans-4-(tert-Butyl)cyclohexyl)ethynyl)benzene (103a) 
 
 
colorless oil (76%; regioisomer: 3%) 
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1H-NMR (300 MHz, CDCl3) δ: 7.48 - 7.35 (m, 2 H), 7.33 - 7.20 (m, 3 H), 2.36 (tt, J1=12.0 Hz, 
J2=3.5 Hz, 1 H), 2.14 (d, J=12.4 Hz, 2 H), 1.90 - 1.76 (m, 2 H), 1.53 - 1.36 (m, 2 H), 1.12 - 0.98 
(m, 3 H), 0.88 (s, 9 H). 
13C-NMR (75 MHz, CDCl3) δ: 131.5, 128.1, 127.4, 124.1, 94.6, 80.0, 47.3, 33.7, 32.4, 30.4, 
27.5, 26.9. 
MS (70 eV, EI) m/z (%): 240 (11) [M+], 155 (12), 141 (11), 136 (33), 131 (14), 130 (100), 129 
(14), 128 (15), 121 (11), 115 (16), 57 (13). 
IR (ATR) ν~  (cm-1): 2944 (m), 2856 (m), 1490 (m), 1478 (w), 1468 (w), 1444 (m), 1392 (w), 
1366 (m), 1234 (w), 1070 (w), 1048 (w), 1026 (w), 964 (w), 928 (w), 914 (w), 898 (w), 754 (vs), 
690 (s), 668 (w). 
HRMS (EI) for C18H24 (240.1878): 240.1878. 
 
4-((trans-4-(tert-Butyl)cyclohexyl)ethynyl)benzonitrile (103b) 
 
 
white crystals (84%; regioisomer: 3%) 
m. p.: 103.8 – 105.5 °C. 
1H-NMR (300 MHz, CDCl3) δ: 7.56 (d, J=8.5 Hz 2 H), 7.45 (d, J=8.3 Hz ,2 H), 2.37 (tt, J1=12.0 
Hz, J2=3.6 Hz, 1 H), 2.11 (d, J=13.6 Hz, 2 H), 1.89 - 1.76 (m, 2 H), 1.50 - 1.34 (m, 2 H), 1.10 - 
0.96 (m, 3 H), 0.86 (s, 9 H). 
13C-NMR (75 MHz, CDCl3) δ: 132.1, 131.8, 129.1, 118.6, 110.7, 99.7, 78.9, 47.3, 33.3, 32.4, 
30.4, 27.4, 26.8. 
MS (70 eV, EI) m/z (%): 265 (6) [M+], 209 (16), 180 (13), 166 (11), 156 (12), 155 (100), 153 
(13), 140 (12), 136 (45), 121 (11), 57 (58), 40 (17). 
IR (ATR) ν~  (cm-1): 2948 (m), 2938 (m), 2928 (s), 2858 (m), 2226 (m), 1604 (m), 1502 (m), 
1448 (m), 1390 (w), 1364 (s), 1234 (w), 1178 (m), 966 (w), 894 (m), 832 (vs). 
HRMS (EI) for C19H23N (265.1830): 265.1822. 
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tert-Butyl((4-(trans-4-(tert-butyl)cyclohexyl)but-3-yn-1-yl)oxy)dimethylsilane (103c) 
 
 
slightly yellow oil (79%; regioisomer: <5%) 
1H-NMR (300 MHz, CDCl3) δ: 3.69 (t, J=7.2 Hz, 2 H), 2.37 (td, J1=7.2 Hz, J2=2.1 Hz, 2 H), 
2.14 - 2.03 (m, 1 H), 1.98 (d, J=12.4 Hz, 2 H), 1.81 - 1.68 (m, 2 H), 1.36 - 1.21 (m, 2 H), 1.10 - 
0.93 (m, 3 H), 0.91 (s, 9 H), 0.83 (s, 9 H), 0.08 (s, 6 H). 
13C-NMR (75 MHz, CDCl3) δ: 86.0, 76.3, 62.5, 47.4, 34.0, 32.4, 29.9, 27.5, 26.9, 25.9, 23.2, 
18.4,‒5.2. 
MS (70 eV, EI) m/z (%): 265 (1) [M-tBu]+, 81 (2), 72 (3), 69 (2), 67 (2), 59 (5), 58 (33), 57 (8), 
55 (4), 44 (2), 43 (3), 43 (100),42 (7), 41 (6). 
IR (ATR) ν~  (cm-1): 2930 (m), 2858 (m), 1472 (w), 1464 (w), 1450 (w), 1364 (w), 1252 (m), 
1236 (w), 1100 (s), 1058 (w), 1006 (w), 916 (w), 898 (w), 882 (w), 832 (vs), 812 (m), 774 (vs), 
734 (w), 664 (w). 
HRMS (EI) for C16H29OSi+ (265.1988) [M-tBu]+: 265.1996. 
 
((trans-4-(tert-Butyl)cyclohexyl)ethynyl)triisopropylsilane (103d) 
 
 
slightly yellow oil (75%;regioisomer: 2%) 
1H-NMR (300 MHz, CDCl3) δ: 2.23 - 2.11 (m, 1 H), 2.06 (d, J=12.4 Hz, 2 H), 1.82 - 1.70 (m, 2 
H), 1.47 - 1.24 (m, 3 H), 1.11 - 1.03 (m, 20 H), 0.99 (dd, J1=8.9 Hz, J2=3.5 Hz, 3 H), 0.84 (s, 9 
H). 
13C-NMR (75 MHz, CDCl3) δ: 114.1, 78.7, 47.4, 34.0, 32.4, 30.8, 27.5, 26.9, 18.6, 11.3. 
MS (70 eV, EI) m/z (%): 320 (1), 279 (5), 278 (27), 277 (100), 249 (10), 235 (5), 221 (9), 207 
(6), 99 (3), 73 (3), 59 (3), 57 (4). 
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IR (ATR) ν~  (cm-1): 2940 (s), 2892 (m), 2864 (s), 2174 (w), 1464 (m), 1450 (w), 1366 (m), 1234 
(w), 1076 (w), 1066 (w), 1016 (w), 996 (m), 882 (s), 860 (w), 756 (w), 678 (vs), 668 (vs), 638 
(m). 
HRMS (EI) for C21H40Si (320.2899): 320.2905. 
 
tert-Butyldimethyl((4-(trans-4-methylcyclohexyl)but-3-yn-1-yl)oxy)silane (103e) 
 
 
slightly yellow oil (74%;regioisomer: 3%) 
1H-NMR (400 MHz, C6D6) δ: 3.68 (t, J=7.1 Hz, 2 H), 2.42 (td, J1=7.0 Hz, J2=2.1 Hz, 2 H), 2.22 
- 2.09 (m, 1 H), 2.06 - 1.94 (m, 2 H), 1.53 - 1.37 (m, 4 H), 1.16 - 1.06 (m, 1 H), 1.04 - 0.97 (m, 1 
H), 0.96 (s, 9 H), 0.74 (d, J=6.6 Hz, 3 H), 0.72 - 0.65 (m, 1 H), 0.04 (s, 6 H). 
13C-NMR (101 MHz, C6D6) δ: 86.4, 77.4, 63.1, 35.1, 34.3, 32.5, 30.4, 26.5, 24.1, 23.0, 18.9, 
‒4.8. 
MS (70 eV, EI) m/z (%): 223 (70) [M-tBu]+, 149 (15), 147 (40), 129 (37), 121 (11), 105 (13), 
101 (22), 93 (10), 91 (10), 89 (19), 81 (16), 75 (100), 73 (33), 59 (11). 
IR (ATR) ν~  (cm-1): 2950 (m), 2928 (m), 2858 (m), 1472 (w), 1462 (w), 1448 (w), 1252 (m), 
1100 (s), 1058 (w), 916 (w), 876 (w), 834 (vs), 810 (m), 774 (vs), 730 (w), 664 (w). 
HRMS (EI) for C13H23OSi+ (223.1528) [M-tBu]+: 223.1505. 
 
Triisopropyl((trans-4-methylcyclohexyl)ethynyl)silane (103f) 
 
 
colorless oil (71%; regioisomer: 4%) 
1H-NMR (400 MHz, C6D6) δ: 2.07 (tt, J1=11.6 Hz, J2=3.7 Hz, 1 H), 1.93 (dd, J1=13.5 Hz, J2=3.4 
Hz, 2 H), 1.49 - 1.41 (m, 2 H), 1.41 - 1.31 (m, 2 H), 1.29 - 1.16 (m, 18 H), 1.15 - 1.06 (m, 4 H), 
0.77 - 0.69 (m, 3 H), 0.69 - 0.57 (m, 2 H). 
13C-NMR (101 MHz, C6D6) δ: 114.9, 79.5, 34.9, 34.0, 32.3, 31.1, 22.9, 19.3, 12.1. 
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MS (70 eV, EI) m/z (%): 278 (1) [M+], 236 (21), 235 (100), 207 (23), 193 (19), 179 (23), 165 
(27). 
IR (ATR) ν~  (cm-1): 2940 (m), 2924 (s), 2892 (m), 2864 (s), 2170 (w), 1462 (m), 1448 (m), 1382 
(w), 1366 (w), 1236 (w), 1092 (w), 1074 (w), 1056 (w), 1010 (w), 996 (w), 918 (w), 882 (s), 836 
(w), 670 (vs), 656 (s), 642 (m). 
HRMS (EI) for C18H34Si (278.2430): 278.2448. 
 
tert-Butyl((trans-4-(4-((tert-butyldimethylsilyl)oxy)but-1-yn-1-yl)cyclohexyl)oxy)-
dimethylsilane (103g) 
 
 
slightly yellow oil (88%; 6%) 
1H-NMR (400 MHz, C6D6) δ: 3.68 (t, J=7.0 Hz, 2 H), 3.56 (ddd, J1=12.5 Hz, J2=8.5 Hz, J3=3.4 
Hz, 1 H), 2.41 (td, J1=7.0 Hz, J2=1.9 Hz, 2 H), 2.25 (br. s., 1 H), 1.96 (dt, J1=9.3 Hz, J2=3.9 Hz, 2 
H), 1.89 - 1.78 (m, 2 H), 1.49 - 1.38 (m, 2 H), 1.33 - 1.23 (m, 2 H), 0.97 (s, 9 H), 0.96 (s, 9 H), 
0.04 (s, 6 H), 0.02 (s, 6 H). 
13C-NMR (101 MHz, C6D6) δ: 85.5, 77.8, 70.4, 63.1, 34.8, 31.1, 29.3, 26.5, 26.4, 24.1, 18.9, 
18.6, ‒4.15, ‒4.80. 
MS (70 eV, EI) m/z (%): 396 (1) [M+], 340 (13), 339 (49), 207 (12), 147 (33), 133 (19), 131 (11), 
91 (11), 89 (10), 75 (100), 73 (56). 
IR (ATR) ν~  (cm-1): 2930 (m), 2898 (w), 2886 (w), 2858 (m), 1472 (w), 1464 (w), 1252 (m), 
1094 (s), 1058 (w), 1046 (m), 1006 (w), 916 (w), 896 (w),878 (w), 852 (m), 832 (vs), 814 (m), 
772 (vs), 732 (w), 666 (m). 
HRMS (EI) for C22H44O2Si2 (396.2880): 396.2858. 
 
tert-Butyldimethyl((trans-4-((triisopropylsilyl)ethynyl)-cyclohexyl)oxy)silane (103h) 
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colorless oil (92%; regioisomer: 6%) 
1H-NMR (400 MHz, C6D6) δ: 3.52 - 3.57 (m, 1 H), 2.23 (br. s., 1 H), 1.91 - 1.81 (m, 4 H), 1.42 - 
1.35 (m, 2 H), 1.31 - 1.24 (m, 2 H), 1.24 - 1.18 (m, 18 H), 1.15 - 1.08 (m, 3 H), 0.96 (s, 9 H), 0.02 
(s, 6 H). 
13C-NMR (101 MHz, C6D6) δ: 113.1, 79.4, 69.1, 33.5, 29.5, 29.1, 25.7, 18.6, 17.9, 11.3, ‒5.0. 
MS (70 eV, EI) m/z (%): 394 (6) [M+], 352 (22), 352 (78), 338 (16), 337 (50), 309 (13), 261 (15), 
233 (11), 181 (15), 157 (11), 153 (14), 133 (10), 129 (16), 119 (34), 112 (16), 75 (100), 73 (40), 
59 (18). 
IR (ATR) ν~  (cm-1): 2938 (s), 2892 (m), 2864 (s), 2168 (w), 1462 (m), 1382 (w), 1362 (w), 1252 
(m), 1098 (s), 1048 (s), 1028 (m), 1006 (m), 996 (m), 962 (w), 876 (m), 858 (s), 834 (vs), 816 
(m), 772 (vs), 700 (w), 674 (vs), 610 (w). 
HRMS (EI) for C23H46OSi2 (394.3087): 394.3087. 
 
4-((trans-4-((tert-Butyldimethylsilyl)oxy)cyclohexyl)-ethynyl)benzonitrile (103i) 
 
 
slightly yellow oil (94%; regioisomer: 4%) 
1H-NMR (400 MHz, C6D6) δ: 7.01 (d, J=8.4 Hz, 2 H), 6.82 (m, J=8.4 Hz, 2 H), 3.59 - 3.52 (m, 1 
H), 2.37 - 2.29 (m, 1 H), 1.96 - 1.87 (m, 2 H), 1.84 - 1.76 (m, 2 H), 1.45 - 1.34 (m, 2 H), 1.33 - 
1.23 (m, 2 H), 0.98 (s, 9 H), 0.04 (s, 6 H). 
13C-NMR (101 MHz, C6D6) δ: 132.4, 132.3, 129.0, 118.8, 111.9, 98.8, 80.4, 69.9, 34.4, 30.1, 
29.6, 26.4, 18.6, -4.2. 
MS (70 eV, EI) m/z (%): 339 (1) [M+], 283 (21), 282 (100), 206 (31), 75 (82). 
IR (ATR) ν~  (cm-1): 2948 (m), 2928 (m), 2898 (w), 2856 (m), 2226 (w), 1604 (w), 1500 (w), 
1472 (w), 1462 (w), 1450 (w), 1374 (w), 1248 (m), 1094 (s), 1042 (m), 1006 (w), 896 (w), 876 
(m), 856 (s), 830 (vs), 796 (m), 772 (s), 670 (m), 654 (w). 
HRMS (EI) for C21H29NOSi (339.2018): 339.2007. 
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tert-Butyl((trans-4-((4-iodophenyl)ethynyl)cyclohexyl)-oxy)dimethylsilane (108) 
 
 
The reaction was carried out at a 4 mmol scale. 
orange oil (79%; regioisomer: >4%) 
1H-NMR (300 MHz, CDCl3) δ: 7.61 (d, J=8.6 Hz, 2 H), 7.11 (d, J=8.3 Hz, 2 H), 3.74 - 3.61 (m, 
1 H), 2.57 - 2.43 (m, 1 H), 2.16 - 1.95 (m, 2 H), 1.95 - 1.80 (m, 2 H), 1.57 - 1.31 (m, 4 H), 0.90 
(s, 9 H), 0.07 (s, 6 H). 
13C-NMR (75 MHz, CDCl3) δ: 136.8, 132.7, 123.1, 94.8, 92.6, 79.2, 69.2, 33.7, 29.5, 28.6, 25.4, 
17.7, ‒5.1. 
MS (70 eV, EI) m/z (%): 440 (1) [M+], 384 (18), 383 (75), 308 (23), 307 (100), 256 (24), 254 
(12), 182 (12), 181 (24), 180 (12), 75 (90), 73 (15). 
IR (ATR) ν~  (cm-1): 2928 (m), 2896 (w), 2856 (m), 1482 (m), 1472 (w), 1462 (w), 1452 (w), 
1250 (m), 1096 (s), 1058 (m), 1046 (m), 1024 (m), 1006 (m), 942 (w), 874 (m), 854 (s), 834 (vs), 
818 (vs), 772 (vs), 740 (w), 730 (w), 668 (m). 
HRMS (EI) for C20H29IOSi (440.1032): 440.1023. 
 
5.4 Preparation of (1R,4r)-4-((4-((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)-
phenyl)ethynyl)cyclohexanol (106) 
 
tert-Butyl(((1R,4r)-4-((4-((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)phenyl)ethynyl)-
cyclohexyl)-oxy)dimethylsilane 
 
 
In a dry and N2-flushed 10 mL Schlenk-tube, a solution of Pd(dba)2 (20 µmol, 11.5 mg), S-Phos 
(20 µmol, 8.2 mg) and tert-butyl((trans-4-((4-iodophenyl)ethynyl)cyclohexyl)-
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oxy)dimethylsilane (108; 0.7 mmol, 0.308 g) in THF (0.7 mL) and NEP (N-ethylpyrrolidone) 
(0.2 mL) was stirred for five minutes, before menthylzinc iodide (11) was added. The reaction 
progress was monitored by gas chromatography (GC) analysis. Conversion was complete after 
six hours. The reaction mixture was quenched with saturated NH4Cl aq. solution (2 mL), and 
water was added (2 mL). The phases were separated and the aqueous phase extracted with Et2O 
(3 × 10 mL). The combined organic layers were dried over Na2SO4 and the solvents were 
evaporated. The crude product was purified via column chromatography (SiO2; n-pentane:Et2O 
80:1) furnishing the title compound (0.250 g; 79%) as an orange oil (d.r. > 99:1; >4% 
regioisomer). 
 
1H-NMR (400 MHz, CDCl3) δ: 7.31 (d, J=8.0 Hz, 2 H), 7.08 d, J=8.0 Hz, 2 H), 3.70 - 3.64 (m, 1 
H), 2.53 - 2.47 (m, 1 H), 2.40 (td, J1=11.5 Hz, J2=3.3 Hz, 1 H), 2.10 - 2.00 (m, 2 H), 1.95 - 1.88 
(m, 2 H), 1.85 - 1.71 (m, 4 H), 1.52 - 1.35 (m, 6 H), 1.17 - 0.98 (m, 4 H), 0.94 - 0.84 (m, 11 H), 
0.78 (d, J=6.9 Hz, 3 H), 0.65 (d, J=6.8 Hz, 3 H), 0.07 (s, 6 H). 
13C-NMR (101 MHz, CDCl3) δ: 146.3, 132.0, 131.5, 127.4, 126.6, 121.1, 92.8, 80.5, 69.8, 47.9, 
47.4, 45.0, 35.3, 34.2, 33.2, 30.2, 29.0, 27.4, 25.9, 25.8, 24.5, 22.50, 21.5, 18.2, 18.1, 15.3, ‒4.7. 
MS (70 eV, EI) m/z (%): 452 (4) [M+], 396 (20), 395 (67), 320 (39), 319 (100), 268 (87), 181 
(46), 139 (22), 129 (30), 128 (23), 83 (90), 75 (79), 73 (20), 69 (34), 57 (33), 55 (25). 
IR (ATR) ν~  (cm-1): 2948 (m), 2928 (m), 2858 (m), 1472 (w), 1462 (w), 1452 (w), 1368 (w), 
1362 (w), 1252 (m), 1096 (s), 1046 (m), 1024 (w), 1006 (w), 874 (m), 856 (s), 832 (vs), 772 (s), 
668 (m). 
HRMS (EI) for C30H48OSi (452.3474): 452.3482. 
 
Preparation of (1R,4r)-4-((4-((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)-
phenyl)ethynyl)cyclohexanol (106) 
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To a solution of tert-butyl(((1R,4r)-4-((4-((1R,2S,5R)-2-isopropyl-5-methylcyclohexyl)phenyl)-
ethynyl)cyclohexyl)-oxy)dimethylsilane (0.5 mmol; 0.226 g) in THF (7.5 mL), TBAF·3 H2O 
(tetrabutylammonium fluoride trihydrate) (1.0 mmol; 0.316 g) was added. The reaction mixture 
was stirred overnight at room temperature. NH4Cl sat. aq. solution (10 mL) was added. Phases 
were separated and the organic phase was extracted with Et2O (3 x 20 mL). The combined 
organic layers were washed with brine and dried over Na2SO4. The solvents were evaporated and 
the crude product was purified via column chromatography (SiO2; n-pentane:Et2O 10:1) 
furnishing the title compound as a slightly yellow, highly viscous substance (94%). 
 
1H-NMR (400 MHz, C6D6) δ: 7.48 (d, J=8.2 Hz, 2 H), 6.91 (d, J=8.0 Hz, 2 H), 3.39 - 3.30 (m, 1 
H), 2.38 - 2.30 (m, 1 H), 2.26 (td, J=11.55, 3.41 Hz, 1 H), 2.02 - 1.91 (m, 2 H), 1.83 - 1.76 (m, 2 
H), 1.74 - 1.62 (m, 3 H), 1.52 - 1.38 (m, 4 H), 1.35 - 1.26 (m, 2 H), 1.17 - 1.07 (m, 2 H), 1.04 - 
0.89 (m, 3 H), 0.86 (d, J=6.6 Hz, 3 H), 0.77 (d, J=7.0 Hz, 3 H), 0.65 (d, J=6.8 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 146.8, 132.5, 122.5, 93.5, 81.9, 69.4, 48.6, 47.9, 45.6, 35.9, 34.6, 
33.8, 31.2, 29.9, 28.1, 25.2, 23.1, 22.0, 15.9. 
MS (70 eV, EI) m/z (%): 338 (26) [M+], 311 (24), 310 (100), 268 (67), 183 (21), 181 (39), 172 
(88), 165 (21), 155 (26), 143 (27), 141 (37), 130 (21), 129 (61), 128 (41), 83 (78), 69 (35), 57 
(31), 55 (27), 41 (22). 
IR (ATR) ν~  (cm-1): 3340 (w), 2928 (vs), 2866 (s), 1502 (m), 1452 (s), 1366 (m), 1104 (m), 
1068 (vs), 1034 (m), 1000 (m), 832 (vs), 818 (m). 
HRMS (EI) for C24H34O (338.2610): 338.2605. 
 
5.5 Preparation of tosylates for X-ray analysis 
To a solution of the respective TBS-protected cyclohexanol (102i or 103h) (0.25 mmol; 98.7 mg) 
in THF (1.5 mL), TBAF·3 H2O (tetrabutylammonium fluoride trihydrate) (1.0 mmol; 0.316 g) 
was added. The reaction mixture was stirred overnight at room temperature. NH4Cl sat. aq. 
solution (10 mL) was added. Phases were separated and the organic phase was extracted with 
Et2O (3 x 20 mL). The combined organic layers were washed with brine and dried over Na2SO4. 
The solvents were evaporated. The crude product was dissolved in a mixture CH2Cl2 (1 mL) and 
pyridine (0.25 mL). 4-DMAP (4-dimethylaminopyridine; 0.25 mmol; 30.5 mg) and TsCl (p-
tolylsulfonyl chloride; 0.80 mmol; 0.152 g) were added and the reaction mixture was stirred 
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overnight at room temperature. NH4Cl sat. aq. solution (10 mL) was added. Phases were 
separated and the organic phase was extracted with CH2Cl2 (3 x 20 mL). The solvents were 
evaporated and the crude product was purified via column chromatography. 
 
cis-3-Ethynylcyclohexyl 4-methylbenzenesulfonate 
 
 
colorless crystals (71%) 
m. p.: 81.6 – 83.0 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.77 (d, J=8.4 Hz, 2 H), 6.71 (d, J=8.0 Hz, 2 H), 4.36 - 4.26 (m, 1 
H), 2.27 - 2.21 (m, 1 H), 1.83 (s, 3 H), 1.81 - 1.72 (m, 3 H), 1.52 - 1.41 (m, 2 H), 1.18 - 1.02 (m, 
2 H), 0.94 - 0.83 (m, 1 H), 0.65 - 0.53 (m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 144.4, 136.2, 130.1, 86.7, 79.8, 69.3, 39.2, 32.5, 31.8, 28.4, 23.4, 
21.5. 
MS (70 eV, EI) m/z (%): 278 (1) [M+], 214 (22), 173 (12), 155 (20), 132 (19), 106 (13), 105 (13), 
91 (100), 79 (11), 78 (17), 65 (14). 
IR (ATR) ν~  (cm-1): 3270 (m), 1358 (m), 1342 (m), 1188 (s), 1176 (s), 1096 (m), 938 (s), 922 
(vs), 892 (s), 882 (s), 852 (s), 826 (s), 810 (s), 794 (m), 784 (m), 698 (s), 686 (s), 664 (vs). 
HRMS (EI) for C15H18O3S (278.0977): 278.0977. 
 
trans-4-Ethynylcyclohexyl 4-methylbenzenesulfonate 
 
 
colorless crystals (73%) 
m. p.: 56.1 – 57.6 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.75 (d, J=8.4 Hz, 2 H), 6.72 (d, J=8.0 Hz, 2 H), 4.50 - 4.39 (m, 1 
H), 1.93 (d, J=2.3 Hz, 1 H), 1.84 (s, 3 H), 1.80 - 1.68 (m, 3 H), 1.63 - 1.54 (m, 2 H), 1.32 - 1.23 
(m, 2 H), 1.16 - 1.07 (m, 2 H). 
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13C-NMR (101 MHz, C6D6) δ: 144.4, 136.2, 130.1, 128.2, 87.0, 79.9, 69.5, 30.4, 29.0, 27.6, 
21.5. 
MS (70 eV, EI) m/z (%): 278 (1) [M+], 173 (27), 172 (16), 155 (37), 123 (12), 107 (11), 106 
(100), 92 (22), 91 (55), 91 (74), 79 (31), 78 (64), 77 (19), 67 (13), 65 (42), 41 (15). 
IR (ATR) ν~  (cm-1): 3292 (w), 3282 (m), 2956 (w), 1598 (w), 1444 (m), 1376 (w), 1348 (s), 
1320 (m), 1304 (m), 1292 (m), 1258 (m), 1240 (w), 1188 (m), 1172 (vs), 1152 (m), 1122 (m), 
1096 (s), 1058 (m), 1048 (m), 1034 (m), 1018 (m), 956 (s), 930 (s), 904 (s), 874 (m), 858 (vs), 
810 (vs), 786 (s), 706 (m), 666 (vs), 642 (vs), 618 (s). 
HRMS (EI) for C15H18O3S (278.0977): 278.0971. 
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6. Fe-Mediated Diastereoselective Csp2-Csp3 Cross-Coupling Reactions. 
6.1 Preparation of starting materials 
 
Preparation of cyclohexyl iodides 
A suspension of I2 (1.2 equiv) in CH2Cl2 (0.8 M) was cooled to 0 °C and PPh3 (1.1 equiv) was 
added portionwise. The reaction mixture was stirred for 1 h at 0 °C. N-methylimidazole (NMI; 
1.25 equiv) was added, followed by dropwise addition of the respective cycloalcohol (1.0 equiv). 
The reaction mixture was warmed to room temperature and stirred for 1 h. NH4Cl sat. aq. 
solution was added, the phases were separated and the aqueous phase was extracted with 3x 
CH2Cl2. The combined organic layers were washed with brine and dried over Na2SO4. The 
solvents were evaporated and the residue was subjected to column chromatography (SiO2; i-
hexane) yielding the title compound.78 
 
tert-butyl((2-iodocyclohexyl)oxy)dimethylsilane (36) 
 
 
colorless oil (47%) 
(Mixture of diastereomers; signals of the major diastereomer are given) 
1H-NMR (300 MHz, CDCl3) δ:4.53 - 4.39 (m, 1 H), 3.36 (s br., 1 H), 2.32 - 2.20 (m, 1 H), 1.96 - 
1.84 (m, 1 H), 1.79 - 1.60 (m, 3 H), 1.57 - 1.30 (m, 3 H), 0.95 (s, 9 H), 0.14 (s, 3 H), 0.08 (s, 3 
H). 
13C-NMR (75 MHz, CDCl3) δ: 71.7, 42.3, 34.1, 33.4, 25.9, 25.3, 21.4, 18.2, ‒4.3, ‒4.5. 
MS (70 eV, EI) m/z (%): 325 (1) [M-CH3]+, 284 (14), 283 (100), 215 (11), 185 (29), 155 (28), 83 
(10), 81 (40), 75 (40), 73 (19), 71 (11), 69 (13), 57 (26), 55 (14), 40 (12). 
IR (ATR) ν~  (cm-1): 2932 (m), 2856 (m), 1250 (m), 1166 (m), 1100 (s), 1074 (m), 1060 (m), 
1030 (m), 1020 (m), 894 (m), 868 (m), 834 (vs), 806 (m), 774 (vs), 678 (m), 668 (m). 
HRMS (EI) for C11H22OISi [M-CH3]+ (325.0485): 325.0413. 
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tert-Butyl(((1R)-2-iodocyclohexyl)oxy)dimethylsilane (113) 
 
 
colorless oil (45%) 
1H-NMR (300 MHz, CDCl3) δ: 4.52 - 4.41 (m, 1 H), 3.36 (s br., 1 H), 2.32 - 2.20 (m, 1 H), 1.96 
- 1.85 (m, 1 H), 1.78 - 1.55 (m, 4 H), 1.48 - 1.34 (m, 2 H), 0.95 (s, 9 H), 0.14 (s, 3 H), 0.08 (s, 3 
H). 
13C-NMR (75 MHz, CDCl3) δ: 71.8, 42.3, 34.1, 33.4, 25.9, 25.3, 21.4, 18.2, ‒4.3, ‒4.5. 
MS (70 eV, EI) m/z (%): 325 (1) [M-CH3]+, 284 (13), 283 (77), 191 (13), 190 (19), 185 (29), 176 
(12), 175 (100), 155 (45), 91 (11), 81 (45), 75 (89), 73 (16), 71 (12), 57 (63), 55 (12), 43 (11). 
IR (ATR) ν~  (cm-1): 2934 (m), 2856 (m), 1250 (m), 1168 (m),  1100 (s), 1072 (m), 1060 (m), 
1028 (m), 1020 (m), 984 (m), 894 (m), 868 (s), 834 (vs), 806 (m), 774 (vs), 678 (m),668 (m). 
HRMS (EI) for C11H22OISi [M-CH3]+ (325.0485): 325.0492. 
 
tert-Butyl((2-iodocyclopentyl)oxy)dimethylsilane (117) 
 
 
colorless oil (48%) 
1H-NMR (300 MHz, CDCl3) δ: 4.43 (ddd, J1=6.26, J2=3.55, J3=3.27 Hz, 1 H), 4.06 - 3.98 (m, 1 
H), 2.41 - 2.28 (m, 1 H), 2.16 – 1.97 (m, 2 H), 1.80 (quint, J=7.39 Hz, 2 H), 1.60 - 1.49 (m, 1 H), 
0.89 (s, 9 H), 0.10 (s, 3 H), 0.07 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 82.5, 35.8, 35.0, 32.3, 25.8, 22.3, 18.0, ‒4.5, ‒4.8. 
MS (70 eV, EI) m/z (%): 311 (2) [M-CH3]+, 272 (2), 271 (4), 270 (100), 269 (2), 185 (72), 141 
(41), 99 (5), 75 (21), 52 (4). 
IR (ATR) ν~  (cm-1): 2954 (m), 2928 (m), 2856 (w), 1252 (m), 1132 (w), 1112 (m), 1076 (s), 
1036 (m), 1020 (m), 1006 (m), 880 (s), 832 (vs), 810 (m), 774 (vs), 668 (m). 
HRMS (EI) for C10H20IOSi (311.0328) [M-CH3]+: 311.0331 
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(1R,2R)-cyclohex-3-ene-1,2-diyl diacetate (obtained from the mixture of (R,R)-10 and (R,R)-
11 via acetylation using Ac2O in pyridine)132 
 
 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 98:2; flow: 0.3 mL/min 
  
 
Preparation of (1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohex-3-en-1-yl acetate and 
(1R,6R)-6-((tert-butyldimethylsilyl)oxy)cyclo- hex-2-en-1-yl acetate: 
 
 
To a solution of a mixture of (1R,2R)-2-hydroxycyclohex-3-en-1-yl acetate (10) and (1R,6R)-6-
hydroxycyclohex-2-en-1-yl acetate (11)132 (24.46 mmol; 3.82 g) and imidazole (49.00 mmol; 
3.34 g) in DMF (50 mL) was slowly added TBSCl (26.90 mmol; 4.05 g). The reaction mixture 
was stirred overnight at room temperature. NH4Cl sat. aq. solution (150 mL) and Et2O (50 mL) 
were added, phases were separated and the aqueous phase was extracted with Et2O (3 x 50 mL). 
The combined organic layers were washed with brine (100 mL) and dried over Na2SO4. The 
solvents were evaporated and the residue was subjected to column chromatography (SiO2; n-
pentane/Et2O 15:1) yielding 5.95 g (90%) of the title compound as a colorless oil. 
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(Mixture of regioisomers; signals of only one regioisomer are given) 
1H-NMR (300 MHz, CDCl3) δ: 5.90 - 5.78 (m, 1 H), 5.78 - 5.67 (m, 1 H), 4.82 (ddd, J1=10.37, 
J2=6.77, J3=3.32 Hz, 1 H), 4.23 (dd, J1=4.56, J2=2.07 Hz, 1 H), 2.15 (td, J1=8.78, J2=4.01 Hz, 2 
H), 2.06 (s, 3 H), 1.77 - 1.60 (m, 2 H), 0.89 (s, 9 H), 0.09 - 0.05 (m, 6 H). 
13C-NMR (75 MHz, CDCl3) δ: 170.4, 128.3, 124.6, 74.6, 69.7, 29.2, 25.7, 23.7, 21.3, 18.1, ‒4.6 
‒4.7. 
MS (70 eV, EI) m/z (%): 213 (4) [M-tBu]+, 184 (4), 159 (5), 152 (3), 135 (10 ), 127 (5), 118 (10), 
117 (100), 79 (24), 75 (32), 73 (10), 43 (8). 
IR (ATR) ν~  (cm-1): 2954 (w), 2930 (w), 2858 (w), 1736 (s), 1370 (m), 1236 (s), 1098 (s), 1048 
(m), 1034 (m), 1006 (m), 988 (w), 948 (w), 934 (w), 888 (m), 864 (m), 832 (vs), 816 (m), 774 
(vs), 748 (w), 724 (w), 680 (w), 666 (w), 654 (w), 642 (w). 
HRMS (EI) for C10H17O3Si (213.0947) [M-tBu]+: 213.0931. 
 
Preparation of (1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl acetate: 
 
 
(1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohex-3-en-1-yl acetate and (1R,6R)-6-((tert-
butyldimethylsilyl)oxy)cyclo- hex-2-en-1-yl acetate (22.00 mmol; 5.95 g) were dissolved in 
EtOAc (150 mL). Pd/C (10% Pd) (0.60 g) was added and the reaction mixture was reduced with 
H2 (1 atm) for 6 h at room temperature. The reaction mixture was filtered and the solvent was 
evaporated, yielding 5.99 g (99%) of the title compound as a colorless oil. 
 
1H-NMR (300 MHz, CDCl3) δ: 4.62 (td, J1=8.78, J2=4.56 Hz, 1 H), 3.61 - 3.52 (m, 1 H), 2.04 (s, 
3 H), 2.01 – 1.93 (m, 1 H), 1.90 - 1.82 (m, 1 H), 1.71 - 1.62 (m, 2 H), 1.45 - 1.25 (m, 4 H), 0.87 
(s, 9 H), 0.06 (s, 3 H), 0.05 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 170.4, 76.7, 72.3, 33.7, 29.6, 25.7, 23.4, 23.4, 21.4, 17.9, ‒4.6, 
‒4.8. 
MS (70 eV, EI) m/z (%): 273 (24) [M+H+], 213 (92), 197 (9), 173 (28), 156 (100), 117 (80), 116 
(12), 115 (8), 77 (18), 75 (11). 
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IR (ATR) ν~  (cm-1): 2932 (m), 2858 (w), 1736 (s), 1370 (m), 1236 (vs), 1106 (s), 1048 (s), 1038 
(m), 1024 (m), 1006 (w), 952 (m), 874 (s), 832 (vs), 816 (m), 774 (s), 668 (m). 
HRMS (EI) for C14H29O3Si (273.1886) [M+H+]: 273.1880. 
 
Preparation of (1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexanol: 
 
 
(1R,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl acetate (22.00 mmol; 5.99 g) was dissolved 
in MeOH (150 mL) and K2CO3 (44.00 mmol; 6.08 g) was added. The reaction mixture was 
stirred overnight at room temperature. It was then concentrated in vacuo and NH4Cl sat. aq. 
solution (150 mL) and Et2O (150 mL) were added. The phases were separated and the aqueous 
layer was extracted with Et2O (3 x 50 mL). The combined organic phases were washed with brine 
(50 mL) and dried over Na2SO4. The solvents were evaporated yielding 4.95 g (98%) of the title 
compound as a colorless oil. 
 
1H-NMR (300 MHz, CDCl3) δ: 3.34 (d, J=5.81 Hz, 2 H), 2.29 (s br., 1 H), 1.98 (dd, J1=5.94, 
J2=3.18 Hz, 1 H), 1.90 - 1.81 (m, 1 H), 1.73 - 1.61 (m, 2 H), 1.31 - 1.21 (m, 4 H), 0.91 (s, 9 H), 
0.10 (s, 3 H), 0.09 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 77.2, 75.5, 33.5, 31.5, 25.8, 24.4, 24.1, 18.0, ‒4.1,‒4.7. 
MS (70 eV, EI) m/z (%): 215 (2) [M-CH3]+, 174 (17), 173 (100), 171 (8), 155 (15), 131 (9), 105 
(48), 81 (44), 79 (8), 76 (5), 75 (74), 73 (11). 
IR (ATR) ν~  (cm-1): 2930 (m), 2858 (m), 1250 (m), 1090 (s), 1080 (s), 1072 (s), 1050 (m), 946 
(m), 876 (s), 832 (vs), 814 (m), 774 (s), 668 (m). 
HRMS (EI) for C11H23O2Si (215.1467) [M-CH3]+: 215.1440. 
 
6.2 Preparation of (hetero)arylmagnesium reagents 
 
6.2.1 Mg-insertion into (hetero)aryl halides 
A dry and Ar-flushed 50 mL Schlenk-tube, equipped with a stirring bar and a septum, was 
charged with anhydrous LiCl (6.25 mmol; 265 mg) and heated to 130 °C under high vacuum (1 
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mbar) for 3 h. After cooling to room temperature under Ar, Mg turnings (6.25 mmol; 152 mg), 
1,2-dibromoethane (0.02 ml) and freshly distilled THF (10 mL) were added. The reaction mixture 
was shortly heated to reflux and was cooled to room temperature under Ar. Under vigorous 
stirring the respective (hetero)aryl bromide (5 mmol) was added slowly at the appropriate 
temperature. The reaction mixture was stirred under Ar overnight and was titrated by using a 
stoichiometric amount of iodine (50 mg) in THF (2 mL).129 
 
p-Tolylmagnesium bromide 
 
 
0.39 M (78%) 
reaction temperature: 25 °C 
 
Naphthalen-1-ylmagnesium bromide 
 
 
0.45 M (90%) 
reaction temperature: 25 °C 
 
Quinolin-3-ylmagnesium bromide 
 
 
0.42 M (84%) 
reaction temperature: 0 °C 
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(4-(Pivaloyloxy)phenyl)magnesium bromide 
 
 
0.38 M (76%) 
reaction temperature: ‒20 °C 
 
Mesitylmagnesium bromide 
 
 
0.43 M (86%) 
reaction temperature: 25 °C 
 
6.2.1 Br/Mg-exchange reaction using iPrMgCl·LiCl on (hetero)aryl bromides 
A dry and Ar-flushed 25 mL Schlenk-tube, equipped with a stirring bar and a septum, was 
charged with a solution of the respective bromide (1 equiv) in THF (2.0 M solution). The 
exchange reagent iPrMgCl·LiCl (1.1 equiv; 1.20 M) was added dropwise at the appropriate 
temperature. The reaction mixture was stirred at the same temperature, and the completion of the 
Br/Mg-exchange was checked by GC-analysis, using tridecane (C13H28) as internal standard. 
After completion of the reaction, the resulting solution was titrated by using a stoichiometric 
amount of iodine (50 mg) in THF (2 mL). 130 
 
(4-Cyanophenyl)magnesium chloride 
 
 
0.68 M (96%) 
reaction temperature: 0 °C 
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reaction time: 3 h 
 
(4-(Trifluoromethyl)phenyl)magnesium chloride 
 
 
0.67 M (95%) 
reaction temperature: 0 °C 
reaction time: 2 h 
 
Pyridin-3-ylmagnesium chloride 
 
 
0.61 M (87%) 
reaction temperature: 0 °C 
reaction time: 3 h 
 
(6-Chloropyridin-3-yl)magnesium chloride 
 
 
0.65 M (92%) 
reaction temperature: ‒20 °C 
reaction time: 3 h 
 
(3,5-Bis(trifluoromethyl)phenyl)magnesium chloride 
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0.70 M (99%) 
reaction temperature: 0 °C 
reaction time: 2 h 
 
(2-Cyano-5-fluorophenyl)magnesium chloride 
 
 
0.69 M (98%) 
reaction temperature: ‒20 °C 
reaction time: 30 min 
 
(2-(Ethoxycarbonyl)-6-fluorophenyl)magnesium chloride 
 
 
0.70 M (99%) 
reaction temperature: ‒78 °C 
reaction time: 1 h 
 
6.3 Diastereoselective FeCl2-mediated Csp2-Csp3 cross-coupling with the TBS-protected 
cyclic iodohydrine derivatives 
A dry and Ar-flushed 10 mL Schlenk-tube, equipped with a stirring bar and a septum, was 
charged with a solution of FeCl2·2 LiCl (1.0 M in THF; 0.43 mmol; 0.43 mL) and anhydrous 
THF (0.5 mL). The respective protected 2-iodocycloalcohol (0.5 mmol) and 4-fluorosytrene (0.25 
mmol; 30.5 mg) were added via syringe. The reaction mixture was cooled to -50 °C and a 
solution of the corresponding Grignard reagent (0.85 mmol) was added dropwise via syringe. The 
reaction mixture was stirred for 1 h at this temperature and was then allowed to warm to room 
temperature overnight. It was then quenched with NH4Cl sat. aq. solution (20 mL) and Et2O (20 
mL) was added, the phases were separated and the aqueous phase was extracted with Et2O (4 x 
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20 mL). The combined organic layers were dried over Na2SO4. The solvents were evaporated and 
the residue was subjected to column chromatography yielding the respective title compound. 
tert-Butyldimethyl((trans-2-phenylcyclohexyl)oxy)silane (36a) 
 
 
colorless oil (61 %) 
1H-NMR (400 MHz, CDCl3) δ: 7.32 - 7.09 (m, 5 H), 3.53 (td, J1=9.8 Hz, J2=4.4 Hz, 1 H), 2.44 
(ddd, J1=12.7 Hz, J2=9.5 Hz, J3=3.5 Hz, 1 H), 1.99 (ddd, J1=8.0 Hz, J2=4.6 Hz, J3=4.4 Hz, 1 H), 
1.88 - 1.78 (m, 2 H), 1.78 - 1.69 (m, 1 H), 1.61 - 1.59 (m, 1 H), 1.45 - 1.25 (m, 3 H), 0.66 (s, 9 
H), ‒0.20 (s, 3 H), ‒0.53 (s, 3 H). 
13C-NMR (101 MHz, CDCl3) δ: 145.0, 128.3, 127.9, 126.0, 75.9, 53.0, 36.7, 32.8, 26.0, 25.7, 
25.3, 17.8, ‒4.7, ‒5.7. 
MS (70 eV, EI) m/z (%): 289 (1) [M-H]+, 235 (5), 234 (17), 233 (100), 157 (4), 135 (2), 129 (2), 
115 (2), 91 (5), 75 (12). 
IR (ATR) ν~  (cm-1): 2928 (m), 2856 (m), 1248 (m), 1094 (s), 982 (m), 880 (s), 854 (s), 834 (vs), 
810 (m), 772 (vs), 752 (s), 698 (vs), 666 (m). 
HRMS (EI) for C18H29OSi (289.1988) [M-H]+: 289.1984. 
 
tert-Butyldimethyl((trans-2-(p-tolyl)cyclohexyl)oxy)silane (36b) 
 
 
colorless oil (62 %)  
1H-NMR (300 MHz, CDCl3) δ: 7.10 (s, 4 H), 3.54 (td, J1=9.6 Hz, J2=4.6 Hz, 1 H), 2.49 - 2.39 
(m, 1 H), 2.33 (s, 3 H), 2.05 - 1.97 (m, 1 H), 1.89 - 1.73 (m, 3 H), 1.64 - 1.54 (m, 1 H), 1.46 - 
1.32 (m, 3 H), 0.70 (s, 9 H), ‒0.17 (s, 3 H), ‒0.48 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 142.0, 135.3, 128.5, 128.2, 76.0, 52.6, 36.7, 32.9, 26.1, 25.7, 
25.3, 21.0, 17.9, ‒4.7, ‒5.6. 
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MS (70 eV, EI) m/z (%): 304 (1) [M+], 249 (5), 248 (18), 247 (100), 171 (5), 149 (4), 129 (2), 
105 (15), 75 (33), 73 (7). 
IR (ATR) ν~  (cm-1): 2928 (m), 2856 (m), 1472 (w), 1248 (m), 1092 (s), 984 (m), 882 (m), 856 
(s), 846 (m), 828 (vs), 810 (s), 772 (vs), 666 (m). 
HRMS (EI) for C19H32OSi (304.2222): 304.2183. 
 
tert-Butyldimethyl((trans-2-(4-(trifluoromethyl)phenyl)cyclohexyl)oxy)silane (36c) 
 
 
slightly yellow oil (67 %) 
1H NMR (300 MHz, CDCl3) δ: 7.53 (d, J=8.0 Hz, 2 H), 7.32 (d, J=8.0 Hz, 2 H), 3.56 (td, J1=9.4 
Hz, J2=4.4 Hz, 1 H), 2.59 - 2.48 (m, 1 H), 2.09 - 1.95 (m, 1 H), 1.91 - 1.74 (m, 3 H), 1.62 - 1.54 
(m, 1 H), 1.47 - 1.26 (m, 3 H), 0.65 (s, 9 H), ‒0.15 (s, 3 H), ‒0.52 (s, 3 H).  
13C-NMR (75 MHz, CDCl3) δ: 149.3 (d, J=1.1 Hz), 128.6, 128.4 (q, J=32.3 Hz), 124.8 (q, J=3.9 
Hz), 124.4 (q, J=271.8 Hz), 75.8, 53.0, 36.6, 32.5, 25.9, 25.5, 25.1, 17.8, ‒4.5, ‒5.7. 
19F-NMR (282 MHz, CDCl3) δ: ‒62.3 (s). 
MS (70 eV, EI) m/z (%): 359 (1) [M+H+], 339 (21), 302 (100), 301 (68), 207 (96), 179 (41), 159 
(42), 140 (15), 129 (12), 127 (30), 109 (10), 101 (16), 75 (11). 
IR (ATR) ν~  (cm-1): 2930 (m), 2858 (w), 1324 (vs), 1250 (m), 1162 (m), 1122 (s), 1094 (s), 
1070 (s), 1018 (w), 984 (m), 882 (m), 846 (s), 830 (vs), 812 (m), 772 (s), 668 (w), 658 (m), 604 
(m). 
HRMS (EI) for C19H30OF3Si (359.2013) [M+H+]: 359.1843. 
 
((trans-2-(3,5-Bis(trifluoromethyl)phenyl)cyclohexyl)oxy)(tert-butyl)dimethylsilane (36d) 
 
TBSO
CF3
CF3
 
colorless oil (75 %)  
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1H-NMR (300 MHz, CDCl3) δ: 7.75 - 7.65 (m, 3 H), 3.57 (td, J1=9.7 Hz, J2=4.4 Hz, 1 H), 2.70 - 
2.59 (m, 1 H), 2.05 (d, J=2.5 Hz, 1 H), 1.95 - 1.79 (m, 3 H), 1.68 - 1.57 (m, 1 H), 1.48 - 1.37 (m, 
3 H), 0.65 (s, 9 H), ‒0.12 (s, 3 H), ‒0.52 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 147.7, 131.2 (q, J=33.0 Hz), 128.5 (d, J=2.5 Hz), 123.6 (q, 
J=272.4 Hz), 120.1 (sept, J=3.9 Hz), 75.7, 53.0, 36.5, 32.3, 25.7, 25.4, 25.0, 17.6, ‒4.5, ‒5.9. 
19F-NMR (282 MHz, CDCl3) δ: ‒62.9 (s). 
MS (70 eV, EI) m/z (%): 426 (1) [M+], 370 (19), 369 (100), 301 (14), 275 (6), 227 (4), 209 (11), 
195 (2), 159 (2), 133 (3), 75 (7), 57 (2). 
IR (ATR) ν~  (cm-1): 2932 (w), 2860 (w), 1382 (m), 1366 (w), 1276 (vs), 1260 (m), 1170 (s), 
1130 (vs), 1098 (s), 1006 (w), 924 (m), 898 (w), 874 (s), 832 (s), 814 (m), 774 (s), 706 (m), 682 
(s), 668 (w), 656 (w). 
HRMS (EI) for C20H28OF6Si (426.1814): 426.1655. 
 
tert-Butyldimethyl((trans-2-(naphthalen-1-yl)cyclohexyl)oxy)silane (36e) 
 
 
colorless oil (90 %) 
1H NMR (400 MHz, CDCl3) δ: 8.31 (d, J=8.5 Hz, 1 H), 7.88 - 7.82 (m, 1 H), 7.73 (d, J=7.4 Hz, 
1 H), 7.55 - 7.40 (m, 4 H), 3.77 (br s., 1 H), 3.49 (t, J=9.5 Hz, 1 H), 2.16 - 2.08 (m, 1 H), 2.00 - 
1.86 (m, 2 H), 1.85 (dd, J1=8.6 Hz, J2=2.4 Hz, 1 H), 1.81 - 1.72 (m, 1 H), 1.65 - 1.46 (m, 3 H), 
0.49 (s, 9 H), ‒0.22 (s, 3 H), ‒0.81 (s, 3 H). 
13C-NMR (101 MHz, CDCl3) δ: 142.1, 133.7, 133.3, 128.3, 126.2, 125.3, 125.2, 125.0, 124.5, 
123.0, 77.2, 45.9, 37.1, 33.2, 26.4, 25.4, 25.4, 17.5, ‒4.9, ‒5.9. 
MS (70 eV, EI) m/z (%):339 (1) [M-H]+, 325 (1), 284 (20), 283 (100), 210 (3), 208 (4), 179 (3), 
165 (4), 141 (8), 75 (11), 73 (3). 
IR (ATR) ν~  (cm-1): 2928 (m), 2856 (m), 1248 (m), 1096 (s), 1084 (m), 972 (m), 880 (m), 862 
(m), 832 (s), 814 (m), 792 (m), 772 (vs), 666 (m). 
HRMS (EI) for C22H31OSi (339.2149) [M-H]+: 339.2136. 
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tert-Butyl((trans-2-mesitylcyclohexyl)oxy)dimethylsilane (36f) 
 
 
 
colorless oil (80 %)  
1H-NMR (300 MHz, CDCl3) δ: 6.76 (d, J=10.57 Hz, 2 H), 4.11 - 4.03 (m, 1 H), 3.07 – 2.98 (m, 
1 H), 2.43 (s, 3 H), 2.33 (s, 3 H), 2.22 (s, 3 H), 2.05 - 1.95 (m, 2 H), 1.82 - 1.69 (m, 3 H), 1.38 - 
1.27 (m, 3 H), 0.65 (s, 9 H), ‒0.13 (s, 3 H), ‒0.48 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 138.2, 137.3, 135.4, 134.7, 130.8, 128.9, 72.3, 48.2, 37.6, 29.8, 
26.8, 25.5, 25.3, 22.3, 21.7, 20.6, 17.7, -4.6, -5.7. 
MS (70 eV, EI) m/z (%): 332 (1) [M+], 276 (22), 275 (100), 199 (7), 157 (7), 143 (3), 133 (35), 
105 (3), 75 (78), 73 (13). 
IR (ATR) ν~  (cm-1): 2950 (m), 2928 (m), 2856 (m), 1472 (w), 1248 (m), 1090 (s), 988 (m), 880 
(m), 848 (s), 834 (vs), 802 (m), 772 (vs), 666 (m). 
HRMS (EI) for C21H36O1Si1 (332.2535): 332.2520. 
 
2-(trans-2-((tert-Butyldimethylsilyl)oxy)cyclohexyl)-4-fluorobenzonitrile (36g) 
 
 
colorless oil (65 %) 
1H-NMR (300 MHz, CDCl3) δ: 7.59 (dd, J1=8.6 Hz, J2=5.5 Hz, 1 H), 7.10 - 6.93 (m, 2 H), 3.70 - 
3.54 (m, 1 H), 3.01 (t, J=10.2 Hz, 1 H), 2.07 - 1.96 (m, 1 H), 1.94 - 1.73 (m, 3 H), 1.62 - 1.28 (m, 
4 H), 0.66 (s, 9 H), ‒0.08 (s, 3 H), ‒0.42 (s, 3 H).  
13C-NMR (75 MHz, CDCl3) δ: 165.2 (d, J=255 Hz), 152.7 (d, J=8.4 Hz), 134.8 (d, J=9.5 Hz), 
117.8, 114.6 (d, J=21.3 Hz), 114.1 (d, J=22.7 Hz), 110.0, 75.5, 52.1, 36.2, 32.2, 25.5, 25.4, 24.8, 
17.6, ‒4.3, ‒5.7. 
19F-NMR (282 MHz, CDCl3) δ: ‒102.6 - ‒102.7 (m) (minor), ‒103.9 - ‒104.2 (m) (major). 
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MS (70 eV, EI) m/z (%): 332 (1) [M-H]+, 276 (100), 277 (21), 202 (20), 134 (5), 101 (5), 61 (2), 
59 (10), 57 (8), 41 (8). 
IR (ATR) ν~  (cm-1): 2930 (m), 2858 (m), 2226 (w), 1608 (m), 1586 (m), 1492 (w), 1472 (w), 
1464 (w), 1450 (w), 1362 (w), 1290 (w), 1274 (w), 1242 (m), 1228 (w), 1178 (w), 1160 (w), 
1130 (w), 1096 (w), 1004 (m), 944 (m), 902 (w), 870 (s), 834 (vs), 818 (s), 796 (m), 774 (s), 690 
(m), 668 (m). 
HRMS (EI) for C19H27ONFSi (332.1852) [M-H]+: 332.1844. 
 
4-(trans-2-((tert-Butyldimethylsilyl)oxy)cyclohexyl)benzonitrile (36h) 
 
 
slightly yellow oil (62 %)  
1H-NMR (300 MHz, CDCl3) δ: 7.56 (d, J=8.1 Hz, 2 H), 7.30 (d, J=8.3 Hz, 2 H), 3.54 (td, J1=9.7 
Hz, J2=4.5 Hz, 1 H), 2.52 (ddd, J1=12.5 Hz, J2=9.7 Hz, J3=3.2 Hz, 1 H), 2.09 - 1.94 (m, 1 H), 
1.90 - 1.76 (m, 2 H), 1.68 - 1.12 (m, 5 H), 0.64 (s, 9 H), ‒0.15 (s, 3 H), ‒0.52 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 150.9, 131.7, 129.1, 119.2, 109.7, 75.5, 53.3, 36.5, 32.3, 25.7, 
25.5, 25.0, 17.7, -4.5, ‒5.6. 
MS (70 eV, EI) m/z (%): 316 (12) [M+H+], 310 (14), 267 (10), 258 (30), 238 (5), 199 (18), 177 
(7), 176 (100), 171 (4), 75 (10),  
IR (ATR) ν~  (cm-1): 2928 (m), 2856 (m), 2228 (w), 1608 (w), 1472 (w), 1462 (w), 1250 (m), 
1128 (w), 1090 (s), 982 (m), 882 (m), 848 (s), 830 (vs), 814 (m), 772 (s), 666 (m). 
HRMS (EI) for C19H30ONSi (316.2096) [M+H+]: 316.2080. 
 
4-(trans-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)phenyl pivalate (36i) 
 
 
colorless crystals (62 %)  
m.p.: 74.4 – 75.6 °C. 
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1H-NMR (600 MHz, CDCl3) δ: 7.19 (d, J=8.5 Hz, 2 H), 6.95 (d, J=8.5 Hz, 2 H), 3.52 (td, J1=9.8 
Hz, J2=4.2 Hz, 1 H), 2.46 (ddd, J1=12.7 Hz, J2=9.5 Hz, J3=3.6 Hz, 1 H), 2.03 - 1.98 (m, 1 H), 
1.88 - 1.78 (m, 2 H), 1.75 (d, J=12.6 Hz, 1 H), 1.58 - 1.52 (m, 1 H), 1.47 - 1.39 (m, 2 H), 1.39 - 
1.34 (m, 9 H), 1.33 - 1.26 (m, 1 H), 0.71 (s, 9 H), ‒0.16 (s, 3 H), ‒0.46 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 177.1, 149.4, 142.3, 129.0, 120.8, 75.9, 52.4, 39.0, 36.7, 32.8, 
27.2, 26.0, 25.7, 25.2, 17.9, ‒4.8, ‒5.5. 
MS (70 eV, EI) m/z (%): 390 (1) [M+], 335 (25), 334 (100), 333 (48), 249 (31), 235 (9), 181 (8), 
75 (15), 73 (10), 57 (66). 
IR (ATR) ν~  (cm-1): 2928 (m), 2856 (w), 1754 (s), 1506 (w), 1250 (m), 1196 (m), 1164 (m), 
1120 (vs), 1078 (s), 984 (m), 896 (m), 882 (m), 860 (m), 848 (s), 834 (s), 814 (m), 802 (m), 776 
(vs), 668 (m). 
HRMS (EI) for C23H38O3Si (390.2590): 390.2543. 
 
3-(trans-2-((tert-Butyldimethylsilyl)oxy)cyclohexyl)quinoline (36j) 
 
 
slightly yellow oil (57 %) 
1H-NMR (300 MHz, CDCl3) δ: 8.81 (d, J=2.1 Hz, 1 H), 8.07 (d, J=8.3 Hz, 1 H), 7.91 (d, J=1.7 
Hz, 1 H), 7.75 (d, J=8.1 Hz, 1 H), 7.64 (td, J1=7.7 Hz, J2=1.2 Hz, 1 H), 7.50 (t, J=7.4 Hz, 1 H), 
3.64 (td, J1=9.6 Hz, J2=4.4 Hz, 1 H), 2.68 (ddd, J1=12.6 Hz, J2=9.6 Hz, J3=3.5 Hz, 1 H), 2.09 - 
2.01 (m, 1 H), 1.97 - 1.70 (m, 4 H), 1.52 - 1.32 (m, 3 H), 0.61 (s, 9 H), ‒0.19 (s, 3 H), ‒0.64 (s, 3 
H). 
13C-NMR (75 MHz, CDCl3) δ: 152.1, 147.1, 137.6, 133.9, 129.1, 128.4, 128.1, 127.3, 126.3, 
75.9, 50.5, 36.6, 32.2, 25.9, 25.5, 25.1, 17.7, ‒4.6, ‒5.6. 
MS (70 eV, EI) m/z (%): 341 (1) [M+], 326 (4), 285 (21), 284 (100), 210 (41), 186 (4), 167 (4), 
142 (14), 115 (4), 41 (19). 
IR (ATR) ν~  (cm-1): 2928 (m), 2856 (m), 1250 (m), 1092 (s), 964 (m), 876 (s), 834 (vs), 816 
(m), 772 (vs), 748 (s), 666 (m), 618 (m). 
HRMS (EI) for C21H31ONSi (341.2175): 341.2188. 
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3-(trans-2-((tert-Butyldimethylsilyl)oxy)cyclohexyl)pyridine (36k) 
 
 
yellow oil (80 %)  
1H-NMR (300 MHz, CDCl3) δ: 8.37 - 8.52 (m, 2 H), 7.50 (ddd, J1=7.8 Hz, J2=1.7 Hz, J3=1.5 
Hz, 1 H), 7.20 (dd, J1=7.7 Hz, J2=4.9 Hz, 1 H), 3.52 (td, J1=9.7 Hz, J2=4.6 Hz, 1 H), 2.47 (ddd, 
J1=12.6 Hz, J2=9.6 Hz, J3=3.3 Hz, 1 H), 2.05 - 1.97 (m, 1 H), 1.90 - 1.74 (m, 3 H), 1.65 - 1.54 
(m, 1 H), 1.44 - 1.28 (m, 3 H), 0.66 (s, 9 H), ‒0.16 (s, 3 H), ‒0.50 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 150.1, 147.4, 140.2, 135.4, 123.0, 75.7, 50.5, 36.5, 32.2, 25.8, 
25.6, 25.1, 17.7, ‒4.5, ‒5.6. 
MS (70 eV, EI) m/z (%): 290 (3) [M-H]+, 276 (12), 236 (16), 234 (41), 161 (10), 160 (100), 130 
(6), 92 (10), 75 (57), 73 (22), 59 (7), 41 (7). 
IR (ATR) ν~  (cm-1): 2928 (m), 2856 (m), 1424 (m), 1250 (m), 1090 (s), 982 (m), 880 (s), 854 
(s), 834 (vs), 824 (s), 812 (s), 772 (vs), 714 (s), 666 (m). 
HRMS (EI) for C17H28ONSi (290.1945) [M-H]+: 290.1960. 
 
tert-Butyldimethyl(((1R,2S)-2-(naphthalen-1-yl)cyclohexyl)-oxy)silane (116a): 
 
 
colorless oil (87 %) 
1H-NMR (300 MHz, CDCl3) δ: 8.29 (d, J=8.0 Hz, 1 H), 7.86 - 7.80 (m, 1 H), 7.71 (dd, J1=7.2 
Hz, J2=1.7 Hz, 1 H), 7.52 - 7.40 (m, 4 H), 3.81 - 3.71 (m, 1 H), 3.52 - 3.41 (m, 1 H), 2.14 - 2.06 
(m, 1 H), 1.98 - 1.81 (m, 3 H), 1.63 - 1.30 (m, 4 H), 0.47 (s, 9 H), ‒0.25 (s, 3 H), ‒0.83 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 142.1, 133.8, 133.3, 128.3, 126.2, 125.3, 125.2, 125.0, 124.5, 
123.1, 77.2, 45.9, 37.2, 33.2, 26.4, 25.4, 25.3, 17.5, ‒4.8, ‒5.9. 
MS (70 eV, EI) m/z (%): 340 (1) [M+], 284 (20), 283 (100), 209 (3), 207 (4), 185 (3), 179 (3), 
165 (4), 152 (2), 141 (12), 75 (23). 
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IR (ATR) ν~  (cm-1): 2928 (m), 2856 (m), 1472 (w), 1248 (m), 1096 (s), 1084 (m), 972 (m), 880 
(m), 862 (m), 832 (s), 814 (m), 792 (m), 772 (vs), 728 (w), 666 (m), 630 (w). 
HRMS (EI) for C22H32OSi (340.2222): 340.2218. 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 100:0; flow: 0.5 mL/min 
  
 
 
4-((1S,2R)-2-((tert-Butyldimethylsilyl)oxy)cyclohexyl)-benzonitrile (116b): 
 
 
colorless oil (64 %)  
1H-NMR (300 MHz, CDCl3) δ: 7.56 (d, J=8.3 Hz, 2 H), 7.31 (d, J=8.3 Hz, 2 H), 3.54 (td, J1=9.7 
Hz, J2=4.6 Hz, 1 H), 2.58 - 2.48 (m, 1 H), 2.06 - 1.97 (m, 1 H), 1.89 - 1.73 (m, 3 H), 1.63 - 1.55 
(m, 1 H), 1.44 - 1.28 (m, 3 H), 0.69 - 0.61 (m, 9 H), ‒0.15 (s, 3 H), ‒0.52 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 150.9, 131.8, 129.1, 119.3, 109.8, 75.6, 53.3, 36.5, 32.3, 25.7, 
25.5, 25.0, 17.8, ‒4.4, ‒5.6. 
MS (70 eV, EI) m/z (%): 314 (1) [M-H]+, 260 (5), 259 (20), 258 (100), 142 (1), 116 (5), 77 (1), 
75 (31), 59 (2), 57 (2). 
IR (ATR) ν~  (cm-1): 2928 (m), 2856 (m), 2228 (w), 1608 (w), 1472 (w), 1250 (m), 1128 (w), 
1090 (s), 982 (m), 882 (m), 848 (s), 830 (vs), 814 (m), 772 (s), 666 (m). 
HRMS (EI) for C19H28ONSi (314.1945) [M-H]+: 314.1946. 
HPLC Data: 
 
C. Experimental Section  195 
 
Chiralcel OD-H; n-heptane : i-propanol 100:0; flow: 0.5 mL/min 
 
 
2-((1S,2R)-2-((tert-Butyldimethylsilyl)oxy)cyclohexyl)-4-fluorobenzonitrile (116c): 
 
 
white solid (69 %) 
m.p.: 57.0 – 58.1 °C. 
1H-NMR (300 MHz, CDCl3) δ: 7.60 (dd, J1=8.4 Hz, J2=5.7 Hz, 1 H), 7.08 – 6.94 (m, 2 H), 3.63 
(d, J=9.1 Hz, 1 H), 3.01 (t, J=9.9 Hz, 1 H), 2.02 (d, J=11.3 Hz, 1 H), 1.92 - 1.83 (m, 2 H), 1.78 
(d, J=5.5 Hz, 1 H), 1.59 - 1.35 (m, 4 H), 0.66 (s, 9 H), ‒0.07 (s, 3 H), ‒0.42 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 165.2 (d, J=255.1 Hz), 152.7 (d, J=8.3 Hz), 134.8 (d, J=9.7 Hz), 
117.8, 114.6 (d, J=22.2 Hz), 114.1 (d, J=22.8 Hz), 110.0, 75.5, 52.1 (d, J=1.4 Hz), 36.3, 32.2, 
25.5, 25.4, 24.9, 17.6, ‒4.2, ‒5.7. 
19F-NMR (282 MHz, CDCl3) δ: -104.0 - -104.1 (m). 
MS (70 eV, EI) m/z (%): 318 (3) [M-CH3]+, 283 (10), 278 (7), 277 (27), 276 (100), 202 (34), 175 
(9), 75 (60), 73 (14), 57 (13), 41 (8). 
IR (ATR) ν~  (cm-1): 2928 (m), 2856 (m), 2226 (w), 1608 (m), 1584 (w), 1490 (m), 1472 (w), 
1274 (w), 1244 (m), 1088 (s), 1004 (m), 944 (m), 872 (s), 836 (vs), 814 (s), 794 (m), 772 (vs), 
688 (m), 668 (m). 
HRMS (EI) for C18H25ONFSi (318.1689) [M-CH3]+: 318.1679. 
HPLC Data: 
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Chiralcel OD-H; n-heptane : i-propanol 100:0; flow: 0.3 mL/min 
  
 
Ethyl 2-((1S,2R)-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)-3-fluorobenzoate (116d): 
 
 
colorless oil (73 %)  
1H-NMR (300 MHz, CDCl3) δ: 7.39 (d, J=7.7 Hz, 1 H), 7.22 - 7.05 (m, 2 H), 4.36 (qd, J1=7.1 
Hz, J2=2.6 Hz, 2 H), 4.03 - 4.12 (m, 1 H), 3.21 - 3.31 (m, 1 H), 1.86 - 2.01 (m, 3 H), 1.70 - 1.82 
(m, 2 H), 1.27 - 1.42 (m, 6 H), 0.61 (s, 9 H), ‒0.10 (s, 3 H), ‒0.42 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 168.2 (d, J=3.6 Hz), 162.0 (d, J=246.4 Hz), 135.6 (d, J=6.9 Hz), 
131.7 (d, J=14.2 Hz), 126.8 (d, J=9.3 Hz), 124.9 (d, J=3.0 Hz), 118.5 (d, J=24.0 Hz), 72.4 (d, 
J=5.1 Hz), 61.1, 47.5, 37.0, 29.8 (d, J=4.1 Hz), 26.0, 25.5, 25.0, 17.6, 14.3, ‒4.3, ‒5.8. 
19F-NMR (282 MHz, CDCl3) δ: ‒112.1 (d, J=9.5 Hz). 
MS (70 eV, EI) m/z (%): 379 (1) [M-H]+, 335 (8), 325 (8), 324 (28), 323 (100), 277 (91), 203 
(13), 185 (23), 147 (7), 75 (22), 73 (16). 
IR (ATR) ν~  (cm-1): 2930 (m), 2856 (m), 1724 (s), 1450 (m), 1286 (m), 1258 (vs), 1228 (m), 
1178 (m), 1144 (m), 1112 (s), 1092 (vs), 1026 (m), 988 (m), 940 (m), 882 (s), 854 (s), 832 (vs), 
810 (m), 772 (vs), 754 (vs), 666 (m). 
HRMS (EI) for C21H32O3FSi (379.2110) [M-H]+: 379.2080. 
HPLC Data: 
Chiralcel OD-H; n-heptane : i-propanol 100:0; flow: 0.5 mL/min 
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tert-Butyldimethyl((trans-2-phenylcyclopentyl)oxy)silane (118a): 
 
 
colorless oil (56 %) 
1H-NMR (400 MHz, CDCl3) δ: 7.30 - 7.15 (m, 5 H), 4.02 (q, J=7.0 Hz, 1 H), 2.91 - 2.84 (m, 1 
H), 2.12 – 1.95 (m, 2 H), 1.88 - 1.61 (m, 4 H), 0.78 (s, 9 H), ‒0.19 (s, 3 H), ‒0.24 (s, 3 H). 
13C-NMR (101 MHz, CDCl3) δ: 144.0, 128.1, 127.7, 126.0, 81.6, 54.4, 34.8, 30.9, 25.8, 21.9, 
18.0, ‒5.0, ‒5.1. 
MS (70 eV, EI) m/z (%): 261 (2) [M-CH3]+, 221 (5), 220 (21), 219 (100), 143 (15), 115 (6), 91 
(9), 75 (66), 73 (10). 
IR (ATR) ν~  (cm-1): 2956 (m), 2928 (m), 2856 (w), 1472 (w), 1250 (m), 1114 (s), 1088 (m), 
1070 (m), 1006 (w), 888 (m), 860 (m), 834 (vs), 774 (vs), 754 (s), 698 (vs), 668 (m). 
HRMS (EI) for C16H25OSi (261.1675) [M-CH3]+: 261.1681. 
 
tert-Butyldimethyl((trans-2-(naphthalen-1-yl)cyclopentyl)oxy)silane (118b): 
 
 
colorless oil (80 %)  
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1H-NMR (400 MHz, CDCl3) δ: 8.30 (d, J=8.2 Hz, 1 H), 7.91 - 7.84 (m, 1 H), 7.74 (d, J=8.1 Hz, 
1 H), 7.57 - 7.38 (m, 4 H), 4.34 (q, J=6.1 Hz, 1 H), 3.91 - 3.84 (m, 1 H), 2.37 - 2.29 (m, 1 H), 
2.13 - 1.87 (m, 4 H), 1.84 - 1.76 (m, 1 H), 0.80 (s, 9 H), ‒0.17 (s, 3 H), ‒0.28 (s, 3 H).  
13C-NMR (101 MHz, CDCl3) δ: 140.6, 133.8, 132.7, 128.5, 126.4, 125.4, 125.4, 125.3, 124.4, 
122.7, 81.3, 49.0, 35.1, 31.3, 25.7, 22.5, 17.9, ‒5.0, ‒5.1. 
MS (70 eV, EI) m/z (%): 326 (1) [M+], 270 (22), 269 (100), 195 (8), 193 (18), 191 (9), 165 (12), 
141 (16), 115 (4), 75 (66), 73 (11), 57 (3). 
IR (ATR) ν~  (cm-1): 2954 (w), 2928 (w), 2856 (w), 1472 (w), 1250 (m), 1114 (m), 1094 (m), 
1078 (m), 1062 (m), 1032 (w), 1006 (w), 890 (m), 864 (m), 834 (s), 810 (m), 794 (m), 772 (vs), 
730 (w), 668 (m). 
HRMS (EI) for C21H30OSi (326.2066): 326.2053. 
 
tert-Butyldimethyl((trans-2-(4-(trifluoromethyl)phenyl)cyclopentyl)oxy)silane (118c): 
 
 
slightly yellow oil (65 %)  
1H NMR (300 MHz, CDCl3) δ: 7.55 (d, J=8.0 Hz, 2 H), 7.35 (d, J=8.0 Hz, 2 H), 4.03 (q, J=7.0 
Hz, 1 H), 2.96 (q, J=7.8 Hz, 1 H), 2.16 - 1.99 (m, 2 H), 1.94 - 1.62 (m, 4 H), 0.79 (s, 9 H), ‒0.15 
(s, 3 H), ‒0.23 (s, 3 H).  
13C-NMR (75 MHz, CDCl3) δ: 148.3 (d, J=1.1 Hz), 128.4 (q, J= 32.0 Hz), 127.9, 125.0 (q, J= 
3.9 Hz), 124.4 (q, J= 272.1 Hz), 81.4, 54.2, 34.8, 30.8, 25.7, 21.8, 18.0, ‒4.9, ‒5.1. 
19F-NMR (282 MHz, CDCl3) δ: ‒62.3 (s). 
MS (70 eV, EI) m/z (%): 344 (1) [M+], 329 (2), 288 (33), 287 (94), 194 (11), 193 (100), 159 (8), 
153 (4), 127 (7), 75 (46), 73 (13). 
IR (ATR) ν~  (cm-1): 2956 (w), 2930 (w), 2858 (w), 1620 (w), 1472 (w), 1324 (vs), 1252 (m), 
1164 (m), 1122 (vs), 1084 (m), 1068 (s), 1018 (m), 1006 (w), 890 (m), 860 (m), 832 (vs), 774 (s), 
668 (m), 604 (m). 
HRMS (EI) for C18H27OF3Si (344.1783): 344.2131. 
 
4-(trans-2-((tert-Butyldimethylsilyl)oxy)cyclopentyl)benzonitrile (118d): 
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slightly yellow oil (75 %)  
1H-NMR (300 MHz, CDCl3) δ: 7.58 (d, J=8.3 Hz, 2 H), 7.33 (d, J=8.0 Hz, 2 H), 4.00 (q, J=7.3 
Hz, 1 H), 3.00 - 2.87 (m, 1 H), 2.16 – 1.95 (m, 2 H), 1.93 - 1.61 (m, 4 H), 0.78 (s, 9 H), ‒0.16 (s, 
3 H), ‒0.25 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 149.8, 131.9, 128.4, 119.1, 109.8, 81.4, 54.5, 34.7, 30.5, 25.6, 
21.7 17.9, ‒4.9, ‒5.2. 
MS (70 eV, EI) m/z (%): 300 (1) [M-H] +, 245 (18), 244 (100), 168 (2), 142 (2), 116 (6), 101 (1), 
75 (38), 73 (10),59 (3), 57 (2), 41 (3). 
IR (ATR) ν~  (cm-1): 2956 (m), 2930 (w), 2856 (w), 2228 (w), 1608 (w), 1472 (w), 1250 (m), 
1114 (m), 1084 (m), 1006 (w), 890 (m), 860 (m), 832 (vs), 774 (vs), 668 (m). 
HRMS (EI) for C18H26ONSi (300.1789) [M-H]+: 300.1763. 
 
4-(trans-2-((tert-Butyldimethylsilyl)oxy)cyclopentyl)phenyl pivalate (118e): 
 
 
colorless oil (60 %)  
1H-NMR (300 MHz, CDCl3) δ: 7.23 (d, J=8.4 Hz, 2 H), 6.98 (d, J=8.6 Hz, 2 H), 4.02 (q, J=6.9 
Hz, 1 H), 2.94 - 2.85 (m, 1 H), 2.14 - 1.97 (m, 2 H), 1.88 - 1.65 (m, 4 H), 1.37 (s, 9 H), 0.81 (s, 9 
H), ‒0.15 (s, 3 H), ‒0.19 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 177.1, 149.4, 141.3, 128.4, 121.0, 81.5, 53.8, 39.0, 34.7, 30.9, 
27.2, 25.8, 21.8, 18.0, ‒4.9, ‒5.0. 
MS (70 eV, EI) m/z (%): 376 (1) [M+], 320 (20), 319 (100), 235 (17), 217 (5), 161 (6), 85 (5), 75 
(39), 73 (24), 57 (78), 41 (6). 
IR (ATR) ν~  (cm-1): 2956 (w), 2930 (w), 1754 (m), 1508 (m), 1472 (w), 1250 (m), 1200 (m), 
1166 (m), 1112 (vs), 1028 (w), 1018 (w), 890 (m), 862 (m), 834 (s), 814 (m), 774 (s), 668 (w). 
HRMS (EI) for C22H36O3Si (376.2434): 376.2389. 
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2-(trans-2-((tert-Butyldimethylsilyl)oxy)cyclopentyl)-4-fluorobenzonitrile (118f): 
 
 
colorless oil (68 %)  
1H-NMR (300 MHz, CDCl3) δ: 7.62 (dd, J1=8.5 Hz, J2=5.6 Hz, 1 H), 7.08 - 6.95 (m, 2 H), 4.14 
(q, J=7.3 Hz, 1 H), 3.42 - 3.31 (m, 1 H), 2.28 - 2.16 (m, 1 H), 2.08 - 1.66 (m, 5 H), 0.78 (s, 9 H), 
‒0.11 (s, 3 H), ‒0.23 (s, 3 H).  
13C-NMR (75 MHz, CDCl3) δ: 165.2 (d, J=255.0 Hz), 152.9 (d, J=8.3 Hz), 135.1 (d, J=9.6 Hz), 
117.7, 114.6 (d, J=19.4 Hz), 114.3 (d, J=19.6 Hz), 109.3 (d, J=3.1 Hz), 81.2, 52.8 (d, J=1.4 Hz), 
34.7, 30.9, 25.6, 21.7, 17.8, ‒4.9, ‒5.2. 
19F-NMR (282 MHz, CDCl3) δ: ‒103.4 - ‒103.6 (m). 
MS (70 eV, EI) m/z (%): 319 (1) [M+], 286 (3), 263 (18), 262 (100), 188 (12), 186 (2), 171 (1), 
134 (2), 101 (1), 75 (22), 73 (8), 57 (2). 
IR (ATR) ν~  (cm-1): 2956 (m), 2930 (w), 2884 (w), 2858 (w), 2226 (w), 1608 (m), 1582 (m), 
1490 (m), 1472 (m), 1464 (w), 1362 (w), 1250 (m), 1234 (m), 1186 (w), 1156 (w), 1118 (s), 1096 
(m), 1060 (w), 1006 (w), 984 (w), 940 (w), 870 (s), 834 (vs), 774 (vs), 690 (m), 668 (m). 
HRMS (EI) for C18H26ONFSi (319.1768): 319.1676. 
 
Ethyl 2-(trans-2-((tert-butyldimethylsilyl)oxy)cyclopentyl)-3-fluorobenzoate (118g): 
 
 
colorless oil (69 %)  
1H-NMR (600 MHz, CDCl3) δ: 7.43 (d, J=7.1 Hz, 1 H), 7.20 (td, J1=8.0 Hz, J2=5.2 Hz, 1 H), 
7.15 - 7.10 (m, 1 H), 4.49 - 4.44 (m, 1 H), 4.41 - 4.30 (m, 2 H), 3.61 - 3.54 (m, 1 H), 2.19 - 2.10 
(m, 1 H), 2.04 (dq, J1=12.8 Hz, J2=6.5 Hz, 1 H), 1.92 - 1.79 (m, 3 H), 1.67 - 1.61 (m, 1 H), 1.38 
(t, J=7.1 Hz, 3 H), 0.74 (s, 9 H), ‒0.20 (s, 3 H), ‒0.31 (s, 3 H). 
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13C-NMR (75 MHz, CDCl3) δ: 167.9 (d, J=4.0 Hz), 162.0 (d, J=246.5 Hz), 135.2 (d, J=6.0 Hz), 
131.6 (d, J=14.0 Hz), 127.0 (d, J=9.4Hz), 124.9 (d, J=3.1 Hz), 118.5 (d, J=23.3 Hz), 79.0 (d, 
J=4.8 Hz), 61.2, 48.5 (d, J=2.0 Hz), 36.0, 30.3 (d, J=4.0 Hz), 25.7, 22.9, 17.9, 14.2, ‒5.2, ‒5.3. 
19F-NMR (282 MHz, CDCl3) δ: ‒112.0 (d, J=9.5 Hz). 
MS (70 eV, EI) m/z (%): 365 (1) [M-H]+, 310 (11), 309 (49), 264 (18), 263 (100), 235 (9), 221 
(6), 189 (21), 171 (23), 159 (5), 133 (5), 75 (11), 73 (9). 
IR (ATR) ν~  (cm-1): 2956 (m), 2930 (m), 2856 (w), 1724 (s), 1472 (w), 1454 (m), 1284 (s), 1250 
(s), 1182 (m), 1128 (s), 1112 (s), 1084 (m), 1062 (m), 1026 (m), 1006 (m), 936 (m), 892 (m), 866 
(m), 834 (vs), 814 (m), 774 (vs), 758 (vs), 668 (m). 
HRMS (EI) for C20H30O3FSi (365.1953) [M-H]+: 365.1941. 
 
((trans-2-(3,5-Bis(trifluoromethyl)phenyl)cyclopentyl)oxy)(tert-butyl)dimethylsilane (118h): 
 
 
colorless oil (68 %)  
1H-NMR (300 MHz, CDCl3) δ: 7.76 - 7.67 (m, 3 H), 3.99 (q, J=7.6 Hz, 1 H), 3.07 - 2.96 (m, 1 
H), 2.18 - 2.03 (m, 2 H), 1.94 - 1.78 (m, 3 H), 1.77 - 1.66 (m, 1 H), 0.78 (s, 9 H), ‒0.13 (s, 3 H), 
‒0.26 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 146.4, 131.4 (q, J=32.8 Hz), 127.8, 123.5 (q, J=272.6 Hz), 120.1 
(sept, J=3.9 Hz), 81.2, 53.8, 34.5, 29.8, 25.6, 21.3, 17.8, ‒4.8, ‒5.4. 
19F-NMR (282 MHz, CDCl3) δ: ‒62.9 (s). 
MS (70 eV, EI) m/z (%): 397 (3) [M-CH3]+, 356 (17), 355 (100), 261 (7), 259 (5), 235 (7), 209 
(3), 133 (4), 77 (6), 75 (11), 73 (11), 57 (5). 
IR (ATR) ν~  (cm-1): 2958 (w), 2932 (w), 1384 (m), 1276 (s), 1260 (m), 1170 (s), 1130 (vs), 890 
(m), 866 (m), 836 (s), 774 (s), 706 (w), 682 (m), 670 (w). 
HRMS (EI) for C18H23OF6Si (397.1422) [M-CH3]+: 397.1422. 
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5-(trans-2-((tert-Butyldimethylsilyl)oxy)cyclopentyl)-2-chloropyridine (118i): 
 
 
slightly yellow oil (48 %) 
1H-NMR (300 MHz, CDCl3) δ: 8.26 (d, J=2.4 Hz, 1 H), 7.52 (dd, J1=8.2 Hz, J2=2.5 Hz, 1 H), 
7.25 (d, J=8.2 Hz, 1 H), 3.96 (q, J=7.1 Hz, 1 H), 2.93 - 2.82 (m, 1 H), 2.19 - 1.97 (m, 3 H), 1.83 - 
1.66 (m, 3 H), 0.79 (s, 9 H), ‒0.12 (s, 3 H), ‒0.21 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 149.2, 149.2, 138.1, 137.6, 123.7, 81.1, 52.0, 34.5, 30.1, 25.7, 
21.5, 17.9, ‒4.8, ‒5.0. 
MS (70 eV, EI) m/z (%): 296 (3) [M-CH3]+, 256 (39), 254 (97), 180 (11), 144 (15), 117 (7), 86 
(36), 84 (54), 75 (100), 59 (15), 57 (10), 47 (13), 42 (12). 
IR (ATR) ν~  (cm-1): 2954 (m), 2930 (m), 2856 (w), 1470 (m), 1456 (m), 1250 (m), 1106 (s), 
1086 (m), 1024 (m), 1006 (w), 890 (m), 860 (m), 832 (vs), 774 (vs), 742 (m), 668 (m). 
HRMS (EI) for C15H23ONClSi (296.1237) [M-CH3]+: 296.1234. 
 
3-(trans-2-((tert-Butyldimethylsilyl)oxy)cyclopentyl)quinoline (118j): 
 
 
slightly yellow oil (60 %) 
1H-NMR (300 MHz, CDCl3) δ: 8.85 (d, J=2.2 Hz, 1 H), 8.09 (d, J=8.3 Hz, 1 H), 7.95 (d, J=1.8 
Hz, 1 H), 7.77 (d, J=8.1 Hz, 1 H), 7.65 (td, J1=7.7 Hz, J2=1.2 Hz, 1 H), 7.52 (t, J=7.2 Hz, 1 H), 
4.14 (q, J=7.1 Hz, 1 H), 3.16 - 3.05 (m, 1 H), 2.23 - 2.14 (m, 1 H), 2.10 - 2.01 (m, 1 H), 1.96 - 
1.68 (m, 4 H), 0.79 (s, 9 H), ‒0.15 (s, 3 H), ‒0.25 (s, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 152.5, 147.1, 136.5, 133.2, 129.1, 128.5, 128.1, 127.3, 126.4, 
81.1, 52.9, 34.7, 30.3, 25.7, 21.8, 17.9, ‒4.8, ‒5.0. 
MS (70 eV, EI) m/z (%): 327 (1) [M+], 312 (3), 271 (18), 270 (100), 196 (62), 194 (6), 167 (6), 
142 (7), 115 (3), 75 (25), 73 (12). 
IR (ATR) ν~  (cm-1): 2954 (m), 2928 (m), 2856 (w), 1494 (w), 1472 (w), 1250 (m), 1112 (s), 
1084 (m), 1006 (w), 896 (m), 870 (s), 834 (vs), 814 (m), 774 (vs), 748 (vs), 668 (m), 618 (w). 
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HRMS (EI) for C20H29ONSi (327.2018): 327.2006. 
 
6.4 TBS-deprotection for X-ray analysis 
A dry and 4-(trans-2-((tert-butyldimethylsilyl)oxy)cyclopentyl)- benzonitrile (118d; 1.66 mmol; 
0.50 g) was dissolved in THF (4 ml) and Bu4NF·3 H2O (4.98 mmol; 1.57 g) was added. The 
reaction mixture was stirred at room temperature overnight. NH4Cl sat. aq. solution (20 ml) and 
Et2O (20 ml) were added, the phases were separated and the aqueous phase was extracted with 
Et2O (3 x 20 mL). The combined organic layers were dried over Na2SO4. The solvents were 
evaporated and the residue was subjected to column chromatography (SiO2; n-pentane/Et2O 1:1) 
yielding 0.29 g (93%) of the title compound as a white solid. 
 
4-(trans-2-Hydroxycyclopentyl)benzonitrile 
 
 
m.p.: 72.7 – 73.9 °C. 
1H-NMR (300 MHz, CDCl3) δ: 7.60 (d, J=8.25 Hz, 2 H), 7.38 (d, J=8.25 Hz, 2 H), 4.18 (q, 
J=7.03 Hz, 1 H), 3.06 – 2.82 (m, 1 H), 2.34 - 2.00 (m, 2 H), 1.97 - 1.63 (m, 4 H). 
13C-NMR (75 MHz, CDCl3) δ: 149.3, 132.3, 128.2, 118.9, 110.1, 80.2, 54.2, 34.5, 31.7, 21.8. 
MS (70 eV, EI) m/z (%): 187 (66) [M+], 169 (65), 168 (44), 154 (100), 143 (46), 131 (34), 129 
(47), 116 (54), 105 (15), 89 (16), 57 (25). 
IR (ATR) ν~  (cm-1): 3462 (m), 2956 (m), 2870 (w), 2234 (m), 1606 (m), 1504 (w), 1328 (m), 
1300 (m), 1176 (w), 1090 (s), 1072 (m), 834 (vs). 
HRMS (EI) for C12H13ON (187.0997): 187.0991. 
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7. Diastereoselective Pd-Catalyzed Cross-Coupling Reactions of 
Piperidinylzinc Reagents 
7.1 Preparation of starting materials 
 
tert-Butyl 4-((triisopropylsilyl)oxy)piperidine-1-carboxylate 
 
 
To a solution of tert-butyl 4-hydroxypiperidine-1-carboxylate (100 mmol; 20.1 g) and imidazole 
(250 mmol; 17.0 g) in DMF (250 mL) was slowly added TIPSCl (120 mmol; 23.1 g; 25.7 mL) 
via syringe. The reaction mixture was stirred for further 6 h at room temperature. NaHCO3 sat. 
aq. solution (500 mL) was added, phases were separated and the aqueous phase was extracted 
with Et2O (4 x 300 mL). The combined organic layers were washed with brine (300 mL) and 
dried over Na2SO4. The solvents were evaporated and the residue was subjected to column 
chromatography (SiO2; n-pentane/Et2O 15:1) yielding 34.1 g (95%) of the title compound. 
 
1H-NMR (400 MHz, C6D6) δ: 3.68 (ddd, J1=10.2 Hz, J2=6.8 Hz, J3=3.3 Hz, 4 H), 3.27 (br. s., 1 
H), 1.57 - 1.50 (m, 2 H), 1.48 (s, 9 H), 1.45 - 1.37 (m, 2 H), 1.12 - 1.01 (m, 18 H), 0.99 - 0.92 (m, 
3 H). 
13C-NMR (101 MHz, C6D6) δ: 155.1, 79.2, 67.9, 35.1, 28.9, 18.6, 18.4, 13.2, 12.9, 12.6. 
MS (70 eV) m/z (%): 259 (15), 258 (77), 215 (18), 214 (100), 131 (13), 56 (12). 
IR (ATR) ν~  (cm-1): 2944 (m), 2866 (m), 1698 (vs), 1464 (m), 1420 (s), 1366 (m), 1274 (m), 
1230 (s), 1172 (s), 1110 (s), 1086 (s), 1068 (s), 1044 (vs), 1012 (m), 994 (m), 882 (s), 870 (s), 
850 (m), 802 (m), 678 (s), 658 (s), 632 (m). 
HRMS (ESI) for C19H39NO3SiNa+ (380.2591) [M+Na+]: 380.2592. 
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tert-Butyl 2-methyl-4-((triisopropylsilyl)oxy)piperidine-1-carboxylate 
 
 
A solution of t-butyl 4-((triisopropylsilyl)oxy)piperidine-1-carboxylate (17 mmol; 6.08 g) and 
TMEDA (17 mmol; 1.97 g; 2.53 mL) in anhydrous Et2O (60 mL) was cooled to ‒78 °C. sBuLi 
(1.07 M in hexanes) (20.4 mmol; 19.07 mL) was slowly added via syringe. The reaction mixture 
was stirred for 4 h at this temperature before MgCl2 (0.5 M in THF) (8.5 mmol; 17 mL) was 
added. After the addition was complete, CuCN·2 LiCl (1 M in THF) (17 mmol; 17 mL) was 
dropped to the reaction mixture. The reaction mixture was stirred for 15 min at -78 °C before 
methyl iodide (17 mmol; 2.41 g; 1.06 mL) was added. The reaction mixture was kept for 4 h at -
78 °C and was then allowed to warm to room temperature. NH4Cl sat. aq. solution (100 mL) was 
added, the phases were separated and the aqueous phase was extracted with Et2O (4 x 30 mL). 
The combined organic layers were washed with brine (50 mL) and dried over Na2SO4. The 
solvents were evaporated and the residue was subjected to column chromatography (SiO2; 
i-hexane/Et2O 10:1) yielding 4.87 g (77%) of the title compound as a colorless oil. 
 
1H-NMR (400 MHz, C6D6) δ: 4.48 (br. s., 1 H), 4.02 (br. s., 1 H), 3.91 - 3.75 (m, 1 H), 3.39 - 
3.23 (m, 1 H), 1.53 - 1.35 (m, 13 H), 1.23 - 0.69 (m, 24 H). 
13C-NMR (75 MHz, C6D6) δ: 155.2, 79.1, 66.1, 46.6, 37.4, 34.2, 33.9, 29.0, 19.7, 18.7, 18.4, 
13.2, 12.8. 
MS (70 eV) m/z (%): 371 (1) [M+], 273 (16), 272 (79), 230 (13), 229 (19), 228 (100), 184 (12), 
142 (16), 131 (42). 
IR (ATR) ν~  (cm-1): 2942 (m), 2892 (w), 2866 (m), 1694 (s), 1464 (m), 1412 (m), 1390 (m), 
1378 (m), 1364 (m), 1342 (m), 1290 (w), 1272 (w), 1250 (w), 1212 (w), 1174 (s), 1134 (m), 1112 
(m), 1090 (s), 1072 (s), 1054 (vs), 1028 (m), 1004 (m), 934 (w), 918 (w), 882 (s), 864 (m), 800 
(w), 768 (w), 674 (s), 656 (s). 
HRMS (ESI) for C20H42NO3Si+ (372.2934) [M+H+]: 372.2927. 
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7.2 Cross-coupling of (1-(tert-butoxycarbonyl)-4-methylpiperidin-2-yl)zinc chloride 
(119a) 
A dry and Ar-flushed 10 mL Schlenk-tube equipped with a stirring bar was charged with a 
solution of t-butyl 4-methylpiperidine-1-carboxylate (120a; 1 mmol; 0.20 g) and TMEDA (1 
mmol; 0.12 g; 0.45 mL) in anhydrous Et2O (2 mL). It was cooled to ‒78 °C and sBuLi (1.14 M in 
hexanes) (1.2 mmol; 1.05 mL) was slowly added via syringe. The reaction mixture was stirred for 
4 h at this temperature before ZnCl2 (1.0 M in THF) (1.2 mmol; 1.2 mL) was added. The reaction 
mixture was stirred for 15 min at ‒78 °C and was then warmed to room temperature. Et2O was 
removed in vacuo (8 min; 1 mbar). Meanwhile, a solution of the respective aryl iodide (0.7 
mmol), Pd(dba)2 (11.5 mg; 0.02 mmol) and SPhos (8.2 mg; 0.02 mmol) was prepared and stirred 
for 10 min. The piperidinylzinc reagent was added to this mixture at room temperature. The 
reaction mixture was then heated to 55 °C for 15 h. NH4Cl sat. aq. solution (20 mL) was added, 
the phases were separated and the aqueous phase was extracted with Et2O (4 x 10 mL). The 
combined organic layers were washed with brine (10 mL) and dried over Na2SO4. The solvents 
were evaporated and the residue was subjected to column chromatography yielding the respective 
title compound. 
 
cis-tert-Butyl 2-(4-methoxyphenyl)-4-methylpiperidine-1-carboxylate (121a) 
 
 
colorless oil (78 %) 
1H-NMR (400 MHz, C6D6) δ: 7.10 (d, J=8.4 Hz, 2 H), 6.81 (d, J=8.6 Hz, 2 H), 4.91 (dd, J1=9.4 
Hz, J2=6.4 Hz, 1 H), 4.11 (ddd, J1=13.6 Hz, J2=7.0 Hz, J3=2.9 Hz, 1 H), 3.33 (s, 3 H), 3.14 (ddd, 
J1=13.7 Hz, J2=10.7 Hz, J3=5.6 Hz, 1 H), 1.83 - 1.73 (m, 1 H), 1.66 (ddd, J1=13.3 Hz, J2=6.2 Hz, 
J3=3.6 Hz, 1 H), 1.54 - 1.44 (m, 1 H), 1.38 (s, 9 H), 1.36 - 1.27 (m, 1 H), 0.93 - 0.84 (m, 1 H), 
0.67 (d, J=6.8 Hz, 3 H).  
13C-NMR (101 MHz, C6D6) δ: 159.1, 156.1, 137.5, 127.2, 114.3, 79.2, 56.7, 55.1, 38.8, 38.6, 
31.7, 28.8, 27.0, 21.8. 
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MS (70 eV, EI) m/z (%): 305 (2) [M+], 250 (10), 249 (67), 248 (23), 205 (14), 204 (100), 162 
(10), 134 (10), 121 (15), 96 (14), 57 (28). 
IR (ATR) ν~  (cm-1): 2952 (w), 2929 (w), 1686 (vs), 1612(w), 1522 (s), 1477 (w), 1455 (m), 
1403 (s), 1364 (s), 1328 (m), 1292 (m), 1279 (m), 1243 (vs), 1173 (s), 1148 (vs), 1126 (m), 1112 
(m), 1090 (m), 1066 (m), 1035(s), 1000 (w),864 (m), 827 (s), 775 (m), 758 (m). 
HRMS (EI) for C18H27NO3 (305.1991): 305.1977. 
 
cis-tert-Butyl 4-methyl-2-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate (121b) 
 
 
colorless oil (81 %) 
1H-NMR (400 MHz, C6D6) δ: 7.39 (d, J=8.0 Hz, 2 H), 7.00 (d, J=8.2 Hz, 2 H), 4.68 (dd, J1=9.8 
Hz, J2=6.3 Hz, 1 H), 3.90 (ddd, J1=13.7, J2=6.6 Hz, J3=3.9 Hz, 1 H), 3.08 (ddd, J1=13.9 Hz, 
J2=10.0 Hz, J3=5.5 Hz, 1 H), 1.69 (dddd, J1=13.3 Hz, J2=10.0 Hz, J3=6.9 Hz, J4=6.7 Hz, 1 H), 
1.55 - 1.49 (m, 1 H), 1.42 - 1.33 (m, 1 H), 1.29 (s, 9 H), 1.05 (dt, J1=13.5 Hz, J2=10.4 Hz, 1 H), 
0.88 - 0.80 (m, 1 H), 0.62 (d, J=6.8 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 155.9, 150.0 (d, J=1.0 Hz), 129.1 (q, J=32.1 Hz), 126.4, 125.8 (q, 
J=3.8 Hz), 125.5 (q, J=271.7 Hz), 79.6, 57.3, 39.5, 38.7, 31.6, 28.6, 27.2, 21.8. 
19F-NMR (376 MHz, C6D6) δ: ‒61.98 (s). 
MS (70 eV, EI) m/z (%): 343 (1) [M+], 288 (19), 287 (73), 270 (16), 268 (11), 243 (15), 242 (64), 
228 (12), 200 (23), 199 (10), 187 (12), 186 (15), 172 (21), 159 (30), 142 (28), 98 (24), 97 (14), 57 
(100), 55 (10), 41 (22). 
IR (ATR) ν~  (cm-1): 2929 (w), 2871 (w), 1688 (s), 1619 (w), 1478 (w), 1455 (w), 1415 (m), 
1402 (m), 1392 (m), 1378 (w), 1365 (m), 1349 (w), 1323 (vs), 1290 (w), 1278 (w), 1243 (m), 
1223 (w), 1150 (s), 1120 (vs), 1111 (vs), 1090 (m), 1066 (vs), 1016 (m), 1000 (w), 971 (w), 924 
(w), 863 (w), 834 (m), 815 (w), 775 (m), 759 (w), 658 (w), 605 (w). 
HRMS (EI) for C18H24F3NO2 (343.1759): 343.1756. 
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cis-tert-Butyl 2-(3-chlorophenyl)-4-methylpiperidine-1-carboxylate (121c) 
 
 
colorless crystals (76 %) 
m.p.: 47.3 – 49.2 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.24 (s, 1 H), 7.05 (d, J=7.04 Hz, 1 H), 6.95 - 6.81 (m, 2 H), 4.64 
(dd, J1=10.1 Hz, , J2=6.2 Hz, 1 H), 3.91 (ddd, , J1=13.6 Hz, , J2=6.7 Hz, , J3=3.5 Hz, 1 H), 3.09 - 
3.00 (m, 1 H), 1.73 - 1.63 (m, 1 H), 1.48 - 1.44 (m, 1 H), 1.40 - 1.33 (m, 1 H), 1.31 (s, 9 H), 1.10 
- 1.00 (m, 1 H), 0.84 - 0.75 (m, 1 H), 0.61 (d, J=6.65 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 155.9, 148.2, 134.9, 130.2, 127.0, 126.5, 124.1, 79.6, 57.3, 39.4, 
38.7, 31.6, 28.7, 27.1, 21.8. 
MS (70 eV, EI) m/z (%): 309 (1) [M+], 255 (26), 254 (15), 253 (79), 236 (15), 210 (28), 209 (16), 
208 (87), 194 (12), 192 (10), 166 (19), 153 (10), 152 (11), 142 (27), 138 (14), 125 (21), 98 (37), 
97 (18), 57 (100), 41 (21). 
IR (ATR) ν~  (cm-1): 2916 (s), 2850 (m), 1682 (vs), 1476 (m), 1398 (s), 1362 (s), 1338 (m), 1284 
(s), 1244 (s), 1174 (s), 1148 (vs), 1122 (s), 1098 (s), 1088 (s), 1078 (s), 1034 (m), 1004 (m), 906 
(m), 864 (s), 852 (s), 790 (s), 778 (vs), 756 (s), 710 (s), 694 (vs), 676 (m). 
HRMS (EI) for C17H24ClNO2 (309.1496): 309.1487. 
 
cis-tert-Butyl 2-(3-cyanophenyl)-4-methylpiperidine-1-carboxylate (121d) 
 
N
Me
Boc
CN
 
colorless crystals (64 %) 
m.p.: 77.8 – 79.3 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.22 (s, 1 H), 7.08 - 6.91 (m, 2 H), 6.76 (t, J=7.7 Hz, 1 H), 4.49 
(dd, J1=10.4 Hz, J2=5.9 Hz, 1 H), 3.79 (ddd, J1=13.7 Hz, J2=6.6 Hz, J3=3.9 Hz, 1 H), 2.98 (ddd, 
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J1=13.7 Hz, J2=9.8 Hz, J3=5.6 Hz, 1 H), 1.71 - 1.59 (m, 1 H), 1.40 - 1.29 (m, 2 H), 1.29 - 1.15 
(m, 9 H), 0.90 (dt, J1=13.1 Hz, J2=10.6 Hz, 1 H), 0.83 - 0.74 (m, 1 H), 0.60 (d, J=6.6 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 155.1, 146.4, 129.6, 129.1, 128.9, 128.6, 118.6, 112.6, 79.0, 56.5, 
39.0, 37.9, 30.8, 27.8, 26.5, 21.1. 
MS (70 eV, EI) m/z (%): 300 (1) [M+], 245 (16), 244 (37), 227 (11), 200 (32), 199 (100), 185 
(17), 171 (12), 157 (24), 144 (10), 143 (15), 142 (10), 129 (16), 116 (14), 98 (20), 57 (52), 41 
(17). 
IR (ATR) ν~  (cm-1): 2952 (w), 2920 (w), 2230 (w), 1682 (vs), 1482 (m), 1440 (w), 1404 (s), 
1374 (m), 1364 (m), 1338 (w), 1328 (w), 1288 (m), 1248 (m), 1182 (m), 1150 (vs), 1122 (m), 
1096 (m), 1010 (m), 924 (w), 874 (m), 862 (w), 798 (s), 778 (m), 758 (w), 734 (w), 694 (s), 636 
(w). 
HRMS (EI) for C18H24N2O2 (300.1838): 300.1860. 
 
cis-tert-Butyl 2-(4-(ethoxycarbonyl)phenyl)-4-methylpiperidine-1-carboxylate (121e) 
 
 
white solid (67 %) 
m.p.: 108.8 – 110.3 °C.  
1H-NMR (400 MHz, C6D6) δ: 8.20 (d, J=8.4 Hz, 2 H), 7.12 (d, J=8.4 Hz, 2 H), 4.74 (dd, J1=9.7 
Hz, J2=6.2 Hz, 1 H), 4.15 (q, J=7.1 Hz, 2 H), 3.96 (ddd, J1=13.7 Hz, J2=6.6 Hz, J3=3.7 Hz, 1 H), 
3.12 (ddd, J1=13.7, J2=10.2 Hz, J3=5.4 Hz, 1 H), 1.70 (dddd, J1=13.3 Hz, J2=10.2 Hz, J3=7.1 Hz, 
J4=6.8 Hz, 1 H), 1.54 (ddd, J1=13.4 Hz, J2=5.9 Hz, J3=3.9 Hz, 1 H), 1.43 - 1.36 (m, 1 H), 1.29 (s, 
9 H), 1.13 (dt, J1=13.4 Hz, J2=10.2 Hz, 1 H), 1.03 (t, J=7.1 Hz, 3 H), 0.89 - 0.80 (m, 1 H), 0.61 
(d, J=7.1 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 166.5, 156.0, 152.1, 130.4, 129.8, 126.0, 79.6, 61.1, 57.6, 39.4, 
38.7, 31.6, 28.7, 27.2, 21.8, 14.6. 
MS (70 eV, EI) m/z (%): 347 (1) [M+], 292 (15), 291 (81), 262 (16), 247 (11), 246 (55), 219 (15), 
218 (100), 176 (10), 174 (11), 142 (14), 98 (20), 97 (17), 57 (42), 43 (10). 
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IR (ATR) ν~  (cm-1): 2928 (w), 1715 (s), 1715 (s), 1689 (vs), 1610 (w), 1476 (w), 1455 (w), 1401 
(m), 1392 (m), 1364 (s), 1350 (w), 1326 (w), 1307 (m), 1271 (vs), 1245 (s), 1222 (m), 1173 (s), 
1149 (s), 1121 (s), 1101 (vs), 1066 (m), 1019 (m), 852 (m), 768 (m), 757 (m), 740 (w), 705 (m).  
HRMS (EI) for C20H29NO4 (347.2097): 347.2099. 
 
cis-tert-Butyl 4-methyl-2-(pyridin-4-yl)piperidine-1-carboxylate (121f) 
 
N
Me
Boc N  
slightly yellow oil (73 %) 
1H-NMR (300 MHz, C6D6) δ: 8.56 (dd, J1=4.6 Hz, J2=1.4 Hz, 2 H), 6.79 (d, J=5.6 Hz, 2 H), 
4.62 (dd, J1=9.3 Hz, J2=6.4 Hz, 1 H), 3.89 (ddd, J1=13.6 Hz, J2=6.6 Hz, J3=3.8 Hz, 1 H), 3.03 
(ddd, J1=13.8 Hz, J2=10.0 Hz, J3=5.3 Hz, 1 H), 1.72 - 1.59 (m, 1 H), 1.54 - 1.38 (m, 2 H), 1.36 - 
1.18 (m, 9 H), 1.09 - 0.97 (m, 1 H), 0.81 (dddd, J1=16.9 Hz, J2=5.2 Hz, J3=4.1 Hz, J4=3.9 Hz, 1 
H), 0.58 (d, J=6.9 Hz, 3 H). 
13C-NMR (75 MHz, C6D6) δ: 155.8, 153.9, 150.7, 121.0, 79.8, 56.5, 39.3, 38.0, 31.5, 28.6, 27.1, 
21.6. 
MS (70 eV, EI) m/z (%): 276 (10) [M+], 221 (40), 220 (78), 202 (17), 176 (55), 175 (73), 142 
(35), 133 (30), 120 (17), 119 (17), 106 (16), 98 (97), 57 (100), 56 (15), 55 (19), 41 (23), 41 (23). 
IR (ATR) ν~  (cm-1): 2954 (w), 2928 (w), 1688 (vs), 1598 (m), 1478 (w), 1456 (w), 1404 (s), 
1364 (s), 1338 (m), 1316 (m), 1280 (m), 1246 (s), 1228 (m), 1174 (s), 1150 (vs), 1128 (m), 1092 
(m), 1064 (m), 1018 (m), 994 (m), 972 (w), 862 (m), 818 (m), 800 (m), 776 (m), 760 (m), 634 
(m). 
HRMS (EI) for C16H24N2O2 (276.1838): 276.1830. 
 
7.3 Cross-coupling of (1-(tert-butoxycarbonyl)-4-phenylpiperidin-2-yl)zinc chloride 
(119b) 
A dry and Ar-flushed 10 mL Schlenk-tube equipped with a stirring bar was charged with a 
solution of tert-butyl 4-phenylpiperidine-1-carboxylate (120b; 1 mmol; 0.26 g) and TMEDA (1 
mmol; 0.12 g; 0.45 mL) in anhydrous Et2O (2 mL). It was cooled to -78 °C and sBuLi (1.14 M in 
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hexanes) (1.2 mmol; 1.05 mL) was slowly added via syringe. The reaction mixture was stirred for 
4 h at this temperature before ZnCl2 (1.0 M in THF) (1.2 mmol; 1.2 mL) was added. The reaction 
mixture was stirred for 15 min at ‒78 °C and was then allowed to warm to room temperature. 
Et2O was removed in vacuo (8 min; 1 mbar). Meanwhile, a solution of the respective aryl iodide 
(0.7 mmol), Pd(dba)2 (28.8 mg; 0.05 mmol) and RuPhos (23.3 mg; 0.05 mmol) was prepared and 
stirred for 10 min. The piperidinylzinc reagent was added to this mixture at room temperature. 
The reaction mixture was then heated to 55 °C for 15 h. NH4Cl sat. aq. solution (20 mL) was 
added, the phases were separated and the aqueous phase was extracted with Et2O (4 x 10 mL). 
The combined organic layers were washed with brine (10 mL) and dried over Na2SO4. The 
solvents were evaporated and the residue was subjected to column chromatography yielding the 
respective title compound. 
 
cis-tert-Butyl 4-phenyl-2-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate (121g) 
 
 
colorless oil (64 %) 
1H-NMR (300 MHz, C6D6) δ: 7.40 (d, J=8.3 Hz, 2 H), 7.13 (d, J=8.0 Hz, 2 H), 7.10 - 7.04 (m, 1 
H), 6.98 (d, J=8.0 Hz, 2 H), 6.90 (d, J=7.2 Hz, 2 H), 4.65 (dd, J1=11.6 Hz, J2=6.1 Hz, 1 H), 3.99 
(ddd, J1=13.8 Hz, J2=7.2 Hz, J3=3.9 Hz, 1 H), 3.23 (ddd, J1=13.9 Hz, J2=9.5 Hz, J3=6.2 Hz, 1 H), 
2.58 - 2.46 (m, 1 H), 2.06 – 1.92 (m, 1 H), 1.78 - 1.69 (m, 1 H), 1.55 - 1.45 (m, 1 H), 1.43 - 1.33 
(m, 1 H), 1.29 (s, 9 H). 
13C-NMR (75 MHz, C6D6) δ: 155.9, 149.9 (d, J=1.1 Hz), 146.4, 129.3 (q, J=32.1 Hz), 129.2, 
127.4, 127.0, 126.3, 125.9 (q, J=3.9 Hz), 125.5 (q, J=271.8 Hz), 79.8, 58.4, 40.3, 39.0, 38.6, 31.8, 
28.6. 
19F-NMR (282 MHz, C6D6) δ: ‒61.30 (s) (minor), ‒61.94 (s) (major). 
MS (70 eV, EI) m/z (%): 405 (1) [M+], 350 (24), 349 (100), 304 (21), 288 (10), 200 (13), 187 
(12), 186 (14), 172 (10), 159 (11), 118 (32), 104 (15), 90 (19); 59 (85); 41 (11). 
 
C. Experimental Section  212 
 
IR (ATR) ν~  (cm-1): 2976 (w), 2932 (w), 1688 (s), 1620 (w), 1478 (w), 1454 (w), 1402 (m), 
1366 (m), 1322 (vs), 1292 (m), 1248 (m), 1162 (s), 1120 (vs), 1110 (vs), 1066 (s), 1038 (w), 
1016 (m), 950 (w), 878 (w), 860 (w), 836 (m), 818 (w), 760 (m), 700 (s), 662 (w). 
HRMS (EI) for C23H26F3NO2 (405.1916): 405.1922. 
 
cis-tert-Butyl 2-(4-cyanophenyl)-4-phenylpiperidine-1-carboxylate (121h) 
 
 
colorless crystals (79 %) 
m.p.: 137.0-138.3 °C 
1H-NMR (400 MHz, C6D6) δ: 7.19 – 7.15 (m, 2 H), 7.15 - 7.06 (m, 3 H), 6.89 (d, J=7.0 Hz, 2 
H), 6.79 (d, J=8.2 Hz, 2 H), 4.52 (dd, J1=11.7 Hz, J2=6.0 Hz, 1 H), 3.91 (ddd, J1=13.7 Hz, 
J2=7.07 Hz, J3=4.0 Hz, 1 H), 3.20 (ddd, J1=13.8 Hz, J1= 9.3 Hz, J1=6.1 Hz, 1 H), 2.52 - 2.42 (m, 
1 H), 2.00 - 1.90 (m, 1 H), 1.67 - 1.60 (m, 1 H), 1.45 - 1.32 (m, 2 H), 1.27 (s, 9 H). 
13C-NMR (101 MHz, C6D6) δ: 155.8, 150.7, 146.3, 132.6, 129.2, 127.4, 127.1, 126.4, 119.3, 
111.3, 79.9, 58.6, 40.5, 39.0, 38.4, 31.7, 28.6. 
IR (ATR) ν~  (cm-1): 2940 (w), 2922 (w), 2842 (w), 2222 (w), 1698 (s), 1604 (w), 1446 (w), 
1390 (m), 1366 (m), 1328 (m), 1280 (m), 1254 (s), 1166 (s), 1150 (vs), 1094 (w), 1024 (w), 980 
(w), 858 (w), 840 (m), 782 (m), 764 (m), 756 (m), 708 (m). 
MS (70 eV, EI) m/z (%): 363 (1) [M+H+], 306 (73), 262 (35), 261 (62), 184 (19), 157 (40), 144 
(27), 143 (45), 129 (28), 118 (36), 116 (18), 104 (37), 91 (25), 57 (100), 41 (26). 
HRMS (EI) for C23H27N2O2+ (363.2067) [M+H+]: 363.2060. 
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cis-tert-Butyl 2-(4-(methoxycarbonyl)phenyl)-4-phenylpiperidine-1-carboxylate (121i) 
 
 
colorless oil (67 %) 
1H-NMR (400 MHz, C6D6) δ: 8.13 (d, J=8.4 Hz, 2 H), 7.11 - 6.98 (m, 5 H), 6.84 (d, J=7.2 Hz, 2 
H), 4.63 (dd, J1=11.7 Hz, J2=6.0 Hz, 1 H), 4.00 (ddd, J1=13.7 Hz, J2= 7.4 Hz, J3= 3.6 Hz, 1 H), 
3.47 (s, 3 H), 3.21 (ddd, J1=13.8 Hz, J2= 9.6 Hz, J3=6.2 Hz, 1 H), 2.52 - 2.42 (m, 1 H), 2.04 - 
1.85 (m, 1 H), 1.74 - 1.67 (m, 1 H), 1.55 - 1.43 (m, 1 H), 1.36 - 1.27 (m, 1 H), 1.24 (s, 9 H). 
13C-NMR (101 MHz, C6D6) δ: 167.0, 155.9, 152.2, 146.6, 130.5, 129.6, 129.1, 127.5, 126.9, 
126.0, 79.8, 58.8, 52.9, 40.2, 39.0, 38.5, 31.8, 28.7. 
MS (70 eV, EI) m/z (%): 395 (1) [M+], 340 (21), 339 (100), 295 (30), 294 (48), 280 (41), 190 
(19), 177 (17), 176 (27), 162 (29), 118 (23), 104 (25), 91 (21); 57 (45); 41 (19). 
IR (ATR) ν~  (cm-1): 2950 (w), 1720 (s), 1690 (vs), 1610 (w), 1434 (m), 1402 (s), 1366 (m), 
1324 (m), 1312 (m), 1276 (vs), 1248 (s), 1168 (s), 1148 (s), 1132 (s), 1104 (s), 1060 (w), 1018 
(m), 950 (w), 878 (w), 854 (m), 772 (m), 758 (s), 700 (s). 
HRMS (EI) for C24H29NO4 (395.2097): 395.2082. 
 
7.3 Cross-coupling of (1-(tert-butoxycarbonyl)-4-((triisopropylsilyl)oxy)piperidin-2-
yl)zinc chloride (119c) 
A dry and Ar-flushed 10 mL Schlenk-tube equipped with a stirring bar was charged with a 
solution of tert-butyl 4-((triisopropylsilyl)oxy)piperidine-1-carboxylate (120c; 1 mmol; 0.36 g) 
and TMEDA (1 mmol; 0.12 g; 0.45 mL) in anhydrous Et2O (2 mL). It was cooled to ‒78 °C and 
sBuLi (1.14 M in hexanes) (1.2 mmol; 1.05 mL) was slowly added via syringe. The reaction 
mixture was stirred for 4 h at this temperature before ZnCl2 (1.0 M in THF) (1.2 mmol; 1.2 mL) 
was added. The reaction mixture was stirred for 15 min at ‒78 °C and was then allowed to warm 
to room temperature. Et2O was removed in vacuo (8 min; 1 mbar). Meanwhile, a solution of the 
respective aryl iodide (0.7 mmol), Pd(dba)2 (28.8 mg; 0.05 mmol) and RuPhos (23.3 mg; 0.05 
mmol) was prepared and stirred for 10 min. The piperidinylzinc reagent was added to this 
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mixture at room temperature. The reaction mixture was then heated to 55 °C for 60 h. NH4Cl sat. 
aq. solution (20 mL) was added, the phases were separated and the aqueous phase was extracted 
with Et2O (4 x 10 mL). The combined organic layers were washed with brine (10 mL) and dried 
over Na2SO4. The solvents were evaporated and the residue was subjected to column 
chromatography yielding the respective title compound. 
 
cis-tert-Butyl 2-(4-(ethoxycarbonyl)phenyl)-4-((triisopropylsilyl)oxy)piperidine-1-
carboxylate (121j) 
 
 
colorless oil (84 %) 
1H-NMR (400 MHz, C6D6) δ: 8.17 (d, J=8.4 Hz, 2 H), 7.20 (d, J=8.0 Hz, 2 H), 5.32 (dd, J1=6.2 
Hz, J2=3.2 Hz, 1 H), 4.24 - 4.16 (m, 1 H), 4.13 (q, J=7.11 Hz, 2 H), 3.89 - 3.82 (m, 1 H), 3.45 (td, 
J1=12.7 Hz, J2=3.5 Hz, 1 H), 2.06 (dt, J1=14.0 Hz, J2=3.5 Hz, 1 H), 1.78 (ddd, J1=14.1 Hz, J2=7.1 
Hz, J3=3.0 Hz, 1 H), 1.58 - 1.49 (m, 1 H), 1.39 (s, 9 H), 1.31 (d, J=7.0 Hz, 1 H), 1.02 (t, J=7.0 
Hz, 3 H), 0.98 - 0.77 (m, 18 H), 0.77 - 0.69 (m, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 166.6, 155.7, 149.7, 130.3, 129.4, 126.3, 79.8, 65.7, 61.0, 53.3, 
37.7, 36.6, 33.5, 32.7, 30.5, 30.5, 30.2, 28.7, 23.5, 18.5, 18.4, 14.7, 14.7, 12.7. 
MS (70 eV, EI) m/z (%): 505 (1) [M+], 407 (32), 406 (100), 363 (31), 362 (91), 231 (74), 230 
(85), 188 (21), 186 (85), 159 (38), 144 (23), 131 (44), 103 (21), 75 (22), 57 (29), 41 (19). 
IR (ATR) ν~  (cm-1): 2940 (m), 2924 (m), 2865 (m), 1717 (s), 1693 (vs), 1462 (m), 1414 (m), 
1403 (m), 1390 (m), 1381 (m), 1364 (s), 1271 (vs), 1254 (m), 1214 (m), 1170 (s), 1103 (vs), 1080 
(s), 1067 (s), 1044 (s), 1021 (s), 995 (m), 985 (m), 953 (m), 880 (s), 850 (m), 777 (m), 773 (m), 
721 (m), 713 (m), 679 (s), 660 (s), 631 (m). 
HRMS (EI) for C28H47NO5Si (505.3224): 505.3221. 
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cis-tert-Butyl 2-(4-fluorophenyl)-4-((triisopropylsilyl)oxy)piperidine-1-carboxylate (121k) 
 
N
Boc
OTIPS
F  
colorless oil (87 %) 
1H-NMR (300 MHz, C6D6) δ: 7.04 (dd, J1=8.3 Hz, J2=5.3 Hz, 2 H), 6.83 (t, J=8.7 Hz, 2 H), 5.30 
- 5.25 (m, 1 H), 4.16 (ddd, J1=13.3 Hz, J2=4.7 Hz, J3=2.9 Hz, 1 H), 3.89 - 3.83 (m, 1 H), 3.40 (td, 
J1=12.7 Hz, J2=3.5 Hz, 1 H), 2.06 - 1.97 (m, 1 H), 1.78 (ddd, J1=14.1 Hz, J2=6.9 Hz, J3=3.3 Hz, 1 
H), 1.63 - 1.52 (m, 1 H), 1.40 (s, 9 H), 1.11 - 1.04 (m, 1 H), 1.02 - 0.83 (m, 18 H), 0.83 - 0.73 (m, 
3 H). 
13C-NMR (75 MHz, C6D6) δ: 155.7, 162.2 (d, J=243.2 Hz), 139.9 (d, J=3.1 Hz), 127.9 (d, J=7.8 
Hz), 115.4 (d, J=21.3 Hz), 79.7, 65.8, 52.8, 37.7, 36.4, 33.7, 28.8, 18.5, 18.5, 12.7. 
19F-NMR (282 MHz, C6D6) δ: ‒116.44 - ‒116.36 (m) (minor), -117.97 - ‒117.82 (m) (major). 
MS (70 eV, EI) m/z (%): 452 (1) [M+], 309 (22), 308 (86), 187 (18), 186 (100), 177 (87), 176 
(18), 174 (18), 173 (19), 159 (40), 157 (20), 156 (22), 150 (26), 144 (35), 142 (16), 131 (35), 103 
(24), 75 (25), 41 (17). 
IR (ATR) ν~  (cm-1): 2972 (w), 2932 (w), 2232 (w), 1684 (s), 1608 (w), 1508 (w), 1474 (w), 
1454 (m), 1434 (w), 1410 (m), 1392 (m), 1380 (m), 1364 (s), 1338 (s), 1312 (m), 1280 (m), 1270 
(m), 1248 (m), 1220 (m), 1156 (vs), 1104 (s), 1070 (m), 1056 (m), 1018 (m), 982 (s), 964 (m), 
910 (m), 870 (m), 854 (m), 838 (s), 794 (m), 780 (m), 758 (m), 724 (w), 680 (m), 670 (m), 660 
(m). 
HRMS (EI) for C25H42FNO3Si (452.2918): 452.2938. 
 
cis-tert-Butyl 2-(4-(trifluoromethyl)phenyl)-4-((triisopropylsilyl)oxy)piperidine-1-
carboxylate (121l) 
 
 
colorless crystals (81 %) 
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m. p.: 94.8 – 95.9°C 
1H-NMR (400 MHz, C6D6) δ: 7.37 (d, J=8.2 Hz, 2 H), 7.10 (d, J=8.2 Hz, 2 H), 5.35 (d, J=5.1 
Hz, 1 H), 4.16 (d, J=12.9 Hz, 1 H), 3.85 - 3.80 (m, 1 H), 3.39 (td, J1=12.7 Hz, J2=3.6 Hz, 1 H), 
2.01 (d, J=14.3 Hz, 1 H), 1.73 (ddd, J1=14.1 Hz, J2=7.1 Hz, J3=3.0 Hz, 1 H), 1.53 - 1.47 (m, 1 
H), 1.41 (s, 9 H), 1.04 - 1.00 (m, 1 H), 0.84 - 0.80 (m, 18 H), 0.75 - 0.62 (m, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 155.7, 148.4 (d, J=1.0 Hz), 128.8 (q, J=32.3 Hz), 126.6, 125.7 (q, 
J=3.7 Hz), 125.5 (q, J=271.6 Hz), 79.9, 65.5, 52.7, 37.4, 36.3, 33.4, 28.7, 18.5, 18.4, 12.7. 
19F-NMR (376 MHz, C6D6) δ: ‒62.12 (s) (major), ‒62.20 (s) (minor). 
MS (70 eV, EI) m/z (%): 501 (1) [M+], 403 (23), 402 (100), 358 (24), 230 (31), 186 (22), 131 
(22), 57 (12).  
IR (ATR) ν~  (cm-1): 2944 (m), 2868 (m), 1696 (s), 1418 (m), 1366 (m), 1328 (vs), 1164 (s), 
1126 (s), 1082 (m), 1070 (m). 
HRMS (EI) for C26H42F3NO3Si (501.2886): 501.2877. 
 
cis-tert-Butyl 2-(4-cyanophenyl)-4-((triisopropylsilyl)oxy)piperidine-1-carboxylate (121m) 
 
 
slightly yellow oil (81 %) 
1H-NMR (400 MHz, C6D6) δ: 7.09 (d, J=8.2 Hz, 2 H), 6.90 (d, J=8.0 Hz, 2 H), 5.21 (d, J=4.3 
Hz, 1 H), 4.08 (dd, J1=9.68 Hz, J2=3.42 Hz, 1 H), 3.79 - 3.75 (m, 1 H), 3.28 (td, J1=12.6 Hz, 
J2=3.7 Hz, 1 H), 1.89 (d, J=14.1 Hz, 1 H), 1.66 (ddd, J1=14.1 Hz, J2=7.1 Hz, J3=3.0 Hz, 1 H), 
1.50 - 1.41 (m, 2 H), 1.39 (s, 9 H), 0.80 (t, J=6.9 Hz, 18 H), 0.72 - 0.63 (m, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 155.5, 149.4, 132.3, 126.9, 119.3, 110.8, 80.0, 65.4, 52.8, 37.3, 
36.3, 33.3, 28.8, 28.7, 18.6, 18.4, 18.4, 12.9, 12.6, 12.3. 
MS (70 eV, EI) m/z (%): 459 (1) [M+H+], 360 (19), 359 (65), 316 (27), 315 (100), 230 (18), 187 
(10), 186 (58), 184 (24), 159 (19), 157 (14), 156 (14), 144 (21), 131 (11), 75 (13), 57 (10). 
IR (ATR) ν~  (cm-1): 2941 (m), 2865 (m), 1691 (vs), 1461 (m), 1414 (m), 1403 (m), 1390 (m), 
1381 (m), 1364 (s), 1355 (m), 1334 (m), 1281 (m), 1252 (m), 1215 (m), 1166 (s), 1127 (m), 1117 
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(m), 1079 (s), 1067 (s), 1043 (s), 1021 (m), 1013 (s), 985 (s), 880 (s), 873 (s), 830 (m), 796 (m), 
771 (m), 746 (m), 697 (m), 680 (s), 659 (s), 641 (m), 636 (m). 
HRMS (EI) for C26H43N2O3Si+ (459.3037) [M+H+]: 459.3022. 
 
7.4 Cross-coupling of (trans-2-(tert-butoxycarbonyl)decahydroisoquinolin-3-yl)zinc 
chloride (119d) 
A dry and Ar-flushed 10 mL Schlenk-tube equipped with a stirring bar was charged with a 
solution of trans-tert-butyl octahydroisoquinoline-2(1H)-carboxylate (120d; 1 mmol; 0.24 g) and 
TMEDA (1 mmol; 0.12 g; 0.45 mL) in anhydrous Et2O (2 mL). It was cooled to ‒78 °C and 
sBuLi (1.14 M in hexanes) (1.2 mmol; 1.05 mL) was slowly added via syringe. The reaction 
mixture was stirred for 4 h at this temperature before ZnCl2 (1.0 M in THF) (1.2 mmol; 1.2 mL) 
was added. The reaction mixture was stirred for 15 min at ‒78 °C and was then allowed to warm 
to room temperature. Et2O was removed in vacuo (8 min; 1 mbar). Meanwhile, a solution of the 
respective aryl iodide (0.7 mmol), Pd(dba)2 (28.8 mg; 0.05 mmol) and RuPhos (23.3 mg; 0.05 
mmol) was prepared and cooled to 0 °C. The piperidinylzinc reagent was added to this mixture 
and stirred for 4 h. The reaction mixture was then warmed to room temperature and stirred for 12 
h and finally heated to 55 °C for 12 h. NH4Cl sat. aq. solution (20 mL) was added, the phases 
were separated and the aqueous phase was extracted with Et2O (4 x 10 mL). The combined 
organic layers were washed with brine (10 mL) and dried over Na2SO4. The solvents were 
evaporated and the residue was subjected to column chromatography yielding the respective title 
compound. 
 
tert-Butyl 3-(4-(trifluoromethyl)phenyl)octahydroisoquinoline-2(1H)-carboxylate (121n) 
 
N
Boc
H
H
CF3  
colorless crystals (69 %) 
m.p.: 104.1 – 105.5 °C. 
1H-NMR (599 MHz, C6D6) δ: 7.42 (d, J=8.2 Hz, 2 H), 7.07 (d, J=8.2 Hz, 2 H), 4.16 (dd, J1=10.8 
Hz, J2=5.1 Hz, 1 H), 4.04 (dd, J1=12.8 Hz, J2=5.1 Hz, 1 H), 2.65 (dd, J1=12.6 Hz, J2=10.7 Hz, 1 
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H), 1.56 (d, J=8.0 Hz, 2 H), 1.52 (ddd, J1=13.3 Hz, J2=4.8 Hz, J3=3.3 Hz, 1 H), 1.44 - 1.36 (m, 2 
H), 1.17 (s, 9 H), 1.10 - 0.95 (m, 4 H), 0.79 - 0.64 (m, 3 H). 
13C-NMR (152 MHz, C6D6) δ: 156.9, 152.6 (d, J=1.4 Hz), 128.8 (q, J=32.3 Hz), 126.5, 125.7 (q, 
J=3.6 Hz), 125.6 (q, J=271.8 Hz), 79.8, 59.6, 52.2, 41.6, 41.0, 39.9, 33.2, 31.2, 28.4, 26.7, 26.4. 
19F-NMR (376 MHz, C6D6) δ: ‒61.83 (s). 
MS (70 eV, EI) m/z (%): 383 (1) [M+], 328 (24), 327 (100), 326 (10), 283 (27), 282 (67), 240 
(13), 182 (11), 182 (18), 181 (17), 177 (35), 138 (40), 137 (19), 57 (60). 
IR (ATR) ν~  (cm-1): 2920 (w), 2854 (w), 1680 (s), 1368 (m), 1326 (vs), 1306 (m), 1282 (m), 
1258 (m), 1250 (m), 1160 (vs), 1142 (m), 1118 (vs), 1104 (s), 1090 (m), 1068 (vs), 1020 (m), 854 
(m), 838 (s), 788 (m), 662 (m), 612 (m). 
HRMS (EI) for C21H28F3NO2 (383.2072): 383.2075. 
 
tert-Butyl 3-(4-cyanophenyl)octahydroisoquinoline-2(1H)-carboxylate (121o) 
 
 
colorless crystals (54 %) 
m.p.: 83.3 – 84.6 °C.  
1H-NMR (400 MHz, C6D6) δ: 7.11 (m, J=8.4 Hz, 2 H), 6.86 (m, J=8.2 Hz, 2 H), 4.04 - 3.94 (m, 
2 H), 2.56 (dd, J1=12.8 Hz, J2=10.8 Hz, 1 H), 1.55 (d, J=9.0 Hz, 2 H), 1.42 - 1.33 (m, 3 H), 1.14 
(s, 9 H), 1.09 - 1.01 (m, 2 H), 0.96 - 0.83 (m, 2 H), 0.77 - 0.62 (m, 3 H). 
13C-NMR (101 MHz, CDCl3) δ: 156.6, 152.1, 132.2, 126.4, 119.2, 110.4, 79.7, 59.6, 52.1, 41.3, 
40.7, 39.7, 32.9, 30.8, 28.2, 26.4, 26.1. 
MS (70 eV, EI) m/z (%): 340 (1) [M+], 284 (65), 240 (37), 239 (100), 182 (37), 143 (35), 138 
(37), 74 (45), 59 (73), 57 (89), 45 (52), 41 (63). 
IR (ATR) ν~  (cm-1): 2922 (m), 2844 (w), 2230 (w), 1686 (vs), 1372 (m), 1364 (m), 1328 (m), 
1306 (m), 1280 (m), 1252 (m), 1222 (m), 1162 (vs), 1140 (m), 1128 (m), 1118 (m), 1102 (m), 
836 (m), 788 (m). 
HRMS (EI) for C21H28N2O2 (340.2152): 340.2152. 
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tert-Butyl 3-(4-methoxyphenyl)octahydroisoquinoline-2(1H)-carboxylate (121p) 
 
 
colorless crystals (60 %) 
m.p.: 73.1 – 74.7 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.19 (d, J=8.0 Hz 2 H), 6.85 (d, J=8.8 Hz, 2 H), 4.50 (dd, J1=10.1 
Hz, J2=5.6 Hz, 1 H), 4.04 (dd, J1=13.0 Hz, J2=5.6 Hz, 1 H), 3.36 (s, 3 H), 2.89 (dd, J1=12.9 Hz, 
J2= 9.7 Hz, 1 H), 1.75 (ddd, J1=13.3 Hz, J2=5.6 Hz, J3=3.7 Hz, 1 H), 1.55 (d, J=8.0 Hz, 2 H), 
1.44 (td, J1=6.0 Hz, J2=2.8 Hz, 2 H), 1.36 - 1.27 (m, 10 H), 1.14 - 1.01 (m, 3 H), 0.89 - 0.69 (m, 3 
H). 
13C-NMR (101 MHz, C6D6) δ: 159.0, 157.0, 139.0, 131.0, 127.4, 114.2, 79.2, 58.8, 55.2, 52.6, 
41.1, 40.8, 39.9, 33.5, 31.6, 30.6, 28.7, 26.9, 26.6. 
MS (70 eV, EI) m/z (%): 345 (2) [M+], 290 (20), 289 (100), 288 (36), 245 (20), 244 (85), 181 
(11), 137 (10), 136 (15), 121 (18), 57 (14). 
IR (ATR) ν~  (cm-1): 2930 (m), 2918 (m), 2854 (m), 1684 (vs), 1520 (s), 1466 (m), 1444 (m), 
1390 (m), 1366 (s), 1324 (m), 1304 (m), 1278 (m), 1238 (vs), 1224 (s), 1166 (vs), 1142 (s), 1126 
(s), 1102 (s), 1090 (m), 1078 (m), 1036 (s), 1018 (m), 976 (m), 876 (m), 858 (m), 828 (vs), 816 
(m), 786 (s), 764 (m).  
HRMS (EI) for C21H31NO3 (345.2304): 345.2296. 
 
7.5 Cross-coupling of (1-(tert-butoxycarbonyl)-5-methylpiperidin-2-yl)zinc chloride 
(119e) 
A dry and Ar-flushed 10 mL Schlenk-tube equipped with a stirring bar was charged with a 
solution of t-butyl 3-methylpiperidine-1-carboxylate (120e; 1 mmol; 0.20 g) and TMEDA (1 
mmol; 0.12 g; 0.45 mL) in anhydrous Et2O (2 mL). It was cooled to ‒78 °C and sBuLi (1.14 M in 
hexanes) (1.2 mmol; 1.05 mL) was slowly added via syringe. The reaction mixture was stirred for 
4 h at this temperature before ZnCl2 (1.0 M in THF) (1.2 mmol; 1.2 mL) was added. The reaction 
mixture was stirred for 15 min at ‒78 °C and was then allowed to warm to room temperature. 
Et2O was removed in vacuo (8 min; 1 mbar). Meanwhile, a solution of the respective aryl iodide 
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(0.7 mmol), Pd(dba)2 (28.8 mg; 0.05 mmol) and RuPhos (23.3 mg; 0.05 mmol) was prepared and 
cooled to 0 °C. The piperidinylzinc reagent was added to this mixture at this temperature and 
stirred for 6 h. It was then kept at room temperature for further 12 h and eventually heated to 40 
°C for 12 h. NH4Cl sat. aq. solution (20 mL) was added, the phases were separated and the 
aqueous phase was extracted with Et2O (4 x 10 mL). The combined organic layers were washed 
with brine (10 mL) and dried over Na2SO4. The solvents were evaporated and the residue was 
subjected to column chromatography yielding the respective title compound. 
 
trans-tert-Butyl 2-(4-cyanophenyl)-5-methylpiperidine-1-carboxylate (121q) 
 
 
colorless oil (61 %; 10 % regioisomer) 
1H-NMR (400 MHz, C6D6) δ: 7.04 (m, J=8.4 Hz, 2 H), 6.80 (d, J=8.0 Hz, 2 H), 5.22 (br. s., 1 
H), 3.67 (d, J=13.6 Hz, 1 H), 2.70 (dd, J1=13.4 Hz, J2=3.7 Hz, 1 H), 1.78 - 1.67 (m, 1 H), 1.41 (s, 
9 H), 1.39 - 1.28 (m, 3 H), 1.24 - 1.14 (m, 1 H), 0.90 (d, J=7.0 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 155.4, 146.3, 137.7, 132.4, 131.8, 126.7, 118.5, 110.6, 79.0, 53.5, 
45.1, 28.0, 27.7, 25.7, 23.0, 17.0. 
MS (70 eV, EI) m/z (%): 300 (1) [M+], 245 (23), 244 (87), 227 (17), 200 (30), 199 (96), 143 (11), 
142 (32), 129 (16), 116 (26), 98 (11), 57 (100), 43 (18), 41 (18). 
IR (ATR) ν~  (cm-1): 2960 (w), 2928 (w), 2228 (w), 1684 (s), 1476 (w), 1456 (m), 1414 (s), 1392 
(m), 1364 (s), 1328 (m), 1246 (m), 1172 (s), 1142 (vs), 1102 (w), 1084 (m), 1058 (m), 1018 (w), 
990 (m), 878 (w), 854 (m), 838 (m), 768 (m). 
HRMS (EI) for C18H24N2O2 (300.1838): 300.1840. 
 
trans-tert-Butyl 2-(4-(ethoxycarbonyl)phenyl)-5-methylpiperidine-1-carboxylate (121r): 
 
 
colorless oil (63 %) 
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1H-NMR (400 MHz, C6D6) δ: 8.17 (d, J=8.4 Hz, 2 H), 7.15 (d., 2 H), 5.41 (br. s., 1 H), 4.15 (q, 
J=7.0 Hz, 2 H), 3.78 (d, J=13.4 Hz, 1 H), 2.88 (dd, J1=13.5 Hz, J2=3.6 Hz, 1 H), 1.87 - 1.77 (m, 1 
H), 1.62 - 1.54 (m, 1 H), 1.49-1.43 (m, 10 H), 1.40 - 1.27 (m, 2 H), 1.03 (t, J=7.1 Hz, 3 H), 0.94 
(d, J=7.0 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 166.5, 156.3, 147.2, 130.6, 130.5, 130.4, 129.8, 127.1, 79.6, 61.1, 
54.4, 45.8, 28.8, 28.5, 26.5, 23.9, 17.8, 14.7. 
MS (70 eV, EI) m/z (%): 347 (1) [M+], 292 (16), 291 (92), 262 (17), 247 (11), 246 (53), 219 (15), 
218 (100), 142 (13), 98 (12), 57 (18). 
IR (ATR) ν~  (cm-1): 2964 (w), 2932 (w), 1716 (s), 1686 (vs), 1610 (w), 1476 (w), 1456 (m), 
1416 (s), 1392 (m), 1364 (s), 1342 (w), 1324 (m), 1312 (m), 1270 (vs), 1246 (s), 1172 (s), 1142 
(vs), 1122 (s), 1102 (vs), 1058 (m), 1018 (s), 988 (m), 892 (w), 878 (m), 864 (m), 836 (w), 766 
(m), 746 (m), 724 (w), 696 (m).  
HRMS (EI) for C20H29NO4 (347.2097): 347.2096. 
 
7.6 Preparation of piperidin-4-ylzinc iodides  
Anhydrous LiCl (4.5 mmol; 0.19 g) was placed in an Ar-flushed flask and dried for 20 min at 
150-170 °C under high vacuum (1 mbar). Zn powder (9 mmol; 0.59 g; 150 mesh, Chemetall) was 
added under Ar and the heterogeneous mixture of Zn and LiCl was dried again under vigorous 
stirring for 20 min at 150-170 °C under high vacuum (1 mbar). The reaction mixture was 
evacuated and refilled with Ar three times. A catalytic amount of 1,2-dibromoethane and THF (6 
mL) were added. The mixture was gently heated in order to activate the Zn surface. The 
respective 4-iodopiperidine was added neat at room temperature. The resulting reaction mixture 
was stirred for 4 h at ambient temperature. It was then separated from the remaining Zn powder 
via syringe filter (25 mm with 1 µm glass fiber membrane) and transferred to an Ar-flushed 
Schlenk flask. The concentrations of all piperidinylzinc reagents were determined via titration 
with I2 (50 mg in 2 mL THF).
79 
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(1-(tert-Butoxycarbonyl)-2-(4-(trifluoromethyl)phenyl)-piperidin-4-yl)zinc iodide (122a) 
 
0.35 M (70%) 
 
(1-Tosyl-2-(4-(trifluoromethyl)phenyl)piperidin-4-yl)zinc iodide (122b) 
 
0.39 M (78%) 
 
(2-Methyl-1-tosylpiperidin-4-yl)zinc iodide (122c) 
 
0.42 M (84%) 
 
7.7 Cross-coupling of piperidin-4-ylzinc iodides (122a-c) 
A dry and Ar-flushed 10 mL Schlenk-tube, equipped with a magnetic stirring bar and a septum 
was charged with TMPP2PdCl2 (0.05 mmol; 63 mg), the respective aryl iodide (0.8 mmol), THF 
(0.8 mL) and NEP (0.02 mL). The mixture was stirred for 5 min at room temperature and then 
cooled to ‒10 °C. The corresponding piperidin-4-ylzinc iodide (0.36 – 0.39 M solution in THF) 
was slowly added via syringe. The reaction mixture was kept for 12 h at ‒10 °C and subsequently 
5 h at -5 °C. NH4Cl sat. aq. solution (20 mL) was added, the phases were separated and the 
aqueous phase was extracted with CH2Cl2 (4 x 20 mL). The combined organic layers were 
washed with brine (20 mL) and dried over Na2SO4. The solvents were evaporated and the residue 
was subjected to column chromatography yielding the respective title compound. 
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trans-tert-Butyl 4-(4-cyanophenyl)-2-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate 
(124a) 
 
 
colorless crystals (74 %) 
m.p.: 72.9 – 74.6 °C.  
1H-NMR (300 MHz, C6D6) δ: 7.39 (d, J=8.3 Hz, 2 H), 7.03 (d, J=8.3 Hz, 2 H), 6.97 (d, J=7.7 
Hz, 2 H), 6.44 (d, J=8.0 Hz, 2 H), 5.78 (s, 1 H), 5.40 (s, 1 H), 4.40 (s, 1 H), 4.03 (s, 1 H), 2.54 (d, 
J=10.2 Hz, 1 H), 2.04 (br. s., 1 H), 1.84 (d, J=13.8 Hz, 1 H), 1.50 (dd, J1=14.0 Hz, J2=5.1 Hz, 9 
H), 1.18 - 1.10 (m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 154.7, 149.7, 144.2, 131.8, 129.0 (q, J=32.5 Hz), 126.9, 126.6, 
125.5 (q, J=3.7 Hz), 124.4 (q, J=271.9 Hz), 118.1, 110.9, 79.6, 52.9, 39.9, 36.9, 34.7, 32.1, 28.0. 
19F-NMR (282 MHz, C6D6) δ: ‒62.14 (s) (minor), ‒62.19 (s) (major)  
MS (70 eV) m/z (%): 330 (20), 329 (19), 328 (11), 311 (14), 227 (19), 213 (33), 207 (21), 200 
(32), 188 (11), 187 (59), 186 (100), 185 (17), 173 (13). 
IR (ATR) ν~  (cm-1): 2976 (vw), 2932 (w), 2868 (vw), 2228 (w), 1686 (s), 1620 (w), 1608 (w), 
1506 (vw), 1478 (vw), 1454 (w), 1414 (m), 1366 (m), 1326 (vs), 1282 (m), 1258 (w), 1236 (w), 
1218 (w), 1156 (vs), 1118 (vs), 1068 (s), 1016 (m), 986 (w), 968 (w), 912 (w), 886 (w), 862 (w), 
834 (s), 810 (w), 770 (w), 728 (w), 722 (w). 
HRMS (ESI) for C24H25F3N2O2Cl- (465.1557) [M+Cl-]: 465.1564. 
 
trans-tert-Butyl 4-phenyl-2-(4-(trifluoromethyl)phenyl)-piperidine-1-carboxylate (124b) 
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colorless oil (50 %) 
1H-NMR (400 MHz, C6D6) δ: 7.37 (d, J=8.2 Hz, 2 H), 7.13 (d, J=7.6 Hz, 2 H), 7.11 – 6.97 (m, 3 
H), 6.87 (d, J=7.4 Hz, 2 H), 5.83 (s, 1 H), 5.44 (s, 1 H), 4.48 (d, J=8.8 Hz, 1 H), 4.07 (d, J=9.9 
Hz, 1 H), 2.63 (d, J=6.6 Hz, 1 H), 2.35 - 2.24 (m, 1 H), 2.09 (dd, J1=13.7 Hz, J2=1.8 Hz, 1 H), 
1.79 (td, J1=13.3 Hz, J2=5.2 Hz, 1 H), 1.65 - 1.35 (m, 9 H). 
13C-NMR (101 MHz, C6D6) δ: 155.7, 146.1, 145.6, 129.7 (q, J=32.5 Hz), 129.2, 127.6, 127.3, 
127.1, 126.2 (q, J=3.9 Hz), 126.1 (q, J=271.8 Hz), 80.1, 54.1, 41.2, 37.8, 36.2, 33.7, 28.9. 
19F-NMR (376 MHz, C6D6) δ: ‒62.15 (s). 
MS (70 eV, EI) m/z (%): 405 (1) [M+], 350 (22), 349 (100), 304 (21), 200 (14), 187 (10), 186 
(12), 159 (10), 118 (37), 104 (15), 90 (19), 59 (89), 41 (13); 18 (25). 
IR (ATR) ν~  (cm-1): 2976 (w), 2932 (w), 2868 (vw), 1688 (s), 1620 (w), 1494 (vw), 1478 (w), 
1454 (w), 1414 (m), 1394 (m), 1366 (m), 1324 (vs), 1300 (m), 1282 (m), 1268 (m), 1256 (w), 
1234 (m), 1214 (w), 1154(s), 1118 (vs), 1068 (s), 1016 (s), 986 (w), 964 (w), 912 (w), 888 (w), 
862 (w), 838 (m), 760 (m), 730 (w), 722 (w), 698 (s), 638 (w). 
HRMS (EI) for C23H26F3NO2 (405.1916): 405.1932. 
 
4-(trans-1-Tosyl-2-(4-(trifluoromethyl)phenyl)piperidin-4-yl)benzonitrile (124c) 
 
 
white crystals (70 %) 
m.p.: 181.7 – 183.3 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.74 (d, J=8.2 Hz, 2 H), 7.35 (d, J=8.4 Hz, 2 H), 7.07 (d, J=8.2 
Hz, 2 H), 6.98 (m, J=8.4 Hz, 2 H), 6.83 (d, J=8.0 Hz, 2 H), 6.35 (d, J=8.2 Hz, 2 H), 5.38 (d, 
J=3.3 Hz, 1 H), 3.97 - 3.85 (m, 1 H), 2.69 - 2.58 (m, 1 H), 2.05 - 1.96 (m, 1 H), 1.94 (s, 3 H), 
1.76 (d, J=13.8 Hz, 1 H), 1.52 (td, J1=13.4 Hz, J2=5.3 Hz, 1 H), 1.16 (qd, J1=12.7 Hz, J2=4.4 Hz, 
1 H), 0.95 (d, J=12.9 Hz, 1 H). 
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13C-NMR (101 MHz, C6D6) δ: 150.0, 143.7, 143.5 (d, J=1.1 Hz), 139.6, 132.7, 130.3, 129.9 (q, 
J=32.2 Hz), 127.8, 127.7, 127.7, 126.3 (q, J=3.7 Hz), 125.2 (q, J=271.7 Hz), 119.1, 111.5, 55.5, 
42.0, 37.0, 34.4, 31.8, 21.5. 
19F-NMR (282 MHz, C6D6) δ: ‒62.16 (s). 
MS (70 eV) m/z (%): 386 (37), 377 (25), 376 (100), 375 (21), 374 (16), 329 (17), 281 (10), 208 
(13), 207 (56), 200 (14), 199 (12), 186 (43); 172 (13); 159 (29); 155 (21); 131 (20); 103 (10), 92 
(10); 91 (73). 
IR (ATR) ν~  (cm-1): 2956 (w), 2930 (w), 2232 (m), 1412 (w), 1326 (vs), 1256 (m), 1158 (vs), 
1110 (s), 1094 (s), 1072 (s), 1018 (s), 944 (m), 928 (s), 906 (m), 838 (s), 826 (s), 800 (m), 716 
(s), 702 (s), 664 (vs), 650 (s). 
HRMS (ESI) for C26H23F3N2O2SCl- (529.1126) [M+Cl-]: 529.1122. 
 
Methyl 4-(trans-1-tosyl-2-(4-(trifluoromethyl)phenyl)-piperidin-4-yl)benzoate (124d) 
 
 
colorless crystals (69 %) 
m.p.: 68.8 – 70.5 °C.  
1H-NMR (300 MHz, C6D6) δ: 8.06 (d, J=8.2 Hz, 2 H), 7.76 (d, J=8.2 Hz, 2 H), 7.36 (d, J=8.2 
Hz, 2 H), 7.14 (d, J=8.0 Hz, 3 H), 6.83 (d, J=8.0 Hz, 2 H), 6.68 (d, J=8.2 Hz, 2 H), 5.40 (d, J=3.4 
Hz, 1 H), 3.94 (d, J=14.2 Hz, 1 H), 3.52 (s, 3 H), 2.74 - 2.63 (m, 1 H), 2.25 - 2.13 (m, 1 H), 1.94 
(s, 3 H), 1.87 (br. s., 1 H), 1.63 (dd, J1=13.4 Hz, J2=5.3 Hz, 2 H), 1.34 - 1.25 (m, 1 H), 1.08 (d, 
J=14.6 Hz, 1 H). 
13C-NMR (75 MHz, C6D6) δ: 166.8, 150.5, 143.7 (d, J=1.2 Hz), 143.6, 139.8, 130.6, 130.2, 
129.8 (q, J=32.3 Hz), 129.7, 128.0, 127.8, 127.2, 126.3 (q, J=3.8 Hz), 125.3 (q, J=272.0 Hz), 
55.7, 52.0, 42.2, 37.1, 34.4, 31.9, 21.5. 
19F-NMR (282 MHz, C6D6) δ ppm ‒62.22 (s). 
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MS (70 eV, EI) m/z (%): 527 (11) [M+], 371 (35), 362 (24), 361 (100), 360 (27), 359 (12), 186 
(21), 155 (11), 90 (22). 
IR (ATR) ν~  (cm-1): 2952 (vw), 2930 (vw), 2876 (vw), 1718 (s), 1610 (w), 1494 (vw), 1450 (w), 
1436 (w), 1412 (w), 1326 (vs), 1278 (s), 1182 (w), 1156 (vs), 1114 (vs), 1096 (s), 1068 (s), 1016 
(m), 954 (w), 932 (s), 908 (m), 840 (m), 816 (m), 802 (w), 770 (m), 742 (m), 716 (m), 708 (m), 
690 (s), 658 (s), 646 (m). 
HRMS (EI) for C27H26F3NO4S (527.1535): 527.1537. 
 
4-(trans-2-methyl-1-tosylpiperidin-4-yl)benzonitrile (124e) 
 
 
colorless crystals (84 %) 
m.p.: 106.2 – 107.1 °C.  
1H-NMR (400 MHz, C6D6) δ: 7.77 (d, J=8.2 Hz, 2 H), 7.01 (m, J=8.2 Hz, 2 H), 6.85 (m, J=8.0 
Hz, 2 H), 6.43 (d, J=8.2 Hz, 2 H), 4.41 - 4.33 (m, J1=6.2 Hz, J2=6.2 Hz, J3=6.1 Hz, J4=5.9 Hz, 1 
H), 3.86 - 3.78 (m, 1 H), 2.64 (td, J1=12.9 Hz, J1= 3.0 Hz, 1 H), 2.24 - 2.15 (m, J1=12.5 Hz, 
J2=12.5 Hz, J3=3.7 Hz, J4=3.5 Hz, 1 H), 1.94 (s, 3 H), 1.38 (td, J1=13.1 Hz, J2=5.3 Hz, 1 H), 1.25 
- 1.12 (m, 1 H), 1.12 - 1.06 (m, 1 H), 1.03 (dt, J1=13.1 Hz, J2=1.6 Hz, 1 H), 0.80 (d, J=6.8 Hz, 3 
H). 
13C-NMR (101 MHz, C6D6) δ: 150.6, 143.1, 139.9, 132.6, 130.1, 128.0, 127.8, 119.3, 111.3, 
48.8, 40.3, 37.8, 36.5, 32.6, 21.5, 15.6. 
MS (70 eV, EI) m/z (%): 354 (3) [M+], 340 (21), 339 (100), 155 (35), 90 (47), 58 (9). 
IR (ATR) ν~  (cm-1): 2982 (vw), 2946 (vw), 2918 (vw), 2868 (vw), 2226 (w), 1604 (w), 1504 
(w), 1446 (vw), 1370 (w), 1348 (w), 1332 (m), 1316 (w), 1302 (w), 1290 (w), 1276 (w), 1256 
(w), 1206 (w), 1178 (w), 1158 (s), 1148 (m), 1118 (w), 1104 (w), 1092 (m), 1070 (m), 1056 (w), 
1018 (w), 1012 (w), 996 (m), 972 (m), 930 (m), 880 (w), 858 (m),848 (w), 828 (m), 816 (m), 800 
(w), 722 (w), 710 (s), 698 (s), 652 (s), 624 (w). 
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HRMS (EI) for C20H22N2O2S (354.1402): 354.1384. 
 
Methyl 4-(trans-2-methyl-1-tosylpiperidin-4-yl)benzoate (124f) 
 
 
colorless crystals (89 %) 
m.p.: 129.8 – 131.5 °C.  
1H-NMR (400 MHz, C6D6) δ: 8.08 (d, J=8.4 Hz, 2 H), 7.78 (m, J=8.2 Hz, 2 H), 6.84 (m, J=8.0 
Hz, 2 H), 6.75 (d, J=8.4 Hz, 2 H), 4.39 (qd, J1=6.2 Hz, J2=6.0 Hz, 1 H), 3.88 - 3.81 (m, 1 H), 3.52 
(s, 3 H), 2.69 (td, J1=12.9 Hz, J2=3.0 Hz, 1 H), 2.36 (tt, J1=12.5 Hz, J2=3.6 Hz, 1 H), 1.93 (s, 3 
H), 1.52 (td, J1=13.1 Hz, J2=5.3 Hz, 1 H), 1.36 - 1.25 (m, 1 H), 1.25 - 1.19 (m, 1 H), 1.15 (dt, 
J1=13.1 Hz, J2=1.7 Hz, 1 H), 0.84 (d, J=7.0 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 167.0, 152.1, 143.0, 140.0, 130.5, 130.1, 129.5, 127.8, 127.5, 
52.9, 49.0, 40.5, 38.0, 36.5, 32.8, 21.5, 15.7. 
MS (70 eV, EI) m/z (%): 387 (3) [M+], 372 (23), 371 (100), 210 (8), 155 (23), 90 (33), 58 (9). 
IR (ATR) ν~  (cm-1): 2984 (vw), 2960 (w), 2936 (w), 2910 (w), 2856 (w), 1720 (s), 1608 (w), 
1596 (w), 1434 (m), 1380 (w), 1330 (m), 1304 (m), 1280 (vs), 1252 (m), 1210 (w), 1198 (w), 
1188 (w), 1174 (m), 1156 (vs), 1142 (s), 1110 (m), 1094 (s), 1070 (m), 1056 (m), 1018 (w), 994 
(m), 970 (m), 958 (w), 926 (m), 882 (w), 864 (m), 848 (m), 824 (w), 814 (m), 798 (w), 770 (m), 
704 (s), 684 (s), 648 (m). 
HRMS (EI) for C21H25NO4S (387.1504): 387.1522. 
 
7.8 Cross-coupling of (1-(tert-butoxycarbonyl)-6-methylpiperidin-2-yl)zinc chloride 
(127) ‒ Pd-1,2-migration 
A dry and Ar-flushed 10 mL Schlenk-tube equipped with a stirring bar was charged with a 
solution of t- butyl 2-methylpiperidine-1-carboxylate (1 mmol; 0.20 g) and TMEDA (1 mmol; 
0.12 g; 0.45 mL) in anhydrous Et2O (2 mL). It was cooled to ‒78 °C and sBuLi (1.14 M in 
hexanes) (1.2 mmol; 1.05 mL) was slowly added via syringe. The reaction mixture was stirred for 
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4 h at this temperature before ZnCl2 (1.0 M in THF) (1.2 mmol; 1.2 mL) was added. The reaction 
mixture was stirred for 15 min at ‒78 °C and was then allowed to warm to room temperature. 
Et2O was removed in vacuo (8 min; 1 mbar). Meanwhile, a solution of the respective aryl iodide 
(0.7 mmol), Pd(dba)2 (28.8 mg; 0.05 mmol) and RuPhos (23.3 mg; 0.05 mmol) was prepared and 
cooled to 0 °C. The piperidinylzinc reagent was added to this mixture and stirred for 12 h. The 
reaction mixture was then warmed to room temperature and stirred for 12 h and finally heated to 
40 °C for 12 h. NH4Cl sat. aq. solution (20 mL) was added, the phases were separated and the 
aqueous phase was extracted with Et2O (4 x 10 mL). The combined organic layers were washed 
with brine (10 mL) and dried over Na2SO4. The solvents were evaporated and the residue was 
subjected to column chromatography yielding the respective title compound. 
 
trans-tert-Butyl 2-methyl-5-phenylpiperidine-1-carboxylate (128a) 
 
 
colorless oil (90 %) 
1H-NMR (400 MHz, C6D6) δ: 7.34 (d, J=7.6 Hz, 2 H), 7.21 (t, J=7.7 Hz, 2 H), 7.08 (t, J=7.4 Hz, 
1 H), 4.41 - 4.33 (m, 2 H), 3.10 (dd, J1=14.0 Hz, J2=4.3 Hz, 1 H), 2.59 (br. s., 1 H), 1.75 - 1.58 
(m, 3 H), 1.58 - 1.39 (m, 9 H), 1.05 (d, J=6.8 Hz, 3 H), 0.94 - 0.88 (m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 155.2, 144.7, 128.9, 128.7, 128.3, 126.6, 126.4, 79.2, 47.3, 42.5, 
38.6, 28.9, 26.3, 26.1, 16.9. 
MS (70 eV, EI) m/z (%): 275 (1) [M+], 219 (29), 204 (44), 160 (24), 104 (16), 102 (17), 97 (24), 
85 (24), 83 (22), 71 (31), 69 (24), 59 (26), 57 (100), 55 (28), 43 (24), 41 (25). 
IR (ATR) ν~  (cm-1): 2930 (m), 2920 (w), 1684 (vs), 1452 (m), 1414 (m), 1390 (m), 1364 (s), 
1338 (m), 1326 (m), 1308 (m), 1278 (m), 1240 (s), 1166 (s), 1148 (s), 1116 (s), 1078 (m), 1068 
(m), 1050 (m), 1036 (m), 874 (m), 860 (m), 838 (m), 828 (m), 786 (m), 766 (m), 734 (m), 698 
(s), 640 (w). 
HRMS (EI) for C19H25NO2 (275.1885): 275.1874. 
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trans-tert-Butyl 5-(4-methoxyphenyl)-2-methylpiperidine-1-carboxylate (128b) 
 
 
colorless liquid (61 %) 
1H-NMR (400 MHz, C6D6) δ: 7.27 (d, J=8.5 Hz, 2 H), 6.84 (d, J=8.5 Hz, 2 H), 4.42 - 4.33 (m, 2 
H), 3.34 (s, 3 H), 3.14 (dd, J1=13.9 Hz, J2=4.3 Hz, 1 H), 2.64 - 2.59 (m, 1 H), 1.77 - 1.60 (m, 3 
H), 1.58 - 1.52 (m, 1 H), 1.48 (s, 9 H), 1.07 (d, J=6.8 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 158.8, 155.3, 136.4, 129.2, 127.4, 114.4, 114.3, 79.2, 55.1, 47.3, 
42.7, 37.8, 29.0, 28.8, 26.3, 16.9. 
MS (70 eV, EI) m/z (%): 305 (13) [M+], 249 (79), 234 (36), 232 (23), 204 (32), 190 (29), 175 
(21), 148 (35), 147 (22), 134 (57), 121 (46), 102 (37), 91 (23), 58 (31), 57 (100), 43 (79), 41 (21). 
IR (ATR) ν~  (cm-1): 2972 (w), 2934 (w), 1684 (vs), 1612 (m), 1522 (s), 1456 (m), 1412 (s), 
1390 (m), 1364 (s), 1340 (m), 1306 (m), 1246 (vs), 1168 (vs), 1148 (vs), 1114 (s), 1090 (m), 
1036 (s), 878 (m), 828 (s), 808 (m), 768 (m).  
HRMS (EI) for C18H27NO3 (305.1991): 305.1990. 
 
trans-tert-Butyl 2-methyl-5-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate (128c) 
 
 
colorless oil (82 %) 
1H-NMR (400 MHz, C6D6) δ: 7.39 (d, J=8.2 Hz, 2 H), 7.18 (d, 2 H), 4.36 - 4.30 (m, 1 H), 4.26 
(d, J=14.4 Hz, 1 H), 2.98 (dd, J1=14.1 Hz, J2=4.4 Hz, 1 H), 2.41 (br. s., 1 H), 1.65 - 1.54 (m, 1 
H), 1.49 - 1.39 (m, 9 H), 1.35 (td, J1=11.6 Hz, J2=4.8 Hz, 2 H), 1.01 (d, J=6.8 Hz, 3 H), 0.85 
(ddd, J1=12.7 Hz, J2=4.3 Hz, J3=4.1 Hz, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 155.1, 148.7 (d, J=1.1 Hz), 128.8 (q, J=32.2 Hz), 128.0, 125.7 (q, 
J=3.8 Hz), 125.5 (q, J=271.7 Hz), 79.5, 47.1, 41.7, 38.2, 28.9, 26.1, 25.8, 16.6. 
19F-NMR (376 MHz, C6D6) δ: ‒61.92 (s) (minor), ‒62.05 (s) (major). 
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MS (70 eV, EI) m/z (%): 343 (2) [M+], 288 (12), 287 (31), 273 (13), 272 (100), 270 (16), 242 
(10), 228 (52), 172 (14), 57 (82). 
IR (ATR) ν~  (cm-1): 2980 (w), 2930 (w), 1680 (s), 1412 (m), 1366 (m), 1328 (s), 1310 (m), 1254 
(m), 1236 (m), 1162 (s), 1148 (s), 1116 (vs), 1090 (s), 1070 (s), 1054 (m), 1038 (m), 1018 (m), 
882 (m), 866 (m), 834 (s), 768 (m), 708 (m), 648 (m).  
HRMS (EI) for C18H24F3NO2 (343.1759): 343.1757. 
 
trans-tert-Butyl 5-(4-cyanophenyl)-2-methylpiperidine-1-carboxylate (128d) 
 
 
colorless oil (53 %) 
1H-NMR (400 MHz, C6D6) δ: 7.08 (d, J=8.4 Hz, 2 H), 6.99 (d, J=8.2 Hz, 2 H), 4.30 - 4.21 (m, 1 
H), 4.17 (d, J=14.2 Hz, 1 H), 2.92 (dd, J1=14.2 Hz, J2=4.3 Hz, 1 H), 2.32 (br. s., 1 H), 1.61 - 1.52 
(m, 1 H), 1.44 (s, 9 H), 1.34 - 1.26 (m, 2 H), 0.99 (d, J=6.8 Hz, 3 H), 0.87 - 0.79 (m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 155.0, 149.5, 132.3, 128.8, 126.8, 126.2, 119.4, 110.8, 79.6, 47.1, 
41.4, 38.4, 28.9, 26.0, 25.6, 16.6. 
MS (70 eV, EI) m/z (%): 300 (4) [M+], 245 (13), 244 (36), 229 (64), 227 (16), 200 (12), 199 (46), 
185 (36), 142 (15), 130 (10), 129 (18), 58 (20), 57 (100), 43 (52), 41 (14). 
IR (ATR) ν~  (cm-1): 2972 (w), 2934 (w), 2228 (w), 1682 (vs), 1608 (w), 1476 (w), 1454 (w), 
1414 (s), 1392 (m), 1364 (s), 1340 (m), 1308 (m), 1256 (m), 1240 (m), 1166 (s), 1148 (s), 1118 
(m), 1100 (w), 1090 (m), 1052 (m), 1038 (w), 880 (w), 864 (w), 832 (m), 770 (w).  
HRMS (EI) for C18H24N2O2 (300.1838): 300.1831. 
 
trans-tert-Butyl 2-methyl-5-(pyridin-3-yl)piperidine-1-carboxylate (128e) 
 
 
yellow oil (60 %) 
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1H-NMR (400 MHz, C6D6) δ: 8.69 (d, J=2.1 Hz, 1 H), 8.47 (dd, J1=4.7 Hz, J2=1.4 Hz, 1 H), 
7.47 (d, J=7.8 Hz, 1 H), 6.79 (dd, J1=7.8 Hz, J2=4.9 Hz, 1 H), 4.31 (dd, J1=9.8 Hz, J2=6.3 Hz, 1 
H), 4.23 (d, J=14.1 Hz, 1 H), 2.96 (dd, J1=14.2 Hz, J2=4.4 Hz, 1 H), 2.39 (br. s., 1 H), 1.61 - 1.52 
(m, 1 H), 1.52-1.37 (m, 10 H), 1.36 - 1.29 (m, 1 H), 0.99 (d, J=6.8 Hz, 3 H), 0.88 - 0.80 (m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 155.1, 150.7, 148.3, 139.5, 134.8, 123.4, 79.5, 47.1, 41.8, 36.3, 
28.9, 26.1, 25.6, 16.6. 
MS (70 eV, EI) m/z (%): 276 (11) [M+], 221 (19), 220 (21), 205 (24), 203 (25), 176 (43), 175 
(15), 161 (75), 133 (16), 119 (27), 106 (40), 105 (17), 57 (100), 41 (15). 
IR (ATR) ν~  (cm-1): 2976 (w), 2934 (w), 1680 (vs), 1476 (w), 1408 (s), 1390 (m), 1382 (m), 
1364 (s), 1340 (s), 1312 (m), 1296 (w), 1256 (m), 1244 (m), 1232 (m), 1182 (m), 1172 (m), 1146 
(s), 1120 (s), 1088 (s), 1048 (m), 1040 (m), 1022 (m), 1000 (m), 986 (w), 912 (w), 878 (m), 862 
(m), 824 (m), 802 (m), 780 (m), 770 (s), 748 (w), 726 (w), 712 (s), 640 (m), 624 (m). 
HRMS (EI) for C16H24N2O2 (276.1838): 276.1834. 
 
7.9 Synthesis of N-tosyl piperidines 
To a solution of the respective t-butyl piperidine-1-carboxylate (Boc-protected amine) (1 equiv) 
in Et2O (3 mL per 1 mmol) was added trifluoroacetic acid (TFA; 40 equiv) at 0 °C. The reaction 
mixture was stirred for 15 h at room temperature, then cooled to 0 °C and carefully neutralized 
using NaHCO3 sat. aq. solution. The resulting mixture was extracted with CH2Cl2 (4 x). The 
combined organic phases were washed with brine and dried over Na2SO4. The solvents were 
removed via rotary evaporation. The crude deprotected amine (quant. yield) was added to a 
solution of p-tolyl-1-sulfonyl chloride (TsCl; 2 equiv) and NEt3 (2 equiv) in THF (0.2 M). The 
reaction mixture was stirred for 15 h. NH4Cl sat. aq. solution was added. The phases were 
separated and the aqueous layer was extracted with CH2Cl2 (4 x). The combined organic phases 
were washed with brine and dried over Na2SO4. The solvents were evaporated and the crude 
product was purified via column chromatography to give the respective title compound. 
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2-Tosyl-3-(4-(trifluoromethyl)phenyl)decahydroisoquinoline (121na) 
 
 
white crystals (78 %; 0.4 mmol scale) 
m.p.: 194.1 – 195.6 °C. 
1H-NMR (300 MHz, CDCl3) δ: 7.50 (d, J=8.3 Hz, 2 H), 7.43 (d, J=8.3 Hz, 2 H), 7.39 (d, J=8.0 
Hz, 2 H), 7.24 (d, J=8.0 Hz, 2 H), 4.12 (dd, J1=11.5 Hz, J2=3.7 Hz, 1 H), 3.91 (dd, J1=11.3 Hz, 
J2=3.6 Hz, 1 H), 2.56 - 2.37 (m, 4 H), 1.95 - 1.77 (m, 3 H), 1.73 (t, J=3.3 Hz, 1 H), 1.70 - 1.49 
(m, 3 H), 1.47 - 1.28 (m, 2 H), 1.17 - 0.98 (m, 3 H). 
13C-NMR (75 MHz, CDCl3) δ: 145.7 (d, J=1.3 Hz), 143.2, 134.8, 129.5, 129.2 (q, J=32.2 Hz), 
129.1, 128.4, 128.1, 127.9, 127.8, 127.4, 124.5 (q, J=3.9 Hz), 124.1 (q, J=272.1 Hz), 63.1, 53.7, 
43.6, 41.0, 40.7, 32.0, 29.9, 26.0, 25.6, 21.3. 
MS (70 eV, EI) m/z (%): 437 (12) [M+], 293 (17), 292 (100), 283 (14), 282 (74), 281 (44), 280 
(28), 159 (19), 155 (21), 91 (36), 67 (11). 
IR (ATR) ν~  (cm-1): 2922 (w), 2900 (w), 2846 (vw), 1600 (vw), 1446 (vw), 1426 (vw), 1344 
(m), 1326 (s), 1186 (w), 1160 (vs), 1126 (s), 1106 (m), 1086 (m), 1070 (m), 1046 (w), 1034 (w), 
1020 (w), 968 (w), 940 (w), 914 (w), 856 (w), 848 (w), 834 (w), 812 (w), 748 (w), 728 (m), 708 
(w), 666 (w), 654 (w). 
HRMS (EI) for C23H26F3NO2S (437.1636): 437.1635. 
 
4-(trans-5-Methyl-1-tosylpiperidin-2-yl)benzonitrile (121qa) 
 
 
white crystals (75 %; 0.3 mmol scale) 
m.p.: 113.1 – 114.4 °C.  
1H-NMR (400 MHz, C6D6) δ: 7.55 (d, J=8.2 Hz, 2 H), 7.01 (d, J=8.4 Hz, 2 H), 6.90 (d, J=8.2 
Hz, 2 H), 6.77 (d, J=8.0 Hz, 2 H), 4.58 (t, J=5.0 Hz, 1 H), 3.25 (dd, J1=12.9 Hz, J2=3.7 Hz, 1 H), 
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2.98 (dd, J1=12.9 Hz, J2=5.3 Hz, 1 H), 1.92 (s, 3 H), 1.60 - 1.50 (m, 1 H), 1.41 - 1.31 (m, 2 H), 
1.08 (dddd, J1=13.9 Hz, J2=9.9 Hz, J3=4.5 Hz, J4=4.3 Hz, 1 H), 0.71 - 0.64 (m, 1 H), 0.62 (d, 
J=6.9 Hz, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 146.1, 143.3, 138.3, 132.3, 129.9, 128.5, 128.0, 119.2, 111.7, 
58.0, 49.6, 28.7, 27.6, 27.1, 21.5, 18.3. 
MS (70 eV, EI) m/z (%): 354 (10) [M+], 253 (16), 252 (100), 200 (14), 199 (99), 198 (28), 197 
(49), 155 (36), 129 (26), 116 (20), 91 (53), 65 (10). 
IR (ATR) ν~  (cm-1): 2952 (w), 2928 (w), 2226 (w), 1602 (w), 1456 (w), 1344 (s), 1320 (w), 
1304 (w), 1162 (vs), 1096 (m), 1086 (m), 1068 (m), 1052 (m), 1020 (w), 1012 (m), 928 (m), 904 
(m), 840 (m), 830 (m), 808 (s), 754 (w), 722 (vs), 656 (s). 
HRMS (EI) for C20H22N2O2S (354.1402): 354.1398. 
 
4-(trans-1-Tosyl-2-(4-(trifluoromethyl)phenyl)piperidin-4-yl)benzonitrile (124aa) 
 
 
white crystals (72 %; 0.5 mmol scale) 
m.p.: 182.6 – 183.1 °C.  
1H-NMR (400 MHz, CDCl3) δ: 7.82 (d, J=8.2 Hz, 2 H), 7.63 (d, J=8.2 Hz, 2 H), 7.56 (d, J=8.2 
Hz, 2 H), 7.47 (d, J=8.2 Hz, 2 H), 7.37 (d, J=8.0 Hz, 2 H), 7.10 (d, J=8.2 Hz, 2 H), 5.52 (d, J=3.5 
Hz, 1 H), 4.08 (d, J=14.2 Hz, 1 H), 3.17 - 3.08 (m, 1 H), 2.73 - 2.64 (m, 1 H), 2.49 (s, 3 H), 2.41 
(d, J=13.5 Hz, 1 H), 1.91 (td, J1=13.5 Hz, J2=5.5 Hz, 1 H), 1.63 (d, J=12.9 Hz, 1 H), 1.52 (qd, 
J1=12.7 Hz, J2=4.5 Hz, 1 H). 
13C-NMR (101 MHz, CDCl3) δ: 149.9, 143.7, 142.5 (d, J=0.8 Hz), 138.0, 132.5, 129.9, 129.6 (q, 
J=32.6 Hz), 127.4, 127.0, 127.0, 125.9 (q, J=3.7 Hz), 124.0 (q, J=272.1 Hz), 118.6, 110.7, 55.0, 
41.6, 36.8, 34.1, 31.3, 21.5. 
MS (70 eV, EI) m/z (%): 484 (11) [M+], 339 (43), 330 (25), 329 (100), 328 (24), 327 (12), 186 
(23), 172 (12), 159 (11), 155 (15), 90 (30). 
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IR (ATR) ν~  (cm-1): 2956 (vw), 2932 (w), 2232 (w), 1606 (w), 1598 (w), 1506 (vw), 1452 (w), 
1434 (w), 1412 (w), 1376 (w), 1348 (w),1328 (vs), 1290 (m), 1256 (w), 1196 (w), 1158 (vs), 
1110 (vs), 1096 (s), 1072 (s), 1034 (w), 1018 (m), 944 (m), 928 (m), 906 (m), 838 (s), 802 (w), 
738 (w), 716 (m), 702 (m), 664 (s), 650 (m), 634 (w). 
HRMS (EI) for C26H23F3N2O2S (484.1432): 484.1439. 
 
trans-2-Methyl-1-tosyl-5-(4-(trifluoromethyl)phenyl)-piperidine (128ca) 
 
 
white crystals (73 %; 0.5 mmol scale) 
m.p.: 133.0 – 135.9 °C. 
1H-NMR (599 MHz, C6D6) δ: 7.63 (d, J=8.2 Hz, 2 H), 7.31 (d, J=8.0 Hz, 2 H), 7.04 (d, J=8.2 
Hz, 2 H), 6.77 (d, J=8.0 Hz, 2 H), 3.59 - 3.52 (m, 1 H), 3.43 (dd, J1=12.6 Hz, J2=3.8 Hz, 1 H), 
3.27 (dd, J1=12.6 Hz, J2=5.5 Hz, 1 H), 2.52 - 2.44 (m, 1 H), 1.91 (s, 3 H), 1.48 - 1.43 (m, 1 H), 
1.42 - 1.36 (m, 1 H), 1.16 (dddd, J1=13.2 Hz, J2=6.5 Hz, J3=6.4 Hz, J4=3.3 Hz, 1 H), 1.01 - 0.97 
(m, 1 H) 1.02 (d, J=6.6 Hz, 3 H).  
13C-NMR (152 MHz, CDCl3) δ: 147.7 (d, J=1.1 Hz), 143.1, 138.4, 129.9, 129.1 (q, J=32.0 Hz), 
128.7, 128.1, 125.8 (q, J=3.8 Hz), 125.5 (q, J=271.8 Hz), 52.5, 47.8, 39.4, 30.1, 26.8, 21.4, 17.3. 
MS (70 eV, EI) m/z (%): 397 (2) [M+], 383 (19), 382 (100), 155 (18), 91 (12). 
IR (ATR) ν~  (cm-1): 2940 (w), 2926 (w), 1686 (w), 1446 (w), 1384 (w), 1322 (s), 1300 (m), 
1288 (m), 1264 (m), 1238 (m), 1196 (m), 1180 (m), 1154 (s), 1112 (vs), 1094 (s), 1082 (s), 1066 
(s), 1042 (m), 1016 (m), 994 (m), 978 (m), 966 (s), 960 (m), 908 (m), 872 (m), 840 (m), 820 (s), 
738 (w), 710 (s), 684 (s), 646 (s), 632 (m), 606 (m). 
HRMS (EI) for C20H22F3NO2S (397.1323): 397.1320. 
 
cis-1-Tosyl-2-(4-(trifluoromethyl)phenyl)-4-((triisopropylsilyl)oxy)piperidine 
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colorless crystals (56 %; 20 mmol scale) 
m.p.: 93.8 – 95.3 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.68 (d, J=8.2 Hz, 2 H), 7.29 (d, J=8.2 Hz, 2 H), 7.14 (d, J=8.0 
Hz, 2 H), 6.79 (d, J=8.0 Hz, 2 H), 5.19 (d, J=2.9 Hz, 1 H), 3.71 (dt, J1=13.9 Hz, J2=3.8 Hz, 1 H), 
3.62 (br. s., 1 H), 3.55 - 3.47 (m, 1 H), 1.97 - 1.93 (m, 1 H), 1.93 (s, 3 H), 1.65 (ddd, J1=14.2 Hz, 
J2=6.6 Hz, J3=2.9 Hz, 1 H), 1.45 - 1.36 (m, 1 H), 1.26 - 1.19 (m, 1 H), 0.97 - 0.73 (m, 18 H), 0.70 
- 0.59 (m, 3 H). 
13C-NMR (101 MHz, C6D6) δ: 146.5 (d, J=1.1 Hz), 143.2, 139.7, 130.0, 129.1 (q, J=32.2 Hz), 
127.8, 127.4, 125.6 (q, J=3.8 Hz), 125.4 (d, J=271.8 Hz), 65.4, 54.8, 38.3, 37.4, 32.6, 21.4, 18.4, 
18.4, 12.6. 
MS (70 eV) m/z (%): 524 (13), 523 (34), 522 (100), 314 (14), 310 (44), 298 (40), 296 (15), 284 
(24), 272 (10), 242 (20), 159 (25), 157 (11), 155 (26); 129 (16); 101 (12); 91 (59); 87 (11); 75 
(20), 61 (10). 
IR (ATR) ν~  (cm-1): 2938 (w), 2866 (w), 1326 (vs), 1312 (s), 1302 (m), 1162 (s), 1156 (s), 1124 
(vs), 1110 (s), 1080 (s), 1070 (s), 1058 (m), 1036 (m), 1016 (s), 950 (m), 936 (s), 936 (s), 898 
(m), 882 (m), 820 (m), 746 (m), 716 (s), 688 (s), 678 (s), 658 (s), 650 (s), 630 (m). 
HRMS (ESI) for C28H41F3NO3SSi+ (556.2523) [M+H+]: 556.2524. 
 
2-Methyl-1-tosyl-4-((triisopropylsilyl)oxy)piperidine 
 
 
viscous oil (65 %; 10 mmol scale) 
1H-NMR (300 MHz, C6D6) δ: 7.80 (d, J=8.3 Hz, 2 H), 6.82 (d, J=8.0 Hz, 2 H), 4.29 - 4.18 (m, 1 
H), 3.74 - 3.63 (m, 2 H), 3.48 - 3.37 (m, 1 H), 1.91 (s, 3 H), 1.56 - 1.43 (m, 2 H), 1.42 - 1.34 (m, 
2 H), 1.31 (d, J=7.2 Hz, 3 H), 1.08 - 0.92 (m, 18 H), 0.92 - 0.86 (m, 3 H). 
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13C-NMR (75 MHz, C6D6) δ: 142.7, 140.4, 130.0, 127.8, 65.9, 48.8, 37.9, 36.3, 33.6, 21.5, 19.9, 
18.6, 12.7. 
MS (70 eV, EI) m/z (%): 424 (1), 384 (12), 383 (26), 382 (100), 90 (12). 
IR (ATR) ν~  (cm-1): 2942 (m), 2890 (m), 2866 (m), 1598 (vw), 1494 (w), 1464 (m), 1380 (w), 
1346 (m), 1328 (m), 1250 (w), 1216 (w), 1162 (vs), 1130 (s), 1106 (m), 1088 (m), 1060 (s), 1040 
(s), 1018 (m), 988 (m), 966 (vs), 914 (s), 882 (s), 870 (s), 814 (m), 776 (m), 712 (s), 700 (s), 678 
(vs), 654 (s), 642 (s). 
HRMS (EI) for C21H36NO3SSi+ (410.2185) [M-CH3]+: 410.2207. 
 
7.10 TIPS-deprotection 
To a solution of the respective 4-((triisopropylsilyl)oxy)piperidine (1 equiv) in THF (0.2 M) was 
added nBu4NF·3 H2O (2 equiv) portionwise. The reaction mixture was stirred for 15 h at room 
temperature, then H2O was added, the phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3 x). The combined organic layers were washed with brine and dried over 
Na2SO4. The solvents were evaporated and the crude product was subjected to column 
chromatography. 
 
tert-Butyl cis-2-(4-fluorophenyl)-4-hydroxypiperidine-1-carboxylate 
 
 
viscous oil (89 %; 5 mmol scale) 
1H-NMR (300 MHz, C6D6) δ: 7.37 (d, J=8.3 Hz, 2 H), 7.09 (d, J=8.3 Hz, 2 H), 5.17 (br. s., 1 H), 
3.98 (ddd, J1=13.6 Hz, J2=5.0 Hz, J3=2.8 Hz, 1 H), 3.60 - 3.48 (m, 1 H), 3.20 (td, J1=12.9 Hz, 
J2=3.5 Hz, 1 H), 1.85 - 1.72 (m, 1 H), 1.61 (ddd, J1=14.4 Hz, J2=6.8 Hz, J3=3.2 Hz, 1 H), 1.53 - 
1.41 (m, 1 H), 1.36 (s, 9 H), 1.28 - 1.14 (m, 1 H). 
13C-NMR (75 MHz, C6D6) δ: 155.0, 147.3 (d, J=1.1 Hz), 128.2 (q, J=32.3 Hz), 126.1, 124.8 (q, 
J=271.8 Hz), 125.0 (q, J=3.6 Hz), 79.3, 63.9, 52.2, 35.6, 35.5, 31.9, 27.9. 
MS (70 eV, EI) m/z (%): 345 (0.3) [M+], 290 (12), 289 (68), 270 (11), 244 (40), 228 (11), 200 
(18), 186 (11), 172 (15), 59 (100), 41 (13), 18 (11). 
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IR (ATR) ν~  (cm-1): 3438 (w), 2978 (w), 2932 (w), 1664 (s), 1620 (w), 1478 (w), 1454 (w), 
1416 (m), 1394 (m), 1366 (m), 1324 (vs), 1280 (m), 1252 (m), 1210 (w), 1160 (s), 1112 (vs), 
1068 (vs), 1040 (s), 1016 (m), 988 (w), 970 (w), 958 (w), 940 (m), 862 (m), 838 (m), 830 (m), 
774 (w), 760 (w). 
HRMS (EI) for C17H22F3NO3 (345.1552): 345.1562. 
 
cis-1-Tosyl-2-(4-(trifluoromethyl)phenyl)piperidin-4-ol 
 
 
white crystals (87 %; 10 mmol scale) 
m.p.: 114.0 – 115.5 °C. 
1H-NMR (400 MHz, C6D6) δ: 7.50 (d, J=8.2 Hz, 2 H), 7.21 (d, J=8.4 Hz, 2 H), 7.07 (d, J=8.2 
Hz, 2 H), 6.68 (d, J=7.9 Hz, 2 H), 4.85 (t, J=4.7 Hz, 1 H), 3.52 - 3.42 (m, 1 H), 3.40 - 3.30 (m, 1 
H), 3.26 (br. s., 1 H), 1.89 - 1.80 (m, 3 H), 1.64 (dt, J1=14.3 Hz, J2=4.1 Hz, 1 H), 1.47 (ddd, 
J=14.3 Hz, J2=6.2 Hz, J3=3.3 Hz, 1 H), 1.36 - 1.28 (m, 1 H), 1.06 - 0.99 (m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 146.0 (d, J=1.2 Hz), 143.2, 139.2, 130.0, 129.3 (q, J=32.2 Hz), 
127.8, 127.8, 125.5 (q, J=3.9 Hz), 125.4 (q, J=271.3 Hz), 64.6, 55.4, 38.9, 36.6, 32.1, 21.4. 
19F-NMR (376 MHz, C6D6) δ: ‒62.10 (s) (major), ‒62.25 (s) (minor). 
MS (70 eV) m/z (%): 399 (1) [M+], 254 (41), 245 (16), 244 (100), 243 (13), 242 (40), 226 (35), 
200 (12), 199 (13), 172 (25), 159 (19), 155 (32), 91 (61); 65 (12). 
IR (ATR) ν~  (cm-1): 2938 (w), 1622 (w), 1598 (w), 1456 (w), 1426 (w), 1326 (vs), 1260 (w), 
1162 (vs), 1116 (s), 1096 (m), 1068 (s), 1046 (s), 1020 (m), 982 (m), 932 (m), 854 (m), 832 (m), 
814 (s), 720 (s), 706 (m), 654 (s). 
HRMS (ESI) for C19H21F3NO3S+ (400.1189) [M+H+]: 400.1189. 
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2-Methyl-1-tosylpiperidin-4-ol 
 
 
viscous oil (73 %; 7 mmol scale) 
 
1H-NMR (300 MHz, C6D6) δ: 7.73 (d, J=8.0 Hz, 2 H), 6.80 (d, J=8.0 Hz, 2 H), 4.13 - 3.98 (m, 1 
H), 3.60 - 3.29 (m, 3 H), 1.91 (s, 3 H), 1.53 - 1.33 (m, 2 H), 1.23 (d, J=6.9 Hz, 3 H), 1.17 (d, 
J=3.6 Hz, 2 H), 1.01 - 0.90 (m, 1 H).  
13C-NMR (75 MHz, C6D6) δ: 142.8, 140.0, 130.0, 127.8, 64.8, 48.9, 37.6, 36.7, 32.9, 21.5, 19.6. 
MS (70 eV, EI) m/z (%): 269 (3) [M+], 255 (14), 254 (100), 210 (9), 155 (26), 90 (38). 
IR (ATR) ν~  (cm-1): 3526 (w), 2924 (w), 2882 (w), 1598 (w), 1494 (w), 1454 (w), 1424 (w), 
1402 (w), 1382 (w), 1366 (w), 1344 (m), 1322 (m), 1304 (m), 1288 (m), 1234 (w), 1216 (w), 
1184 (w), 1158 (s), 1148 (s), 1132 (s), 1098 (m), 1080 (s), 1056 (m), 1038 (m), 1018 (m), 1008 
(w), 982 (m), 942 (m), 912 (s), 890 (w), 852 (m), 814 (m), 788 (w), 732 (w), 710 (s), 688 (vs), 
642 (s). 
HRMS (EI) for C13H19NO3S (269.1086): 269.1078. 
 
7.11 Iodination 
In a dry and Ar-flushed Schlenk-flask I2 (1.2 equiv) was dissolved in CH2Cl2 (0.6 M). The 
solution was cooled to 0 °C and PPh3 (1.2 equiv) was added portionwise. The resulting yellow 
suspension was stirred for 1 h 30 min at 0 °C before N-methyl-imidazole (NMI; 1.25 equiv) was 
added. The respective piperidin-4-ol (1 equiv) was transferred drop- or portionwise to this 
mixture. The reaction mixture was allowed to proceed for 6 h at 0 °C, then quenched with 
NaHSO3 sat. aq. solution. Phases were separated and the aqueous layer was extracted with 
CH2Cl2 (3x). Solvents were evaporated and the crude product was subjected to column 
chromatography.78 
 
 
 
 
C. Experimental Section  239 
 
tert-Butyl 4-iodo-2-(4-(trifluoromethyl)phenyl)piperidine-1-carboxylate (123a) 
 
 
yellow oil (68 %; 7 mmol scale) 
1H-NMR (300 MHz, C6D6) δ: 7.26 (d, J=8.3 Hz, 2 H), 6.78 (d, J=8.3 Hz, 2 H), 5.22 (br. s., 1 H), 
3.76 (d, J=13.0 Hz, 1 H), 3.53 (tt, J1=12.4 Hz, J2=3.9 Hz, 1 H), 2.50 (dt, J1=13.6 Hz, J2=1.8 Hz, 1 
H), 2.26 - 2.07 (m, 2 H), 1.82 (qd, J1=12.4 Hz, J2=4.4 Hz, 1 H), 1.72 - 1.61 (m, 1 H), 1.41 (s, 9 
H). 
13C-NMR (75 MHz, C6D6) δ: 155.3, 143.6 (d, J=1.1 Hz), 129.6 (q, J=32.3 Hz), 129.0, 127.2, 
126.3 (q, J=3.9 Hz), 125.4, 125.2 (q, J=272.1 Hz), 80.4, 56.1, 42.4, 41.7, 39.6, 28.7, 20.3. 
MS (70 eV, EI) m/z (%): 455 (1) [M+], 399 (22), 328 (12), 272 (49), 228 (42), 199 (18), 159 (16), 
61 (13), 59 (100), 41 (13), 18 (38). 
IR (ATR) ν~  (cm-1): 2974 (w), 2932 (w), 2870 VW 1690 (s), 1620 (w), 1478 (w), 1452 (w), 
1412 (s), 1366 (m), 1324 (vs), 1264 (m), 1248 (m), 1154 (vs), 1122 (vs), 1068 (s), 1014 (m), 
1004 (m), 982 (m), 954 (w), 910 (m), 870 (w),852 (m), 836 (m), 794 (w), 772 (m), 732 (w),  722 
(w), 642 (w). 
HRMS (EI) for C17H21F3INO2 (455.0569): 455.0561. 
 
4-iodo-1-tosyl-2-(4-(trifluoromethyl)phenyl)piperidine (123b) 
 
 
slightly yellow crystals (55 %; 8 mmol scale) 
m.p.: 132.6 – 133.8 °C. 
1H-NMR (400 MHz, C6D6) δ:7.64 (d, J=8.2 Hz, 2 H), 7.25 (d, J=8.4 Hz, 2 H), 6.95 (d, J=8.2 Hz, 
2 H), 6.78 (d, J=7.9 Hz, 2 H), 4.98 (d, J=2.9 Hz, 1 H), 3.52 - 3.38 (m, 2 H), 2.46 - 2.29 (m, 2 H), 
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1.99 (td, J1=13.4 Hz, J2=5.4 Hz, 1 H), 1.89 (s, 3 H), 1.66 (qd, J1=12.6 Hz, J2=4.6 Hz, 1 H), 1.50 - 
1.43 (m, 1 H). 
13C-NMR (101 MHz, C6D6) δ: 143.8, 142.4 (d, J=1.2 Hz), 139.3, 130.3, 129.9 (q, J=32.3 Hz), 
127.8, 127.6, 126.4 (q, J=3.7 Hz), 125.2 (q, J=272.0 Hz), 57.9, 43.7, 40.8, 38.3, 21.5, 19.0. 
MS (70 eV) m/z (%): 509 (1) [M+], 383 (22), 382 (100), 226 (12), 199 (63), 186 (23), 185 (10), 
184 (53), 159 (54), 155 (87), 91 (67), 65 (11), 55 (10). 
IR (ATR) ν~  (cm-1): 1326 (vs), 1292 (m), 1154 (s), 1118 (s), 1102 (m), 1090 (s), 1070 (s), 1058 
(s), 1044 (m), 1016 (m), 998 (m), 954 (s), 930 (s), 906 (m), 854 (m), 844 (m), 828 (m), 816 (s), 
742 (m), 710 (s), 694 (s), 652 (vs). 
HRMS (ESI) for C19H19F3INO2SCl- (543.9827) [M+Cl-]:543.9817.  
 
2-Methyl-4-iodo-1-tosylpiperidine (123c) 
 
 
yellow oil (59 %; 5 mmol scale) 
1H-NMR (300 MHz, C6D6) δ: 7.63 (d, J=8.3 Hz, 2 H), 6.77 (d, J=8.0 Hz, 2 H), 4.00 - 3.84 (m, 1 
H), 3.67 (tt, J1=12.3 Hz, J2=4.4 Hz, 1 H), 3.38 (dt, J1=13.8 Hz, J2=1.7 Hz, 1 H), 2.41 (ddd, 
J1=13.7 Hz, J2=12.2 Hz, J3=3.2 Hz, 1 H), 1.99 - 1.90 (m, 1 H), 1.88 (s, 3 H), 1.81 - 1.67 (m, 1 H), 
1.67 - 1.57 (m, 2 H), 0.58 (d, J=6.9 Hz, 3 H). 
13C-NMR (75 MHz, C6D6) δ: 143.1, 139.6, 130.1, 127.7, 52.4, 44.3, 42.2, 39.2, 21.5, 20.1, 15.5. 
MS (70 eV, EI) m/z (%): 379 (1) [M+], 363 (12), 253 (15), 252 (100), 155 (52), 90 (61), 69 (10), 
66 (10), 58 (17), 56 (12). 
IR (ATR) ν~  (cm-1): 2974 (w),  2924 (w), 2870 (vw), 1598 (w), 1494 (vw), 1444 (w), 1380 (w), 
1330 (s), 1302 (m), 1258 (m), 1204 (w), 1178 (m), 1150 (vs), 1092 (s), 1070 (m), 1056 (m), 1018 
(w), 1008 (m), 988 (s), 964 (w), 914 (s), 878 (w), 852 (m), 814 (s), 724 (w), 708 (m), 684 (vs), 
644 (s). 
HRMS (EI) for C13H18INO2S (379.0103): 379.0118. 
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1. X-ray Structures 
 
1.1 Sulfoxide-alkene hybrid ligands 
 
(1R,4S,7R)-2-(4-Methoxyphenyl)-7-((R)-p-tolylsulfinyl)-bicyclo[2.2.1]hept-2-ene (46a): 
   
C7
C4
C3 C2
C5 C6
C1
O1
S1
C8
C9
C10
C11
C15
C20
C19
C12
C13
C14
C16 C17
C18
O2
C21
 
 
Crystal data 
net formula C21H22O2S 
Mr/g mol−1 338.464 
crystal size/mm 0.21 × 0.19 × 0.09 
T/K 200(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system monoclinic 
space group P21 
a/Å 6.44350(10) 
b/Å 7.4994(2) 
c/Å 18.0502(4) 
α/° 90 
β/° 90.3361(15) 
γ/° 90 
V/Å3 872.21(3) 
Z 2 
calc. density/g cm−3 1.28877(4) 
µ/mm−1 0.195 
absorption correction none 
refls. measured 7321 
Rint 0.0237 
mean σ(I)/I 0.0417 
θ range 3.16–27.47 
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observed refls. 3559 
x, y (weighting scheme) 0.0433, 0.0402 
hydrogen refinement constr 
Flack parameter −0.05(6) 
refls in refinement 3995 
parameters 219 
restraints 1 
R(Fobs) 0.0356 
Rw(F2) 0.0852 
S 1.052 
shift/errormax 0.001 
max electron density/e Å−3 0.147 
min electron density/e Å−3 −0.280 
 
(1S,4R,7S)-2-(4-methoxyphenyl)-7-((R)-p-tolylsulfinyl)-bicyclo[2.2.1]hept-2-ene (46b) 
S+
OMe
Me
O-
  C7
C4 C5
C6
C3
C2
C1
S1
O1
C8
C12
C11
C13C10
C9
C14
C15
C16
C17
C18
O2
C21
C19
C20
 
Crystal data 
net formula C21H22O2S 
Mr/g mol−1 338.464 
crystal size/mm 0.14 × 0.05 × 0.04 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system orthorhombic 
space group P212121 
a/Å 6.3806(2) 
b/Å 13.0486(2) 
c/Å 21.0871(5) 
α/° 90 
β/° 90 
γ/° 90 
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V/Å3 1755.67(7) 
Z 4 
calc. density/g cm−3 1.28052(5) 
µ/mm−1 0.194 
absorption correction none 
refls. measured 11548 
Rint 0.0433 
mean σ(I)/I 0.0315 
θ range 3.27–25.34 
observed refls. 2912 
x, y (weighting scheme) 0.0465, 0.1943 
hydrogen refinement constr 
Flack parameter −0.06(7) 
refls in refinement 3215 
parameters 219 
restraints 0 
R(Fobs) 0.0330 
Rw(F2) 0.0840 
S 1.078 
shift/errormax 0.001 
max electron density/e Å−3 0.216 
min electron density/e Å−3 −0.216 
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1.2 Products of the diastereoselective cross-coupling of cycloalkylzinc reagents with aryl 
halides 
 
1-[(1R,2S,5R)-2-Isopropyl-5-methylcyclohexyl]-4-methoxybenzene (69a) 
   
Crystal data 
net formula C17H26O 
Mr/g mol−1 246.388 
crystal size/mm 0.25 × 0.23 × 0.18 
T/K 200(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system orthorhombic 
space group P212121 
a/Å 6.5955(2) 
b/Å 7.8820(2) 
c/Å 29.1769(8) 
α/° 90 
β/° 90 
γ/° 90 
V/Å3 1526.78(7) 
Z 4 
calc. density/g cm−3 1.07898(5) 
µ/mm−1 0.064 
absorption correction none 
refls. measured 10226 
Rint 0.0382 
mean σ(I)/I 0.0278 
θ range 3.17–26.03 
observed refls. 1415 
x, y (weighting scheme) 0.0524, 0.1045 
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hydrogen refinement constr 
Flack parameter −2(2) 
refls in refinement 1748 
parameters 167 
restraints 0 
R(Fobs) 0.0386 
Rw(F2) 0.0972 
S 1.075 
shift/errormax 0.001 
max electron density/e Å−3 0.117 
min electron density/e Å−3 −0.152 
 
Methyl 4-[cis-3-methylcyclohexyl]benzoate (78a) 
    
Crystal data 
net formula C15H20O2 
Mr/g mol−1 232.318 
crystal size/mm 0.25 × 0.15 × 0.08 
T/K 200(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system monoclinic 
space group C2/c 
a/Å 15.7972(5) 
b/Å 6.3827(2) 
c/Å 26.2140(8) 
α/° 90 
β/° 96.5673(19) 
γ/° 90 
V/Å3 2625.78(14) 
Z 8 
calc. density/g cm−3 1.17536(6) 
µ/mm−1 0.076 
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absorption correction none 
refls. measured 8464 
Rint 0.0438 
mean σ(I)/I 0.0439 
θ range 3.18–26.01 
observed refls. 1767 
x, y (weighting scheme) 0.0937, 0.7066 
hydrogen refinement constr 
refls in refinement 2560 
parameters 157 
restraints 0 
R(Fobs) 0.0574 
Rw(F2) 0.1739 
S 1.047 
shift/errormax 0.001 
max electron density/e Å−3 0.359 
min electron density/e Å−3 −0.162 
 
(3β)-3-(4-Methoxyphenyl)cholest-5-ene (88) 
  
Crystal data 
net formula C34H52O 
Mr/g mol−1 476.776 
crystal size/mm 0.29 × 0.18 × 0.15 
T/K 200(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system monoclinic 
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space group P21 
a/Å 16.2591(5) 
b/Å 9.4526(3) 
c/Å 18.8939(5) 
α/° 90 
β/° 95.5080(18) 
γ/° 90 
V/Å3 2890.41(15) 
Z 4 
calc. density/g cm−3 1.09565(6) 
µ/mm−1 0.063 
absorption correction none 
refls. measured 19089 
Rint 0.0537 
mean σ(I)/I 0.0438 
θ range 3.16–25.05 
observed refls. 4138 
x, y (weighting scheme) 0.0663, 0.3301 
hydrogen refinement constr 
Flack parameter 0(2) 
refls in refinement 5439 
parameters 643 
restraints 1 
R(Fobs) 0.0462 
Rw(F2) 0.1221 
S 1.031 
shift/errormax 0.001 
max electron density/e Å−3 0.189 
min electron density/e Å−3 −0.228 
 
Flack parameter meaningless, 4744 Friedel pairs merged. 
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1.3 Products of the diastereoselective cross-coupling of cycloalkylzinc reagents with 
alkynyl bromides 
 
cis-3-Ethynylcyclohexyl 4-methylbenzenesulfonate 
 
   
Crystal data 
net formula C15H18O3S 
Mr/g mol−1 278.368 
crystal size/mm 0.33 × 0.20 × 0.06 
T/K 200(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group C2/c 
a/Å 19.7276(13) 
b/Å 5.8406(5) 
c/Å 25.346(3) 
α/° 90 
β/° 92.474(8) 
γ/° 90 
V/Å3 2917.7(5) 
Z 8 
calc. density/g cm−3 1.2674(2) 
µ/mm−1 0.223 
absorption correction 'multi-scan' 
transmission factor range 0.89479–1.00000 
refls. measured 4971 
Rint 0.0503 
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mean σ(I)/I 0.1020 
θ range 4.34–25.17 
observed refls. 1533 
x, y (weighting scheme) 0.0722, 0 
hydrogen refinement constr 
refls in refinement 2568 
parameters 173 
restraints 0 
R(Fobs) 0.0749 
Rw(F2) 0.1694 
S 1.090 
shift/errormax 0.001 
max electron density/e Å−3 0.492 
min electron density/e Å−3 −0.297 
 
trans-4-Ethynylcyclohexyl 4-methylbenzenesulfonate 
   
Crystal data 
net formula C15H18O3S 
Mr/g mol−1 278.368 
crystal size/mm 0.30 × 0.22 × 0.18 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system triclinic 
space group P1bar 
a/Å 6.5644(6) 
b/Å 9.8375(9) 
c/Å 12.2208(11) 
α/° 69.467(8) 
β/° 76.561(8) 
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γ/° 84.673(7) 
V/Å3 718.76(11) 
Z 2 
calc. density/g cm−3 1.28623(20) 
µ/mm−1 0.226 
absorption correction 'multi-scan' 
transmission factor range 0.84382–1.00000 
refls. measured 5283 
Rint 0.0411 
mean σ(I)/I 0.0778 
θ range 4.21–26.35 
observed refls. 1804 
x, y (weighting scheme) 0.0564, 0 
hydrogen refinement constr 
refls in refinement 2899 
parameters 173 
restraints 0 
R(Fobs) 0.0476 
Rw(F2) 0.1139 
S 0.885 
shift/errormax 0.001 
max electron density/e Å−3 0.382 
min electron density/e Å−3 −0.348 
 
4-((trans-4-(tert-Butyl)cyclohexyl)ethynyl)benzonitrile (103b) 
  
C19
C18
C16
C17
C13
C14
C15
C12
C11
C10
C9
C8
C5
C6
C7
C2
C3
C4
C1
N1
 
Crystal data 
net formula C19H23N 
Mr/g mol−1 265.393 
crystal size/mm 0.15 × 0.13 × 0.05 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
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crystal system triclinic 
space group P1bar 
a/Å 9.1411(3) 
b/Å 9.3602(3) 
c/Å 10.5855(4) 
α/° 96.576(2) 
β/° 113.547(2) 
γ/° 98.372(2) 
V/Å3 806.43(5) 
Z 2 
calc. density/g cm−3 1.09297(7) 
µ/mm−1 0.063 
absorption correction none 
refls. measured 7170 
Rint 0.0293 
mean σ(I)/I 0.0452 
θ range 3.28–27.82 
observed refls. 2380 
x, y (weighting scheme) 0.0556, 0.1610 
hydrogen refinement constr 
refls in refinement 3744 
parameters 184 
restraints 0 
R(Fobs) 0.0527 
Rw(F2) 0.1381 
S 1.030 
shift/errormax 0.001 
max electron density/e Å−3 0.159 
min electron density/e Å−3 −0.182 
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1.4 Products of the diastereoselective Fe-mediated cross-coupling 
 
4-(trans-2-((tert-butyldimethylsilyl)oxy)cyclohexyl)phenyl pivalate (36i) 
  
C22
C20
C23
C21
C19
O3
O2
C16
C17
C15
C14
C13
C18 C8
C9
C10
C11
C12
C7
O1
Si1 C2
C1
C3
C4
C5
C6
 
Crystal data 
net formula C23H38O3Si 
Mr/g mol−1 390.632 
crystal size/mm 0.37 × 0.10 × 0.08 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system monoclinic 
space group P21/c 
a/Å 6.10750(10) 
b/Å 14.1338(3) 
c/Å 27.6415(5) 
α/° 90 
β/° 96.5671(11) 
γ/° 90 
V/Å3 2370.42(8) 
Z 4 
calc. density/g cm−3 1.09460(4) 
µ/mm−1 0.117 
absorption correction none 
refls. measured 15796 
Rint 0.0342 
mean σ(I)/I 0.0368 
θ range 3.24–27.50 
observed refls. 4067 
x, y (weighting scheme) 0.0713, 1.4216 
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hydrogen refinement constr 
refls in refinement 5417 
parameters 252 
restraints 0 
R(Fobs) 0.0559 
Rw(F2) 0.1563 
S 1.021 
shift/errormax 0.001 
max electron density/e Å−3 0.716 
min electron density/e Å−3 −0.258 
 
4-(trans-2-Hydroxycyclopentyl)benzonitrile 
 
  
O1
C1
C2
C3
C4
C5
C6
C11 C10
C9
C8
C7
C12 N1
 
Crystal data 
net formula C12H13NO 
Mr/g mol−1 187.238 
crystal size/mm 0.34 × 0.31 × 0.21 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group P21/c 
a/Å 6.3875(4) 
b/Å 9.6599(6) 
c/Å 16.5535(8) 
α/° 90 
β/° 91.420(5) 
γ/° 90 
V/Å3 1021.08(10) 
Z 4 
calc. density/g cm−3 1.21800(12) 
µ/mm−1 0.078 
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absorption correction 'multi-scan' 
transmission factor range 0.98653–1.00000 
refls. measured 6866 
Rint 0.0326 
mean σ(I)/I 0.0530 
θ range 4.22–26.32 
observed refls. 1210 
x, y (weighting scheme) 0.0625, 0 
hydrogen refinement constr 
refls in refinement 2059 
parameters 147 
restraints 0 
R(Fobs) 0.0522 
Rw(F2) 0.1311 
S 1.009 
shift/errormax 0.001 
max electron density/e Å−3 0.199 
min electron density/e Å−3 −0.243 
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1.6 Products of the diastereoselective cross-coupling of piperidinylzinc reagents 
 
cis-tert-Butyl 2-(3-cyanophenyl)-4-methylpiperidine-1-carboxylate (121d) 
N
Me
Boc
NC
  
C1
O1
O2
N1
C6
C8
C13
C12
C11
C10
C14
N2
C9
C5 C4
C7
C3
C2
C15
C18
C17
C16
 
Crystal data 
net formula C18H24N2O2 
Mr/g mol−1 300.395 
crystal size/mm 0.60 × 0.13 × 0.07 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system triclinic 
space group P1bar 
a/Å 6.3135(4) 
b/Å 10.2813(10) 
c/Å 13.8719(10) 
α/° 76.283(7) 
β/° 85.876(6) 
γ/° 77.838(7) 
V/Å3 854.90(12) 
Z 2 
calc. density/g cm−3 1.16698(16) 
µ/mm−1 0.076 
absorption correction 'multi-scan' 
transmission factor range 0.72269–1.00000 
refls. measured 5884 
Rint 0.0355 
mean σ(I)/I 0.0856 
θ range 4.24–26.33 
observed refls. 1872 
x, y (weighting scheme) 0.0371, 0 
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hydrogen refinement constr 
refls in refinement 3435 
parameters 203 
restraints 0 
R(Fobs) 0.0427 
Rw(F2) 0.0891 
S 0.830 
shift/errormax 0.001 
max electron density/e Å−3 0.163 
min electron density/e Å−3 −0.141 
 
cis-tert-Butyl 2-(4-cyanophenyl)-4-phenylpiperidine-1-carboxylate (121h) 
  
N2
C17
C14 C15
C16
C11
C12
C13
C5
C4
C3
C2
O1
C1
O2
N1
C6
C7
C8
C9
C10
C18
C19
C20
C21C22
C23
 
Crystal data 
net formula C23H26N2O2 
Mr/g mol−1 362.465 
crystal size/mm 0.39 × 0.22 × 0.12 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group P21/c 
a/Å 14.5271(9) 
b/Å 11.6682(8) 
c/Å 12.0141(8) 
α/° 90 
β/° 98.276(7) 
γ/° 90 
V/Å3 2013.9(2) 
Z 4 
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calc. density/g cm−3 1.19548(12) 
µ/mm−1 0.076 
absorption correction 'multi-scan' 
transmission factor range 0.96746–1.00000 
refls. measured 8788 
Rint 0.0314 
mean σ(I)/I 0.0756 
θ range 4.23–26.32 
observed refls. 2310 
x, y (weighting scheme) 0.0279, 0 
hydrogen refinement constr 
refls in refinement 4068 
parameters 247 
restraints 0 
R(Fobs) 0.0352 
Rw(F2) 0.0680 
S 0.806 
shift/errormax 0.001 
max electron density/e Å−3 0.156 
min electron density/e Å−3 −0.144 
 
2-Tosyl-3-(4-(trifluoromethyl)phenyl)decahydroisoquinoline (121na) 
  
C12
C11
C10
C9
C14C13
C8
N1
C16
C15
C17
C22
C21
C20
C19
C18
C23
F1
F2
F3
S1
O2
O1
C1
C2
C3
C4
C5
C6
C7
 
Crystal data 
net formula C23H26F3NO2S 
Mr/g mol−1 437.529 
crystal size/mm 0.52 × 0.05 × 0.02 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
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crystal system monoclinic 
space group C2/c 
a/Å 31.5413(5) 
b/Å 5.49050(10) 
c/Å 25.8592(4) 
α/° 90 
β/° 110.7934(8) 
γ/° 90 
V/Å3 4186.55(12) 
Z 8 
calc. density/g cm−3 1.38831(4) 
µ/mm−1 0.201 
absorption correction none 
refls. measured 12910 
Rint 0.0338 
mean σ(I)/I 0.0306 
θ range 3.37–25.36 
observed refls. 3115 
x, y (weighting scheme) 0.0296, 5.6059 
hydrogen refinement constr 
refls in refinement 3826 
parameters 300 
restraints 0 
R(Fobs) 0.0383 
Rw(F2) 0.0938 
S 1.088 
shift/errormax 0.001 
max electron density/e Å−3 0.223 
min electron density/e Å−3 −0.367 
 
F atoms disordered, split model applied, sof ratio about 1:1. 
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4-(trans-5-Methyl-1-tosylpiperidin-2-yl)benzonitrile (121qa) 
  
C14
C15
C16
C17
C20
C18
C19
S1
O1
O2
N1
C5
C6
C7
C8
C9
C13
N2
C10
C11
C4
C1
C3
C2
C12
 
Crystal data 
net formula C20H22N2O2S 
Mr/g mol−1 354.467 
crystal size/mm 0.40 × 0.08 × 0.05 
T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system triclinic 
space group P1bar 
a/Å 5.4884(2) 
b/Å 11.8978(8) 
c/Å 14.2002(7) 
α/° 77.357(5) 
β/° 86.323(4) 
γ/° 87.652(4) 
V/Å3 902.58(8) 
Z 2 
calc. density/g cm−3 1.30429(12) 
µ/mm−1 0.195 
absorption correction 'multi-scan' 
transmission factor range 0.98356–1.00000 
refls. measured 6364 
Rint 0.0211 
mean σ(I)/I 0.0554 
θ range 4.36–26.34 
observed refls. 2403 
x, y (weighting scheme) 0.0431, 0 
hydrogen refinement constr 
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refls in refinement 3645 
parameters 228 
restraints 0 
R(Fobs) 0.0371 
Rw(F2) 0.0847 
S 0.886 
shift/errormax 0.001 
max electron density/e Å−3 0.209 
min electron density/e Å−3 −0.269 
 
4-(trans-1-Tosyl-2-(4-(trifluoromethyl)phenyl)piperidin-4-yl)benzonitrile (124aa) 
N
Ts
F3C
CN
(prepared from Boc-protected piperidine
via deprotection and tosylation)   
S1
O1
O2
C1
C2
C3
C6
C5
C4
C7
N1
C8
C9
C10
C11
C12
C13
C14
C15
C16
C17
C18
C19
F3
F2F1
C20
C21
C22
C23
C24
C25
C26
N2
 
Crystal data 
net formula C26H23F3N2O2S 
Mr/g mol−1 484.534 
crystal size/mm 0.35 × 0.04 × 0.04 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system monoclinic 
space group C2/c 
a/Å 22.4013(9) 
b/Å 14.5297(5) 
c/Å 15.9116(7) 
α/° 90 
β/° 116.2671(19) 
γ/° 90 
V/Å3 4641.0(3) 
Z 8 
calc. density/g cm−3 1.38694(9) 
µ/mm−1 0.190 
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absorption correction none 
refls. measured 14235 
Rint 0.0717 
mean σ(I)/I 0.0550 
θ range 3.15–25.34 
observed refls. 2969 
x, y (weighting scheme) 0.0316, 6.9720 
hydrogen refinement constr 
refls in refinement 4228 
parameters 308 
restraints 0 
R(Fobs) 0.0448 
Rw(F2) 0.1096 
S 1.009 
shift/errormax 0.001 
max electron density/e Å−3 0.298 
min electron density/e Å−3 −0.337 
 
4-(trans-1-Tosyl-2-(4-(trifluoromethyl)phenyl)piperidin-4-yl)benzonitrile (124c) 
  N2
C26
C23
C22
C21
C20
C25
C24
C10
C11
C9
C8
N1
C12
C13
C14
C15
C16
C17
C18
C19
F1
F3
F2
S1
O2
O1
C1
C6
C5
C2
C3
C4
C7
 
Crystal data 
net formula C26H23F3N2O2S 
Mr/g mol−1 484.534 
crystal size/mm 0.21 × 0.15 × 0.096 
T/K 173(2) 
radiation MoKα 
diffractometer 'KappaCCD' 
crystal system monoclinic 
space group C2/c 
a/Å 22.3664(8) 
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b/Å 14.5275(6) 
c/Å 15.9004(5) 
α/° 90 
β/° 116.2098(18) 
γ/° 90 
V/Å3 4635.3(3) 
Z 8 
calc. density/g cm−3 1.38865(9) 
µ/mm−1 0.191 
absorption correction none 
refls. measured 10097 
Rint 0.0369 
mean σ(I)/I 0.0542 
θ range 3.15–27.49 
observed refls. 3352 
x, y (weighting scheme) 0.0577, 3.2402 
hydrogen refinement constr 
refls in refinement 5236 
parameters 308 
restraints 0 
R(Fobs) 0.0484 
Rw(F2) 0.1319 
S 1.037 
shift/errormax 0.001 
max electron density/e Å−3 0.361 
min electron density/e Å−3 −0.378 
 
4-(trans-2-methyl-1-tosylpiperidin-4-yl)benzonitrile (124e) 
  
C7
C4
C3
C2
C1
C6
C5
O1
S1
O2
C13
C12
N1
C9
C8
C10
C11
C14
C19
C15
C16
C17
C18
C20 N2
 
Crystal data 
net formula C20H22N2O2S 
Mr/g mol−1 354.467 
crystal size/mm 0.22 × 0.16 × 0.06 
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T/K 173(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system triclinic 
space group P1bar 
a/Å 7.4047(6) 
b/Å 9.5212(9) 
c/Å 13.7988(11) 
α/° 88.074(7) 
β/° 76.203(7) 
γ/° 87.599(7) 
V/Å3 943.66(14) 
Z 2 
calc. density/g cm−3 1.24752(19) 
µ/mm−1 0.186 
absorption correction 'multi-scan' 
transmission factor range 0.82353–1.00000 
refls. measured 4869 
Rint 0.0434 
mean σ(I)/I 0.1372 
θ range 4.29–23.29 
observed refls. 1212 
x, y (weighting scheme) 0.0470, 0 
hydrogen refinement constr 
refls in refinement 2652 
parameters 228 
restraints 0 
R(Fobs) 0.0539 
Rw(F2) 0.1174 
S 0.831 
shift/errormax 0.001 
max electron density/e Å−3 0.205 
min electron density/e Å−3 −0.200 
 
Crystal had poor scattering strength, data collection merely up to a resolution of 0.90 Å. 
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trans-2-Methyl-1-tosyl-5-(4-(trifluoromethyl)phenyl)-piperidine (128ca) 
  
C7
C4
C3
C2
C5
C6
C1
S1
O2
O1 N1
C8
C9
C14
C15
C16
C17
C19
C18
C20
F2
F3
F1
C10
C11
C12
C13
 
Crystal data 
net formula C20H22F3NO2S 
Mr/g mol−1 397.455 
crystal size/mm 0.37 × 0.23 × 0.17 
T/K 243(2) 
radiation MoKα 
diffractometer 'Oxford XCalibur' 
crystal system monoclinic 
space group P21/n 
a/Å 10.1552(5) 
b/Å 11.7039(5) 
c/Å 16.2918(8) 
α/° 90 
β/° 98.366(4) 
γ/° 90 
V/Å3 1915.76(16) 
Z 4 
calc. density/g cm−3 1.37804(12) 
µ/mm−1 0.212 
absorption correction 'multi-scan' 
transmission factor range 0.94343–1.00000 
refls. measured 7447 
Rint 0.0271 
mean σ(I)/I 0.0604 
θ range 4.30–26.33 
observed refls. 2580 
x, y (weighting scheme) 0.0432, 0 
hydrogen refinement constr 
refls in refinement 3883 
parameters 273 
restraints 10 
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R(Fobs) 0.0368 
Rw(F2) 0.0840 
S 0.881 
shift/errormax 0.001 
max electron density/e Å−3 0.284 
min electron density/e Å−3 −0.379 
 
The F atoms of the CF3 group are disordered over three sites. A split 
model has been applied. The sof ratios are 0.83:0.09:0.08. The F atoms 
on the highest occupied site have been refined anisotropically. 
 
 
D. Appendix  267 
2. Ligand Screening and NMR Experiments for the Pd-Catalyzed Cross-
Coupling of Substituted Cycloalkylzinc Reagents with Aryl Halides 
 
Catalyst screening for the cross-coupling reaction: 
 
Me ZnCl Me CO2Me
PdLn or NiL3 (2 mol%)
-10 °C, THF
I CO2Me
 
Table A. Screening for the most diastereoselective cross-coupling catalyst. 
 
Entry 
Source of 
transition-metal 
Ligand 
Ratio 
metal:ligand 
time d.r. 
1 Pd(PPh3)4 PPh3 1:4 48 h 92:8 
2 PdCl2 P(o-tolyl)3 1:2 15 h 90:10 
3 Pd(dba)2 SPhos 1:1 15 h 87:13 
4 PEPPSI-IPrb IPrb 1:1 15 h 90:10 
5 PdCl2 TMPPc 1:2 15 h 95:5 
6 PdCl2 tBu3P 1:2 15 h 80:20 
7 Ni(acac)2 
 
tris(2,4-di-tert-
butylphenyl) 
phosphite 
 
1:3 15 h 79:21 
 
[a]Determined by capillary GC analysis. 
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[b]PEPPSI: Pyridine, Enhanced, Precatalyst, Preparation, Stabilization and Initiation.155 IPr: 1,3-
bis-{2,6-diisopropylphenyl}imidazolylidene. 
[c]TMPP: tris(2,4,6-trimethoxyphenyl)phosphine83 
 
NMR studies: 
All NMR spectra were recorded on a Bruker Avance 600 spectrometer equipped with a 5 mm 
broadband triple resonance Z-gradient probe. Temperature stability was controlled by a Bruker 
BVTE 3900 temperature unit. NMR data were processed and evaluated with TOPSPIN 2.1. The 
temperature was regulated via a BVTE 3900-unit. 1H-Spectra were calibrated using TMS as 
standard. 31P-Spectra were calibrated using an external H3PO4-standard. 
 
 
 
Figure 1: 1H31P-HMBC of 10a and TMPP (3:1) in d8-THF at 263 K. 
                                                 
155 M. G. Organ, S. Avola, I. Dubovyk, N. Hadei, E. A. B. Kantchev, C. J. O'Brien, C. Valente, Chem. Eur. J. 2006, 
12, 4749. 
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Figure 1 shows a section from the 1H31P-HMBC. As highlighted by the labelling, only one single 
species in the reaction mixture displays 1H-31P couplings with protons in the aromatic and 
cyclohexyl region. Thus, it can be unambiguously shown, that only one single intermediate which 
contains both the P-ligand and the cyclohexyl moiety is formed. 
 
 
Figure 2: 1D-section from the 1H31P-HMBC (see Figure 1). Signals labelled with * can be 
ascribed to T1 noise. 
 
Figure 2 shows a 1D-section of the 1H31P-HMBC (Figure 1) in the region of the intermediate. 
The aromatic signal δ = 6.3 ppm can be ascribed to the P-ligand, the signals δ = 2.8 ppm as well 
as in the region from δ = 1.4 ppm to 1.7 ppm can be ascribed to the cyclohexyl moiety. Since in 
this HMBC the signal intensity is proportional to J HX under certain conditions, the cyclohexyl 
signals can be differentiated (4JHX < 3JHX). The most intense of the cyclohexyl signals at δ = 2.8 
ppm represents the methine signal showing the strongest coupling with the P of the TMPP-ligand 
(3JHP). The neighboring methylene protons show signals in the region from δ = 1.4 ppm to 1.7 
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ppm with lower intensities (4JHP). Due to the Karplus equation156, the axial and equatorial protons 
can be distinguished. 
 
 
Figure 3: Sections from the 1H-NMR spectra coupled to 31P (above) and decoupled (below) at 
263 K in d8-THF in the region of the methine signal. 
 
Figure 3 shows two 1H-NMR spectra in the region of the methine signal, coupled to 31P (above) 
and decoupled from 31P (below). By comparing the two spectra the 3JHP coupling constant can be 
determined. The pseudo-triplet in the decoupled spectrum displays at a closer look two different 
coupling constants. The larger coupling is ca. 11 Hz  and can be ascribed to an axial-axial 3JHH-
coupling.156 Thus, one can conclude that the methine proton must occupy the axial position. If the 
methine proton occupied an equatorial position, only equatorial-axial or equatorial-equatorial 
couplings would occur, whose coupling constants are around 2-5 Hz. 
 
                                                 
156 M. Hesse, H. Meier, B. Zeeh, Spektroskopische Methoden in der organischen Chemie, Thieme, 2005. 
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